

ACTEMRA

Products Affected

- ACTEMRA INTRAVENOUS

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent Use with a Biologic Disease-Modifying Antirheumatic Drug (DMARD) or Targeted Synthetic DMARD. Exclude for indication of COVID-19 treatment in hospitalized patients (ie, non-D use).
Required Medical Information	Diagnosis, concurrent medications, previous drugs tried
Age Restrictions	(Initial therapy only): GCA/RA-18 years and older. PJIA/SJIA-2 years and older.
Prescriber Restrictions	RA, SJIA, PJIA, GCA - Prescribed by or in consultation with a rheumatologist (initial therapy).
Coverage Duration	Approve through end of plan year
Other Criteria	RA initial - approve if the patient meets one of the following (A or B): A) patient has tried ONE of the following drugs in the past: Enbrel, a preferred adalimumab product, Rinvoq or Xeljanz/XR (Note: if the patient does not meet this requirement, previous trial(s) with: Cimzia, Kevzara, infliximab, golimumab SC/IV, Orencia or a non-preferred adalimumab product will also count.). OR B) patient has heart failure or a previously treated lymphoproliferative disorder. PJIA, initial-approve if the patient meets one of the following (A or B): A) patient has tried ONE of the following drugs in the past: Enbrel, Rinvoq, Xeljanz or a preferred adalimumab product. (Note: if the patient does not meet this requirement, a previous trial with the drug Kevzara, infliximab, Orencia or a non-preferred adalimumab product will be counted.), OR B) patient has heart failure or a previously treated lymphoproliferative disorder. Systemic-onset JIA, approve. Giant cell arteritis, initial-approve if the patient has tried or is currently taking a systemic corticosteroid or corticosteroid is contraindicated. Cont tx, RA/PJIA/SJIA/GCA - approve if the pt had a response as determined by the prescriber. Cytokine release syndrome associated with chimeric antigen receptor (CAR) T-Cell therapy-approve. Please Note: preferred adalimumab products include Hadlima, Simlandi.

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ACTEMRA SQ

Products Affected

- ACTEMRA ACTPEN
- ACTEMRA SUBCUTANEOUS

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with a Biologic DMARD or Targeted Synthetic DMARD.
Required Medical Information	Diagnosis, concurrent medications, previous drugs tried.
Age Restrictions	Interstitial lung disease-18 years and older (initial and continuation). GCA/RA-18 years and older (initial only). SJIA/PJIA-2 years and older (initial only).
Prescriber Restrictions	RA/GCA/PJIA/SJIA - Prescribed by or in consultation with a rheumatologist (initial therapy only). Lung disease-presc/consult-pulmonologist or rheum (initial and cont)
Coverage Duration	Approve through end of plan year
Other Criteria	INITIAL THERAPY: RHEUMATOID ARTHRITIS (RA) [A or B]: A) tried one of the following: Enbrel, preferred adalimumab product (see Example 1), Rinvoq or Xeljanz/XR (Note: trials with the following will also count: Cimzia, infliximab, Kevzara, golimumab SC/IV, non-preferred adalimumab product, Orencia), or B) heart failure or a previously treated lymphoproliferative disorder. POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA) [A or B]: A) tried one of the following: Enbrel, Rinvoq, Xeljanz, preferred adalimumab product. (Note: trials with Kevzara, infliximab, Orencia or a non-preferred adalimumab product will also count), or B) heart failure or a previously treated lymphoproliferative disorder. SYSTEMIC-ONSET JIA (SJIA): Approve. GIANT CELL ARTERITIS: tried or is currently taking a one systemic CS or CS is contraindicated. INTERSTITIAL LUNG DISEASE ASSOCIATED WITH SYSTEMIC SCLEROSIS (A and B): A) elevated acute phase reactants and B) diagnosis confirmed by high-resolution computed tomography. CONTINUATION THERAPY: ALL INDICATIONS: patient had a response to therapy. Example 1: preferred adalimumab products include Hadlima, Simlandi.
Indications	All FDA-approved Indications.

Effective August 1, 2026

PA Criteria	Criteria Details
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ACTIMMUNE

Products Affected

- ACTIMMUNE

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Chronic granulomatous disease - prescribed by or in consultation with an immunologist, hematologist or infectious disease specialist. Malignant osteopetrosis- prescribed by or in consultation with an endocrinologist or hematologist.
Coverage Duration	1 year
Other Criteria	Chronic granulomatous disease - approve if diagnosis has been established by a molecular genetic test identifying a gene-related pathogenic variant linked to chronic granulomatous disease. Malignant osteopetrosis, severe - approve if pt has had radiographic (X-ray) imaging demonstrating skeletal features related to osteopetrosis or pt had a molecular genetic test identifying a gene-related pathogenic variant linked to severe, malignant osteopetrosis.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

ACYCLOVIR (TOPICAL)

Products Affected

- *acyclovir topical ointment*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

ADALIMUMAB

Products Affected

- HADLIMA
- HADLIMA PUSHTOUCH
- HADLIMA(CF)
- HADLIMA(CF) PUSHTOUCH
- SIMLANDI(CF) AUTOINJECTOR
SUBCUTANEOUS AUTO-INJECTOR,
KIT 40 MG/0.4 ML, 80 MG/0.8 ML
- SIMLANDI(CF) SUBCUTANEOUS
SYRINGE KIT 20 MG/0.2 ML, 40
MG/0.4 ML

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with another biologic DMARD or targeted synthetic DMARD.
Required Medical Information	Diagnosis
Age Restrictions	Initial therapy only: CD-6 years and older, UC-5 years and older, AS/PsA/RA/PP/ Pyoderma gangrenosum/ sarcoidosis/ scleritis/ sterile corneal ulceration/ non-radiographic axial spondyloarthritis-18 years and older, JIA/UV/Behcet's disease-2 years and older, HS-12 years and older
Prescriber Restrictions	Initial therapy only for all dx, prescribed by or in consultation with one of the following specialists-RA/JIA/JRA/Ankylosing spondylitis/nr-axSpA, rheumatologist. PsA, rheumatologist or dermatologist. PP, dermatologist. UC/ CD, gastroenterologist. HS/pyoderma gangrenosum - dermatologist.UV/scleritis/sterile corneal ulceration-ophthalmologist. Behcet's- rheum, dermatologist, ophthalmologist, gastro, neuro. Sarcoidosis, pulm, ophthalmologist, dermatologist.
Coverage Duration	Approve through end of plan year
Other Criteria	INITIAL THERAPY: CROHN'S DISEASE (CD): approve. JUVENILE IDIOPATHIC ARTHRITIS (JIA)/JRA (one of A, B, C, D, or E): A) tried one other systemic therapy (e.g., MTX, sulfasalazine, leflunomide, NSAID), B) tried a biologic (e.g., etanercept, abatacept, infliximab, anakinra, tocilizumab), C) will be starting on adalimumab concurrently with MTX, sulfasalazine, or leflunomide, D) patient has absolute contraindication to MTX, sulfasalazine, or leflunomide, or E) patient has aggressive disease. HIDRADENITIS SUPPURATIVA (HS): tried one other therapy (e.g., intralesional or oral CS, systemic antibiotics,

PA Criteria	Criteria Details
	isotretinoin). PLAQUE PSORIASIS (PP) [A or B]: A) tried at least one traditional systemic agent (e.g., MTX, cyclosporine (CSA), acitretin, PUVA) for at least 3 months, unless intolerant (Note: a trial of a biologic will also count) or B) contraindication to MTX. RHEUMATOID ARTHRITIS (RA): tried one conventional synthetic DMARD for at least 3 months (Note: a 3-month trial of a biologic will also count). ULCERATIVE COLITIS: approve. BEHCET'S DISEASE (A or B): A) tried one conventional therapy (e.g., systemic CS, azathioprine, MTX, CSA, chlorambucil, cyclophosphamide, interferon alfa), or B) has ophthalmic manifestations. SARCOIDOSIS (A and B): A) tried one CS, and B) tried one immunosuppressant (e.g. MTX, mycophenolate mofetil, chlorambucil, thalidomide, infliximab, chloroquine). SCLERITIS/STERILE CORNEAL ULCERATION: tried one other therapy (e.g. CS, CSA). NON RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: objective signs of inflammation defined as either (A or B): A) C-reactive protein elevated beyond upper limit of normal, or B) sacroiliitis on MRI. CONTINUATION THERAPY: ALL INDICATIONS: patient had a response to therapy.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Behcet's disease, pyoderma gangrenosum, sarcoidosis, scleritis/sterile corneal ulceration, non-radiographic axial spondyloarthritis.
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ADBRY

Products Affected

- ADBRY

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with another monoclonal antibody therapy (examples: Dupixent, Cinqair, Ebglyss, Fasenra, Nemluvio, Nucala, Tezspire, or Xolair). Concurrent use with Janus Kinase Inhibitors (JAKis) [oral or topical] (examples: Cibinqo, Leqselvi, Rinvoq/LQ, Opzelura)
Required Medical Information	Diagnosis
Age Restrictions	AD-12 years of age and older (initial therapy)
Prescriber Restrictions	Atopic Dermatitis-prescribed by or in consultation with an allergist, immunologist or dermatologist (initial therapy)
Coverage Duration	Initial-Atopic Dermatitis-4 months, Continuation-1 year
Other Criteria	Atopic Dermatitis, initial-approve. Continuation- Approve if the patient has been receiving Adbry for at least 4 months and patient has responded to therapy. Note: A patient who has received less than 4 months of therapy or who is restarting therapy with Adbry should be considered under initial therapy.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

ADEMPAS

Products Affected

- ADEMPAS

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent Use with Phosphodiesterase Inhibitors Used for Pulmonary Hypertension or Other Soluble Guanylate Cyclase Stimulators.
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	PAH and CTEPH- must be prescribed by or in consultation with a cardiologist or a pulmonologist.
Coverage Duration	1 year
Other Criteria	For PAH - must have PAH (WHO Group 1) and had a right heart catheterization to confirm the diagnosis of PAH (WHO Group 1).
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

ADSTILADRIN

Products Affected

- ADSTILADRIN

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with a urologist or an oncologist
Coverage Duration	1 year
Other Criteria	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Non-Muscle Invasive Bladder Cancer, approve initial therapy if the patient meets (A and B): A) patient has high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive disease, and B) the patient has carcinoma in situ (CIS) OR the patient has high-grade papillary Ta/T1 tumors without CIS. Non-Muscle Invasive Bladder Cancer, continuation of therapy - approve.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

AIMOVIG

Products Affected

- AIMOVIG AUTOINJECTOR

PA Criteria	Criteria Details
Exclusion Criteria	Combination therapy with another cGRP inhibitor for migraine headache prevention
Required Medical Information	Diagnosis, number of migraine headaches per month
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Approve if the patient meets the following criteria (A and B): A) Patient has greater than or equal to 4 migraine headache days per month (prior to initiating a migraine-preventative medication), AND B) If pt is currently taking Aimovig, the pt has had significant clinical benefit from the medication. Examples of significant clinical benefit include a reduction in the overall number of migraine days per month or a reduction in number of severe migraine days per month from the time that Aimovig was initiated.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

AKEEGA

Products Affected

- AKEEGA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Prostate cancer, metastatic castration-resistant or metastatic castration-sensitive- Approve if the patient meets the following (A, B, and C): A)Patient has a BReast CAncer (BRCA) mutation, AND B) The medication is used in combination with prednisone, AND C) Patient meets one of the following (i or ii): i. The medication is used concurrently with a gonadotropin-releasing hormone (GnRH) analog, Note: Examples are leuprolide acetate, Lupron Depot (leuprolide acetate intramuscular injection), Trelstar (triptorelin pamoate intramuscular injection), Zoladex (goserelin acetate subcutaneous implant), Vantas (histrelin acetate subcutaneous implant), Firmagon (degarelix acetate subcutaneous injection), and Orgovyx (relugolix tablets).OR ii. Patient has had a bilateral orchiectomy.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

Effective August 1, 2026

ALDURAZYME

Products Affected

- ALDURAZYME

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, genetic and lab test results
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a geneticist, endocrinologist, a metabolic disorder sub-specialist, or a physician who specializes in the treatment of lysosomal storage disorders
Coverage Duration	1 year
Other Criteria	Approve if the patient has a laboratory test demonstrating deficient alpha-L-iduronidase activity in leukocytes, fibroblasts, plasma, or serum OR has a molecular genetic test demonstrating biallelic pathogenic or likely pathogenic alpha-L-iduronidase gene variants.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

ALECENSA

Products Affected

- ALECENSA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	Pediatric diffuse high grade glioma- less than or equal to 21 years old, All others- 18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Non-small cell lung cancer-approve if the patient has both (A and B): A) either (i or ii): i) medication is used as adjuvant treatment following tumor resection (note: for tumors greater than or equal to 4 cm or node positive) or ii) advanced or metastatic disease and B) anaplastic lymphoma kinase (ALK)-positive disease as detected by an approved test. Anaplastic large cell lymphoma-approve if the patient has anaplastic lymphoma kinase (ALK)-positive disease and (i or ii): (i) the medication is used for palliative-intent therapy, or (ii) pt has relapsed or refractory disease. Erdheim-Chester disease-approve if the patient has anaplastic lymphoma kinase (ALK) rearrangement/fusion-positive disease. Inflammatory Myofibroblastic Tumor- pt has anaplastic lymphoma kinase (ALK)-positive disease AND (i or ii): (i) pt has advanced, recurrent or metastatic disease, or (ii) tumor is inoperable. Large B-Cell Lymphoma- pt has ALK-positive disease AND pt has relapsed or refractory disease. Pediatric diffuse high grade glioma- approve if (A and B): A) ALK-positive disease, and B) either (i or ii): i) medication is used as adjuvant treatment AND tumor is not diffuse midline glioma, H3 K27-altered or pontine location, or ii) medication is used for recurrent or progressive disease.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.

PA Criteria	Criteria Details
Off-Label Uses	Anaplastic large cell lymphoma, Erdheim Chester disease, Inflammatory Myofibroblastic Tumor, Large B-Cell Lymphoma, Pediatric Diffuse High Grade Glioma
Part B Prerequisite	No
Prerequisite Therapy Required	No

ALOSETRON

Products Affected

- *alosetron*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

ALPHA 1 PROTEINASE INHIBITORS

Products Affected

- PROLASTIN-C INTRAVENOUS SOLUTION

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Alpha1-Antitrypsin Deficiency with Emphysema (or Chronic Obstructive Pulmonary Disease)-approve if the patient has a baseline (pretreatment) AAT serum concentration of less than 80 mg/dL or 11 micromol/L.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

ALUNBRIG

Products Affected

- ALUNBRIG ORAL TABLET 180 MG, 30 MG, 90 MG
- ALUNBRIG ORAL TABLETS,DOSE PACK

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	ALK status
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Erdheim-Chester disease-approve if the patient has anaplastic lymphoma kinase (ALK) rearrangement/fusion-positive disease. Inflammatory myofibroblastic tumor (IMT)-approve if the patient has ALK positive disease and has advanced, recurrent or metastatic disease or the tumor is inoperable. NSCLC, must be ALK-positive, as detected by an approved test, have advanced or metastatic disease and patients new to therapy must have a trial of Alecensa, Ensacove or Lorbrena prior to approval of Alunbrig. Peripheral T-Cell Lymphoma- approve if patient has ALK-positive anaplastic large cell lymphoma (ALCL).
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Erdheim-Chester disease, Inflammatory myofibroblastic tumor (IMT), Peripheral T-Cell Lymphoma
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ANKTIVA

Products Affected

- ANKTIVA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 and older (initial therapy)
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or urologist (initial/maintenance therapy)
Coverage Duration	Initial-6 months, Maintenance-3 months
Other Criteria	Part B vs Part D determination will be made at time of prior authorization review per CMS guidance. INITIAL-NON-MUSCLE INVASIVE BLADDER CANCER-all of (i, ii, iii): i) Patient has high risk Bacillus Calmette-Guerin (BCG) unresponsive disease, AND ii) Patient has carcinoma in situ, AND iii) Medication is used in combination with BCG.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ANTIBIOTICS (IV)

Products Affected

- *amikacin injection solution 1,000 mg/4 ml, 500 mg/2 ml*
- *ampicillin sodium injection recon soln 1 gram, 10 gram, 2 gram, 250 mg, 500 mg*
- *ampicillin sodium intravenous*
- *ampicillin-sulbactam*
- *azithromycin intravenous*
- *aztreonam*
- *BICILLIN L-A*
- *cefoxitin*
- *cefoxitin in dextrose, iso-osm*
- *ceftaroline fosamil*
- *ceftazidime*
- *cefuroxime sodium injection recon soln 750 mg*
- *cefuroxime sodium intravenous*
- *ciprofloxacin in 5 % dextrose*
- *clindamycin in 5 % dextrose*
- *clindamycin phosphate injection*
- *colistin (colistimethate na)*
- *doxy-100*
- *doxycycline hyclate intravenous*
- *ertapenem*
- *gentamicin in nacl (iso-osm) intravenous piggyback 100 mg/100 ml, 60 mg/50 ml, 80 mg/100 ml, 80 mg/50 ml*
- *gentamicin injection*
- *gentamicin sulfate (ped) (pf)*
- *imipenem-cilastatin*
- *levofloxacin in d5w*
- *lincomycin*
- *linezolid in dextrose 5%*
- *meropenem intravenous recon soln 1 gram, 2 gram, 500 mg*
- *metro i.v.*
- *metronidazole in nacl (iso-os)*
- *moxifloxacin-sod.chloride(iso)*
- *nafcillin in dextrose iso-osm intravenous piggyback 2 gram/100 ml*
- *nafcillin injection*
- *oxacillin*
- *oxacillin in dextrose(iso-osm) intravenous piggyback 2 gram/50 ml*
- *PENICILLIN G POT IN DEXTROSE INTRAVENOUS PIGGYBACK 2 MILLION UNIT/50 ML, 3 MILLION UNIT/50 ML*
- *penicillin g potassium*
- *penicillin g sodium*
- *pfizerpen-g*
- *STREPTOMYCIN*
- *sulfamethoxazole-trimethoprim intravenous*
- *tazicef injection*
- *TEFLARO*
- *tigecycline*
- *tobramycin sulfate injection recon soln*
- *tobramycin sulfate injection solution*
- *VIBATIV INTRAVENOUS RECON SOLN 750 MG*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A

PA Criteria	Criteria Details
Prescriber Restrictions	N/A
Coverage Duration	3 months
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

ANTIFUNGALS (IV)

Products Affected

- *fluconazole in nacl (iso-osm) intravenous piggyback 200 mg/100 ml, 400 mg/200 ml*
- *voriconazole intravenous recon soln*
- *voriconazole-hpbc*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	3 months
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

ARCALYST

Products Affected

- ARCALYST

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent biologic therapy
Required Medical Information	N/A
Age Restrictions	Initial tx CAPS/Pericarditis-Greater than or equal to 12 years of age.
Prescriber Restrictions	Initial tx CAPS-prescribed by, or in consultation with, a rheumatologist, geneticist, allergist/immunologist, or dermatologist. DIRA initial-rheum, geneticist, dermatologist, or a physician specializing in the treatment of autoinflammatory disorders. Pericarditis-cardiologist or rheum
Coverage Duration	CAPS-3 mos initial, 1 yr cont. DIRA-6 mos initial, 1 yr cont. Pericard-3 mos initial, 1 yr cont
Other Criteria	INITIAL THERAPY: DEFICIENCY OF INTERLEUKIN-1 RECEPTOR ANTAGONIST (DIRA) [all of A, B, and C]: A) weighs at least 10 kg, B) genetic test has confirmed bi-allelic pathogenic variants in the IL1RN gene, and C) had clinical benefit with anakinra subcutaneous injection. PERICARDITIS: pericarditis is recurrent. CONTINUATION THERAPY: ALL INDICATIONS: patient had a positive response to therapy.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ARIKAYCE

Products Affected

- ARIKAYCE

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, previous medication history (as described in Other Criteria field)
Age Restrictions	MAC-18 years and older (initial therapy)
Prescriber Restrictions	MAC initial-Prescribed by a pulmonologist, infectious disease physician or a physician who specializes in the treatment of MAC lung infections.
Coverage Duration	1 year
Other Criteria	INITIAL THERAPY: MYCOBACTERIUM AVIUM COMPLEX (MAC) LUNG DISEASE (all of A, B, and C): A) positive sputum culture for MAC [Note: any positive sputum culture taken after completion of a background multidrug regimen (throughout, see Example 1 below) fulfills this criterion], B) MAC isolate is susceptible to amikacin, and C) Arikayce will be used in combination with a background multidrug regimen. CONTINUATION THERAPY: MAC LUNG DISEASE (A and B): A) Arikayce prescribed in combination with a background multidrug regimen and B) patient meets one of the following (a or b): a) patient has not achieved negative sputum cultures for MAC or b) patient has achieved negative sputum cultures for MAC for less than 12 months. Example 1: background multidrug regimen example - a macrolide (azithromycin or clarithromycin), ethambutol, and a rifamycin (rifampin or rifabutin).
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	No

ASPARLAS

Products Affected

- ASPARLAS

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	1 month to 21 years
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	1 year
Other Criteria	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

AUBAGIO

Products Affected

- *teriflunomide*

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use of teriflunomide with other disease-modifying agents used for multiple sclerosis (MS)
Required Medical Information	Relapsing form of MS, to include, clinically-isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a neurologist or MS specialist.
Coverage Duration	Authorization will be for 1 year.
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

AUGTYRO

Products Affected

- AUGTYRO ORAL CAPSULE 160 MG, 40 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	NSCLC - 18 and older, Solid tumors - 12 and older, Pediatric Diffuse High-Grade Glioma-less than 18
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Non-Small Cell Lung Cancer-approve if the patient has locally advanced or metastatic disease, patient has ROS1-positive non-small cell lung cancer and the mutation was detected by an approved test. Note: If the patient has non-small cell lung cancer with neurotrophic receptor tyrosine kinase (NTRK) gene fusion, see Solid Tumors indication. Solid tumors - approve if tumor is positive for neurotrophic tyrosine receptor kinase (NTRK) gene fusion AND tumor is locally advanced or metastatic or surgical resection will likely result in severe morbidity. Pediatric Diffuse High-Grade Gliomas - approve if tumor is positive for neurotrophic receptor tyrosine kinase (NTRK) gene fusion AND the medication is used as adjuvant therapy or for recurrent or progressive disease.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Pediatric Diffuse High-Grade Gliomas
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	No

AUSTEDO

Products Affected

- AUSTEDO ORAL TABLET 12 MG, 6 MG, 9 MG
- AUSTEDO XR
- AUSTEDO XR TITRATION KT(WK1-4) ORAL TABLET, EXT REL 24HR DOSE PACK 12-18-24-30 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	TD - Prescribed by or in consultation with a neurologist or psychiatrist. Chorea HD - prescribed by or in consultation with a neurologist.
Coverage Duration	1 year
Other Criteria	Chorea associated with Huntington's Disease-approve if the diagnosis of Huntington's Disease is confirmed by genetic testing. Tardive dyskinesia-approve.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

AVMAPKI-FAKZYNJA

Products Affected

- AVMAPKI-FAKZYNJA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER- ALL of the following (A, B and C): A) Patient has recurrent low-grade serous cancer, AND B) The cancer has a KRAS mutation, AND C) Patient has tried at least one systemic therapy. Note: Examples of systemic therapy include one or more of the following medications: paclitaxel, carboplatin, bevacizumab, letrozole, anastrozole, or exemestane.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Fallopian Tube or Primary Peritoneal Cancer
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

AVONEX

Products Affected

- AVONEX INTRAMUSCULAR PEN INJECTOR KIT
- AVONEX INTRAMUSCULAR SYRINGE KIT

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use of other disease-modifying agent used for multiple sclerosis
Required Medical Information	Relapsing form of Multiple Sclerosis (MS), to include clinically-isolated syndrome, relapsing-remitting disease, and active secondary progressive disease
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or after consultation with a neurologist or an MS specialist.
Coverage Duration	Authorization will be for 1 year
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

AYVAKIT

Products Affected

- AYVAKIT

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	GIST-approve if the tumor is positive for platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation or if the patient has tried two of the following: Gleevec (imatinib), Sutent (sunitinib), Sprycel (dasatinib), Stivarga (regorafenib) or Qinlock (ripretinib). Myeloid/Lymphoid Neoplasms with eosinophilia-approve if the tumor is positive for PDGFRA D842V mutation. Systemic mastocytosis-Approve if the patient has a platelet count greater than or equal to 50,000/mcL and patient has either indolent systemic mastocytosis or one of the following subtypes of advanced systemic mastocytosis-aggressive systemic mastocytosis, systemic mastocytosis with an associated hematological neoplasm or mast cell leukemia.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Myeloid/Lymphoid neoplasms with Eosinophilia
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

BALVERSA

Products Affected

- BALVERSA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Urothelial Carcinoma, locally advanced or metastatic-approve if the patient has susceptible fibroblast growth factor receptor 3 genetic alterations AND the patient has progressed during or following prior platinum-containing chemotherapy, other chemotherapy or checkpoint inhibitor therapy. Pancreatic adenocarcinoma- approve if (A, B, C and D): A) patient has a fibroblast growth factor receptor (FGFR) genetic alterations, and B) locally advanced, recurrent or metastatic disease, and C) medication is used for subsequent therapy and D) medication is used as a single agent. NSCLC- approve if patient has metastatic disease and FGFR alterations.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Pancreatic adenocarcinoma, non-small cell lung cancer
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

BENLYSTA

Products Affected

- BENLYSTA

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent Use with Other Biologics or Lupkynis
Required Medical Information	Diagnosis
Age Restrictions	5 years and older (initial).
Prescriber Restrictions	SLE-Prescribed by or in consultation with a rheumatologist, clinical immunologist, nephrologist, neurologist or dermatologist (initial and continuation). Lupus Nephritis-nephrologist or rheum. (Initial/cont)
Coverage Duration	1 year
Other Criteria	Lupus Nephritis Initial-approve if the patient has a diagnosis of lupus nephritis confirmed on biopsy (For example, World Health Organization class III, IV, or V lupus nephritis), AND the medication is being used concurrently with an immunosuppressive regimen (ex: azathioprine, cyclophosphamide, leflunomide, methotrexate, mycophenolate mofetil and/or a systemic corticosteroid). Cont-approve if the medication is being used concurrently with an immunosuppressive regimen (ex: azathioprine, cyclophosphamide, leflunomide, methotrexate, mycophenolate mofetil and/or a systemic corticosteroid) AND the patient has responded to Benlysta subcutaneous or intravenous. SLE-Initial-The patient has autoantibody-positive SLE, defined as positive for antinuclear antibodies [ANA] and/or anti-double-stranded DNA [anti-dsDNA] antibody AND Benlysta is being used concurrently with at least one other standard therapy (i.e., antimalarials [e.g., hydroxychloroquine], a systemic corticosteroid [e.g., prednisone], and/or other immunosuppressants [e.g., azathioprine, mycophenolate mofetil, methotrexate]) unless the patient is determined to be intolerant due to a significant toxicity. Continuation-Benlysta is being used concurrently with at least one other standard therapy (i.e., antimalarials [e.g., hydroxychloroquine], a systemic corticosteroid [e.g., prednisone], and/or other immunosuppressants [e.g., azathioprine, mycophenolate mofetil, methotrexate]) unless the patient is determined to

PA Criteria	Criteria Details
	be intolerant due to a significant toxicity AND The patient has responded to Benlysta subcutaneous or intravenous.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

BENLYSTA IV

Products Affected

- BENLYSTA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	5 years and older (initial).
Prescriber Restrictions	SLE-Prescribed by or in consultation with a rheumatologist, clinical immunologist, nephrologist, neurologist or dermatologist (initial and continuation). Lupus Nephritis-nephrologist or rheum. (Initial/cont)
Coverage Duration	SLE-Initial-4 months, cont-1 year, Lupus Nephritis-6 mo initial, 1 year cont
Other Criteria	Lupus Nephritis Initial-approve if the patient has a diagnosis of lupus nephritis confirmed on biopsy (For example, World Health Organization class III, IV, or V lupus nephritis), AND the medication is being used concurrently with an immunosuppressive regimen (ex: azathioprine, cyclophosphamide, leflunomide, methotrexate, mycophenolate mofetil and/or a systemic corticosteroid). Cont-approve if the medication is being used concurrently with an immunosuppressive regimen (ex: azathioprine, cyclophosphamide, leflunomide, methotrexate, mycophenolate mofetil and/or a systemic corticosteroid) AND the patient has responded to Benlysta subcutaneous or intravenous. SLE-Initial-The patient has autoantibody-positive SLE, defined as positive for antinuclear antibodies [ANA] and/or anti-double-stranded DNA [anti-dsDNA] antibody AND Benlysta is being used concurrently with at least one other standard therapy (i.e., antimalarials [e.g., hydroxychloroquine], a systemic corticosteroid [e.g., prednisone], and/or other immunosuppressants [e.g., azathioprine, mycophenolate mofetil, methotrexate]) unless the patient is determined to be intolerant due to a significant toxicity. Continuation-Benlysta is being used concurrently with at least one other standard therapy (i.e., antimalarials [e.g., hydroxychloroquine], a systemic corticosteroid [e.g., prednisone], and/or other immunosuppressants [e.g., azathioprine, mycophenolate mofetil, methotrexate]) unless the patient is determined to

PA Criteria	Criteria Details
	be intolerant due to a significant toxicity AND The patient has responded to Benlysta subcutaneous or intravenous.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

BESREMI

Products Affected

- BESREMI

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use with other interferon products
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or hematologist
Coverage Duration	1 year
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

BETASERON/EXTAVIA

Products Affected

- BETASERON SUBCUTANEOUS KIT

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with other disease-modifying agent used for multiple sclerosis
Required Medical Information	Relapsing form of Multiple Sclerosis (MS), to include clinically-isolated syndrome, relapsing-remitting disease, and active secondary progressive disease
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or after consultation with a neurologist or an MS specialist.
Coverage Duration	Authorization will be for 1 year
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

BEXAROTENE (ORAL)

Products Affected

- *bexarotene*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or dermatologist (initial and continuation)
Coverage Duration	1 year
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

BEXAROTENE (TOPICAL)

Products Affected

- bexarotene*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or dermatologist (initial and continuation)
Coverage Duration	1 year
Other Criteria	Cutaneous T-Cell lymphoma-approve if pt has cutaneous manifestations/lesions. Adult T-Cell Leukemia/Lymphoma- approve if the patient has smoldering symptomatic subtype and this medication is used as first-line therapy. Primary cutaneous B-Cell lymphoma-approve if used as skin-directed therapy for either (a or b): a) primary cutaneous marginal zone lymphoma or b) follicle center lymphoma.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Adult T-Cell Leukemia/Lymphoma, Primary Cutaneous B-Cell Lymphoma
Part B Prerequisite	No
Prerequisite Therapy Required	No

BIZENGRI

Products Affected

- BIZENGRI

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	1 year
Other Criteria	CHOLANGIOCARCINOMA- Both (A and B): A) has advanced, unresectable, or metastatic disease and B) the disease is neuregulin 1 (NRG1) gene fusion positive. NON-SMALL CELL LUNG CANCER-All of (A, B and C): A) Patient has advanced, unresectable, or metastatic disease, AND B) The disease is neuregulin 1 (NRG1) gene fusion positive, AND C) Patient has tried at least one systemic regimen. Note: Examples of a systemic regimen include one or more of the following drugs: carboplatin, cisplatin, or programmed cell death protein 1 (PD)-1 or PD-ligand 1 (PD-L1) blockers. PANCREATIC ADENOCARCINOMA-All of (A, B and C): A) Patient has advanced, unresectable, or metastatic disease, AND B) The disease is neuregulin 1 (NRG1) gene fusion positive, AND C) Patient has tried at least one systemic regimen. Note: Examples of systemic regimen include one or more of the following drugs: fluorouracil, leucovorin, irinotecan, oxaliplatin, gemcitabine, paclitaxel, capecitabine.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

BLENREP

Products Affected

- BLENREP

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	1 year
Other Criteria	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Approve if (A, B and C): A) the patient has tried at least two prior systemic lines of therapy and B) has received at least one drug from each of the following drug classes- proteasome inhibitor, [ex: bortezomib, Kyprolis (carfilzomib intravenous infusion), and Ninlaro (ixazomib capsules)] and immunomodulatory drug [ex: lenalidomide, Pomalyst (pomalidomide capsules), and Thalomid (thalidomide capsules], and C) will be used in combination with bortezomib and dexamethasone.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

BONIVA INJECTION

Products Affected

- *ibandronate intravenous*

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with other medications for Osteoporosis
Required Medical Information	Diagnosis, test results
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 12 months.
Other Criteria	Treatment of postmenopausal osteoporosis, must meet ONE of the following 1. T-score (current or at any time in the past) at or below -2.5 at the lumbar spine, femoral neck, or total hip, 2. has had osteoporotic fracture or fragility fracture, 3. had a T-score (current or at any time in the past) between 1.0 and -2.5 at the lumbar spine, femoral neck, or total hip and the physician determines the patient is at high risk for fracture AND has had an inadequate response to oral bisphosphonate therapy after a trial duration of 12 months as determined by the prescribing physician (e.g., ongoing and significant loss of bone mineral density (BMD), lack of BMD increase), had an osteoporotic fracture or fragility fracture while receiving oral bisphosphonate therapy, or experienced intolerability to an oral bisphosphonate (e.g., severe GI-related adverse effects) OR pt cannot take an oral bisphosphonate because the pt cannot swallow or has difficulty swallowing or the pt cannot remain in an upright position post oral bisphosphonate administration or pt has a pre-existing GI medical condition (eg, patient with esophageal lesions, esophageal ulcers, or abnormalities of the esophagus that delay esophageal emptying [stricture, achalasia]), OR pt has tried an IV bisphosphonate (ibandronate or zoledronic acid) OR the patient has had an osteoporotic fracture or a fragility fracture.
Indications	All FDA-approved Indications.

PA Criteria	Criteria Details
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

BOSENTAN/AMBRISENTAN

Products Affected

- *ambrisentan*
- *bosentan oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Pulmonary arterial hypertension (PAH) WHO Group 1, results of right heart cath
Age Restrictions	N/A
Prescriber Restrictions	For treatment of pulmonary arterial hypertension, ambrisentan or bosentan must be prescribed by or in consultation with a cardiologist or a pulmonologist. CTEPH - prescribed by or in consultation with a cardiologist or pulmonologist
Coverage Duration	Authorization will be for 1 year.
Other Criteria	CTEPH - pt must have tried Adempas, has a contraindication to Adempas, or is currently receiving bosentan for CTEPH. Pulmonary arterial hypertension (PAH) WHO Group 1, are required to have had a right-heart catheterization to confirm diagnosis of PAH to ensure appropriate medical assessment.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Chronic thromboembolic pulmonary hypertension (CTEPH) (bosentan)
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

BOSULIF

Products Affected

- BOSULIF ORAL CAPSULE 100 MG, 50 MG
- BOSULIF ORAL TABLET 100 MG, 400 MG, 500 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	ALL - 15 years and older. Myeloid/lymphoid neoplasms w eosinophilia- 18 years and older
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 12 months.
Other Criteria	CML-approve if the patient has Ph-positive or BCR::ABL1-positive CML. For Ph-positive ALL-approve if pt has tried at least one other tyrosine kinase inhibitor for Ph+ ALL. Myeloid/lymphoid neoplasms with eosinophilia - approve if tumor has an ABL1 rearrangement.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Patients with Philadelphia chromosome positive Acute Lymphoblastic Leukemia, myeloid/lymphoid neoplasms with eosinophilia
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

BRAFTOVI

Products Affected

- BRAFTOVI

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, BRAF V600 status
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Melanoma - approve if the patient has unresectable, advanced or metastatic melanoma AND has a BRAF V600 mutation. Colon or Rectal cancer-approve if the patient meets the following (A and B): A) The patient has BRAF V600E mutation-positive disease AND B) meets (i or ii): i) will be used as first-line systemic therapy for metastatic disease in combination with (a and b) a) Erbitux (cetuximab intravenous infusion) or Vectibix (panitumumab intravenous infusion) and b) FOLFOX (5-FU, leucovorin, and oxaliplatin) or ii) patient has previously received a chemotherapy regimen for colon or rectal cancer and this is prescribed in combination with Erbitux or Vectibix (panitumumab intravenous infusion). NSCLC-approve if pt has BRAF V600E mutation-positive recurrent, advanced or metastatic disease AND this medication will be taken in combination with Mektovi (binimetinib tablets). Appendiceal adenocarcinoma-approve if (A, B and C): A) BRAF V600E mutation-positive, and B) pt has advanced or metastatic disease, and C) used in combination with Erbitux (cetuximab intravenous infusion) or Vectibix (panitumumab intravenous infusion).
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Appendiceal adenocarcinoma
Part B Prerequisite	No

Effective August 1, 2026

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

BRIUMVI

Products Affected

- BRIUMVI

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with other disease-modifying agents used for multiple sclerosis (MS)
Required Medical Information	Relapsing form of MS, to include clinically-isolated syndrome, relapsing-remitting disease, and active secondary progressive disease
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with a neurologist or a physician who specializes in the treatment of MS.
Coverage Duration	1 year
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

BRUKINSA

Products Affected

- BRUKINSA ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, prior therapies
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Follicular Lymphoma - approve if pt tried at least two other systemic regimens and will use this in combination with Gazyva (obinutuzumab intravenous infusion). CLL/SLL - approve. Mantle Cell Lymphoma-approve if patient meets one of (A, B, C or D): A) tried at least one systemic regimen, or B) is not a candidate for a chemotherapy regimen, or C) will use this medication in combination with rituximab, or D) patient has TP53 mutation and this medication is used as induction therapy in combination with Venclexta (venetoclax tablets) and Gazyva (obinutuzumab intravenous infusion). Marginal zone lymphoma-approve if the patient has tried at least one systemic regimen. Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma-approve. Hairy Cell Leukemia - approve if pt has received therapy for relapsed or refractory disease AND pt has progressive disease. Primary Central Nervous System Lymphoma - approve if pt has tried at least one systemic regimen and the medication is used in combination with autologous stem cell reinfusion.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Hairy Cell Leukemia, Primary Central Nervous System Lymphoma
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

BYOOVIZ

Products Affected

- BYOOVIZ

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Administered by or under the supervision of an ophthalmologist
Coverage Duration	1 year
Other Criteria	N/A
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Retinopathy of prematurity, diabetic retinopathy, diabetic macular edema
Part B Prerequisite	No
Prerequisite Therapy Required	No

C1 ESTERASE INHIBITORS

Products Affected

- CINRYZE

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	prescribed by or in consultation with an allergist/immunologist or a physician that specializes in the treatment of HAE or related disorders
Coverage Duration	1 year
Other Criteria	Hereditary Angioedema (HAE) Due to C1 Inhibitor (C1-INH) Deficiency [Type I or Type II], Prophylaxis, Initial Therapy: approve if the patient has HAE type I or type II confirmed by low levels of functional C1-INH protein (less than 50 percent of normal) at baseline and lower than normal serum C4 levels at baseline. Patient is currently taking Cinryze for prophylaxis - approve if the patient meets the following criteria (i and ii): i) patient has a diagnosis of HAE type I or II, and ii) according to the prescriber, the patient has had a favorable clinical response since initiating Cinryze as prophylactic therapy compared with baseline. HAE with Normal (C1-INH) [Type III], Prophylaxis: Approve.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

CABLIVI

Products Affected

- CABLIVI INJECTION KIT

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, concurrent medications
Age Restrictions	12 years and older
Prescriber Restrictions	Prescribed by or in consultation with a hematologist
Coverage Duration	Approve for 12 months
Other Criteria	aTTP-approve if the requested medication was initiated in the inpatient setting in combination with plasma exchange therapy AND patient is currently receiving at least one immunosuppressive therapy AND if the patient has previously received Cablivi, he/she has not had more than two recurrences of aTTP while on Cablivi.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

CABOMETYX

Products Affected

- CABOMETYX

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, histology, RET gene rearrangement status for NSCLC
Age Restrictions	Neuroendocrine tumor/Thyroid carcinoma-12 years and older, other dx (except bone cancer)-18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Renal Cell Carcinoma-Approve if the patient has relapsed or stage IV disease. Hepatocellular Carcinoma-approve if the patient has been previously treated with at least one other systemic therapy (e.g., Nexavar, Lenvima). Bone cancer-approve if the patient has Ewing sarcoma or osteosarcoma and has tried at least one previous systemic regimen. Thyroid carcinoma-approve if the patient has differentiated thyroid carcinoma, patient is refractory to radioactive iodine therapy and the patient has tried Lenvima or sorafenib. Endometrial carcinoma-approve if the patient has tried one systemic regimen. GIST-approve if the patient has tried two of the following-imatinib, Ayvakit, sunitinib, dasatinib, Stivarga or Qinlock. NSCLC-approve if the patient has RET rearrangement positive tumor and has progressed on one of the first-line therapies, Gavreto (pralsetinib capsules) or Retevmo (selpercatinib capsules or tablets). Neuroendocrine tumors- approve if (A, B, C and D): A) pt has locally advanced, unresectable, or metastatic disease, and B) patient has well-differentiated neuroendocrine tumors, and C) patient has pancreatic or extra-pancreatic neuroendocrine tumors and D) the medication will be used as subsequent therapy. Adrenal gland tumor- approve if pt has locoregional unresectable or metastatic adrenocortical carcinoma. Pheochromocytoma/paraganglioma- approve if pt has locally unresectable disease.

PA Criteria	Criteria Details
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Patients with Non-Small Cell Lung Cancer, Gastrointestinal stromal tumors (GIST), Bone cancer, Endometrial carcinoma, Adrenal gland tumor, Pheochromocytoma/paraganglioma
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

CALQUENCE

Products Affected

- CALQUENCE (ACALABRUTINIB MAL)

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	CLL and SLL-approve. Mantle Cell Lymphoma- approve if the patient meets (A or B): A) has tried at least one systemic regimen or is not a candidate for a systemic regimen (e.g., rituximab, dexamethasone, cytarabine, carboplatin, cisplatin, oxaliplatin, cyclophosphamide, doxorubicin, vincristine, prednisone, methotrexate, bendamustine, bortezomib, or lenalidomide) or B) this medication is used in combination with rituximab. Marginal Zone Lymphoma-approve if patient has tried at least one systemic regimen (e.g., bendamustine, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone, lenalidomide, or chlorambucil). Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma-approve if the patient has tried at least one systemic regimen (e.g., Brukinsa [zanubrutinib capsules], Imbruvica [ibrutinib tablets and capsules], rituximab, bendamustine, cyclophosphamide, dexamethasone, bortezomib, fludarabine, or cladribine)
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma, Marginal zone lymphoma.
Part B Prerequisite	No

Effective August 1, 2026

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

CAMZYOS

Products Affected

- CAMZYOS

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older (initial and continuation)
Prescriber Restrictions	Prescribed by a cardiologist (initial and continuation)
Coverage Duration	Initial-8 months, continuation- 1 year
Other Criteria	Obstructive hypertrophic cardiomyopathy, initial-Approve if the pt meets the following criteria (i, ii and iii): i.Pt meets both of the following (a and b): a)Pt has at least 1 symptom associated w/obstructive hypertrophic cardiomyopathy (Note: examples include shortness of breath, chest pain, lightheadedness, fainting, fatigue, and reduced ability to perform physical exercise), AND b)Pt has New York Heart Association Class II or III symptoms of heart failure (Note:Class II signifies mild symptoms with moderate physical activity and some exercise limitations whereas Class III denotes noticeable symptoms with minimal physical activity and patients are only comfortable at rest), AND ii.Pt has left ventricular hypertrophy and meets 1 of the following (a or b): a)Pt has maximal left ventricular wall thickness greater than or equal to 15 mm, OR b)Pt has familial hypertrophic cardiomyopathy with a maximal left ventricular wall thickness greater than or equal to 13 mm, AND iii.Pt has a peak left ventricular outflow tract gradient greater than or equal to 50 mmHg (at rest or after provocation [Valsalva maneuver or post exercise]). Cont-Approve if pt meets ALL of the following criteria (i, ii, iii and iv): i.Pt has been established on therapy for at least 8 months (Note: pt who has received less than 8 months of therapy or who is restarting therapy is reviewed under initial therapy), AND ii.Pt meets both of the following (a and b): a)Currently or prior to starting therapy, pt has or has experienced at least 1 symptom associated with obstructive hypertrophic cardiomyopathy, AND

PA Criteria	Criteria Details
	b)Currently or prior to starting therapy, pt is in or was in New York Heart Association Class II or III heart failure, AND iii.Pt has a current left ventricular ejection fraction of greater than or equal to 50 percent, AND iv.Pt meets at least 1 of the following (a or b): a)Pt experienced a beneficial clinical response when assessed by at least 1 objective measure (Note:Examples include improved peak oxygen consumption/mixed venous oxygen tension, decreases in left ventricular outflow tract gradient, reductions in N-terminal pro-B-type natriuretic peptide levels, decreased high-sensitivity cardiac troponin I levels, reduced ventricular mass index, and/or a reduction in maximum left atrial volume index), OR b)Pt experienced stabilization or improvement in at least 1 symptom related to obstructive hypertrophic cardiomyopathy (Note:Examples of symptoms include shortness of breath, chest pain, lightheadedness, fainting, fatigue, ability to perform physical exercise, and/or favorable changes in the Kansas City Cardiomyopathy Questionnaire-23 (KCCQ-23) Clinical Summary Score (CSS) or Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ) Shortness of Breath domain scores.)
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

CAPRELSA

Products Affected

- CAPRELSA ORAL TABLET 100 MG, 300 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	MTC - approve. DTC - approve if refractory to radioactive iodine therapy.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Differentiated (i.e., papillary, follicular, and oncocytic) Thyroid Carcinoma.
Part B Prerequisite	No
Prerequisite Therapy Required	No

CARGLUMIC ACID

Products Affected

- *carglumic acid*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a metabolic disease specialist or a specialist who focuses in the treatment of metabolic diseases
Coverage Duration	NAGS-Pt meets criteria no genetic test - 3mo. Pt had genetic test - 12mo, other-approve 7 days
Other Criteria	N-Acetylglutamate synthase deficiency with hyperammonemia-Approve if genetic testing confirmed a mutation leading to N-acetylglutamate synthase deficiency or if the patient has hyperammonemia. Propionic Acidemia or Methylmalonic Acidemia with Hyperammonemia, Acute Treatment-approve if the patient's plasma ammonia level is greater than or equal to 50 micromol/L and the requested medication will be used in conjunction with other ammonia-lowering therapies.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Acute hyperammonemia due to propionic acidemia (PA) or methylmalonic acidemia (MMA) (generic carglumic acid)
Part B Prerequisite	No
Prerequisite Therapy Required	No

CAYSTON

Products Affected

- CAYSTON

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a pulmonologist, infectious diseases specialist or a physician who specializes in the treatment of cystic fibrosis.
Coverage Duration	1 year
Other Criteria	Approve if the patient has <i>Pseudomonas aeruginosa</i> in culture of the airway (e.g., sputum culture, oropharyngeal culture, bronchoalveolar lavage culture).
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

CEPROTIN

Products Affected

- CEPROTIN (BLUE BAR)
- CEPROTIN (GREEN BAR)

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a hematologist
Coverage Duration	1 year
Other Criteria	Protein C Deficiency, Severe-approve if the patient meets the following criteria A, B and C: A) The diagnosis of protein C deficiency is confirmed by at least one of the following (i, ii, or iii): i. Plasma protein C activity below the lower limit of normal based on the age-specific reference range for the reporting laboratory OR ii. Plasma protein C antigen below the lower limit of normal based on the age-specific reference range for the reporting laboratory OR iii. Genetic testing demonstrating biallelic pathogenic variants in the PROC gene AND B) Acquired causes of protein C deficiency have been excluded AND C) Patient has a current or prior history of symptoms associated with severe protein C deficiency (e.g., purpura fulminans, thromboembolism).
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

CHEMET

Products Affected

- CHEMET

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Blood lead level
Age Restrictions	Approve in patients between the age of 12 months and 18 years
Prescriber Restrictions	Prescribed by or in consultation with a professional experienced in the use of chelation therapy (eg, a medical toxicologist or a poison control center specialist)
Coverage Duration	Approve for 2 months
Other Criteria	Approve if Chemet is being used to treat acute lead poisoning (not as prophylaxis) and prior to starting Chemet therapy the patient's blood lead level was greater than 45 mcg/dL.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

CIMZIA

Products Affected

- CIMZIA
- CIMZIA POWDER FOR RECONST
- CIMZIA STARTER KIT

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with a Biologic DMARD or Targeted Synthetic DMARD
Required Medical Information	Diagnosis, concurrent medications, previous therapies tried
Age Restrictions	18 years and older for AS, nr-axSpA, PsA, RA, CD and PP (initial therapy). 2 years and older for JIA (initial therapy).
Prescriber Restrictions	All dx initial therapy only. RA, AS, JIA, prescribed by or in consultation with a rheumatologist. Crohn's disease, prescribed by or in consultation with a gastroenterologist. PsA prescribed by or in consultation with a rheumatologist or dermatologist. PP, prescribed by or in consultation with a dermatologist. nr-axSpA-prescribed by or in consultation with a rheumatologist
Coverage Duration	Approve through end of plan year
Other Criteria	AS initial tx, approve if the patient has tried TWO of the following drugs in the past: Enbrel, a preferred adalimumab product, Xeljanz/XR, Cosentyx. Note: if the patient does not meet this requirement, a previous trial of another non-preferred adalimumab product will also count. PsA initial tx, approve if the patient has tried TWO of the following drugs in the past: Enbrel, a preferred adalimumab product, Cosentyx, Tremfya, a preferred ustekinumab product, Otezla, Rinvoq, Skyrizi or Xeljanz/XR. Note: if the patient does not meet this requirement, a previous trial of another non-preferred adalimumab/ustekinumab product will also count. RA initial tx, approve if the patient has tried two of the following drugs in the past: Enbrel, a preferred adalimumab product, Rinvoq or Xeljanz/XR. Note: if the patient does not meet this requirement, a previous trial of another non-preferred adalimumab product will also count. CD initial tx, approve if patient has previously tried ONE of the following drugs in the past: a preferred adalimumab product, a preferred infliximab product, a preferred ustekinumab product, Skyrizi, Rinvoq, or Tremfya. Note: if the patient does not meet this requirement, a previous trial of another non-preferred

PA Criteria	Criteria Details
	adalimumab/infliximab/ustekinumab product will also count. Plaque Psoriasis (PP), initial tx-approve if the patient has tried TWO of the following drugs in the past: Enbrel, a preferred adalimumab product, Skyrizi, a preferred ustekinumab product, Otezla, Cosentyx, Tremfya. A trial of a non-preferred adalimumab/ustekinumab also counts. JIA initial tx, approve if the patient has tried TWO of the following drugs in the past: Enbrel, Rinvoq/LQ, Xeljanz, a preferred adalimumab product. Note pt does not meet this requirement, a trial with a non-preferred adalimumab, Simponi Aria, tocilizumab, Kevzara, or infliximab will also count. Cont tx, AS/PsA/RA/CD/PP/JIA - approve if the pt had a response as determined by the prescriber. Non-radiographic axial spondylitis (nr-axSpA), initial tx-approve if the patient has objective signs of inflammation, defined as at least one of the following: C-reactive protein (CRP) elevated beyond the upper limit of normal for the reporting laboratory OR sacroilitis reported on MRI. nr-axSpA continuation tx-approve if the patient has had a response as determined by the prescriber. Please Note: preferred adalimumab products include Hadlima, Simlandi. Preferred infliximab products include Remicade, infliximab IV (brand name product), Zymfentra. Preferred ustekinumab products include Otulfi, Pyzchiva, Selarsdi, Yesintek.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

CINACALCET

Products Affected

- *cinacalcet*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Hypercalcemia d/t parathyroid CA-prescr/consult w/onco or endo. Hypercalcemia w/primary hyperparathyroidism-prescr/consult w/nephro or endo. Hyperparathyroidism in post-renal transplant-prescr/consult w/transplant physician/nephro/endo.
Coverage Duration	12 months
Other Criteria	Hypercalcemia due to parathyroid carcinoma-approve. Hypercalcemia in patients with primary hyperparathyroidism-approve if the patient has failed or is unable to undergo a parathyroidectomy due to a contraindication. Secondary Hyperparathyroidism in patients with chronic kidney disease on dialysis - deny under Medicare Part D (claim should be submitted under the ESRD bundles payment benefit). Hyperparathyroidism in Post-Renal Transplant Patients-approve if the baseline (prior to starting cinacalcet therapy) calcium and intact parathyroid hormone (iPTH) levels are above the normal range, as defined by the laboratory reference values.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	hyperparathyroidism in post-renal transplant patients
Part B Prerequisite	No
Prerequisite Therapy Required	No

CLOBAZAM

Products Affected

- *clobazam oral suspension*
- *clobazam oral tablet*
- SYMPAZAN

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, other medications tried
Age Restrictions	2 years and older (initial therapy)
Prescriber Restrictions	Prescribed by or in consultation with a neurologist (initial therapy)
Coverage Duration	1 year
Other Criteria	Lennox-Gastaut Syndrome, initial therapy-patient has tried and/or is concomitantly receiving one of the following: lamotrigine, topiramate, rufinamide, felbamate, Fintepla, Epidiolex or valproic acid. Treatment refractory seizures/epilepsy, initial therapy-patient has tried and/or is concomitantly receiving at least two other antiepileptic drugs (e.g., valproic acid, lamotrigine, topiramate, clonazepam, levetiracetam, zonisamide, felbamate). Continuation-prescriber confirms patient is responding to therapy.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Dravet Syndrome and treatment-refractory seizures/epilepsy
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

CLOMIPHENE

Products Affected

- *clomid*
- *clomiphene citrate*
- *milophene*

PA Criteria	Criteria Details
Exclusion Criteria	Use in patients for infertility
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Man is defined as an individual with the biological traits of a man, regardless of the individual's gender identity or gender expression. Woman (a woman is defined as an individual with the biological traits of a woman, regardless of the individual's gender identity or gender expression).
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Male hypogonadism
Part B Prerequisite	No
Prerequisite Therapy Required	No

COLUMVI

Products Affected

- COLUMVI

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	1 year
Other Criteria	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Diffuse large B-cell lymphoma-approve if the patient has received one or more lines of systemic therapy and the patient has or will receive pretreatment with obinutuzmab intravenous infusion before the first dose of Columvi. Note: Examples of diffuse large B-cell lymphoma (DLBCL) include DLBCL not otherwise specified, high-grade B-cell lymphoma, and DLBCL arising from indolent lymphoma. Note: Examples of systemic therapy include RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) and DHA (dexamethasone, cytarabine) plus platinum (carboplatin, cisplatin, or oxaliplatin) plus/minus rituximab. Human Immunodeficiency Virus (HIV)-Related B-Cell Lymphoma-approve if the patient has received one or more lines of systemic therapy and the patient has or will receive pretreatment with obinutuzmab intravenous infusion before the first dose of Columvi. Note: HIV-related B-cell lymphomas includes HIV-related diffuse large B-cell lymphoma (DLBCL), primary effusion lymphoma, and human herpes virus-8 (HHV8) positive DLBCL or for HIV-related plasmablastic lymphoma. Note: Examples of systemic therapy include RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) and R-EPOCH (rituximab, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin). Post-transplant lymphoproliferative disorders- approve if the patient has received one or more lines of systemic

PA Criteria	Criteria Details
	therapy and the patient has or will receive pretreatment with obinutuzmab intravenous infusion before the first dose of Columvi. Note: Examples of systemic therapy include RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) and RCEPP (rituximab, cyclophosphamide, etoposide, prednisone, procarbazine).
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Human Immunodeficiency Virus (HIV)-Related B-Cell Lymphoma. Post-transplant lymphoproliferative disorders.
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

COMETRIQ

Products Affected

- COMETRIQ ORAL CAPSULE 100 MG/DAY(80 MG X1-20 MG X3), 60 MG/DAY(80 MG X1-20 MG X1), 140 MG/DAY (20 MG X 3/DAY)

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis.
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	MTC - approve. Non-Small Cell Lung Cancer-approve if patient meets (A, B and C): A) recurrent, advanced, or metastatic disease, B) has RET gene rearrangement-positive tumor, and C) has progressed on one of the first-line therapies, Gavreto (pralsetinib capsules) or Retevmo (selpercatinib capsules or tablets). Differentiated (i.e., papillary, follicular, and oncocytic) Thyroid Carcinoma-approve if the patient's carcinoma is refractory to radioactive iodine therapy and patient has tried tried Lenvima (lenvatinib capsules) or sorafenib tablets.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Non-Small Cell Lung Cancer with RET Gene Rearrangements, Differentiated (i.e., papillary, follicular, and oncocytic) Thyroid Carcinoma
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

COPIKTRA

Products Affected

- COPIKTRA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, previous therapies
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma - approve if the patient has tried at least one Bruton tyrosine kinase inhibitor (examples: ibrutinib, zanubrutinib, acalabrutinib, pirtobrutinib) and at least one Venclexta (venetoclax)- based regimen. T-cell lymphoma- For peripheral T-cell lymphoma, approve. For breast implant-associated anaplastic large cell lymphoma, or hepatosplenic T-cell lymphoma, approve if the patient has relapsed or refractory disease.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	T-cell Lymphoma
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

COSENTYX

Products Affected

- COSENTYX (2 SYRINGES)
- COSENTYX PEN
- COSENTYX PEN (2 PENS)
- COSENTYX SUBCUTANEOUS SYRINGE 150 MG/ML, 75 MG/0.5 ML
- COSENTYX UNOREADY PEN

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent Use with other Biologics or Targeted Synthetic Disease-Modifying Antirheumatic Drugs (DMARDs)
Required Medical Information	Diagnosis and previous medications use
Age Restrictions	PP-6 yr and older. Spondy initial - 18 years of age and older. PsA-2 years and older. Enthesitis-4 years and older, AS/HS initial-12 yr and older
Prescriber Restrictions	PP initial-presc/consult derm. PsA initial - prescribed by or in consultation with a dermatologist or rheumatologist. AS/spondylo/enthesitis initial- by or in consultation with rheumatologist. HS initial - by or in consult w/ dermatologist
Coverage Duration	Approve through end of plan year
Other Criteria	INITIAL THERAPY: HIDRADENITIS SUPPURATIVA (HS): tried at least one other therapy (e.g. systemic antibiotics, isotretinoin). NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: objective signs of inflammation and meets a or b: a) C-reactive protein elevated beyond the upper limit of normal or b) sacroiliitis reported on MRI. PLAQUE PSORIASIS (PP) [A or B]: A) tried at least one traditional systemic agent (e.g., methotrexate [MTX], cyclosporine, acitretin, PUVA) for at least 3 months, unless intolerant (Note: a trial of at least one biologic that is not Cosentyx or a Cosentyx biosimilar also counts) or B) contraindication to MTX. CONTINUATION THERAPY: ALL INDICATIONS: patient has experienced benefit from the medication.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

COSENTYX IV

Products Affected

- COSENTYX INTRAVENOUS

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with other biologics or targeted synthetic disease-modifying antirheumatic drugs (DMARDs)
Required Medical Information	Diagnosis
Age Restrictions	18 years and older (initial therapy)
Prescriber Restrictions	PsA initial - Prescribed by or in consultation with a dermatologist or rheumatologist. AS/Non-radio Axial Spondy-Prescribed by or in consultation with a rheumatologist.
Coverage Duration	Approve through end of plan year
Other Criteria	Non-Radiographic Axial Spondyloarthritis, initial therapy- approve if pt has objective signs of inflammation defined as (a or b): a) C-reactive protein elevated beyond the upper limit of normal for the reporting laboratory or b) sacroiliitis reported on magnetic resonance imaging. For continuation of therapy for all covered indications - approve if the pt has benefit from the medication.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

COTELLIC

Products Affected

- COTELLIC

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Melanoma (unresectable, advanced or metastatic) - being prescribed in combination with Zelboraf AND patient has BRAF V600 mutation positive disease. CNS Cancer-approve if the patient has BRAF V600 mutation-positive disease AND medication is being used for one of the following situations (i, ii, or iii): i. Adjuvant treatment of one of the following conditions (a, b, or c): a) Pilocytic astrocytoma OR b) Pleomorphic xanthoastrocytoma OR c) circumscribed ganglioglioma/neuroglioma/glioneuronal tumor OR ii. Recurrent or progressive disease for one of the following conditions (a, b or c): a) high grade glioma, b) circumscribed glioma OR c) Glioblastoma, OR iii. Melanoma with brain metastases AND medication with be taken in combination with Zelboraf (vemurafenib tablets). Histiocytic Neoplasm-approve if the patient meets one of the following (i, ii, or iii): i. Patient has Langerhans cell histiocytosis OR ii. Patient has Erdheim Chester disease OR iii. Patient has Rosai-Dorfman disease.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Central Nervous System Cancer
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	No

CRESEMBA (ORAL)

Products Affected

- CRESEMBA ORAL

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	3 months
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

CRYSVITA

Products Affected

- CRYSVITA

PA Criteria	Criteria Details
Exclusion Criteria	Chronic Kidney Disease (CKD), Severe Renal Impairment or End Stage Renal Disease
Required Medical Information	Diagnosis, lab values
Age Restrictions	TIO-2 years and older (initial therapy)
Prescriber Restrictions	Prescribed by or in consultation with an endocrinologist or nephrologist (initial therapy)
Coverage Duration	XLH-1 year (initial/cont), TIO-initial-6 months, cont-1 year
Other Criteria	XLH-Initial therapy-Approve if the patient has had a baseline (prior to any XLH treatment serum phosphorus level that was below the normal range for age and patient meets ONE of the following (a or b): a) The patient has had a baseline (i.e., prior to any XLH treatment tubular reabsorption of phosphate corrected for glomerular filtration rate (TmP/GFR) that was below the normal range for age and gender OR b) The patient has had a genetic test confirming the diagnosis of X-linked hypophosphatemia via identification of a PHEX pathogenic variant AND if the patient is greater than or equal to 18 years of age, the patient is currently exhibiting one or more signs or symptoms of XLH. Continuation-approve if the patient is continuing to derive benefit as determined by the prescribing physician. TIO-approve if the patient has a mesenchymal tumor that cannot be curatively resected or identified/localized AND the patient is currently exhibiting one or more signs or symptoms of TIO AND patient has had a baseline (prior to any TIO treatment) serum phosphorus level that was below the normal range for age AND patient has had a baseline (prior to any TIO treatment) tubular reabsorption of phosphate corrected for glomerular filtration rate (TmP/GFR) that was below the normal range for age and gender. Cont-approve if the patient is continuing to derive benefit as determined by the prescribing physician.
Indications	All FDA-approved Indications.

PA Criteria	Criteria Details
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

CYSTEAMINE (OPHTHALMIC)

Products Affected

- CYSTARAN

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an ophthalmologist or a metabolic disease specialist or specialist who focuses in the treatment of metabolic diseases
Coverage Duration	1 year
Other Criteria	Approve if the patient has corneal cysteine crystal deposits confirmed by slit-lamp examination
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

CYSTEAMINE (ORAL)

Products Affected

- CYSTAGON

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use of Cystagon and Procysbi
Required Medical Information	Diagnosis, genetic tests and lab results (as specified in the Other Criteria field)
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a nephrologist or a metabolic disease specialist (or specialist who focuses in the treatment of metabolic diseases)
Coverage Duration	1 year
Other Criteria	Cystinosis, nephropathic-approve if the prescriber confirms the diagnosis was confirmed by genetic testing confirming biallelic pathogenic or likely pathogenic variants in the CTNS gene OR white blood cell cystine concentration above the upper limit of the normal reference range for the reporting laboratory.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

DALFAMPRIDINE

Products Affected

- *dalfampridine*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	18 years and older (initial and continuation therapy)
Prescriber Restrictions	MS. If prescribed by, or in consultation with, a neurologist or MS specialist (initial and continuation).
Coverage Duration	1 year
Other Criteria	Initial-approve if the patient is ambulatory, the requested medication is being used to improve or maintain mobility in a patient with MS and the patient has impaired ambulation as evaluated by an objective measure (e.g., timed 25 foot walk and multiple sclerosis walking scale-12). Continuation-approve if the patient is ambulatory, the requested medication is being used to improve or maintain mobility in a patient with MS and the patient has responded to or is benefiting from therapy.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

DATROWAY

Products Affected

- DATROWAY

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	1 year
Other Criteria	Part B vs Part D determination will be made at time of prior authorization review per CMS guidance. BREAST CANCER - All of (A, B and C): A) Unresectable or metastatic disease, AND B) Human epidermal growth factor receptor 2 (HER2)- negative (immunohistochemistry [IHC] 0, IHC 1+, or IHC 2+/in situ hybridization [ISH]-negative) disease, AND C) Patient meets one (i or ii): i) has hormone receptor (HR)-negative disease (This is triple-negative disease) and is not a candidate for programmed death receptor-1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitor therapy, OR ii) has hormone receptor (HR) positive disease, has received prior endocrine-based therapy, Note: Examples of endocrine therapy are tamoxifen, anastrozole, letrozole, exemestane, AND has received prior chemotherapy for unresectable or metastatic disease. Note: Examples are paclitaxel, doxorubicin, liposomal doxorubicin, gemcitabine, capecitabine, vinorelbine, Halaven (eribulin intravenous infusion), cyclophosphamide, docetaxel. Non-Small Cell Lung Cancer- meets ALL (A, B, and C): A) locally advanced or metastatic disease AND B) EGFR-mutated disease AND C) meets BOTH (i and ii): i. tried at least one prior EGFR-directed therapy AND ii. tried platinum-based chemotherapy.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

DAURISMO

Products Affected

- DAURISMO ORAL TABLET 100 MG, 25 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, medications that will be used in combination, comorbidities
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	AML - approve if Daurismo will be used in combination with cytarabine.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

DEFERASIROX

Products Affected

- *deferasirox*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Serum ferritin level
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a hematologist
Coverage Duration	1 year
Other Criteria	Transfusion-related chronic iron overload, initial therapy - approve if the patient is receiving blood transfusions at regular intervals for various conditions (eg, thalassemia syndromes, myelodysplastic syndrome, chronic anemia, sickle cell disease) AND prior to starting therapy, the serum ferritin level is greater than 1,000 mcg/L. Non-transfusion-dependent thalassemia syndromes chronic iron overload, initial therapy - approve if prior to starting therapy the serum ferritin level is greater than 300 mcg/L. Continuation therapy - approve if the patient is benefiting from therapy as confirmed by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

DEFERIPRONE

Products Affected

- *deferiprone*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Serum ferritin level
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a hematologist
Coverage Duration	1 year
Other Criteria	Iron overload, chronic-transfusion related due to thalassemia syndrome or related to sickle cell disease or other anemias Initial therapy - approve. Continuation therapy - approve is the patient is benefiting from therapy as confirmed by the prescribing physician.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

DIABETIC SUPPLY - ALCOHOL PADS

Products Affected

- alcohol pads*
- DROPSAFE ALCOHOL PREP PADS

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Approve if the prescriber confirms that the medical supply is being requested for a use that is directly associated with delivering insulin to the body.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

DIABETIC SUPPLY - GAUZE PADS

Products Affected

- GAUZE PADS 2 X 2

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Approve if the prescriber confirms that the medical supply is being requested for a use that is directly associated with delivering insulin to the body.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

DIABETIC SUPPLY - NEEDLES

Products Affected

- NOVO PEN NEEDLE
- BD PEN NEEDLE
- EMBECTA PEN NEEDLE

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Approve if the prescriber confirms that the medical supply is being requested for a use that is directly associated with delivering insulin to the body.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

DIABETIC SUPPLY - SYRINGES

Products Affected

- EMBECTA INSULIN SYRINGE
- BD INSULIN SYRINGE

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Approve if the prescriber confirms that the medical supply is being requested for a use that is directly associated with delivering insulin to the body.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

DIACOMIT

Products Affected

- DIACOMIT

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Documentation of diagnosis.
Age Restrictions	6 months and older (initial therapy)
Prescriber Restrictions	Prescribed by or in consultation with an neurologist (initial therapy)
Coverage Duration	1 year
Other Criteria	Dravet Syndrome-Initial therapy-approve if the patient is concomitantly receiving clobazam or is unable to take clobazam due to adverse events. Dravet Syndrome-Continuation-approve if the patient is responding to therapy.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

DIMETHYL FUMARATE

Products Affected

- dimethyl fumarate oral capsule, delayed release(dr/ec) 120 mg, 120 mg (14)- 240 mg (46), 240 mg*

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with other disease-modifying agents used for multiple sclerosis (MS).
Required Medical Information	Relapsing form of Multiple Sclerosis (MS), to include clinically-isolated syndrome, relapsing-remitting disease, and active secondary progressive disease
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a neurologist or MS specialist.
Coverage Duration	Authorization will be for 1 year.
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

DOPTelet

Products Affected

- DOPTelet (10 TAB PACK)
- DOPTelet (15 TAB PACK)
- DOPTelet (30 TAB PACK)
- DOPTelet SPRINKLE

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	For Doptelet Sprinkle: patient must be less than 6 years of age. For Doptelet tablets: Chronic ITP - no restriction, Thrombocytopenia in chronic liver disease - 18 years and older
Prescriber Restrictions	Chronic ITP-prescribed by or after consultation with a hematologist (initial therapy)
Coverage Duration	Thrombo w/chronic liver disease-5 days, chronic/persistent ITP initial-14 weeks, cont-1 year
Other Criteria	THROMBOCYTOPENIA WITH CHRONIC LIVER DISEASE [Doptelet tablets only] (A and B): A) current platelet count less than 50 x 10 ⁹ /L and B) scheduled to undergo a procedure within 10 to 13 days after starting Doptelet therapy. CHRONIC ITP, INITIAL THERAPY [Doptelet tablets and sprinkle] (A and B): A): (i or ii): i) platelet count less than 30,000/mcL or ii) platelet count less than 50,000/mcL and patient is at an increased risk of bleeding, and B) tried one other therapy (e.g., systemic corticosteroids, intravenous immunoglobulin, anti-D immunoglobulin, eltrombopag tablets and oral suspension, romiplostim subcutaneous injection, fostamatinib tablets, rituximab) or had a splenectomy. CHRONIC ITP, CONTINUATION THERAPY: patient had beneficial clinical response and remains at risk for bleeding complications.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

DRONABINOL

Products Affected

- *dronabinol oral capsule*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

DROXIDOPA

Products Affected

- *droxidopa*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Medication history (as described in Other Criteria field)
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a cardiologist or a neurologist
Coverage Duration	12 months
Other Criteria	NOH, approve if the patient meets ALL of the following criteria: a) Patient has been diagnosed with symptomatic NOH due to primary autonomic failure (Parkinson's disease, multiple system atrophy, pure autonomic failure), dopamine beta-hydroxylase deficiency, or non-diabetic autonomic neuropathy, AND b) Patient has tried midodrine
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

DUAL OREXIN RECEPTOR ANTAGONIST

Products Affected

- BELSOMRA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Treatment of insomnia, characterized by difficulties with sleep onset and /or sleep maintenance-approve.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

DUPIXENT

Products Affected

- DUPIXENT PEN SUBCUTANEOUS
PEN INJECTOR 200 MG/1.14 ML, 300
MG/2 ML
- DUPIXENT SYRINGE
SUBCUTANEOUS SYRINGE 200
MG/1.14 ML, 300 MG/2 ML

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with another Monoclonal Antibody (examples: Adbry, Cinqair, Ebglyss, Fasenra, Nemluvio, Nucala, Tezspire, or Xolair). Concurrent use with Janus Kinase Inhibitors (JAKis) [oral or topical].
Required Medical Information	Diagnosis. CONTINUATION CRITERIA: AD: responding positively to therapy. ASTHMA: responding positively to therapy and concurrent use with ICS. COPD (all of A, B and C): A) received Dupixent for at least 6 months and B) continues LABA and LAMA, and C) beneficial response (e.g. reduced symptoms, exacerbations, hospitalizations, ED/urgent care visits, improved lung function). CRSwNP (all of A, B, and C): A) received Dupixent for at least 6 months, B) responding positively to therapy, and C) concurrent use with intranasal CS. EoE (A and B): A) received Dupixent for at least 6 months and B) reduction in intraepithelial eosinophil count, decreased dysphagia/pain upon swallowing, or reduced frequency/severity of food impaction. PRURIGO NODULARIS (A and B): A) received Dupixent for at least 6 months and B) reduction in nodular lesion count, pruritis, or nodular lesion size. CSU (A and B): A) received at least 6 months of Dupixent and B) experienced a beneficial clinical response, defined by decreased itch severity, decreased number of hives or decreased size of hives. Bullous Pemphigoid: meets both (i and ii): i. already received at least 6 months of therapy with Dupixent AND ii. experienced a beneficial clinical response, defined by decreased area of skin involvement, lesions, including blisters or erosions (bullae), urticaria, erythema, or reduced or no need for systemic or topical corticosteroid therapy. AFR (A and B): A) received at least 6 months of Dupixent and B) experienced a beneficial clinical response (e.g. reduced nasal polyp size, improved nasal congestion, reduced sinus opacification, decreased sinonasal symptoms, improved sense of smell, or reduced use of systemic corticosteroids).
Age Restrictions	Initial therapy only: AD-6 months and older, asthma/AFRS-6 years of age and older, Esophagitis-1 yr and older, CSU-2 and older, Chronic Rhinosinusitis- 12 and older, Prurigo nodularis/COPD/BP-18 and older
Prescriber Restrictions	Init therapy only: AD/PN/CSU-Prescr/consult with an allergist, immunologist or derm, asthma-prescr/consult with an allergist,

PA Criteria	Criteria Details
	immunologist or pulmonologist. Rhinosinusitis-prescr/consult with an allergist, immunologist or otolaryngologist. Esophagitis-prescr/consult-allergist or gastro. COPD-prescr/consult with an allergist, immunologist, or pulmonologist. BP-prescr/consult with dermatologist, AFR-prescr/consult with allergist, immunologist, otolaryngologist, rhinologist, pulmonologist, or ID specialist
Coverage Duration	AD-1 yr, asthma/Rhinosinusitis/esophagitis/PN/COPD/CSU/BP/AFR-init-6 mo, cont 1 yr
Other Criteria	INITIAL CRITERIA: AD: approve. ASTHMA (all of A, B, and C): A) blood eosinophil greater than or equal to 150 cells per microliter within previous 6 weeks or prior to Dupixent or another monoclonal antibody or has oral CS-dependent asthma, B) used an ICS in combination with at least one additional asthma controller/maintenance medication, and C) uncontrolled asthma prior to any asthma monoclonal antibody as defined by one of the following (one of a, b, c, d, or e): a) two or more asthma exacerbations requiring oral CS in the past year, b) one or more asthma exacerbations requiring hospital/urgent care/ED visit in the past year, c) FEV1 less than 80 percent predicted or less than 90% predicted for pts less than 18, d) FEV1/FVC less than 0.8 or less than 0.9 for pts less than 18, or e) worsened asthma with oral CS taper. COPD: meets (all of A, B, and C): A) blood eosinophil at least 300 cells per microliter within previous 6 weeks or prior to Dupixent or another monoclonal antibody, and B) received at least 3 months of combination therapy with at least two of LAMA, LABA or ICS, and C) meets (i or ii): i) two or more COPD exacerbations in previous 12 months requiring systemic CS with or without antibiotics or ii) COPD exacerbation requiring hospitalization in previous 12 months. CRSwNP (all of A, B, C and D): A) concurrent use with nasal CS, B) presence of at least two of the following symptoms for 8 weeks: nasal congestion, nasal obstruction, nasal discharge, reduction/loss of smell, C) received oral CS at least 5 days in last 2 years (unless contraindicated) or patient had prior surgery for nasal polyps, and D) diagnosis confirmed by direct exam, endoscopy, or sinus CT. EoE (all of A, B, C, and D): A) weighs 15 kg or more, B) endoscopic biopsy demonstrating greater than or equal to 15 intraepithelial eosinophils per high-power field, C) does not have a secondary cause of EoE, and D) received an Rx-strength PPI for at least 8 weeks. PRURIGO NODULARIS: pruritus lasting at least 6 weeks. CSU: urticaria for greater than 6 weeks (prior to Dupixent), despite non-sedating H1 antihistamine tx. Bullous Pemphigoid Initial: Approve. ALLERGIC FUNGAL RHINOSINUSITIS (AFR): Approve if pt has AFR confirmed by IgE-mediated inflammatory response to fungal hyphae confirmed by specific IgE serology or skin test AND nasal polyps confirmed by direct exam,

PA Criteria	Criteria Details
	endoscopy, or sinus CT AND signs characteristic of AFR on CT scan AND pt has had at least one prior sino-nasal surgery.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ELAHERE

Products Affected

- ELAHERE

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	1 year
Other Criteria	Part B vs Part D determination will be made at time of prior authorization review per CMS guidance. Ovarian, Fallopian Tube, or Primary Peritoneal Cancer-approve if the patient has folate receptor alpha positive disease.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

ELAPRASE

Products Affected

- ELAPRASE

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, genetic and lab test results
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a geneticist, endocrinologist, a metabolic disorder sub-specialist, or a physician who specializes in the treatment of lysosomal storage disorders
Coverage Duration	1 year
Other Criteria	Approve if the patient has laboratory test demonstrating deficient iduronate-2-sulfatase activity in leukocytes, fibroblasts, serum or plasma OR a molecular genetic test demonstrating iduronate-2-sulfatase gene variant.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

ELREXFIO

Products Affected

- ELREXFIO

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	1 year
Other Criteria	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Multiple myeloma-approve if per FDA approved labeling the patient has tried at least four systemic regimens and among the previous regimens tried, the patient has received at least one drug from each of the following classes: proteasome inhibitor, an immunomodulatory drug and an anti-CD38 monoclonal antibody.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

EMGALITY

Products Affected

- EMGALITY PEN
- EMGALITY SUBCUTANEOUS SYRINGE 120 MG/ML

PA Criteria	Criteria Details
Exclusion Criteria	Combination therapy with another cGRP inhibitor for migraine headache prevention
Required Medical Information	Diagnosis, number of migraine or cluster headaches per month
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Migraine headache prevention-Approve if the patient meets the following criteria (A and B): A) Patient has greater than or equal to 4 migraine headache days per month (prior to initiating a migraine-preventative medication), AND B) If pt is currently taking Emgality, pt has had significant clinical benefit from the medication. Examples of significant clinical benefit include a reduction in the overall number of migraine days per month or a reduction in number of severe migraine days per month from the time that Emgality was initiated. Episodic cluster headache treatment-approve if the patient has between one headache every other day and eight headaches per day.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

EMRELIS

Products Affected

- EMRELIS

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist.
Coverage Duration	1 year
Other Criteria	Part B vs Part D determination will be made at time of prior authorization review per CMS guidance. NON-SMALL CELL LUNG CANCER- ALL of the following (A, B and C): A. Patient has locally advanced or metastatic, non-squamous disease, AND B. Tumor has high c-Met protein overexpression, defined as a greater than or equal to 50 percent of tumor cells with strong [3+] staining, as determined by an approved test, AND C. Patient has received at least one prior systemic therapy. Note: Examples are cisplatin, carboplatin, pemetrexed, Keytruda (pembrolizumab intravenous infusion), Tecentriq (atezolizumab intravenous infusion), Opdivo (nivolumab intravenous infusion), Imfinzi (durvalumab intravenous infusion), Libtayo (cemiplimab-rwlc intravenous infusion)
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ENBREL

Products Affected

- ENBREL MINI
- ENBREL SUBCUTANEOUS SOLUTION
- ENBREL SUBCUTANEOUS SYRINGE
- ENBREL SURECLICK

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with biologic therapy or targeted synthetic DMARD
Required Medical Information	Diagnosis, concurrent medications, previous therapies tried.
Age Restrictions	Initial therapy: AS/RA- 18 years and older, JIA/PsA/Behcet's-2 years and older, GVHD-6 years and older, PP-4 years and older
Prescriber Restrictions	Initial only-RA/AS/JIA/JRA,prescribed by or in consult w/ rheumatologist. Psoriatic arthritis, prescribed by or in consultation w/ rheumatologist or dermatologist.Plaque psoriasis (PP), prescribed by or in consult w/ dermatologist.GVHD,prescribed by or in consult w/ oncologist,hematologist,or physician affiliated w/ transplant center.Behcet's disease,prescribed by or in consult w/ rheumatologist,dermatologist,ophthalmologist,gastroenterologist,or neurologist.
Coverage Duration	Approve through end of plan year
Other Criteria	INITIAL THERAPY: RHEUMATOID ARTHRITIS (RA)/JUVENILE IDIOPATHIC ARTHRITIS (JIA)/JRA/ANKYLOSING SPONDYLITIS: approve if the patient has tried one preferred adalimumab product (a trial of a non-preferred adalimumab also counts). PLAQUE PSORIASIS (PP)/PSORIATIC ARTHRITIS: approve if the patient has tried one preferred adalimumab product (a non-preferred adalimumab also counts), unless the patient is less than 18 years of age. GRAFT VERSUS HOST DISEASE (GVHD): approve. BEHCET'S: tried at least one conventional therapy (e.g., systemic corticosteroid, immunosuppressant, interferon alfa, mycophenolate), adalimumab, or infliximab. CONTINUATION THERAPY: ALL INDICATIONS: patient had a response to therapy. Please Note: preferred adalimumab products include Hadlima, Simlandi.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.

PA Criteria	Criteria Details
Off-Label Uses	Graft versus host disease (GVHD), Behcet's disease
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ENDARI

Products Affected

- *glutamine (sickle cell)*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, prescriber specialty
Age Restrictions	Greater than or equal to 5 years of age
Prescriber Restrictions	Prescribed by, or in consultation with, a physician who specializes in sickle cell disease (e.g., a hematologist)
Coverage Duration	Authorization will be for 1 year.
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

ENSACOVE

Products Affected

- ENSACOVE

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	NON-SMALL CELL LUNG CANCER- approve.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

EPIDIOLEX

Products Affected

- EPIDIOLEX

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, previous therapies
Age Restrictions	Patients 1 year and older (initial therapy)
Prescriber Restrictions	Prescribed by or in consultation with a neurologist (initial therapy)
Coverage Duration	1 year
Other Criteria	Dravet Syndrome (initial therapy)-approve if the patient has tried or is concomitantly receiving at least two other antiseizure drugs or if the patient has tried or is concomitantly receiving one of Diacomit or clobazam or Fintepla. Lennox Gastaut Syndrome (initial therapy)-approve if the patient has tried or is concomitantly receiving at least two other antiseizure drugs. Tuberous Sclerosis Complex (initial therapy)-approve if the patient has tried or is concomitantly receiving at least two other antiseizure drugs. Refractory epilepsy (initial therapy)-approve if patient tried or is concomitantly receiving at least two other antiseizure drugs. Continuation of therapy for all indications-approve if the patient is responding to therapy.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Refractory epilepsy
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

EPKINLY

Products Affected

- EPKINLY

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	1 year
Other Criteria	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Diffuse large B-cell lymphoma - approve if the patient has received one or more lines of systemic therapy. Classic follicular lymphoma - approve if pt has received one or more lines of systemic therapy. Human immunodeficiency virus (HIV)-Related B-Cell Lymphoma - approve if the patient has received one or more lines of systemic therapy. Note: HIV-related B-cell lymphomas includes HIV-related diffuse large B-cell lymphoma (DLBCL), primary effusion lymphoma, and human herpes virus-8 (HHV8) positive DLBCL. Post-transplant lymphoproliferative disorders - approve if the patient has received one or more lines of systemic therapy.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Human immunodeficiency virus (HIV)-Related B-Cell Lymphoma. Post-transplant lymphoproliferative disorders.
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

EPOETIN ALFA

Products Affected

- PROCRIT
- RETACRIT

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	MDS anemia = 18 years of age and older
Prescriber Restrictions	MDS anemia, myelofibrosis- prescribed by or in consultation with, a hematologist or oncologist.
Coverage Duration	Chemo-6m,Transfus-1m, CKD-1yr, Myelofibrosis-init-3 mo, cont-1 yr, all others-1 yr
Other Criteria	Anemia in a pt with Chronic Kidney Disease (CKD) not on dialysis- for initial therapy, approve if hemoglobin (Hb) is less than 10.0 g/dL for adults or less than or equal to 11 g/dL for children, or for continuation of therapy in a pt currently on an erythropoiesis-stimulating agent (ESA) approve if Hb is less than or equal to 12 g/dL. Anemia in a pt with cancer due to chemotherapy- approve if pt is currently receiving myelosuppressive chemo as a non-curative treatment and (for initial therapy) Hb is less than 10.0 g/dL or (if currently on ESA) Hb is less than or equal to 12.0 g/dL. Anemia in HIV with zidovudine- for initial therapy, approve if Hb is less than 10.0 g/dL or serum erythropoietin level is 500 mU/mL or less, or for continuation of therapy in a pt currently on ESA, approve if Hb is 12.0 g/dL or less. Surgical pts to reduce RBC transfusions - Approve if Hb is less than or equal to 13, AND surgery is elective, nonvascular and non-cardiac AND pt is unwilling or unable to donate autologous blood prior to surgery. MDS- for initial therapy, approve if Hb is less than 10 g/dL or serum erythropoietin level is 500 mU/mL or less, or for continuation of therapy in a pt currently on ESA approve if Hb is 12.0 g/dL or less. Myelofibrosis- for Initial therapy approve if patient has a Hb less than 10 or serum erythropoietin less than or equal to 500 mU/mL, or for continuation of therapy in pt currently on ESA hemoglobin is less than or equal to 12g/dL. Anemia in patients with chronic renal failure on dialysis -

PA Criteria	Criteria Details
	deny under Medicare Part D (claim should be submitted under the ESRD bundled payment benefit).
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Anemia due to myelodysplastic syndrome (MDS), Myelofibrosis
Part B Prerequisite	No
Prerequisite Therapy Required	No

ERIVEDGE

Products Affected

- ERIVEDGE

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Basal cell carcinoma, locally advanced-patients new to therapy-approve if (A or B): A) pt has recurrent BCC following surgery or radiation therapy OR B) pt is not a candidate for surgery and is not a candidate for radiation therapy. Basal cell carcinoma, locally advanced-patients currently on therapy-approve. Central nervous system cancer (this includes brain and spinal cord tumors)-approve if the patient has medulloblastoma, the patient has tried at least one chemotherapy agent and according to the prescriber, the patient has a mutation of the sonic hedgehog pathway. Basal cell carcinoma, metastatic (this includes primary or recurrent nodal metastases and distant metastases)-approve. Diffuse Basal Cell Carcinoma Formation, including basal cell nevus syndrome (Gorlin syndrome) or other genetic forms of multiple basal cell carcinoma - approve.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Central nervous System Cancer, diffuse basal cell carcinoma formation
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ERLEADA

Products Affected

- ERLEADA ORAL TABLET 240 MG, 60 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Prostate cancer-non-metastatic, castration resistant and prostate cancer-metastatic, castration sensitive-approve if the requested medication will be used in combination with a gonadotropin-releasing hormone (GnRH) analog [for example: leuprolide acetate, Lupron Depot (leuprolide acetate intramuscular injection), Trelstar (triptorelin pamoate intramuscular injection), Zoladex (goserelin acetate subcutaneous implant), Vantas (histrelin acetate subcutaneous implant), Firmagon (degarelix subcutaneous injection), Orgovyx (relugolix tablets)] or if the patient has had a bilateral orchiectomy.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

ERLOTINIB

Products Affected

- *erlotinib oral tablet 100 mg, 150 mg, 25 mg*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 1 year.
Other Criteria	Advanced or Metastatic NSCLC, approve if the patient has EGFR mutation positive non-small cell lung cancer as detected by an approved test. Note-Examples of EGFR mutation-positive non-small cell lung cancer include the following mutations: exon 19 deletions, exon 21 (L858R) substitution mutations, L861Q, G719X and S768I. RCC, approve if the patient meets (A, B, and C): A) has stage IV or relapsed non-clear cell histology RCC and B) has advanced papillary disease including hereditary leiomyomatosis and renal cell carcinoma (HLRCC)-associated renal cell carcinoma and C) erlotinib will be used in combination with bevacizumab. Bone cancer-approve if the patient has chordoma and has tried at least one previous therapy. Pancreatic cancer-approve if the medication is used in combination with gemcitabine and if the patient has locally advanced, metastatic or recurrent disease. Vulvar cancer-approve if the patient has advanced, recurrent or metastatic disease.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Renal Cell Carcinoma, vulvar cancer and Bone Cancer-Chordoma.
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

EVEROLIMUS

Products Affected

- *everolimus (antineoplastic) oral tablet*
- *everolimus (antineoplastic) oral tablet for suspension 2 mg, 3 mg, 5 mg*
- *torpenz*
- *yulithira*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Breast Cancer-HER2 status, hormone receptor (HR) status.
Age Restrictions	All dx except TSC associated SEGA, renal angiomyolipoma or partial onset seizures-18 years and older.
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 1 year.
Other Criteria	Breast Cancer-approve if pt meets ALL the following (A, B, C, D, E, and F):A)pt has recurrent or metastatic,HR+ disease AND B)pt has HER2-negative breast cancer AND C)pt has tried at least 1 prior endocrine therapy AND D)pt meets 1 of the following conditions (i or ii):i.pt is a postmenopausal woman or man OR ii.pt is pre/perimenopausal woman AND is receiving ovarian suppression/ablation with a GnRH agonist, or has had surgical bilateral oophorectomy or ovarian irradiation AND E)pt meets 1 of the following conditions (i or ii): i.Everolimus will be used in combo with exemestane and pt meets 1 of the following:pt is male and is receiving a GnRH analog or pt is a woman or ii. Everolimus will be used in combo with fulvestrant or tamoxifen AND F)pt has not had disease progression while on Everolimus. RCC, relapsed or Stage IV disease-approve if using for non-clear cell disease or if using for clear cell disease, pt has tried 1 prior systemic therapy (e.g., Inlyta, Votrient, Sutent, Cabometyx, Nexavar).TSC Associated SEGA-approve if pt requires therapeutic intervention but cannot be curatively resected. Thymomas and Thymic Carcinomas-approve if pt has tried chemotherapy or cannot tolerate chemotherapy.TSC associated renal angiomyolipoma -approve. WM/LPL - pt has tried at least one systemic regimen. Thyroid Carcinoma, differentiated-approve if pt is refractory to radioactive iodine therapy.

PA Criteria	Criteria Details
	Endometrial Carcinoma-approve if everolimus will be used in combo with letrozole. GIST-approve if pt has tried 2 of the following drugs: Sutent, Sprycel, Stivarga, Ayvakit, Qinlock or imatinib AND there is confirmation that everolimus will be used in combo with 1 of these drugs (Sutent, Stivarga, or imatinib) in the treatment of GIST. TSC-associated partial-onset seizures-approve. NET tumors of the pancreas, GI Tract, Lung and Thymus (carcinoid tumors)-approve. Soft tissue sarcoma-approve if pt has perivascular epitheloid cell tumors (PE Coma) or recurrent angiomyolipoma/lymphangiomyomatosis. Classic hodgkin lymphoma-approve if pt has relapsed or refractory disease AND not a candidate for high-dose therapy and autologous stem cell rescue. Histiocytic neoplasm-approve if pt has Erdheim-Chester disease or, Rosai-Dorfman disease or Langerhans cell histiocytosis. Patient must also have PIK3CA mutation. Meningioma-(A, B and C): A) approve if pt has recurrent or progressive disease AND B) pt has surgically inaccessible disease and radiation therapy is not possible AND C) medication will be used in combination with a somatostatin analogue or bevacizumab. Uterine Sarcoma-approve if the patient has advanced, recurrent, metastatic, or inoperable disease, AND has a perivascular epithelioid cell tumor (PEComa), AND has tried at least one systemic regimen. Note: Examples of systemic regimen include doxorubicin, docetaxel, gemcitabine, ifosfamide, dacarbazine.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	neuroendocrine tumors of the thymus (Carcinoid tumors). Soft tissue sarcoma, classical Hodgkin lymphoma, Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma (WM/LPL), Thymomas and Thymic carcinomas, Differentiated Thyroid Carcinoma, Endometrial Carcinoma, Gastrointestinal Stromal Tumors (GIST), men with breast cancer, Pre-peri-menopausal women with breast cancer, Histiocytic Neoplasm, uterine sarcoma, meningioma
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

FABRAZYME

Products Affected

- FABRAZYME

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with Galafold (migalastat oral capsules) or Elfabrio (pegunigalsidase alfa intravenous infusion).
Required Medical Information	Diagnosis, genetic and lab test results
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a geneticist, endocrinologist, a metabolic disorder sub-specialist, or a physician who specializes in the treatment of lysosomal storage disorders
Coverage Duration	1 year
Other Criteria	Approve if the patient has a laboratory test demonstrating deficient alpha-galactosidase A activity in leukocytes or fibroblasts OR has a molecular genetic test demonstrating a pathogenic variant in the galactosidase alpha (GLA) gene.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

FASENRA

Products Affected

- FASENRA PEN
- FASENRA SUBCUTANEOUS
SYRINGE 10 MG/0.5 ML, 30 MG/ML

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with another monoclonal antibody therapy.
Required Medical Information	Diagnosis
Age Restrictions	Initial therapy only for all ind- Asthma: 6 years of age and older, HES: 12 years or older, EGPA: 18 years and older
Prescriber Restrictions	Initial therapy only for all ind- Asthma: Prescribed by or in consultation with an allergist, immunologist, or pulmonologist. EGPA/HES: Prescribed by or in consultation with an allergist, immunologist, pulmonologist, or rheumatologist.
Coverage Duration	Asthma/HES: 6 months initial, 12 months cont. EGPA: 8 months initial, 12 months cont.
Other Criteria	INITIAL THERAPY: ASTHMA (all of A, B, and C): A) blood eosinophil greater than or equal to 150 cells per microliter within previous 6 weeks prior to Fasenra or another monoclonal antibody, B) used an inhaled corticosteroid (ICS) in combination with at least one additional asthma controller/maintenance medication, and C) uncontrolled asthma prior to any asthma monoclonal antibody as defined by one of the following (a, b, c, d, or e): a) one or more exacerbations requiring a systemic CS in the past year, b) one or more exacerbations requiring hospital/urgent care/emergency department visit in the past year, c) FEV1 less than 80 percent predicted or less than 90 percent predicted for patients less than 18, d) FEV1/FVC less than 0.80, or e) worsened asthma with systemic CS taper. EGPA: (all of A, B, and C): A) active, non-severe disease, and B) currently on systemic CS for at least 4 weeks, and C) blood eosinophil greater than or equal to 150 cells per microliter within previous 4 weeks or prior to treatment with any monoclonal antibody that may alter eosinophil levels. HYPEREOSINOPHILIC SYNDROME (HES): Meets all (A, B and C): A) has FIP1L1-PDGFR-alpha-negative disease, and B) does NOT have an identifiable non-hematologic secondary cause of hypereosinophilic

PA Criteria	Criteria Details
	syndrome, and C) has or had a blood eosinophil level at least 1,000 cells per microliter prior to treatment with any monoclonal antibody therapy that may alter blood eosinophil levels. CONTINUATION THERAPY: ASTHMA (A and B): A) patient has responded to therapy (e.g., decrease in any of the following: asthma exacerbations, asthma symptoms, hospitalizations, emergency department/urgent care visits, physician visits, requirement for oral corticosteroid therapy) and B) continues to receive therapy with an ICS. EGPA: patient has responded to therapy (e.g. reduced rate of relapse, CS dose reduction, reduced eosinophil levels). HES: patient has responded to to therapy (e.g., decreased number of flares, improved fatigue, reduced corticosteroid requirements, and decreased eosinophil levels).
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

FINGOLIMOD

Products Affected

- *fingolimod*

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use of fingolimod with other disease-modifying agents used for multiple sclerosis (MS).
Required Medical Information	Relapsing form of Multiple Sclerosis (MS), to include clinically-isolated syndrome, relapsing-remitting disease, and active secondary progressive disease
Age Restrictions	10 years and older
Prescriber Restrictions	Prescribed by, or in consultation with, a neurologist or an MS specialist.
Coverage Duration	Authorization will be for 1 year.
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

FINTEPLA

Products Affected

- FINTEPLA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	2 years and older (initial therapy)
Prescriber Restrictions	Prescribed by or in consultation with an neurologist (initial therapy)
Coverage Duration	1 year
Other Criteria	Dravet Syndrome-Initial therapy-approve if the patient has tried or is concomitantly receiving at least two other antiepileptic drugs or patient has tried or is concomitantly receiving Epidiolex, Clobazam or Diacomit. Dravet Syndrome-Continuation-approve if the patient is responding to therapy. Lennox-Gastaut Syndrome, initial-approve if the patient has tried or is concomitantly receiving at least two other antiepileptic drugs. Lennox-Gastaut Syndrome, continuation-approve if the patient is responding to therapy.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

FIRMAGON

Products Affected

- FIRMAGON KIT W DILUENT SYRINGE

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a oncologist
Coverage Duration	1 year
Other Criteria	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Patients new to therapy, are required to try Eligard prior to approval of Firmagon.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

FOTIVDA

Products Affected

- FOTIVDA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, other therapies
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 1 year.
Other Criteria	Renal Cell Carcinoma (RCC)-approve if the patient has relapsed or Stage IV disease and has tried at least two other systemic regimens. Note: Examples of systemic regimens for renal cell carcinoma include axitinib tablets, axitinib + pembrolizumab injection, cabozantinib tablets, cabozantinib + nivolumab injection, sunitinib malate capsules, pazopanib tablets, sorafenib tablets, and lenvatinib capsules + everolimus.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

FRUZAQLA

Products Affected

- FRUZAQLA ORAL CAPSULE 1 MG, 5 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years of age and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Colon cancer, rectal cancer, or appendiceal cancer-Approve if the patient meets the following (A, B and C): A.Patient has advanced or metastatic disease, AND B. Patient meets (i or ii): i. has proficient mismatch repair/microsatellite-stable (pMMR/MSS) disease, or ii. patient is ineligible for or progressed on checkpoint inhibitor therapy (examples: Keytruda [pembrolizumab intravenous infusion] and Opdivo [nivolumab intravenous infusion]) and meets ONE of the following (a or b): a. has deficient mismatch repair/microsatellite instability-high (dMMR/MSI-H) disease or b. is polymerase epsilon/delta (POLE/POLD1) mutation positive, AND C. Patient has previously been treated with the following (i, ii, and iii): i.Fluroropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, Note: Examples of fluroropyrimidine agents include 5-fluorouracil (5-FU) and capecitabine. AND ii.An anti-vascular endothelial growth factor (VEGF) agent, Note: Examples of anti-VEGF agents include bevacizumab. AND iii. If the tumor is RAS wild-type (KRAS wild-type and NRAS wild-type) [that is, the tumor or metastases are KRAS and NRAS mutation negative], the patient meets ONE of the following (a or b): a.According to the prescriber, anti-epidermal growth factor receptor (EGFR) therapy is NOT medically appropriate, OR b. The patient has received an anti-EGFR therapy. Note: Examples of anti-EGFR therapy

PA Criteria	Criteria Details
	includes Erbitux (cetuximab intravenous infusion) and Vectibix (panitumumab intravenous infusion).
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Appendiceal cancer
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

FULPHILA

Products Affected

- FULPHILA SUBCUTANEOUS
SYRINGE 6 MG/0.6 ML

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Cancer patients receiving chemotherapy-prescribed by or in consultation with an oncologist or hematologist. PBPC - prescribed by or in consultation with an oncologist, hematologist, or physician that specializes in transplantation.
Coverage Duration	Cancer pts receiving chemo-6 mo. PBPC-30 days.
Other Criteria	Cancer patients receiving chemotherapy, approve if the patient meets one of the following: 1) is receiving myelosuppressive anti-cancer medications that are associated with a high risk of febrile neutropenia (the risk is at least 20% based on the chemotherapy regimen), 2) patient is receiving myelosuppressive anti-cancer medications that are associated with a risk of febrile neutropenia but the risk is less than 20% based on the chemotherapy regimen and the patient has one or more risk factors for febrile neutropenia according to the prescribing physician (eg, aged greater than 65 years receiving full chemotherapy dose intensity, prior chemotherapy or radiation therapy, persistent neutropenia, bone marrow involvement by tumor, recent surgery and/or open wounds, liver dysfunction (bilirubin greater than 2 mg/dL), renal dysfunction (CrCl less than 50 mL/min), poor performance status or HIV infection patients with low CD4 counts), or 3) patient has had a neutropenic complication from prior chemotherapy cycle and did not receive prophylaxis with a colony stimulating factor and a reduced dose or frequency of chemotherapy may compromise treatment.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Patients undergoing PBPC collection and therapy

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	No

FYARRO

Products Affected

- FYARRO

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	1 year
Other Criteria	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Perivascular Epithelioid Cell Tumor (PEComa), Malignant-approve if the patient has locally advanced unresectable disease or metastatic disease.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

GATTEX

Products Affected

- GATTEX 30-VIAL
- GATTEX ONE-VIAL

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	1 year and older
Prescriber Restrictions	Prescribed by or in consultation with a gastroenterologist (initial and continuation)
Coverage Duration	1 year
Other Criteria	Initial-approve if the patient is currently receiving parenteral nutrition on 3 or more days per week or according to the prescriber, the patient is unable to receive adequate total parenteral nutrition required for caloric needs. Continuation-approve if the patient has experienced improvement.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

GAVRETO

Products Affected

- GAVRETO

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	NSCLC-18 years and older, thyroid cancer-12 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	NSCLC-approve if the patient has advanced, recurrent, or metastatic disease and rearranged during transfection (RET) fusion-positive disease detected by an Food and Drug Administration (FDA) approved test. Differentiated Thyroid Cancer- pt has unresectable, recurrent, or metastatic disease AND pt has RET fusion-positive or RET-mutation-positive disease AND disease requires treatment with systemic therapy AND either (i or ii) i) pt has papillary or follicular thyroid carcinoma and the disease is radioactive iodine-refractory or ii) pt has oncocytic (formerly Hurthle cell) carcinoma. Anaplastic thyroid cancer or Medullary Thyroid Cancer- pt has unresectable, recurrent, or metastatic disease AND pt has disease positive for RET pathogenic variant.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Medullary Thyroid Cancer, Anaplastic Thyroid Cancer
Part B Prerequisite	No
Prerequisite Therapy Required	No

GEFITINIB

Products Affected

- *gefitinib*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	NSCLC-approve if the patient has advanced or metastatic disease and the patient has sensitizing EGFR mutation-positive NSCLC as detected by an approved test. Note: Examples of sensitizing EGFR mutation-positive NSCLC include the following mutations: exon 19 deletions, exon 21 (L858R) substitution mutations, L861Q, G719X and S768I.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	NSCLC with EGFR L861Q, G719X, or S768I mutations.
Part B Prerequisite	No
Prerequisite Therapy Required	No

GILOTRIF

Products Affected

- GILOTRIF

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	For NSCLC - EGFR exon deletions or mutations, or if NSCLC is squamous cell type
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 1 year.
Other Criteria	NSCLC EGFR pos - For the treatment of advanced or metastatic non small cell lung cancer (NSCLC)-approve if the patient has sensitizing EGFR mutation-positive NSCLC as detected by an approved test. Note: examples of sensitizing EGFR mutation-positive NSCLC include the following mutations : exon 19 deletions, exon 21 (L858R) substitution mutations, L861Q, G719X and S768I. NSCLC metastatic squamous cell must have disease progression after treatment with platinum based chemotherapy. Head and neck cancer-approve if the patient has non-nasopharyngeal head and neck cancer and the patient has disease progression on or after platinum based chemotherapy. (Part B before Part D Step Therapy - applies only to beneficiaries enrolled in an MA-PD plan)
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Head and neck cancer
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

GLATIRAMER

Products Affected

- *glatiramer subcutaneous syringe 20 mg/ml, 40 mg/ml*
- *glatopa subcutaneous syringe 20 mg/ml, 40 mg/ml*

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with other disease-modifying agent used for multiple sclerosis
Required Medical Information	Relapsing form of Multiple Sclerosis (MS), to include clinically-isolated syndrome, relapsing-remitting disease, and active secondary progressive disease
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or after consultation with a neurologist or an MS specialist.
Coverage Duration	Authorization will be for 1 year.
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

GLUCAGON-LIKE PEPTIDE-1 AGONISTS

Products Affected

- *liraglutide*
- MOUNJARO
- OZEMPIC ORAL
- OZEMPIC SUBCUTANEOUS
- RYBELSUS
- TRULICITY

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 1 year
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

GNRH AGONIST IMPLANTS

Products Affected

- ZOLADEX

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	Endometriosis-18 years and older
Prescriber Restrictions	Prostate cancer/Breast cancer/Head and Neck/Ovarian/Uterine-prescribed by or in consultation with an oncologist. Endometriosis/abnormal uterine bleeding-prescribed by or in consultation with an obstetrician-gynecologist or a health care practitioner who specializes in the treatment of women's health.
Coverage Duration	Abnormal uterine bleeding-2 months, Endometriosis-6 months, all other dx-1 year
Other Criteria	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Abnormal uterine bleeding-Zoladex 3.6mg is used as an endometrial-thinning agent prior to endometrial ablation.Endometriosis-approve Zoladex 3.6 mg. Prostate cancer-approve Zoladex 3.6 mg and/or 10.8 mg. Head and Neck Cancer - Salivary Gland Tumors: approve if patient has recurrent, unresectable, or metastatic disease AND has androgen receptor-positive disease.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Zoladex 3.6mg only: head and neck cancer - salivary gland tumors, Ovarian Cancer including Fallopian Tube Cancer and Primary Peritoneal Cancer, and Uterine Cancer
Part B Prerequisite	No
Prerequisite Therapy Required	No

GOMEKLI

Products Affected

- GOMEKLI ORAL CAPSULE 1 MG, 2 MG
- GOMEKLI ORAL TABLET FOR SUSPENSION

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	2 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	NEUROFIBROMATOSIS TYPE 1- patient has or had symptomatic plexiform neurofibromas prior to starting Gomekli and the tumor is not amenable to complete resection.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

GONADOTROPIN-RELEASING HORMONE AGONISTS - ONCOLOGY

Products Affected

- ELIGARD
- ELIGARD (3 MONTH)
- ELIGARD (4 MONTH)
- ELIGARD (6 MONTH)
- *leuprolide subcutaneous kit*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prostate cancer- prescribed by or in consultation with an oncologist or urologist. Head and neck-salivary gland tumors- prescribed by or in consultation with an oncologist.
Coverage Duration	1 year
Other Criteria	Head and neck cancer-salivary gland tumor- approve if pt has recurrent, unresectable, or metastatic disease AND androgen receptor-positive disease.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Head and neck cancer- salivary gland tumors (Eligard only)
Part B Prerequisite	No
Prerequisite Therapy Required	No

GRALISE/HORIZANT/LYRICA CR

Products Affected

- gabapentin oral tablet extended release 24 hr 300 mg, 450 mg, 600 mg, 750 mg, 900 mg

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 12 months.
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

GROWTH HORMONES

Products Affected

- OMNITROPE

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	GHD in Children/Adolescents. Pt meets one of the following-1-had 2 GH stim tests with the following-levodopa, insulin-induced hypoglycemia, arginine, clonidine, or glucagon and both are less than 10ng/mL OR had at least 1 GH test and results are less than 10ng/mL and has at least one risk factor for GHD (e.g., ht for age curve deviated down across 2 major height percentiles [e.g., from above the 25 percentile to below the 10 percentile], growth rate is less than the expected normal growth rate based on age and gender, low IGF-1 and/or IGFBP-3 levels). 2.brain radiation or tumor resection and pt has 1 GH stim test less than 10ng/mL or has def in at least 1 other pituitary hormone (that is, ACTH, TSH, gonadotropin deficiency [LH and/or FSH] are counted as 1 def], or prolactin).3. congenital hypopituitarism and has one GH stim test less than 10ng/mL OR def in at least one other pituitary hormone and/or the patient has the imaging triad of ectopic posterior pituitary and pituitary hypoplasia with abnormal pituitary stalk 4.pt has multiple pituitary deficiencies and pt has 3 or more pituitary hormone deficiencies or pt has had one GH test less than 10ng/mL 5.pt had a hypophysectomy. Cont-pt responding to therapy
Age Restrictions	ISS 5 y/o or older, SGA 2 y/o or older
Prescriber Restrictions	GHD (Initial tx children or adolescents w/o hypophysectomy), GHD adults or transitional adolescents, ISS (initial), Noonan (initial), Prader Willi (initial for child/adult and cont tx in adults), SHOX (initial), SGA (initial) - prescribed by or in consultation with an endocrinologist. CKD (initial) endocrinologist or nephrologist.
Coverage Duration	ISS - 6 mos initial, 12 months cont tx, SBS 1 month, others 12 mos
Other Criteria	GHD initial in adults and adolescents transitioning into adulthood 1. endocrine must certify not being prescribed for anti-aging or to enhance athletic performance, 2. has either childhood onset or adult onset resulting from GHD alone, multiple hormone deficiency from pituitary dx, hypothalamic dz, pituitary surgery, cranial radiation tx, tumor treatment,

PA Criteria	Criteria Details
	TBI or subarachnoid hemorrhage, AND 3. meets one of the following - A. has known perinatal insults, congenital or genetic defects or structural hypothalamic pituitary defects, B. 3 or more pituitary hormone def (ACTH, TSH, LH/FSH, or prolactin), AND age and gender adjusted IGF1 below the lower limits of the normal reference range AND other causes of low serum IGF-1 have been excluded, C. Neg response to ONE preferred GH stim test (insulin peak response less than or equal to 5 mcg/L, Glucagon peak less than or equal to 3 mcg/L (BMI is less than or equal to 25), less than or equal to 3 and BMI is greater than or equal to 25 and less than or equal to 30 with a high pretest probability of GH deficiency, less than or equal to 1 and BMI is greater than or equal to 25 and less than or equal to 30 with a low pretest probability of GH deficiency or less than or equal to 1 mcg/L (BMI is greater than 30), if insulin and glucagon contraindicated then Arginine test with peak of less than or equal to 6.5 mcg/L, or Macrilen peak equal to or less than 2.8 ng/ml AND BMI is less than or equal to 40. Cont tx - endocrine must certify not being prescribed for anti-aging or to enhance athletic performance. ISS initial - baseline ht less than 1.2 percentile or a standard deviation score (SDS) less than -2.25 for age and gender, open epiphyses, does not have CDGP and height velocity is either growth rate (GR) is a. less than 4 cm/yr for pts greater than or equal to 5 or b. growth velocity is less than 10th percentile. CKD initial - CKD defined by abnormal CrCl, baseline ht less than 5th percentile and baseline ht velocity below 25th percentile. Noonan initial - baseline height less than 5th percentile. PW cont tx in adults or adolescents who don't meet child requir - physician certifies not being used for anti-aging or to enhance athletic performance. SHOX initial - SHOX def by chromo analysis, open epiphyses, height less than 3rd percentile. SGA initial -baseline ht less than 5th percentile and born SGA (birth weight/length more than 2 SD below mean for gestational age/gender and insufficient catch up growth by 2-4 y/o). TS- dx by karyotype analysis and baseline ht less than 5th percentile. TS cont- dx by karyotype analysis and response to tx. Cont Tx for ISS, CKD, Noonan, PW in child/adoles, SHOX, SGA - prescriber confirms response to therapy. SBS - approve if pt already started on somatropin tx for this dx or responded to it in past.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Short bowel syndrome
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	No

HERNEXEOS

Products Affected

- HERNEXEOS

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	NON-SMALL CELL LUNG CANCER-BOTH (A and B): A) Unresectable or metastatic disease, AND B) Human epidermal growth factor receptor 2 (HER2) [ERBB2] activating mutation.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

HIGH RISK MEDICATIONS - ANTIPARKINSON AGENTS

Products Affected

- *benztropine oral*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	Patients aged less than 65 years, approve. Patients aged 65 years and older, other criteria apply
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	For all covered indications, approve if the prescriber confirms he/she has assessed risk versus benefit in prescribing this high-risk medication (HRM) for the patient and he/she would still like to initiate/continue therapy.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

HIGH RISK MEDICATIONS - BENZODIAZEPINES

Products Affected

- *clorazepate dipotassium oral tablet 15 mg, 3.75 mg, 7.5 mg*
- *diazepam injection*
- *diazepam intensol*
- *diazepam oral concentrate*
- *diazepam oral solution*
- *diazepam oral tablet*
- *lorazepam injection*
- *lorazepam intensol*
- *lorazepam oral concentrate*
- *lorazepam oral tablet 0.5 mg, 1 mg, 2 mg*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	Patients aged less than 65 years, approve. Patients aged 65 years and older, other criteria apply.
Prescriber Restrictions	N/A
Coverage Duration	Procedure-related sedation = 1mo. All other conditions = 6 months.
Other Criteria	All medically accepted indications other than insomnia, approve if the physician has assessed risk versus benefit in using the High Risk Medication (HRM) in this patient and has confirmed that he/she would still like to initiate/continue therapy. Insomnia, may approve lorazepam if the patient has had a trial with two of the following: ramelteon, doxepin 3mg or 6 mg, eszopiclone, zolpidem, or zaleplon and the physician has assessed risk versus benefit in using the HRM in this patient and has confirmed that he/she would still like initiate/continue therapy.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

HIGH RISK MEDICATIONS - FIRST GENERATION ANTIHISTAMINES

Products Affected

- *hydroxyzine hcl oral tablet*
- *promethazine oral*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	Patients aged less than 65 years, approve. Patients aged 65 years and older, other criteria apply.
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 12 months.
Other Criteria	For promethazine, for the treatment of emesis, approve if the patient has tried a prescription oral anti-emetic agent (ondansetron, granisetron, dolasetron, aprepitant). For hydroxyzine hydrochloride for the treatment of anxiety, approve if the patient has tried at least two other FDA-approved products. Additionally for all covered indications, the prescriber must confirm that he/she has assessed risk versus benefit in prescribing the requested HRM for the patient and must confirm that he/she would still like to initiate/continue therapy.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

HIGH RISK MEDICATIONS - PHENOBARBITAL

Products Affected

- *phenobarbital*

PA Criteria	Criteria Details
Exclusion Criteria	Coverage is not provided for use in sedation/insomnia.
Required Medical Information	N/A
Age Restrictions	Patients aged less than 65 years, approve. Patients aged 65 years and older, other criteria apply.
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	For the treatment of seizures, approve only if the patient is currently taking phenobarbital. Prior to approval, the physician must have assessed risk versus benefit in prescribing the requested HRM for the patient and must confirm that he/she would still like to initiate/continue therapy.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

HIGH RISK MEDICATIONS - SKELETAL MUSCLE RELAXANTS

Products Affected

- *cyclobenzaprine oral tablet 10 mg, 5 mg*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	Patients aged less than 65 years, approve. Patients aged 65 years and older, other criteria apply.
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 12 months.
Other Criteria	For all covered indications, approve if the prescriber confirms he/she has assessed risk versus benefit in using this High Risk Medication (HRM) in this patient and has confirmed that he/she would still like to initiate/continue therapy.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

HYRNUO

Products Affected

- HYRNUO

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	NON-SMALL CELL LUNG CANCER- all of (A, B AND C): A. Locally advanced or metastatic disease, AND B. Human epidermal growth factor receptor 2 (HER2) [ERBB2] activating mutations, AND C. Received at least one prior systemic therapy. Note: Examples include checkpoint inhibitors such as Keytruda (pembrolizumab intravenous infusion), Libtayo (cemiplimab-rwlc intravenous infusion), Tecentriq (atezolizumab intravenous infusion), Opdivo (nivolumab intravenous infusion), or Imjudo (tremelimumab-actl intravenous infusion) in combination with chemotherapy (e.g., carboplatin, cisplatin, pemetrexed, paclitaxel, albumin-bound paclitaxel, bevacizumab), chemotherapy alone (e.g., docetaxel, gemcitabine, etoposide, vinorelbine, other chemotherapy noted above).
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

IBRANCE

Products Affected

- IBRANCE ORAL CAPSULE 125 MG
- IBRANCE ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Breast cancer (including endocrine-resistant PIK3CA-mutated, HR-positive, HER2-negative locally advanced or metastatic breast cancer) - approve locally advanced, recurrent or metastatic, hormone receptor positive (HR+) [i.e., estrogen receptor positive- (ER+) and/or progesterone receptor positive (PR+)] disease, and HER2-negative breast cancer when the pt meets ONE of the following 1. Pt is postmenopausal and this medication will be used in combination with anastrozole, exemestane, letrozole, or fulvestrant 2, pt is premenopausal or perimenopausal and is receiving ovarian suppression/ablation with GnRH agonists, or has had surgical bilateral oophorectomy, or ovarian irradiation AND this medication will be used in combination with anastrozole, exemestane, letrozole, or fulvestrant 3. pt is a man (a man is defined as an individual with the biological traits of a man, regardless of the individual's gender identity or gender expression) and meets (a or b): a) is receiving GnRH analog AND this medication will be used in combination with anastrozole, exemestane or letrozole or b) this medication will be used in combination with fulvestrant. Liposarcoma-approve if the patient has well-differentiated/dedifferentiated liposarcoma (WD-DDLS).
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Liposarcoma

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	No

IBTROZI

Products Affected

- IBTROZI

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	NON-SMALL CELL LUNG CANCER-locally advanced or metastatic disease and ROS1-positive non-small cell lung cancer as detected by an approved test.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

ICATIBANT

Products Affected

- *icatibant*
- *sajazir*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by, or in consultation with, an allergist/immunologist or a physician that specializes in the treatment of HAE or related disorders
Coverage Duration	Authorization will be for 1 year.
Other Criteria	Hereditary Angioedema (HAE) Due to C1 Inhibitor (C1-INH) Deficiency [Type I or Type II] - Treatment of Acute Attacks, Initial Therapy-the patient has HAE type I or type II as confirmed by the following diagnostic criteria (i and ii): i. the patient has low levels of functional C1-INH protein (less than 50% of normal) at baseline, as defined by the laboratory reference values AND ii. the patient has lower than normal serum C4 levels at baseline, as defined by the laboratory reference values. Patients who have treated previous acute HAE attacks with icatibant -the patient has treated previous acute HAE type I or type II attacks with icatibant AND according to the prescribing physician, the patient has had a favorable clinical response (e.g., decrease in the duration of HAE attacks, quick onset of symptom relief, complete resolution of symptoms, decrease in HAE acute attack frequency or severity) with icatibant treatment. HAE with Normal C1-INH [Type III], Treatment of Acute Attacks: Approve.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	No

ICLUSIG

Products Affected

- ICLUSIG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, the Philadelphia chromosome (Ph) status of the leukemia must be reported. T315I status
Age Restrictions	All indications except ALL - 18 years and older
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 1 year.
Other Criteria	Acute lymphoblastic leukemia, Philadelphia chromosome positive or ABL-class translocation: approve if the patient meets (1, 2 or 3): 1) will use in combination with chemotherapy, or 2) ALL is T315I-positive, or 3) pt tried at least one other tyrosine kinase inhibitor (examples: imatinib or dasatinib). Chronic myeloid leukemia, Philadelphia chromosome positive or BCR::ABL1-positive-approve if patient meets (1, 2 or 3): 1) CML is T315I-positive, or 2) pt tried at least one other tyrosine kinase inhibitor (examples: imatinib, dasatinib, nilotinib), or 3) pt has accelerated-phase or blast-phase CML and no other tyrosine kinase inhibitor is indicated. GIST - approve if the patient tried all of the following therapies first to align with NCCN recommendations which include: Imatinib or Ayvakit (avapritinib tablets), AND Sunitinib or Sprycel (dasatinib tablets), AND Stivarga (regorafenib tablets), AND Qinlock (ripretinib tablets). Myeloid/Lymphoid Neoplasms with Eosinophilia - approve if the tumor has ABL1 rearrangement or FGFR1 rearrangement.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Gastrointestinal Stromal Tumor, Myeloid/Lymphoid Neoplasms with Eosinophilia
Part B Prerequisite	No

Effective August 1, 2026

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

IDHIFA

Products Affected

- IDHIFA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	IDH2-mutation status
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 1 year.
Other Criteria	AML - approve if the patient is IDH2-mutation status positive as detected by an approved test
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

ILARIS

Products Affected

- ILARIS (PF)

PA Criteria	Criteria Details
Exclusion Criteria	When used in combination with concurrent biologic therapy (e.g.TNF antagonists, etanercept, adalimumab, certolizumab pegol, golimumab, infliximab), anakinra, or rilonacept.
Required Medical Information	N/A
Age Restrictions	CAPS-4 years of age and older (initial). SJIA/HIDS/MKD/FMF/TRAPS-2 years of age and older (initial). Still's disease-18 years and older (initial) Note-patients less than 18 should be referred to criteria for systemic juvenile idiopathic arthritis. Acute gout flare-18 years of age and older
Prescriber Restrictions	CAPS initial- Prescribed by or in consultation with a rheumatologist, geneticist, allergist/immunologist, or dermatologist. SJIA/Still's disease (initial), Acute gout flare (initial/cont)- prescribed by or in consultation with a rheumatologist. FMF initial - rheumatologist, nephrologist, geneticist, gastroenterologist, oncologist, hematologist. HIDS/MKD/TRAPS initial - rheumatologist, nephrologist, geneticist, oncologist, hematologist.
Coverage Duration	Acute gout flare-6 mos, all other diagnoses-6 months initial, 1 year cont.
Other Criteria	For renewal of CAPS/SJIA/FMF/HIDS/MKD/TRAPS/Still's - After pt had been started on Ilaris, approve if the pt had a response to therapy as determined by prescribing physician. SJIA, initial therapy - approve. Adult Onset Still's Disease-Initial-approve. Acute gout flare- approve if (i and ii): (i) pt has intolerance, contraindication, or lack of response to NSAIDs and colchicine for the treatment of acute gout flares OR pt is unable to be retreated with a repeat course of corticosteroids (oral or injectable) for acute gout flare, and (ii) patient is receiving or will be taking concomitant urate lowering medication for prevention of gout unless contraindicated (ex: allopurinol, febuxostat, probenecid). FMF, initial-approve if pt has tried colchicine, unless contraindicated and will be taking Ilaris in combination with colchicine, unless colchicine is contraindicated or not tolerated, AND prior to starting Ilaris, the patient meets BOTH of the

PA Criteria	Criteria Details
	following (a and b): a) C-reactive protein level is greater than or equal to 10 mg/L OR elevated to at least two times the upper limit of normal AND b) pt has a history of at least one flare per month despite use of colchicine, OR was hospitalized for a severe flare. HIDS/MKD, initial-approve if prior to starting Ilaris, the patient meets BOTH of the following (a and b): a) C-reactive protein level is greater than or equal to 10 mg/L OR elevated to at least two times the upper limit of normal AND b) Pt has a history of at least three febrile acute flares within the previous 6-month period OR was hospitalized for a severe flare. TRAPS, initial-approve if prior to starting Ilaris, the patient meets BOTH of the following (a and b): a) C-reactive protein level is greater than or equal to 10 mg/L OR elevated to at least two times the upper limit of normal AND b) Pt has a history of at least six flares per year OR was hospitalized for a severe flare.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

IMATINIB

Products Affected

- *imatinib oral tablet 100 mg, 400 mg*
- IMKELDI

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis. For indications of CML and ALL, the Philadelphia chromosome (Ph) status of the leukemia must be reported.
Age Restrictions	ASM, DFSP, HES, MDS/MPD/Myeloid/Lymphoid Neoplasms/Kaposi Sarcoma/Cutaneous Melanoma-18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	For ALL-approve for Ph-positive or ABL-class translocation ALL. CML-approve for Ph-positive or BCR::ABL1-mutation positive CML. Kaposi's Sarcoma-approve if the patient has tried at least one regimen AND has relapsed or refractory disease. Pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT)-patient has tried Turalio or Romvimza or according to the prescriber, the patient cannot take Turalio or Romvimza. Myelodysplastic/myeloproliferative disease-approve if the condition is associated with platelet-derived growth factor receptor (PDGFR) gene rearrangements.Graft versus host disease, chronic-approve if the patient has tried at least one conventional systemic treatment (e.g., imbruvica). Cutaneous melanoma-approve if the patient has an activating KIT mutation, metastatic or unresectable melanoma, and has tried at least one systemic regimen. Myeloid/lymphoid neoplasms with eosinophilia-approve if the tumor has an ABL1 rearrangement or an FIP1L1-PDGFR A or PDGFRB rearrangement. Approve Imkeldi if the patient has had a trial of imatinib tablets (brand or generic) dispersed in a glass of water or apple juice (per product labeling).
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Chordoma, desmoid tumors (aggressive fibromatosis), metastatic or unresectable cutaneous melanoma with activating kit mutation, Kaposi's

Effective August 1, 2026

PA Criteria	Criteria Details
	Sarcoma and pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor, myeloid/lymphoid neoplasms with eosinophilia, GVHD, chronic.
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

IMBRUVICA

Products Affected

- IMBRUVICA ORAL CAPSULE 140 MG, 70 MG
- IMBRUVICA ORAL SUSPENSION
- IMBRUVICA ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	GVHD-1 year and older, other-18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	CLL- Approve. GVHD-Approve if the patient has tried one conventional systemic treatment for graft versus host disease (e.g., corticosteroids [methylprednisolone, prednisone], imatinib, low-dose methotrexate, sirolimus, mycophenolate mofetil, Jakafi [ruxolitinib tablets]). B-cell lymphoma-approve if the patient has tried at least one systemic regimen (e.g., cisplatin, cytarabine, rituximab, oxaliplatin, gemcitabine, ifosfamide, carboplatin, etoposide, or rituximab). Central nervous system Lymphoma (primary)- approve if the patient is not a candidate for or is intolerant to high-dose methotrexate OR has tried at least one therapy (e.g., methotrexate, rituximab, vincristine, procarbazine, cytarabine, thiotepea, carmustine, intrathecal methotrexate, cytarabine, or rituximab). Hairy Cell Leukemia - approve if the patient has tried at least two systemic regimens (cladribine, Nipent [pentostatin injection], rituximab, or Pegasys [peginterferon alfa-2a subcutaneous injection]).
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Central Nervous System Lymphoma (Primary), Hairy Cell Leukemia, B-Cell Lymphoma
Part B Prerequisite	No

Effective August 1, 2026

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

IMDELLTRA

Products Affected

- IMDELLTRA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	1 year
Other Criteria	Part B vs Part D determination will be made at time of prior authorization review per CMS guidance. SMALL CELL LUNG CANCER-patient has primary progressive, relapsed or refractory extensive stage disease and has previously received platinum-based chemotherapy. Note: Examples of platinum medications include cisplatin and carboplatin.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

IMJUDO

Products Affected

- IMJUDO

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	HCC, Esophageal/Esophagogastric Junction Ca, Gastric Ca-30 days, NSCLC-6 months
Other Criteria	Part B vs Part D determination will be made at time of prior authorization review per CMS guidance. HCC-approve if the patient meets (A or B): A) Imjudo will be used as first-line systemic therapy in combination with Imfinzi and either (i or ii): i) has liver-confined unresectable disease and is deemed ineligible for transplant or (ii) has extrahepatic or metastatic disease and is deemed ineligible for resection, transplant, or locoregional therapy or B) Imjudo will be used as subsequent therapy in combination with Imfinzi. Non-Small Cell Lung Cancer-Approve if the patient meets ALL of the following criteria (A, B, and C): A) Patient has recurrent, advanced, or metastatic disease, AND B) Imjudo is used in combination with Imfinzi (durvalumab intravenous infusion), AND C) Patient meets ONE of the following (i, ii, iii, or iv): i. Patient meets BOTH of the following (a and b): a) The tumor is negative for actionable molecular markers-Note: Examples of actionable molecular markers include epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) genomic tumor aberrations, ROS1, BRAF, NTRK1/2/3, MET, RET, and ERBB2 (HER2), [patient may be KRAS G12C mutation positive] AND b) Imjudo is used as first-line therapy, OR ii. Patient meets both of the following (a and b): a) The tumor is positive for ONE of the following [(1) or (2)]: (1) Epidermal growth factor receptor (EGFR) exon 20 mutation positive, OR (2) ERBB2 (HER2) mutation positive, AND b) Imjudo is used as first-line therapy, OR iii. Patient meets BOTH of the

PA Criteria	Criteria Details
	following (a and b): a) The tumor is positive for ONE of the following [(1), (2), (3), or (4)]: (1) BRAF V600E mutation positive, OR (2) NTRK1/2/3 gene fusion positive, OR (3) MET exon 14 skipping mutation positive, OR (4) RET rearrangement positive, AND b) Imjudo is used as first-line or subsequent therapy, OR iv. Patient meets ALL of the following (a, b, and c): a) The tumor is positive for ONE of the following [(1), (2), (3), or (4)]: (1) EGFR exon 19 deletion or exon 21 L858R mutation positive, OR (2) EGFR S768I, L861Q, and/or G719X mutation positive, OR (3) ALK rearrangement positive, OR (4) ROS1 rearrangement, AND b) The patient has received targeted drug therapy for the specific mutation AND c) Imjudo is used as subsequent therapy. Esophageal and Esophagogastric Junction Cancers- approve if pt has adenocarcinoma tumor AND has microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) disease AND Imjudo is used as neoadjuvant therapy AND Imjudo is used in combination with Imfinzi (durvalumab intravenous infusion) AND patient is medically fit for surgery. Gastric cancer-approve if pt has locoregional disease AND has MSI-H or dMMR disease AND Imjudo is used as neoadjuvant therapy AND Imjudo is used in combination with Imfinzi AND patient is medically fit for surgery.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Esophageal and Esophagogastric Junction Cancers, Gastric Cancer
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

IMPAVIDO

Products Affected

- IMPAVIDO

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an infectious diseases specialist
Coverage Duration	1 month
Other Criteria	Ameba related infections: approve if the patient is being treated for an infection due to one of the following: Acanthameoba, Balamuthia mandrillaris, or Naegleria fowleri. Note: Examples of ameba related infections are Acanthamoeba keratitis, granulomatous amebic encephalitis (GAE), and primary amebic meningoencephalitis (PAM).
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Ameba related infections
Part B Prerequisite	No
Prerequisite Therapy Required	No

INBRIJA

Products Affected

- INBRIJA INHALATION CAPSULE,
W/INHALATION DEVICE

PA Criteria	Criteria Details
Exclusion Criteria	Asthma, COPD, other chronic underlying lung disease
Required Medical Information	Diagnosis, medications that will be used in combination
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	1 year
Other Criteria	Approve if the patient is currently taking carbidopa-levodopa and is experiencing off episodes.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

INGREZZA

Products Affected

- INGREZZA
- INGREZZA INITIATION PK(TARDIV)
- INGREZZA SPRINKLE

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	TD - Prescribed by or in consultation with a neurologist or psychiatrist. Chorea HD - prescribed by or in consultation with a neurologist
Coverage Duration	1 year
Other Criteria	Chorea associated with Huntington's Disease- approve if diagnosis is confirmed by genetic testing (for example, an expanded HTT CAG repeat sequence of at least 36).
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

INJECTABLE TESTOSTERONE PRODUCTS

Products Affected

- *testosterone cypionate*
- *testosterone enanthate*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, lab results
Age Restrictions	Delayed puberty or induction of puberty in males-14 years and older, 12 years and older (testosterone cypionate)
Prescriber Restrictions	Gender-Dysphoric/Gender-Incongruent Persons, Persons Undergoing Female-to-Male (FTM) Gender Reassignment (i.e., Endocrinologic Masculinization)-prescribed by or in consultation with an endocrinologist or a physician who specializes in the treatment of transgender patients.
Coverage Duration	Delayed puberty or induction of puberty in males-6 months, all others-12 months
Other Criteria	Hypogonadism (primary or secondary) in males - initial therapy, approve if all of the following criteria are met: 1) patient has persistent signs and symptoms of androgen deficiency (pre-treatment) [eg, depressed mood, decreased energy, progressive decrease in muscle mass, osteoporosis, loss of libido, AND 2) patient has had two pre-treatment serum testosterone (total or available) measurements, each taken in the morning on two separate days, AND 3) the two serum testosterone levels are both low, as defined by the normal laboratory reference values. Hypogonadism (primary or secondary) in males - continuing therapy, approve if the patient meets all of the following criteria: 1) patient has persistent signs and symptoms of androgen deficiency (pre-treatment) AND 2) patient had at least one pre-treatment serum testosterone level that was low. Delayed puberty or induction of puberty in males - Approve testosterone enanthate or testosterone cypionate. Breast cancer in females-approve testosterone enanthate. Male is defined as an individual with the biological traits of a man, regardless of the individual's gender identity or gender expression. Female is defined as an individual with the biological traits of a woman, regardless of the individual's gender identity or gender expression. Gender-Dysphoric/Gender-Incongruent Persons, Persons Undergoing Female-to-

PA Criteria	Criteria Details
	Male (FTM) Gender Reassignment (i.e., Endocrinologic Masculinization)-approve.Note: For a patient who has undergone gender reassignment, use this FTM criterion for hypogonadism indication.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Gender-Dysphoric/Gender-Incongruent Persons, Persons Undergoing Female-to-Male (FTM) Gender Reassignment (i.e., Endocrinologic Masculinization).
Part B Prerequisite	No
Prerequisite Therapy Required	No

INLEXZO

Products Affected

- INLEXZO

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or urologist
Coverage Duration	1 year
Other Criteria	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. NON-MUSCLE INVASIVE BLADDER CANCER-patient has carcinoma in situ (CIS) and Bacillus Calmette-Guerin (BCG)-unresponsive disease.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

INLURIYO

Products Affected

- INLURIYO

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	BREAST CANCER-All of (A, B, C, D, E and F): A) Recurrent, advanced or metastatic disease, AND B) Hormone receptor-positive (HR+) disease (example: estrogen receptor (ER)-positive), AND C) Human epidermal growth factor receptor 2 (HER2)-negative disease, AND D) Estrogen receptor 1 gene (ESR1)-mutated disease, AND E) Tried at least one endocrine therapy, Note: Examples of endocrine therapy include fulvestrant, anastrozole, exemestane, letrozole, and tamoxifen. AND F) ONE of the following (i or ii): i. Patient is a postmenopausal woman or man [See note 1], OR ii. Patient is a pre/perimenopausal woman [See note 1] and meets ONE of the following (a or b): a) Receiving ovarian suppression/ablation with a gonadotropin-releasing hormone (GnRH) agonist, Note: Examples of a GnRH agonist include leuprolide acetate, Lupron Depot (leuprolide acetate intramuscular injection), Trelstar (triptorelin pamoate intramuscular injection), and Zoladex (goserelin acetate subcutaneous injection). OR b) Patient has had surgical bilateral oophorectomy or ovarian irradiation. Note 1- a woman is defined as an individual with the biological traits of a woman, regardless of the individual's gender identity or gender expression, a man is defined as an individual with the biological traits of a man, regardless of the individual's gender identity or gender expression.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.

Effective August 1, 2026

PA Criteria	Criteria Details
Off-Label Uses	Recurrent breast cancer
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

INLYTA

Products Affected

- INLYTA ORAL TABLET 1 MG, 5 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 1 year.
Other Criteria	Advanced renal cell carcinoma, approve. Differentiated thyroid cancer - approve if the patient meets (i or ii): i) Patient meets both (a and b): a) Has papillary or follicular thyroid carcinoma AND b) the disease is refractory to radioactive iodine therapy OR ii) has oncocytic (formulary Hurthle cell) carcinoma. Soft tissue sarcoma-approve if the patient has alveolar soft part sarcoma and the medication will be used in combination with Keytruda. Thymic carcinoma - Approve if the patient has tried at least one chemotherapy regimen and the medication will be used in combination with Bavencio (aveluman intravenous infusion).
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Differentiated (i.e., papillary, follicular, and oncocytic) Thyroid Carcinoma, Soft tissue sarcoma, thymic carcinoma
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

INPEFA

Products Affected

- INPEFA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Heart Failure, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit-approve. Type 2 Diabetes, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit-approve if the patient has chronic kidney disease AND has one or more cardiovascular risk factor(s).Note: Patients with heart failure should be reviewed under criteria for Heart Failure.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

INQOVI

Products Affected

- INQOVI

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Acute Myeloid Leukemia (AML includes Blastic Plasmacytoid Dendritic Cell Neoplasm): Approve if the patient is not a candidate for intensive induction therapy and the medication will be used in combination with Venclexta (venetoclax tablets).
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Myelodysplastic Syndrome With Myeloproliferative Neoplasm Overlap Syndrome
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

INREBIC

Products Affected

- INREBIC

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Myelofibrosis (MF), including Primary MF, Post-Polycythemia Vera MF, and Post-Essential Thrombocythemia MF-approve if the patient has higher-risk disease. Myeloid/Lymphoid Neoplasms with Eosinophilia-approve if the tumor has a JAK2 rearrangement. Accelerated or blast phase myeloproliferative neoplasm- approve if the patient has at least one disease-related symptom (examples: fatigue, fever, night sweats, weight loss, abdominal discomfort, splenomegaly, thrombocytosis, or leukocytosis).
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Myeloid/Lymphoid Neoplasms with Eosinophilia, accelerated or blast phase myeloproliferative neoplasm
Part B Prerequisite	No
Prerequisite Therapy Required	No

ITOVEBI

Products Affected

- ITOVEBI ORAL TABLET 3 MG, 9 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	BREAST CANCER (all of A, B, C, D, E and F): A. Patient meets ONE of the following (i or ii): i. Patient is a postmenopausal female or male, OR ii. Patient meets BOTH of the following (a and b): a. Patient is a pre/perimenopausal female, AND b. Patient is receiving a gonadotropin-releasing hormone (GnRH) agonist OR had surgical bilateral oophorectomy or ovarian irradiation, Note: Examples of a GnRH agonist include leuprolide acetate, leuprolide acetate intramuscular injection, triptorelin pamoate intramuscular injection, goserelin acetate subcutaneous injection. AND B. Patient has locally advanced or metastatic hormone receptor (HR)-positive disease, AND C. Patient has human epidermal growth factor receptor 2 (HER2)-negative disease, AND D. Patient has PIK3CA-mutated breast cancer as detected by an approved test, AND E. Patient meets (i or ii): i) has disease progression while on adjuvant endocrine therapy or ii) had disease recurrence within 12 months after completing adjuvant endocrine therapy, Note: Examples of endocrine therapy include tamoxifen, anastrozole, letrozole, exemestane, toremifene. AND F. The medication will be used in combination with palbociclib capsules/tablets and fulvestrant injection.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

IVERMECTIN (ORAL)

Products Affected

- ivermectin oral tablet 3 mg, 6 mg

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	30 days
Other Criteria	Pediculosis-approve if the patient has infection caused by pediculus humanus capitis (head lice), pediculus humanus corporis (body lice), or has pediculosis pubis caused by phthirus pubis (pubic lice). Scabies-approve if the patient has classic scabies, treatment resistant scabies, is unable to tolerate topical treatment, has crusted scabies or is using ivermectin tablets for prevention and/or control of scabies.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Ascariasis, Enterobiasis (pinworm infection), Hookworm-related cutaneous larva migrans, Mansonella ozzardi infection, Mansonella streptocerca infection, Pediculosis, Scabies. Trichuriasis, Wucheria bancrofti infection
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

IVIG

Products Affected

- GAMUNEX-C

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 12 months.
Other Criteria	Part B versus D determination per CMS guidance to establish if drug used for PID in pt's home.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

IWILFIN

Products Affected

- IWILFIN

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Neuroblastoma-Approve if the patient meets the following (A, B and C): A) Patient has high-risk disease, AND B) The medication is being used to reduce the risk of relapse, AND C) Patient has had at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy. Note: Examples of anti-GD2 immunotherapy includes Unituxin (dinutuximab intravenous infusion).
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

JAKAFI

Products Affected

- JAKAFI
- JAKAFI XR

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	ALL-1 to 21 years of age, GVHD-12 and older, MF/PV/accelerated or blast phase MPN/CMML-2/essential thrombo/myeloid/lymphoid neoplasm/T-cell Lymphoma-18 and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	For polycythemia vera patients must have tried hydroxyurea or peginterferon alfa-2a or Besremi (ropeginterferon alfa-2b-njft subcutaneous injection). ALL-approve if the mutation/pathway is Janus associated kinase (JAK)-related. GVHD, chronic-approve if the patient has tried one conventional systemic treatment for graft versus host disease (for example: prednisone, ibrutinib capsules/tablets). GVHD, acute-approve if the patient has tried one systemic corticosteroid. Atypical chronic myeloid leukemia-approve if the patient has a CSF3R mutation or a janus associated kinase 2 (JAK2) mutation. Chronic monomyelocytic leukemia-2 (CMML-2)-approve if the patient is also receiving a hypomethylating agent. Essential thrombocythemia-approve if the patient has tried hydroxyurea, peginterferon alfa-2a or anagrelide. Myeloid/lymphoid neoplasms-approve if the patient has eosinophilia and the tumor has a janus associated kinase 2 (JAK2) rearrangement. T-Cell Lymphoma - approve if pt has (A or B): A) peripheral T-cell lymphoma or B) meets (i and ii): i) pt has T-cell prolymphocytic leukemia, T-cell large granular lymphocytic leukemia, hepatosplenic T-cell lymphoma, or breast implant-associated anaplastic large cell lymphoma and ii) pt has tried at least one systemic regimen. Accelerated or blast phase myeloproliferative neoplasm-approve if pt has at least one disease-related symptom (examples: fatigue, fever, night sweats,

PA Criteria	Criteria Details
	weight loss, abdominal discomfort, splenomegaly, thrombocytosis, or leukocytosis).
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Acute lymphoblastic leukemia, atypical chronic myeloid leukemia, chronic monomyelocytic leukemia-2 (CMML-2), essential thrombocythemia, myeloid/lymphoid neoplasms, T-Cell lymphoma, accelerated or blast phase myeloproliferative neoplasm
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

JAYPIRCA

Products Affected

- JAYPIRCA ORAL TABLET 100 MG, 50 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Mantle cell lymphoma-approve if the patient has tried at least one systemic chemotherapy regimen or patient is not a candidate for a systemic regimen, AND the patient has tried one Bruton tyrosine kinase inhibitor (BTK) for mantle cell lymphoma. Note: Examples of a systemic regimen contain one or more of the following products: rituximab, cytarabine, carboplatin, cisplatin, oxaliplatin, cyclophosphamide, doxorubicin, vincristine, methotrexate, bendamustine, Velcade (bortezomib intravenous or subcutaneous injection), lenalidomide, gemcitabine, and Venclexta (venetoclax tablets). Note: Examples of BTK inhibitors indicated for mantle cell lymphoma include Brukinsa (zanubrutinib capsules), Calquence (acalabrutinib capsules), and Imbruvica (ibrutinib capsules, tablets, and oral suspension). CLL/SLL-patient tried at least one Bruton tyrosine kinase (BTK) inhibitor. Examples of BTK inhibitor include: Imbruvica (ibrutinib tablets, capsules, or oral solution), Calquence (acalabrutinib tablets), or Brukinsa (zanubrutinib capsules). Richter's Transformation to DLBCL- pt has tried at least one chemotherapy regimen or is not a candidate for a chemotherapy regimen. Marginal Zone Lymphoma - approve if pt has tried at least one Bruton tyrosine kinase inhibitor. Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma - approve if pt has tried at least one systemic regimen. Note: Examples of a systemic regimen contain one or more of the following products: Brukinsa (zanubrutinib

PA Criteria	Criteria Details
	capsules), Imbruvica (ibrutinib tablets, capsules, and oral solution), rituximab, bendamustine, cyclophosphamide, dexamethasone, bortezomib, Kyprolis (carfilzomib intravenous infusion), or Ninlaro (ixazomib capsule).
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Richter's Transformation to Diffuse Large B-Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

JEMPERLI

Products Affected

- JEMPERLI

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	1 year
Other Criteria	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Endometrial cancer-approve if the patient has recurrent, advanced or metastatic disease. Mismatch repair deficient (dMMR) or microsatellite instability high (MSI-H) Solid tumors-approve. Small Bowel Adenocarcinoma-approve if the patient has dMMR or MSI-H disease or DNA polymerase epsilon/delta (POLE/POLD1) mutation and has advanced or metastatic disease. Colon, Rectal, or Appendiceal Cancer- approve if patient has mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) disease or DNA polymerase epsilon/delta (POLE/POLD1) mutation AND is being used for neoadjuvant therapy or advanced or metastatic disease. Anal carcinoma- approve if medication will be used as a single agent and (A or B): A) pt has locally recurrent or progressive disease and medication is administered before proceeding to abdominoperineal resection, or B) pt has metastatic disease, and medication is used as subsequent therapy.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Small Bowel Adenocarcinoma, Colon, Rectal or Appendiceal Cancer, Anal carcinoma
Part B Prerequisite	No

Effective August 1, 2026

PA Criteria	Criteria Details
Prerequisite Therapy Required	No

JYNARQUE

Products Affected

- *tolvaptan (polycys kidney dis)*

PA Criteria	Criteria Details
Exclusion Criteria	Patient is currently receiving another tolvaptan product
Required Medical Information	Diagnosis, renal function
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with a nephrologist
Coverage Duration	1 year (initial and continuation)
Other Criteria	Approve if the patient has rapidly-progressing autosomal dominant polycystic kidney disease (ADPKD) (e.g., reduced or declining renal function, high or increasing total kidney volume [height adjusted]), according to the prescriber.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

KADCYLA

Products Affected

- KADCYLA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist.
Coverage Duration	Breast Cancer-Recurrent/metastatic-1 yr, Breast Cancer-Adjuvant tx-approve 1 yr total, other-1yr
Other Criteria	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Breast Cancer-approve if the patient has human epidermal growth factor receptor 2 (HER2)-positive disease and the patient is using for recurrent or metastatic breast cancer OR if using for adjuvant therapy. NSCLC-approve if pt meets (A, B and C): A) the disease has activating human epidermal growth factor receptor 2 (HER2) [ERBB2] mutations and B) the patient has recurrent, advanced, or metastatic disease and C) pt has tried at least one prior systemic therapy. Salivary gland tumor-approve if the patient has recurrent, unresectable, or metastatic disease and the patient has human epidermal growth factor receptor 2 (HER2)-positive disease.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Non-small cell lung cancer (NSCLC), salivary gland tumor
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

KALYDECO

Products Affected

- KALYDECO

PA Criteria	Criteria Details
Exclusion Criteria	Combination use with other CF Transmembrane Regulator Modulators
Required Medical Information	N/A
Age Restrictions	1 month of age and older
Prescriber Restrictions	prescribed by or in consultation with a pulmonologist or a physician who specializes in CF
Coverage Duration	1 year
Other Criteria	CF - must meet A, B, and C: A) pt must have one mutation in the cystic fibrosis transmembrane conductance regulator gene that is considered to be pathogenic or likely pathogenic B) pt must have positive CF newborn screening test or family history of CF or clinical presentation consistent with signs and symptoms of CF and C) evidence of abnormal cystic fibrosis transmembrane conductance regulator function as demonstrated by i, ii, or iii: (i) elevated sweat chloride test or (ii) two cystic fibrosis-causing cystic fibrosis transmembrane conductance regulator mutations or (iii) abnormal nasal potential difference.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

KANUMA

Products Affected

- KANUMA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, genetic and lab test results
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a geneticist, endocrinologist, a metabolic disorder sub-specialist, or a physician who specializes in the treatment of lysosomal storage disorders
Coverage Duration	1 year
Other Criteria	Approve if the patient has a laboratory test demonstrating deficient lysosomal acid lipase activity in leukocytes, fibroblasts, or liver tissue OR a molecular genetic test demonstrating biallelic pathogenic or likely pathogenic lysosomal acid lipase gene variants.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

KERENDIA

Products Affected

- KERENDIA

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use with spironolactone or eplerenone
Required Medical Information	Diagnosis
Age Restrictions	18 years and older (initial and continuation therapy)
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Diabetic kidney disease-initial-approve if the patient meets the following criteria (i, ii and iii): i. Patient has a diagnosis of type 2 diabetes AND ii. Patient meets one of the following (a or b): a) Patient is currently receiving a maximally tolerated labeled dosage of an angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) OR b) According to the prescriber, patient has a contraindication or has experienced significant intolerance to ACE inhibitor and ARB therapy AND iii. At baseline (prior to the initiation of Kerendia), patient meets all of the following (a, b, and c): a) Estimated glomerular filtration rate greater than or equal to 25 mL/min/1.73 m² AND b) Urine albumin-to-creatinine ratio greater than or equal to 30 mg/g AND c) Serum potassium level less than or equal to 5.0 mEq/L. Diabetic kidney disease-continuation-approve if the patient meets the following criteria (i and ii): i. Patient has a diagnosis of type 2 diabetes AND ii. Patient meets one of the following (a or b): a) Patient is currently receiving a maximally tolerated angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) OR b) According to the prescriber, patient has a contraindication or has experienced significant intolerance to ACE inhibitor and ARB therapy. Heart failure-initial-Pt meets all (i, ii, and iii): i) has left ventricular ejection fraction of at least 40 percent AND ii) tried or is currently receiving one of the following SGLT-2 inhibitors: Farxiga (dapagliflozin tabs, authorized generic) Inpefa (sotagliflozin tabs), or Jardiance (empagliflozin tabs) OR has

PA Criteria	Criteria Details
	contraindication or has experienced significant intolerance to SGLT-2 inhibitors AND iii) at baseline (prior to initiation of Kerendia), meets all (a and b): a) estimated glomerular filtration rate of at least 25 mL/min/1.73m ² AND b) serum potassium level of less than or equal to 5.0 mEq/L. Heart failure-continuation-Pt meets all (i and ii): i) has left ventricular ejection fraction of at least 40 percent AND ii) tried or is currently receiving one of the following SGLT-2 inhibitors: Farxiga (dapagliflozin tabs, authorized generic) Inpefa or (sotagliflozin tabs), or Jardiance (empagliflozin tabs) or has contraindication or has experienced significant intolerance to SGLT-2 inhibitors.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

KESIMPTA

Products Affected

- KESIMPTA PEN

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with other disease-modifying agents used for multiple sclerosis (MS)
Required Medical Information	Relapsing form of Multiple Sclerosis (MS), to include, clinically-isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with a neurologist or a physician who specializes in the treatment of multiple sclerosis
Coverage Duration	Authorization will be for 1 year
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

KEYTRUDA

Products Affected

- KEYTRUDA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	Melanoma, bone cancer - 12 and older, Glioma - less than 18 years, all others- 18 and older (except Merkel cell, MSI-H/dMMR tumors, large B-cell lymph, TMB-H, Classic Hodgkin Lymphoma)
Prescriber Restrictions	Prescribed by or in consultation with an oncologist.
Coverage Duration	1 year
Other Criteria	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	adrenal gland tumor, anal carcinoma, bone cancer, extranodal NK/T-Cell Lymphoma, nasal type, Gestational trophoblastic neoplasia, mycosis fungoides/Sezary syndrome, primary cutaneous anaplastic large cell lymphoma, small cell lung cancer, soft tissue sarcoma, thymic carcinoma, vulvar cancer, pediatric diffuse high grade glioma, Kaposi sarcoma, small bowel adenocarcinoma (without MSI-H or dMMR), thyroid carcinoma (without MSI-H or dMMR), vaginal cancer, chronic lymphocytic leukemia/small lymphocytic leukemia, penile cancer
Part B Prerequisite	No
Prerequisite Therapy Required	No

Effective August 1, 2026

KEYTRUDA QLEX

Products Affected

- KEYTRUDA QLEX

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	Merkel cell carcinoma/TMB-H cancer, melanoma, bone cancer - 12 and older. All others - 18 and older (except MSI-H/dMMR solid tumors), pediatric diffuse high-grade glioma - less than 18 years
Prescriber Restrictions	Prescribed by or in consultation with an oncologist.
Coverage Duration	1 year
Other Criteria	Part B vs Part D determination will be made at time of prior authorization review per CMS guidance.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Thymic carcinoma, anal carcinoma, appendiceal cancers, bone cancer, gestational trophoblastic neoplasia, pediatric diffuse high-grade glioma, penile cancer, small bowel adenocarcinoma, soft tissue sarcoma, vaginal cancer, vulvar cancer
Part B Prerequisite	No
Prerequisite Therapy Required	No

KINERET

Products Affected

- KINERET

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with another biologic DMARD or targeted synthetic DMARD
Required Medical Information	Diagnosis
Age Restrictions	RA/AOSD/Pericarditis-18 years and older, SJIA-2 years and older
Prescriber Restrictions	Initial therapy only-RA, SJIA and Still's disease, prescribed by or consult with a rheumatologist. CAPS (Neonatal-Onset Multisystem Inflammatory Disease or Chronic Infantile Neurological Cutaneous and Articular syndrome), prescribed by or consult with a rheumatologist, geneticist, allergist/immunologist, or dermatologist.DIRA-rheum, geneticist, dermatologist, or physician specializing in autoinflammatory disorder. Pericarditis, prescribed by or consult with cardiologist or rheumatologist.
Coverage Duration	Approve through end of plan year
Other Criteria	RA initial. Approve if the patient has tried TWO of the following drugs in the past: Enbrel, a preferred adalimumab product, Rinvoq, Xeljanz/XR, or a preferred tocilizumab product. [Note: if the patient has not tried TWO of these drugs listed, previous trial(s) with the following drugs can count towards meeting the 'try TWO' requirement: a non-preferred tocilizumab product, Orencia, Cimzia, infliximab, Kevzara, golimumab IV/SC or another non-preferred adalimumab product.] DIRA initial-approve if genetic testing has confirmed bi-allelic pathogenic variants in the IL1RN gene. Adult Onset Still's Disease, approve. SJIA-initial-approve. cont tx - approve if the patient had responded to therapy as determined by the prescriber. Immunotherapy-related toxicities associated with CAR-T cell therapy: approve if patient has or will be treated with CAR-T cell therapy. Pericarditis, initial: approve if (A, B, and C): A) recurrent pericarditis, B) C-reactive protein level greater than 1 mg/dL, and C) for current episode pt is receiving standard treatment or standard treatment is contraindicated [examples of standard treatment: NSAIDs such as ibuprofen, colchicine, systemic corticosteroids]. Pericarditis, cont: experienced beneficial

PA Criteria	Criteria Details
	response. Please Note: preferred adalimumab products include Hadlima, Simlandi. Preferred tocilizumab products include Actemra, Tyenne.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Adult onset Still's disease (SD). Systemic Juvenile Idiopathic Arthritis (SJIA). Immunotherapy-related toxicities associated with Chimeric Antigen Receptor (CAR) T-cell therapy. Pericarditis
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

KISQALI

Products Affected

- KISQALI ORAL TABLET 200 MG/DAY (200 MG X 1), 400 MG/DAY (200 MG X 2), 600 MG/DAY (200 MG X 3)

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Breast cancer - approve for hormone receptor positive (HR+) [i.e., estrogen receptor positive (ER+) and/or progesterone receptor positive (PR+)] disease, and HER2-negative early (stage II or III), recurrent, or metastatic breast cancer [for early breast cancer must be adjuvant treatment and high risk of recurrence] when the pt meets ONE of the following (1, 2, 3 or 4): 1. Pt is postmenopausal and Kisqali will be used in combination with anastrozole, exemestane, or letrozole 2. meets (a, b and c): a) pt is premenopausal or perimenopausal and b) is receiving ovarian suppression/ablation with GnRH agonist, or has had surgical bilateral oophorectomy, or ovarian irradiation AND c) Kisqali will be used in combination with anastrozole, exemestane, or letrozole 3. pt is a man (a man is defined as an individual with the biological traits of a man, regardless of the individual's gender identity or gender expression) who is receiving GnRH analog AND Kisqali will be used in combination with anastrozole, exemestane or letrozole. 4. Patient meets (a and b): a) is postmenopausal, pre/perimenopausal (patient receiving ovarian suppression/ablation with a GnRH agonist or has had surgical bilateral oophorectomy or ovarian irradiation) or a man, and b) Kisqali will be used in combination with fulvestrant. Endometrial cancer - approve if pt meets all of (A, B and C): A) pt has recurrent or metastatic disease, and B) has

PA Criteria	Criteria Details
	estrogen receptor (ER)-positive tumors, and C) if request is for Kisqali, Kisqali will be used in combination with letrozole.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Endometrial cancer
Part B Prerequisite	No
Prerequisite Therapy Required	No

KOMZIFTI

Products Affected

- KOMZIFTI

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	ACUTE MYELOID LEUKEMIA-relapsed or refractory disease and disease is positive for a susceptible nucleophosmin 1 (NPM1) mutation.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

KORLYM

Products Affected

- *mifepristone oral tablet 300 mg*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with an endocrinologist or a physician who specializes in the treatment of Cushing's syndrome
Coverage Duration	1 year
Other Criteria	Endogenous Cushing's Syndrome-Approve if mifepristone is being used to control hyperglycemia secondary to hypercortisolism in patients who have type 2 diabetes mellitus or glucose intolerance AND pt meets (i, ii or iii): i) patient is not a candidate for surgery or surgery has not been curative, or (ii) patient is awaiting surgery for endogenous Cushing's Syndrome or (iii) patient is awaiting therapeutic response after radiotherapy for endogenous Cushing's Syndrome.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

KOSELUGO

Products Affected

- KOSELUGO

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Neurofibromatosis Type 1-approve if prior to starting Koselugo, the patient has symptomatic, inoperable plexiform neurofibromas. Circumscribed Glioma-approve if (A and B): A) the patient has recurrent, refractory or progressive disease AND B) one of (i, ii, or iii): i) the tumor is BRAF fusion positive OR ii) BRAF V600E activating mutation positive OR iii) patient has neurofibromatosis type 1 mutated glioma. Langerhans Cell Histiocytosis- approve.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Circumscribed Glioma, Langerhans Cell Histiocytosis
Part B Prerequisite	No
Prerequisite Therapy Required	No

KRAZATI

Products Affected

- KRAZATI

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Non-Small Cell Lung Cancer (NSCLC)-approve if (A and B): A) the patient has KRAS G12C-mutated locally advanced or metastatic NSCLC, as determined by an approved test AND B) patient meets either (i or ii): i) has been previously treated with at least one systemic regimen [Examples of systemic regimens include those containing one or more of the following products: Keytruda (pembrolizumab intravenous infusion), Opdivo (nivolumab intravenous infusion), Tecentriq (atezolizumab intravenous infusion), Alimta (pemetrexed intravenous infusion), Yervoy (ipilimumab intravenous infusion), Abraxane (albumin-bound paclitaxel intravenous infusion), bevacizumab, cisplatin, carboplatin, docetaxel, gemcitabine, paclitaxel, vinorelbine.] or ii) patient has brain metastases. Colon or Rectal Cancer- approve if pt has unresectable, advanced, or metastatic disease AND pt has KRAS G12C mutation-positive disease AND medication is prescribed as part of a combination regimen or the patient is unable to tolerate combination therapy AND pt has previously received a chemotherapy regimen for colon or rectal cancer. Ampullary adenocarcinoma-approve if (A, B and C): A) metastatic disease, B) KRAS G12C mutation-positive disease, and C) will be used as subsequent therapy. Biliary tract cancer- approve if (A, B and C): A) unresectable or metastatic disease, B) KRAS G12C mutation-positive disease, and C) previously treated with at least one systemic regimen. Pancreatic adenocarcinoma- approve if (A and B): A) KRAS G12C mutation-positive

PA Criteria	Criteria Details
	disease, and B) either (i or ii): (i) locally advanced or metastatic disease and previously treated with at least one systemic regimen, or (ii) recurrent disease after resection. Small bowel adenocarcinoma- approve if (A, B and C): A) advanced or metastatic disease, B) KRAS G12C mutation-positive disease, and C) will be used as subsequent therapy.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Ampullary adenocarcinoma, biliary tract cancer, pancreatic adenocarcinoma, small bowel adenocarcinoma
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

LANREOTIDE

Products Affected

- lanreotide subcutaneous syringe 120 mg/0.5 ml
- SOMATULINE DEPOT SUBCUTANEOUS SYRINGE 60 MG/0.2 ML, 90 MG/0.3 ML

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, previous treatments/therapies
Age Restrictions	N/A
Prescriber Restrictions	Acromegaly-prescribed by or in consultation with an endocrinologist. Carcinoid syndrome-prescribed by or in consultation with an oncologist, endocrinologist or gastroenterologist. All neuroendocrine tumors-prescribed by or in consultation with an oncologist, endocrinologist, or gastroenterologist. Pheochromocytoma/paraganglioma-prescribed by or in consultation with an endo/onc/neuro.
Coverage Duration	1 year
Other Criteria	Acromegaly-approve if the patient has (or had) a pre-treatment (baseline) insulin-like growth factor-1 (IGF-1) level above the upper limit of normal based on age and gender for the reporting laboratory AND the patient meets i., ii., or iii: i. has had an inadequate response to surgery and/or radiotherapy or ii. is not an appropriate candidate for surgery and/or radiotherapy or iii. the patient is experiencing negative effects due to tumor size (e.g., optic nerve compression). Neuroendocrine Tumor(s) [NETs] of the Gastrointestinal Tract, Lung, Thymus (Carcinoid Tumors), and Pancreas (including glucagonomas, gastrinomas, vasoactive intestinal peptide-secreting tumors [VIPomas], insulinomas)-approve. Carcinoid Syndrome/Pheochromocytoma/paraganglioma-approve.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Pheochromocytoma/paraganglioma

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	No

LAPATINIB

Products Affected

- *lapatinib*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis for which lapatinib is being used. Metastatic breast cancer, HER2 status or hormone receptor (HR) status.
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	HER2-positive advanced, recurrent or metastatic breast cancer, approve if lapatinib will be used in combination with capecitabine OR trastuzumab and the patient has tried at least two prior anti-HER2 based regimens OR the medication will be used in combination with an aromatase inhibitor and and the patient has HR+ disease and the patient is a postmenopausal woman or the patient is premenopausal or perimenopausal woman and is receiving ovarian suppression/ablation with a GnRH agonist, surgical bilateral oophorectomy or ovarian irradiation OR the patient is a man and is receiving a GnRH analog. Colon or rectal cancer-approve if the patient has unresectable advanced or metastatic disease that is human epidermal receptor 2 (HER2) amplified and with wild-type RAS and BRAF disease and the patient has tried at least one chemotherapy regimen or is not a candidate for intensive therapy and the medication is used in combination with trastuzumab (Part B before Part D Step Therapy - applies only to beneficiaries enrolled in an MA-PD plan) and the patient has not been previously treated with a HER2-inhibitor. Bone Cancer-approve if the patient has recurrent chordoma and if the patient has epidermal growth-factor receptor (EGFR)-positive disease.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Bone cancer-chordoma, colon or rectal cancer, breast cancer in pre/peri-menopausal women and men

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

LAZCLUZE

Products Affected

- LAZCLUZE ORAL TABLET 240 MG, 80 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	NON-SMALL CELL LUNG CANCER-ALL of the following (A, B and C): A. Locally advanced or metastatic disease, AND B. Epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an approved test, AND C. Used in combination with Rybrevant.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

LEDIPASVIR/SOFOSBUVIR

Products Affected

- LEDIPASVIR-SOFOSBUVIR

PA Criteria	Criteria Details
Exclusion Criteria	Combination use with other direct acting antivirals, excluding ribavirin
Required Medical Information	Diagnosis
Age Restrictions	3 years or older
Prescriber Restrictions	Prescribed by or in consultation w/ GI, hepatologist, ID, or a liver transplant MD
Coverage Duration	Criteria will be applied consistent with current AASLD/IDSA guidance.
Other Criteria	Criteria will be applied consistent with current AASLD/IDSA guidance.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Indications consistent with current AASLD/IDSA guidance
Part B Prerequisite	No
Prerequisite Therapy Required	No

LENALIDOMIDE

Products Affected

- *lenalidomide*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older (except Kaposi Sarcoma, Castleman Disease, Primary CNS Lymphoma)
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 1 year.
Other Criteria	Follicular lymphoma-approve if (A, B or C): A) the patient is using lenalidomide in combination with rituximab or B) using in combination with Gazyva (obinutuzumab intravenous infusion), or C) pt has tried at least one prior therapy. MCL-approve -if the patient is using lenalidomide in combination with rituximab or has tried at least one other regimen. MZL-approve if the patient is using lenalidomide in combination with rituximab or has tried at least one other regimen. Multiple myeloma-approve. MDS-approve if the patient meets one of the following: 1) Pt has symptomatic anemia, OR 2) Pt has transfusion-dependent anemia, OR 3) Pt has anemia that is not controlled with an erythroid stimulating agent (eg, Epogen, Procrit [epoetin alfa injection], Aranesp [darbepoetin alfa injection]), OR 4) meets (i, ii and iii): i) pt has myelodysplastic syndrome/myeloproliferative neoplasm overlap neoplasm, and ii) has SF3B1 mutation, and iii) pt has thrombocytosis . B-cell-lymphoma (other) [examples: diffuse large B-cell lymphoma, high grade B-cell lymphoma, post-transplant lymphoproliferative disorders, HIV-related B-cell lymphoma]-approve if the pt has tried at least one prior therapy. Myelofibrosis-approve if according to the prescriber the patient has anemia with presence of del(5q) and will use this in combination with prednisone. Primary CNS lymphoma-approve if according to the prescriber the patient has relapsed or refractory disease, or is not a candidate for high-dose MTX,

PA Criteria	Criteria Details
	or had intolerance to high-dose MTX. Hodgkin lymphoma, classic-approve if (A and B): A) pt has relapsed or refractory disease, and B) pt is not a candidate for high-dose therapy and autologous stem cell rescue. Castleman disease-approve if the patient has relapsed/refractory or progressive disease. Kaposi Sarcoma-approve if the patient has tried at least one regimen or therapy and the patient has relapsed or refractory disease. Systemic light chain amyloidosis-approve if lenalidomide is used in combination with dexamethasone. Histiocytic neoplasms-approve if (A or B): A) the patient has Langerhans cell histiocytosis with either (i or ii): i) single-system multifocal skin disease or ii) relapsed or refractory disease, or B) pt has Rosai-Dorfman disease. T-Cell lymphoma- approve if (A, B or C): A) pt has peripheral T-cell lymphoma, or B) pt has T-cell leukemia/lymphoma and has tried at least one other regimen, or C) pt has hepatosplenic T-cell lymphoma and has tried at least two other regimens. Chronic lymphocytic leukemia/Small lymphocytic leukemia- approve if (A, B and C): A) relapsed or refractory disease, and B) tried at least one Bruton-tyrosine kinase inhibitor, and C) tried at least one B-cell lymphoma (BCL)2 inhibitor. POEMS Syndrome- approve if used in combination with dexamethasone.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Systemic Amyloidosis Light Chain, B-Cell Lymphoma (other), Myelofibrosis, Castleman Disease, Hodgkin lymphoma (Classic), T-Cell Lymphoma, Primary Central nervous system Lymphoma, Kaposi sarcoma, histiocytic neoplasms, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, POEMS syndrome.
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

LENVIMA

Products Affected

- LENVIMA ORAL CAPSULE 10 MG/DAY (10 MG X 1), 12 MG/DAY (4 MG X 3), 14 MG/DAY (10 MG X 1-4 MG X 1), 18 MG/DAY (10 MG X 1-4 MG X2), 20 MG/DAY (10 MG X 2), 24 MG/DAY (10 MG X 2-4 MG X 1), 4 MG, 8 MG/DAY (4 MG X 2)

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	DTC - Approve if pt meets (i OR ii): i) pt meets (a AND b): a) pt has papillary or follicular thyroid carcinoma and b) the disease is refractory to radioactive iodine therapy OR ii) pt has oncocytic carcinoma. RCC - approve if the pt meets ALL of the following criteria: 1) pt has advanced disease AND if the patient meets i or ii-i. Lenvima is being used in combination with Keytruda OR ii. Lenvima is used in combination with Afinitor/Afinitor Disperz and the patient meets a or b-a. Patient has clear cell histology and patient has tried one antiangiogenic therapy or b. patient has non-clear cell histology. MTC-approve if the patient has tried at least one systemic therapy. Endometrial Carcinoma-Approve if the patient meets (A AND B): A) Pt meets (i OR ii): i) Pt meets (a, b AND c): a) The patient has advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not microsatellite instability-high (MSI-H) AND b) The medication is used in combination with Keytruda (pembrolizumab for intravenous injection) AND c) the patient has tried at least one systemic therapy OR ii) Lenvima is used as a single agent for second-line or subsequent therapy AND B) The patient is not a candidate for curative surgery or radiation. HCC-approve if the patient has unresectable or metastatic disease. Thymic carcinoma-approve if the patient has tried at least one chemotherapy regimen. Melanoma - approve if the patient has

PA Criteria	Criteria Details
	unresectable or metastatic melanoma AND the medication will be used in combination with Keytruda (pembrolizumab intravenous injection) AND the patient has disease progression on anti-programmed death receptor-1 (PD-1)/programmed death-ligand 1 (PD-L1)-based therapy. Anaplastic thyroid carcinoma-approve if the medication is used in combination with Keytruda (pembrolizumab intravenous infusion).
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Patients with Medullary Thyroid Carcinoma (MTC), thymic carcinoma, Melanoma, Anaplastic thyroid carcinoma
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

LIBTAYO

Products Affected

- LIBTAYO

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, previous surgeries or radiation. Anal Carcinoma-meets ALL of the following (A, B and C): A) locally recurrent, metastatic, or progressive disease AND B) meets ONE (i or ii): i. The medication is administered before proceeding to abdominoperineal resection OR ii. The medication is used for subsequent therapy AND C) medication is used as a single agent. Colon, Rectal, and appendiceal Cancer-meets ALL of the following (A and B): A) Disease is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) OR polymerase epsilon/delta (POLE/POLD1) mutation positive with ultra-hypermutated phenotype (tumor mutational burden greater than 50 mutations/megabase) AND B) Patient meets ONE of the following (i or ii): i. locally unresectable, advanced, recurrent, metastatic, or medically inoperable disease OR ii. medication is used for neoadjuvant therapy. Small Bowel Adenocarcinoma-meets ALL of the following (A and B): A) Disease is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) or is polymerase epsilon/delta (POLE/POLD1) mutation positive with ultra-hypermutated phenotype (tumor mutational burden greater than 50 mutations/megabase) AND B) meets ONE (i or ii): i. has locally unresectable or medically inoperable disease OR ii. advanced or metastatic disease.
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	1 year
Other Criteria	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. CSCC-approve if the patient meets one of the following (i, ii, or iii): (i): pt has locally advanced, recurrent, or metastatic disease and is not a candidate for curative surgery or curative radiation or (ii): pt has very-high risk, locally advanced, unresectable, in-transit metastasis, or regional disease and this medication

PA Criteria	Criteria Details
	will be used as neoadjuvant therapy, or (iii): pt has disease that is at a high or very-high risk for recurrence, and this medication will be used as adjuvant therapy [Note: High or very-high risk for disease recurrence is defined as nodal features (extracapsular extension with largest node at least 20 mm in diameter or at least 3 involved nodes) or non-nodal features (in-transit metastases, T4 lesion [with bone invasion], perineural invasion, or locally recurrent tumor with at least 1 additional risk feature)]. Basal Cell Carcinoma-approve if the patient has locally advanced, nodal or metastatic disease. NSCLC (recurrent, advanced or metastatic disease)-approve if the tumor is negative for the following actionable biomarkers: epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R, anaplastic lymphoma kinase (ALK), RET, and ROS1 and meets one of the following (i, ii, iii, or iv): (i): medication is used for first-line or continuation maintenance therapy AND tumor has no actionable mutations, or (ii): medication will be used first line AND the tumor is positive for one of EGFR exon 20 mutation or ERBB2 (HER2) mutation, or NRG1 gene fusion, or (iii): medication will be used as first-line or subsequent therapy AND the tumor is positive for one of BRAF V600E mutation or NTRK1/2/3 gene fusion or MET exon 14 skipping mutation, or (iv): medication will be used as subsequent therapy AND the tumor is positive for one of EGFR S768I, L861Q, and/or G719X mutation. Cervical cancer-approve if pt has local or regional recurrence or distant metastatic disease AND this medication is used as subsequent therapy. Vulvar cancer-approve if pt has advanced, recurrent, or metastatic disease AND this medication is used as subsequent therapy. Vaginal cancer- approve if pt meets (A and B): A) meets (i or ii): i) local or regional recurrence, or ii) distant metastatic disease, and B) used as subsequent therapy.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Cervical cancer, vulvar cancer, vaginal cancer, anal carcinoma, colon/rectal/appendiceal cancer, small bowel adenocarcinoma
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

LIDOCAINE PATCH

Products Affected

- *dermacinrx lidocan*
- *dermacinrx lidocan iii*
- *dermacinrx lidocan iv*
- *dermacinrx lidocan v*
- *dermacinrx lidocan v*
- *dermacinrx lidocan v*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 12 months
Other Criteria	N/A
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Diabetic neuropathic pain, chronic back pain
Part B Prerequisite	No
Prerequisite Therapy Required	No

LIFYORLI

Products Affected

- LIFYORLI ORAL CAPSULE 125 MG/DAY(100 MG X1-25MG X1), 150 MG/DAY(100 MG X1-25MG X2)

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER-patient has platinum-resistant disease, has tried at least one systemic regimen that includes bevacizumab and requested medication will be used in combination with nab-paclitaxel. Note: Examples of a systemic regimen include one or more of the following agents: carboplatin, cisplatin, docetaxel, doxorubicin, gemcitabine, nab-paclitaxel, oxaliplatin, or paclitaxel.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

LIVDELZI

Products Affected

- LIVDELZI

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use with Iqirvo
Required Medical Information	Diagnosis
Age Restrictions	18 years and older (initial)
Prescriber Restrictions	Prescribed by or in consultation with a gastroenterologist, hepatologist, or liver transplant physician (initial)
Coverage Duration	6 months initial, 1 year cont.
Other Criteria	INITIAL THERAPY: PRIMARY BILIARY CHOLANGITIS/CIRRHOSIS-All of (A and B): A): Diagnosis confirmed by TWO of the following i, ii, or iii: i) Alkaline phosphatase is elevated above the upper limit of normal, ii) positive anti-mitochondrial antibodies or other primary biliary cholangitis-specific auto-antibodies, including sp100 or gp210, if anti-mitochondrial antibodies are negative or iii) histologic evidence of primary biliary cholangitis from a liver biopsy, B): Receiving ursodiol therapy and had inadequate response or was unable to tolerate ursodiol therapy. Note: examples of ursodiol therapy include ursodiol generic tablets and capsules, Urso 250, Urso Forte, and Actigall. CONTINUATION THERAPY: PRIMARY BILIARY CHOLANGITIS/CIRRHOSIS- patient has demonstrated a response to therapy. Note: Examples of a response to therapy are improved biochemical markers of primary biliary cholangitis (e.g., alkaline phosphatase [ALP], bilirubin, gamma-glutamyl transpeptidase [GGT], aspartate aminotransferase [AST], alanine aminotransferase [ALT]).
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

LIVTENCITY

Products Affected

- LIVTENCITY

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use with ganciclovir or valganciclovir
Required Medical Information	Diagnosis
Age Restrictions	12 years and older (initial therapy)
Prescriber Restrictions	Prescribed by or in consultation with a hematologist, infectious diseases specialist, oncologist, or a physician affiliated with a transplant center. (initial therapy)
Coverage Duration	2 months
Other Criteria	Cytomegalovirus Infection, Treatment, initial therapy-approve if the patient meets the following criteria (A, B, and C): A) Patient weighs greater than or equal to 35 kg, AND B) Patient is post-transplant, AND Note: This includes patients who are post hematopoietic stem cell transplant or solid organ transplant. C) Patient has cytomegalovirus infection/disease that is refractory to treatment with at least one of the following: cidofovir, foscarnet, ganciclovir, or valganciclovir or patient has a significant intolerance to ganciclovir or valganciclovir. Cytomegalovirus Infection, Treatment, continuation of therapy - approve if patient has responded as demonstrated by cytomegalovirus polymerase chain DNA laboratory results within 4 weeks demonstrating improvement in cytomegalovirus levels.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

LONG ACTING OPIOIDS

Products Affected

- BELBUCA
- *buprenorphine transdermal patch*
- *hydromorphone oral tablet extended release 24 hr*
- *methadone intensol*
- *methadone oral concentrate*
- *methadone oral solution 10 mg/5 ml, 5 mg/5 ml*
- *methadone oral tablet 10 mg, 5 mg*
- *methadose oral concentrate*
- *morphine oral tablet extended release*

PA Criteria	Criteria Details
Exclusion Criteria	Acute (ie, non-chronic) pain
Required Medical Information	Pain type (chronic vs acute), prior pain medications/therapies tried, concurrent pain medications/therapies
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 12 months.
Other Criteria	For pain severe enough to require daily, around-the-clock, long-term opioid treatment, approve if all of the following criteria are met: 1) patient is not opioid naive, AND 2) non-opioid therapies have been tried and are being used in conjunction with opioid therapy according to the prescribing physician, AND 3) the prescribing physician has checked the patient's history of controlled substance prescriptions using state prescription drug monitoring program (PDMP), AND 4) the prescribing physician has discussed risks (eg, addiction, overdose) and realistic benefits of opioid therapy with the patient, AND 5) according to the prescriber physician there is a treatment plan (including goals for pain and function) in place and reassessments are scheduled at regular intervals. Patients with cancer, in hospice, sickle cell disease or who reside in a long term care facility are not required to meet above criteria. Clinical criteria incorporated into the quantity limit edits for all oral long-acting opioids require confirmation that the indication is intractable pain (ie, FDA labeled use) prior to reviewing for quantity exception.
Indications	All FDA-approved Indications.

PA Criteria	Criteria Details
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

LONSURF

Products Affected

- LONSURF

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 1 year.
Other Criteria	Colon, rectal or appendiceal cancer- approve if patients meets (A, B, and C): A) advanced or metastatic disease, B) meets (i or ii): i) has proficient mismatch repair/microsatellite-stable (pMMR/MSS) disease or ii) is ineligible for or progressed on checkpoint inhibitor therapy and meets ONE of the following (a or b): a) has deficient mismatch repair/microsatellite instability-high (dMMR/MSI-H) disease, or b) is polymerase epsilon/delta (POLE/POLD1) mutation positive, and C) has previously been treated with ALL of the following per labeling (i, ii and iii): i) fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, ii) an anti-vascular endothelial growth factor (VEGF) agent (ex: bevacizumab), and iii) if the tumor is wild-type RAS (KRAS wild-type and NRAS wild-type), patient has received anti-EGFR therapy (ex: Erbitux or Vectibix) or EGFR therapy is not medically appropriate. Gastric or Gastroesophageal Junction Adenocarcinoma, approve if the patient has been previously treated with at least two chemotherapy regimens for gastric or gastroesophageal junction adenocarcinoma.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Appendiceal cancer
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

LOQTORZI

Products Affected

- LOQTORZI

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	1 year
Other Criteria	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Nasopharyngeal carcinoma- approve if the patient has recurrent, unresectable, oligometastatic, or metastatic disease. Anal carcinoma- approve if patient meets (A and B): A) meets (i or ii): i) locally recurrent, progressive disease and medication is administered before proceeding to abdominoperineal resection, or ii) metastatic disease, medication is used as subsequent therapy and patient has not received prior checkpoint inhibitors, and B) medication is used as a single agent. Small bowel adenocarcinoma- approve if patient meets (A, B, and C): A) (i or ii): i. locally unresectable or medically inoperable disease or ii. has advanced or metastatic disease and has not received prior checkpoint inhibitors AND, B) patient has deficient mismatch repair/microsatellite instability-high (dMMR/MSI-H) disease or polymerase epsilon/delta (POLE/POLD1) mutation positive disease with ultra-hypermutated phenotype (tumor mutation burden greater than 50 mutations/megabase), and C) medication is used as a single agent. Colon and Rectal Cancer- Approve if the patients meets (A, B, and C): A) ONE of the following (i or ii): i. the disease is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) OR ii. is polymerase epsilon/delta (POLE/POLD1) mutation positive with ultra-hypermutated phenotype (tumor mutation burden greater than 50 mutations/megabase) AND B) ONE of the following (i or ii): i. BOTH of the following (a and b): a)

PA Criteria	Criteria Details
	locally unresectable, advanced, recurrent, metastatic, or medically inoperable disease AND b) has NOT received prior checkpoint inhibitors OR ii. if the medication is used for neoadjuvant therapy AND C) The medication is used as single agent.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Anal carcinoma, small bowel adenocarcinoma, colon and rectal cancer
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

LORBRENA

Products Affected

- LORBRENA ORAL TABLET 100 MG, 25 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	Pediatric Diffuse High-Grade Glioma- less than 18 years old, All others- 18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Erdheim Chester disease-approve if the patient has anaplastic lymphoma kinase (ALK) rearrangement/fusion-positive disease. Inflammatory myofibroblastic tumor (IMT)-approve if the patient has ALK-positive disease and (i or ii): i) advanced, recurrent, or metastatic disease or ii) tumor is inoperable. NSCLC - Approve if the patient has ALK-positive advanced or metastatic NSCLC, as detected by an approved test. NSCLC-ROS1 Rearrangement-Positive, advanced or metastatic NSCLC-approve if the patient has tried at least one of crizotinib, entrectinib or ceritinib. Large B-Cell Lymphoma- approve if ALK-positive disease and disease is relapsed or refractory. Pediatric Diffuse High-Grade Glioma- approve if ALK-positive disease and (i or ii): i) used as adjuvant therapy, or ii) used for recurrent or progressive disease.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Non-small cell lung cancer (NSCLC)-ROS1 Rearrangement-Positive, Erdheim Chester Disease, Inflammatory Myofibroblastic Tumor (IMT), Large B-Cell Lymphoma, Pediatric Diffuse High-Grade Glioma
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

LUMAKRAS

Products Affected

- LUMAKRAS ORAL TABLET 120 MG, 240 MG, 320 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 1 year.
Other Criteria	Non-Small Cell Lung Cancer (NSCLC)-approve if the patient has KRAS G12C-mutated locally advanced or metastatic NSCLC, as determined by an FDA-approved test AND has been previously treated with at least one systemic regimen. Ampullary adenocarcinoma - approve if pt has KRAS G12C-mutated disease as determined by an approved test AND this is used as subsequent therapy. Colon or rectal cancer - approve if pt meets all (A, B, C and D): A) advanced or metastatic disease, and B) KRAS G12C mutation-positive disease, and C) used in combination with Erbitux (cetuximab intravenous infusion) or Vectibix (panitumumab intravenous infusion) or patient is unable to tolerate combination therapy, and D) previously received a chemotherapy regimen for colon or rectal cancer. Pancreatic Adenocarcinoma- approve if patient has KRAS G12C-mutated disease, as determined by an approved test AND either (i or ii): (i) patient has locally advanced or metastatic disease and has been previously treated with at least one systemic regimen OR (ii) patient has recurrent disease after resection. Small bowel adenocarcinoma- approve if pt meets all of (A, B and C): A) has advanced or metastatic disease, and B) has KRAS G12C mutation-positive disease, and C) medication will be used as subsequent therapy.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.

PA Criteria	Criteria Details
Off-Label Uses	Pancreatic Adenocarcinoma, Ampullary Adenocarcinoma, Small Bowel Adenocarcinoma
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

LUMIZYME

Products Affected

- LUMIZYME

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, genetic and lab test results
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a geneticist, neurologist, a metabolic disorder sub-specialist, or a physician who specializes in the treatment of lysosomal storage disorders
Coverage Duration	1 year
Other Criteria	Approve if the patient has a laboratory test demonstrating deficient acid alpha-glucosidase activity in blood, fibroblasts, or muscle tissue OR patient has a molecular genetic test demonstrating biallelic pathogenic or likely pathogenic acid alpha-glucosidase (GAA) gene variants.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

LUNSUMIO

Products Affected

- LUNSUMIO

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	1 year
Other Criteria	Part B vs Part D determination will be made at time of prior authorization review per CMS guidance. Follicular Lymphoma-approve if the patient has received at least two lines of systemic therapy. Note: Examples of systemic therapy for follicular lymphoma include CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) plus rituximab or Gazyva (obinutuzumab intravenous infusion) and CVP (cyclophosphamide, vincristine, prednisone) plus rituximab or Gazyva. B-Cell Lymphoma (examples: diffuse large B-cell lymphoma, high-grade B-cell lymphoma, HIV-related B-cell lymphomas, post-transplant lymphoproliferative disorders)- approve if patient has received at least one line of systemic therapy and will be used in combination with Polivy. Note: Examples of systemic therapy for B-Cell lymphoma include RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) and Pola-R-CHP (Polivy [polatuzumab vedotin-piiq intravenous infusion], rituximab, cyclophosphamide, doxorubicin, prednisone).
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	B-Cell Lymphoma
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

LUNSUMIO VELO

Products Affected

- LUNSUMIO VELO

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	1 year
Other Criteria	Part B vs Part D determination will be made at time of prior authorization review per CMS guidance. FOLLICULAR LYMPHOMA-patient has received at least two lines of systemic therapy. Note: Examples of systemic therapy include CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) plus rituximab or Gazyva (obinutuzumab intravenous infusion), CVP (cyclophosphamide, vincristine, prednisone) plus rituximab or Gazyva, lenalidomide plus rituximab with or without Epcoritamab-bysp subcutaneous injection) or Monjuvi (tafasitamab-cxix intravenous infusion), bendamustine plus Gazyva or rituximab, or Tazverik (tazemetostat tablets). MANTLE CELL LYMPHOMA- all of (A and B): A. Tried at least one covalent Bruton tyrosine kinase inhibitor, Note: Examples of a covalent Bruton tyrosine kinase inhibitors include Brukinsa (zanubrutinib capsules and tablets), Calquence (acalabrutinib tablets), and Imbruvica (ibrutinib capsules, oral suspension, and tablets). AND B. Medication will be used in combination with Polivy (polatuzumab vedotin-piiq intravenous infusion) .
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Mantle cell lymphoma
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

LUPRON DEPOT

Products Affected

- LUPRON DEPOT

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	Premenstrual disorders - 18 years and older
Prescriber Restrictions	Prostate cancer-prescribed by/consultation with oncologist or urologist. Other cancer diagnosis- prescribed by/consultation with an oncologist. Gender dysphoria/reassignment- prescribed by/consultation with endocrinologist or physician who specializes in treatment of transgender patients
Coverage Duration	uterine leiomyomata - 3 months, abnormal uterine bleeding - 6 months, all others - 12 months
Other Criteria	Endometriosis-approve if the pt has tried one of the following, unless contraindicated: a contraceptive, an oral progesterone or depo-medroxyprogesterone injection. An exception can be made if the pt has previously tried a gonadotropin-releasing hormone [GnRH] agonist (e.g. Lupron Depot) or antagonist (e.g. Orilissa). Head and neck cancer-salivary gland tumor- approve if pt has recurrent, unresectable, or metastatic disease AND androgen receptor-positive disease. Premenstrual disorders including PMS and PMDD- approve if pt has severe refractory premenstrual symptoms AND pt has tried an SSRI or combined oral contraceptive. Prostate cancer - for patients new to therapy requesting Lupron Depot 7.5mg, patients are required to try Eligard prior to approval.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	abnormal uterine bleeding, breast cancer, gender dysphoria/gender reassignment, head and neck cancer-salivary gland tumors, ovarian cancer including fallopian tube and primary peritoneal cancers, premenstrual disorders including premenstrual syndrome and premenstrual dysphoric disorder, prophylaxis or treatment of uterine bleeding or menstrual

PA Criteria	Criteria Details
	suppression in pts with hematologic malignancy or undergoing cancer treatment or prior to bone marrow or stem cell transplant, uterine cancer
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

LYNOZYFIC

Products Affected

- LYNOZYFIC

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	1 year
Other Criteria	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. MULTIPLE MYELOMA-all of the following (A and B): A) Tried at least four systemic regimens, AND B) Among the previous regimens tried, the patient has received at least one drug from each of the following classes (i, ii, and iii): i. Proteasome inhibitor, Note: Examples include bortezomib, Kyprolis (carfilzomib intravenous infusion), Ninlaro (ixazomib capsules) AND ii. Immunomodulatory drug, Note: Examples include lenalidomide, Pomalyst (pomalidomide capsules), Thalomid (thalidomide capsules) AND iii. Anti-CD38 monoclonal antibody, Note: Examples include Darzalex (daratumumab intravenous infusion), Darzalex Faspro (daratumumab and hyaluronidase-fihj subcutaneous injection), or Sarclisa (isatuximab-irfc intravenous infusion).
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

LYNPARZA

Products Affected

- LYNPARZA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Ovarian, Fallopian Tube, or Primary Peritoneal Cancer - Maintenance monotherapy-Approve if the patient has a germline or somatic BRCA mutation-positive disease as confirmed by an approved test AND The patient is in complete or partial response to at least one platinum-based chemotherapy regimen (e.g., carboplatin with gemcitabine, carboplatin with paclitaxel, cisplatin with gemcitabine). Ovarian, fallopian tube, or primary peritoneal cancer-maintenance, combination therapy-approve if the medication is used in combination with bevacizumab, the patient has homologous recombination deficiency (HRD)-positive disease, as confirmed by an approved test and the patient is in complete or partial response to first-line platinum-based chemotherapy regimen. Breast cancer, adjuvant-approve if the patient has germline BRCA mutation-positive, HER2-negative breast cancer and the patient has tried neoadjuvant or adjuvant therapy. Breast cancer, recurrent or metastatic disease-approve if the patient has recurrent or metastatic disease and has (i or ii): i) germline BRCA mutation-positive breast cancer or ii) germline PALB2 mutation-positive breast cancer. Pancreatic Cancer-maintenance therapy-approve if the patient has a germline BRCA mutation-positive metastatic disease and the disease has not progressed on at least 16 weeks of treatment with a first-line platinum-based chemotherapy regimen. Prostate cancer-castration resistant-approve if the patient has metastatic disease, the medication is used concurrently with a gonadotropin-releasing hormone (GnRH) analog

PA Criteria	Criteria Details
	or the pateint has had a bilateral orchiectomy, and the patient meets either (i or ii): i) the patient has germline or somatic homologous recombination repair (HRR) gene-mutated disease, as confirmed by an approved test and the patient has been previously treated with at least one androgen receptor directed therapy or ii) the patient has a BRCA mutation and the medication is used in combination with abiraterone plus one of prednisone or prednisolone. Uterine Leiomyosarcoma-approve if the patient has BRCA2-altered disease and has tried at least one systemic regimen.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Uterine Leiomyosarcoma
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

LYTGOBI

Products Affected

- LYTGOBI ORAL TABLET 12 MG/DAY (4 MG X 3), 16 MG/DAY (4 MG X 4), 20 MG/DAY (4 MG X 5)

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Cholangiocarcinoma-approve if the patient has unresectable locally advanced or metastatic disease, tumor has fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements as detected by an approved test and if the patient has been previously treated with at least one systemic regimen. Note: Examples of systemic regimens include gemcitabine + cisplatin, 5-fluorouracil + oxaliplatin or cisplatin, capecitabine + cisplatin or oxaliplatin, gemcitabine + Abraxane (albumin-bound paclitaxel) or capecitabine or oxaliplatin, and gemcitabine + cisplatin + Abraxane.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

MAVYRET

Products Affected

- MAVYRET ORAL PELLETS IN PACKET
- MAVYRET ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	3 years or older
Prescriber Restrictions	Prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or a liver transplant physician
Coverage Duration	Chronic HCV- Criteria will be applied consistent with AASLD/IDSA guidance, Acute HCV-8 weeks
Other Criteria	For Chronic Hepatitis C Virus, criteria will be applied consistent with current AASLD/IDSA guidance. For Acute Hepatitis C Virus (HCV) Genotype 1, 2, 3, 4, 5, or 6: Approve if the patient meets (A, B and C): A) Does not have cirrhosis OR has compensated cirrhosis AND B) has quantifiable HCV RNA AND C) ONE of the following (i, ii, or iii): i. conversion of negative to positive results in anti-HCV antibody, HCV RNA, and/or HCV core antigen OR ii. signs and symptoms of acute hepatitis C virus OR iii. has engaged in a risk behavior for HCV infection within the prior 6 months.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Indications consistent with current AASLD/IDSA guidance
Part B Prerequisite	No
Prerequisite Therapy Required	No

MEGESTROL

Products Affected

- *megestrol oral suspension 400 mg/10 ml (10 ml), 400 mg/10 ml (40 mg/ml), 625 mg/5 ml (125 mg/ml)*
- *megestrol oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	Coverage is not provided for weight gain for cosmetic reasons.
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

MEKINIST

Products Affected

- MEKINIST ORAL RECON SOLN
- MEKINIST ORAL TABLET 0.5 MG, 2 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 1 year.
Other Criteria	Melanoma (not including uveal melanoma)- must be used in patients with BRAF V600 mutation or BRAF fusion-positive, and patient has unresectable, advanced (including Stage III or Stage IV disease), or metastatic melanoma. Note-This includes adjuvant treatment in patients with Stage III disease with no evidence of disease post-surgery. Uveal melanoma - approve if metastatic or unresectable disease. For NSCLC - approve if (A, B and C): A) recurrent, advanced or metastatic disease and B) pt has BRAF V600 Mutation and C) pt will use in combination with Tafenlar. Thyroid cancer, anaplastic-patient has locally advanced or metastatic anaplastic disease AND Mekinist will be taken in combination with Tafenlar AND the patient has BRAF V600-positive disease. Ovarian/fallopian tube/primary peritoneal cancer-approve if the patient has recurrent disease and the medication is used for (a or b): a) low-grade serous carcinoma or b) the patient has BRAF V600 mutation positive disease and the medication will be taken in combination with Tafenlar. Glioma-patient meets (A or B): A) has BRAF V600 mutation positive or BRAF fusion-positive disease and B) meets (i or ii): i) the medication will be used in combination with Tafenlar or ii) pt has circumscribed glioma. Histiocytic neoplasm-approve if patient has Langerhans cell histiocytosis or Erdheim Chester disease or Rosai-Dorfman disease. Solid Tumors [Note: Examples of solid tumors are: biliary tract cancer, brain metastases

PA Criteria	Criteria Details
	due to melanoma, differentiated thyroid carcinoma, gastrointestinal stromal tumors, gastric cancer, esophageal and esophagogastric junction cancers, salivary gland tumors, pancreatic adenocarcinoma, neuroendocrine tumors, occult primary, ampullary adenocarcinoma, small bowel adenocarcinoma]- Approve if the patient meets the following (A and B): A) Patient has BRAF V600 mutation-positive disease, AND B) The medication will be taken in combination with Tafenlar (dabrafenib capsules). Hairy Cell Leukemia, approve if pt has not previously been treated with a BRAF inhibitor therapy and this will be used for relapsed/refractory disease and will be taken in combination with Tafenlar.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Histiocytic Neoplasm, Hairy Cell Leukemia, Epithelioid Hemangioendothelioma
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

MEKTOVI

Products Affected

- MEKTOVI

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, BRAF V600 status, concomitant medications
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Melanoma - approve if the patient meets (A and B): A) has unresectable, advanced or metastatic melanoma AND B) meets (i or ii): i) has a BRAF V600 mutation AND Mektovi will be used in combination with Braftovi or ii) has NRAS mutation AND has tried at least one immune checkpoint inhibitor therapy. Histiocytic neoplasm-approve if the patient has Langerhans cell histiocytosis. NSCLC-approve if pt has BRAF V600E mutation-positive recurrent, advanced or metastatic disease AND this medication will be taken in combination with Braftovi (encorafenib capsules).
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Histiocytic Neoplasms, NRAS-mutated unresectable, advanced or metastatic melanoma
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

MEMANTINE

Products Affected

- *memantine oral capsule, sprinkle, er 24hr*
- *memantine oral solution*
- *memantine oral tablet*
- *memantine-donepezil*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Indication for which memantine is being prescribed.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 12 months.
Other Criteria	N/A
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Patients with mild to moderate vascular dementia.
Part B Prerequisite	No
Prerequisite Therapy Required	No

MEPSEVII

Products Affected

- MEPSEVII

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, genetic and lab test results
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a geneticist, endocrinologist, a metabolic disorder sub-specialist, or a physician who specializes in the treatment of lysosomal storage disorders.
Coverage Duration	1 year
Other Criteria	Approve if the patient has a laboratory test demonstrating deficient beta-glucuronidase activity in leukocytes, fibroblasts, or serum OR has a molecular genetic test demonstrating biallelic pathogenic or likely pathogenic glucuronidase gene variants.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

METHYLERGONOVINE

Products Affected

- *methylergonovine oral*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	7 days
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

MODAFINIL/ARMODAFINIL

Products Affected

- armodafinil*
- modafinil oral tablet 100 mg, 200 mg*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	18 years and older
Prescriber Restrictions	Excessive daytime sleepiness associated with narcolepsy-prescribed by or in consultation with a sleep specialist physician or neurologist
Coverage Duration	Authorization will be for 12 months.
Other Criteria	Excessive sleepiness associated with Shift Work Sleep Disorder (SWSD)-approve. Adjunctive/augmentation treatment for depression in adults-if the patient is concurrently receiving other medication therapy for depression. Excessive daytime sleepiness associated with obstructive sleep apnea/hypoapnea syndrome-approve. Excessive daytime sleepiness associated with Narcolepsy-approve if narcolepsy has been confirmed with polysomnography and a multiple sleep latency test (MSLT). Idiopathic hypersomnia - approve if diagnosis is confirmed by a sleep specialist physician or at an institution that specializes in sleep disorders (i.e., sleep center).
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Excessive daytime sleepiness (EDS) associated with myotonic dystrophy - modafinil only. Adjunctive/augmentation for treatment of depression in adults - modafinil only. Idiopathic hypersomnia - modafinil only.
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

MODEYSO

Products Affected

- MODEYSO

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	HIGH-GRADE GLIOMA (Note: Examples of high-grade glioma include World Health Organization (WHO) Grade 3 or 4 gliomas, such as diffuse midline glioma or glioblastoma)-all the following (A, B and C): A) Histone 3 (H3) K27M mutation, AND B) Recurrent or progressive disease, AND C) Received at one least prior therapy. Note: Examples of prior therapy include radiation, temozolomide, procarbazine, lomustine, or vincristine.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

MONJUVI

Products Affected

- MONJUVI

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	1 year
Other Criteria	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Diffuse large B-Cell Lymphoma - Approve if the patient has been treated with at least one prior chemotherapy regimen. B-cell lymphoma-Approve if the patient has been treated with at least one prior chemotherapy regimen. Follicular lymphoma - approve if pt meets (A and B): A) pt has been treated with at least one prior systemic regimen and B) medication will be used in combination with lenalidomide and rituximab.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	B-Cell Lymphoma (Examples include high-grade B-cell lymphoma, HIV-related B-cell lymphoma, post-transplant lymphoproliferative disorders, histologic transformation of indolent lymphomas to diffuse large B-cell lymphoma)
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

MYFEMBREE

Products Affected

- MYFEMBREE

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, test results
Age Restrictions	18 years and older
Prescriber Restrictions	Fibroids-Prescribed by or in consultation with an obstetrician-gynecologist or a health care practitioner who specializes in the treatment of women's health
Coverage Duration	24 months of total therapy between Myfembree or Oriahnn
Other Criteria	Uterine Fibroids (Leiomyomas)-approve if the patient is premenopausal (before menopause) and is experiencing heavy menstrual bleeding associated with the uterine fibroids, the uterine fibroids have been confirmed by a pelvic ultrasound, including transvaginal ultrasonography or sonohysterography, hysteroscopy, or magnetic resonance imaging. Endometriosis-approve if the patient is premenopausal and patient has previously tried one of the following (i or ii): i. A contraceptive (e.g., combination oral contraceptives, levonorgestrel-releasing intrauterine systems, a depo-medroxyprogesterone injection), unless contraindicated OR ii. An oral progesterone (e.g., norethindrone tablets), unless contraindicated. Note: An exception to this requirement can be made if the patient has previously used a gonadotropin-releasing hormone agonist (e.g., Lupron Depot [leuprolide depot suspension]) or Orilissa (elagolix tablets).
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

NAGLAZYME

Products Affected

- NAGLAZYME

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, genetic and lab test results
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a geneticist, endocrinologist, a metabolic disorder sub-specialist, or a physician who specializes in the treatment of lysosomal storage disorders
Coverage Duration	1 year
Other Criteria	Approve if the patient has a laboratory test demonstrating deficient N-acetylgalactosamine 4-sulfatase (arylsulfatase B) activity in leukocytes or fibroblasts OR has a molecular genetic test demonstrating biallelic pathogenic or likely pathogenic arylsulfatase B gene variants.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

NAYZILAM

Products Affected

- NAYZILAM

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, other medications used at the same time
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	1 year
Other Criteria	Intermittent Episodes of Frequent Seizure Activity (i.e., seizure clusters, acute repetitive seizures)-approve if the patient is currently receiving maintenance antiepileptic medication(s).
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

NEMLUVIO

Products Affected

- NEMLUVIO

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with another monoclonal antibody therapy
Required Medical Information	Diagnosis
Age Restrictions	AD: 12 years and older (initial therapy), PN: 18 years and older (initial therapy)
Prescriber Restrictions	Prescribed by or in consultation with an allergist, immunologist or dermatologist (initial therapy)
Coverage Duration	1 year
Other Criteria	INITIAL CRITERIA: ATOPIC DERMATITIS-approve if this medication will be used with a topical corticosteroid (CS) and/or topical calcineurin inhibitor or AD has improved sufficiently with Nemluvio and topical therapy has been discontinued. PRURIGO NODULARIS-All of (A and B): A) Pruritis for greater than or equal to 6 weeks, AND B) Meets i or ii: i) prurigo nodularis is NOT medication induced or secondary to a non-dermatologic condition such as neuropathy or a psychiatric disease, OR ii) secondary cause of prurigo nodularis has been identified and adequately managed. CONTINUATION CRITERIA: ATOPIC DERMATITIS-patient has received at least 4 months of therapy with Nemluvio and has responded to therapy. PRURIGO NODULARIS-patient has received at least 4 months of therapy with Nemluvio, and experienced beneficial clinical response defined by ONE of the following (A, B, or C): A) reduced nodular lesion count, OR B) Decreased pruritus, OR C) Reduced nodular lesion size. Note: A patient who has received less than 4 months of therapy or who is restarting therapy with Nemluvio should be considered under initial therapy.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	No

NERLYNX

Products Affected

- NERLYNX

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Stage of cancer, HER2 status, previous or current medications tried
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	Adjuvant tx breast cancer-Approve for 1 year (total), all others-1 year
Other Criteria	Breast cancer, adjuvant therapy - approve if the patient meets all of the following criteria: patient will not be using this medication in combination with HER2 antagonists, patient has HER2-positive breast cancer AND Patient has completed one year of adjuvant therapy with trastuzumab OR could not tolerate one year of therapy. Breast cancer, recurrent or metastatic disease HER2 positive disease-approve if the patient has HER-2 positive breast cancer, and patient meets (i or ii): i) Nerlynx will be used in combination with capecitabine and the patient has tried at least two prior anti-HER2 based regimens OR ii) the medication is used in combination with one of the following: capecitabine, paclitaxel, or Kadcyla (ado-trastuzumab emtansine intravenous infusion) and the patient has brain metastases. Breast Cancer, Recurrent or Metastatic HER2 Negative Disease: Approve if pt meets (A, B, C and D): A) has HER2-negative breast cancer AND B) cancer has a HER2-activating mutation AND C) meets (i or ii): i) Pt is a postmenopausal female or a male OR ii) pre/perimenopausal female and meets (a or b): a) receiving ovarian suppression/ovarian ablation with a gonadotropin-releasing hormone (GnRH) agonist OR b) has had surgical bilateral oophorectomy or ovarian irradiation AND D) meets (i or ii): i) meets (a and b): a) has hormone receptor (HR)-positive disease AND b) has tried at least one CDK4/6 inhibitor therapy OR ii) has (HR)-negative disease. Cervical Cancer:

PA Criteria	Criteria Details
	Approve if patient meets (A, B and C): A) HER2-mutant disease AND B) recurrent or metastatic disease AND C) tried at least one systemic regimen.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Breast Cancer - Recurrent or Metastatic HER2 Negative Disease, Cervical Cancer
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

NEXLETOL

Products Affected

- NEXLETOL

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	LDL-C and response to other agents, prior therapies tried, medication adverse event history, medical history (as specified in the Other Criteria field)
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 1 year
Other Criteria	HYPERLIPIDEMIA WITH HeFH (both A and B): A) meets (a, b, c, or d): a) untreated LDL-C greater than or equal to 190 mg/dL, b) phenotypic confirmation (Note 1) of HeFH, c) Dutch Lipid Network criteria score greater than 5, or d) Simon Broome criteria met threshold for definite or possible/probable, AND B) meets (a or b): a) tried one high-intensity statin (throughout, see Definition 1 below) and ezetimibe and LDL-C remains 70 mg/dL or higher or b) statin intolerant (throughout, see Definition 2 below). ESTABLISHED CVD (both A and B): A) patient has/had one of the following conditions: prior MI, ACS, angina, CVA or TIA, CAD, PAD, coronary or other arterial revascularization procedure, B) meets (a or b): a) tried one high-intensity statin and ezetimibe and LDL-C remains 55 mg/dL or higher or b) statin intolerant. PRIMARY HYPERLIPIDEMIA (not associated with established CVD or HeFH) [A or B]: A) tried one high-intensity statin and ezetimibe for 8 weeks or longer and LDL-C remains 70 mg/dL or higher or B) statin intolerant. Note 1: Examples include mutations at the low-density lipoprotein receptor (LDLR), apolipoprotein B (apo B), proprotein convertase subtilisin kexin type 9 (PCSK) or low-density lipoprotein receptor adaptor protein (LDLRAP1) gene. Definition 1: High intensity statin defined as atorvastatin greater than or equal to 40 mg daily or rosuvastatin greater than or equal to 20 mg daily. Definition 2: Statin intolerance defined as experiencing statin related rhabdomyolysis or skeletal-related muscle symptoms while receiving separate trials of

PA Criteria	Criteria Details
	atorvastatin and rosuvastatin and during both trials the skeletal-related symptoms resolved upon discontinuation of the statin.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

NEXLIZET

Products Affected

- NEXLIZET

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	LDL-C and response to other agents, prior therapies tried, medication adverse event history, medical history (as specified in the Other Criteria field)
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 1 year
Other Criteria	HYPERLIPIDEMIA WITH HeFH (both A and B): A) meets (a, b, c, or d): a) untreated LDL-C greater than or equal to 190 mg/dL, b) phenotypic confirmation (Note 1) of HeFH, c) Dutch Lipid Network criteria score greater than 5, or d) Simon Broome criteria met threshold for definite or possible/probable, AND B) meets (a or b): a) tried one high-intensity statin (throughout, see Definition 1 below) and LDL-C remains 70 mg/dL or higher or b) statin intolerant (throughout, see Definition 2 below). ESTABLISHED CVD (both A and B): A) patient has/had one of the following conditions: prior MI, ACS, angina, CVA or TIA, CAD, PAD, coronary or other arterial revascularization procedure, B) meets (a or b): a) tried one high-intensity statin and LDL-C remains 55 mg/dL or higher or b) statin intolerant. PRIMARY HYPERLIPIDEMIA (not associated with established CVD or HeFH) [A or B]: A) tried one high-intensity statin for 8 weeks or longer and LDL-C remains 70 mg/dL or higher or B) statin intolerant. Note 1: Examples include mutations at the low-density lipoprotein receptor (LDLR), apolipoprotein B (apo B), proprotein convertase subtilisin kexin type 9 (PCSK) or low-density lipoprotein receptor adaptor protein (LDLRAP1) gene. Definition 1: High intensity statin defined as atorvastatin greater than or equal to 40 mg daily or rosuvastatin greater than or equal to 20 mg daily. Definition 2: Statin intolerance defined as experiencing statin related rhabdomyolysis or skeletal-related muscle symptoms while receiving separate trials of

PA Criteria	Criteria Details
	atorvastatin and rosuvastatin and during both trials the skeletal-related symptoms resolved upon discontinuation of the statin.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

NILOTINIB

Products Affected

- DANZITEN
- nilotinib hcl oral capsule 150 mg, 200 mg, 50 mg*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	GIST/Myeloid/lymphoid neoplasms/melanoma, cutaneous-18 years and older, ALL - 15 years and older
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 12 months.
Other Criteria	Acute lymphoblastic leukemia, philadelphia chromosome positive-approve. CML, philadelphia chromosome positive or BCR::ABL1-mutation positive chronic myeloid leukemia- approve. For GIST, approve if the patient has tried two of the following: imatinib, avapritinib, sunitinib, dasatinib, regorafenib or ripretinib. Myeloid/lymphoid neoplasms with eosinophilia-approve if the tumor has an ABL1 rearrangement. Pigmented villonodular synovitis/tenosynovial giant cell tumor-approve if the patient has tried Turalio or Romvimza or cannot take Turalio or Romvimza, according to the prescriber. For melanoma, cutaneous - approve if the patient has metastatic or unresectable disease AND has an activating KIT mutation AND has tried at least one systemic regimen.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Philadelphia positive Acute Lymphoblastic Leukemia (ALL) and Gastrointestinal Stromal Tumor (GIST), Pigmented villonodular synovitis/tenosynovial giant cell tumor, Myeloid/Lymphoid neoplasms with Eosinophilia, melanoma cutaneous.
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

NILUTAMIDE

Products Affected

- *nilutamide*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Prostate cancer-approve if nilutamide is used in beneficiaries who have had surgical castration or in combination with a luteinizing hormone-releasing hormone (LHRH) agonist.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

NINLARO

Products Affected

- NINLARO

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 1 year.
Other Criteria	MM - approve if (A, B, C or D): A) this medication will be used in combination with lenalidomide or cyclophosphamide and dexamethasone, OR B) pt had received at least ONE prior regimen for multiple myeloma OR C) this medication will be used following hematopoietic stem cell transplantation or D) the patient is not a candidate for bortezomib or Kyprolis (carfilzomib intravenous infusion) and is also not a transplant candidate. Systemic light chain amyloidosis-approve if the patient has tried at least one other regimen for this condition. Waldenstrom Macroglobulinemia/lymphoplasmacytic lymphoma-approve if used in combination with a rituximab product and dexamethasone (Part B before Part D Step Therapy - applies only to beneficiaries enrolled in an MA-PD plan).
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Patients with systemic light chain amyloidosis, Waldenstrom Macroglobulinemia/lymphoplasmacytic lymphoma, Multiple myeloma after previous treatment (either monotherapy or in combination other than lenalidomide/dexamethasone) or stem cell transplant
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

NITISINONE

Products Affected

- *nitisinone*

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant therapy with nitisinone products
Required Medical Information	Diagnosis, genetic tests and lab results (as specified in the Other Criteria field)
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a metabolic disease specialist (or specialist who focuses in the treatment of metabolic diseases)
Coverage Duration	1 year
Other Criteria	HereditaryTyrosinemia, Type 1-approve if the prescriber confirms the diagnosis was confirmed by genetic testing confirming biallelic pathogenic/likely pathogenic variants in the FAH gene OR elevated levels of succinylacetone in the serum or urine.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

NIVESTYM

Products Affected

- NIVESTYM

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Cancer/AML, MDS, ALL-oncologist or a hematologist. Cancer patients receiving BMT and PBPC-prescribed by or in consultation with an oncologist, hematologist, or a physician who specializes in transplantation. Radiation-expertise in acute radiation. SCN-hematologist. HIV/AIDS neutropenia-infectious disease (ID) physician (MD), hematologist, or MD specializing in HIV/AIDS.
Coverage Duration	chemo/SCN/AML-6 mo.HIV/AIDS-4 mo.MDS-3 mo.PBPC,Drug induce A/N,ALL,BMT, Radiation-1 mo
Other Criteria	Cancer patients receiving chemotherapy, approve if the patient meets one of the following conditions: 1)patient is receiving myelosuppressive anti-cancer medications that are associated with a high risk of febrile neutropenia (the risk is at least 20% based on the chemotherapy regimen), 2)patient is receiving myelosuppressive anti-cancer medications that are associated with a risk of febrile neutropenia but the risk is less than 20% based on the chemotherapy regimen and the patient has one or more risk factors for febrile neutropenia (eg, aged greater than 65 years receiving full chemotherapy dose intensity, prior chemotherapy or radiation therapy, persistent neutropenia, bone marrow involvement by tumor, recent surgery and/or open wounds, liver dysfunction (bilirubin greater than 2 mg/dL), renal dysfunction (CrCl less than 50 mL/min), poor performance status, or HIV infection patients with low CD4 counts), 3)patient has had a neutropenic complication from prior chemotherapy cycle and did not receive prophylaxis with a colony stimulating factor and a reduced dose or frequency of chemotherapy may compromise treatment, or 4)patient has received chemotherapy has febrile neutropenia and has at least one risk factor (eg, sepsis syndrome, aged greater than 65 years, severe neutropenia

PA Criteria	Criteria Details
	[absolute neutrophil count less than 100 cells/mm ³], neutropenia expected to be greater than 10 days in duration, pneumonia or other clinically documented infections, invasive fungal infection, hospitalization at the time of fever, prior episode of febrile neutropenia).
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Neutropenia associated with human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS). Treatment of myelodysplastic syndromes (MDS). Drug induced agranulocytosis or neutropenia. Acute lymphocytic leukemia (ALL), Radiation Syndrome (Hematopoietic Syndrome of Acute Radiation Syndrome)
Part B Prerequisite	No
Prerequisite Therapy Required	No

NON-INJECTABLE TESTOSTERONE PRODUCTS

Products Affected

- *testosterone transdermal gel* 1.62 % (20.25 mg/1.25 gram), 1.62 % (40.5 mg/2.5 gram)
- *testosterone transdermal gel in metered-dose pump* 12.5 mg/ 1.25 gram (1 %), 20.25 mg/1.25 gram (1.62 %)
- *testosterone transdermal solution in metered pump w/app*
- *testosterone transdermal gel in packet* 1 % (25 mg/2.5gram), 1 % (50 mg/5 gram),

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis of primary hypogonadism (congenital or acquired) in males. Diagnosis of secondary (hypogonadotropic) hypogonadism (congenital or acquired) in males. Hypogonadism (primary or secondary) in males, serum testosterone level. [Man is defined as an individual with the biological traits of a man, regardless of the individual's gender identity or gender expression.]
Age Restrictions	N/A
Prescriber Restrictions	Gender-Dysphoric/Gender-Incongruent Persons, Persons Undergoing Female-to-Male (FTM) Gender Reassignment (i.e., Endocrinologic Masculinization)-prescribed by or in consultation with an endocrinologist or a physician who specializes in the treatment of transgender patients.
Coverage Duration	Authorization will be for 12 months.
Other Criteria	Hypogonadism (primary or secondary) in males - initial therapy, approve if all of the following criteria are met: 1) patient has persistent signs and symptoms of androgen deficiency (pre-treatment) [eg, depressed mood, decreased energy, progressive decrease in muscle mass, osteoporosis, loss of libido, AND 2) patient has had two pre-treatment serum testosterone (total or available) measurements, each taken in the morning on two separate days, AND 3) the two serum testosterone levels are both low, as defined by the normal laboratory reference values. Hypogonadism (primary or secondary) in males - continuing therapy, approve if the patient meets all of the following criteria: 1) patient has persistent signs and symptoms of androgen deficiency (pre-treatment) AND 2) patient had at least one pre-treatment serum testosterone level that was low. [Note: male is defined as an individual with the biological traits of a man, regardless of the individual's gender identity or gender expression.] Gender-

PA Criteria	Criteria Details
	Dysphoric/Gender-Incongruent Persons, Persons Undergoing Female-to-Male (FTM) Gender Reassignment (i.e., Endocrinologic Masculinization)-approve.Note: For a patient who has undergone gender reassignment, use this FTM criterion for hypogonadism indication.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Gender-Dysphoric/Gender-Incongruent Persons, Persons Undergoing Female-to-Male (FTM) Gender Reassignment (i.e., Endocrinologic Masculinization)
Part B Prerequisite	No
Prerequisite Therapy Required	No

NUBEQA

Products Affected

- NUBEQA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Prostate cancer - non-metastatic, castration resistant-approve if the requested medication will be used concurrently with a gonadotropin-releasing hormone (GnRH) analog (See Note 1) or if the patient has had a bilateral orchiectomy. Prostate cancer-metastatic, castration sensitive-approve if the medication will be used in combination with a GnRH analog (See Note 1) or if the patient had a bilateral orchiectomy. Note 1: examples of GnRH analogs are leuprolide acetate, Lupron Depot (leuprolide acetate intramuscular injection), Trelstar (triptorelin pamoate intramuscular injection), Zoladex (goserelin acetate subcutaneous implant), Vantas (histrelin acetate subcutaneous implant), Firmagon (degarelix subcutaneous injection), Orgovyx (relugolix tablets).
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

NUCALA

Products Affected

- NUCALA SUBCUTANEOUS AUTO-INJECTOR
- NUCALA SUBCUTANEOUS RECON SOLN
- NUCALA SUBCUTANEOUS SYRINGE 100 MG/ML, 40 MG/0.4 ML

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with another monoclonal antibody therapy.
Required Medical Information	COPD initial - Approve if pt meets all (A, B AND C): A) pt has a blood eosinophil level at least 300 cells per microliter within the previous 6 weeks or prior to treatment with Nucala or another monoclonal antibody therapy that may alter blood eosinophil levels AND B) received at least 3 months of combination therapy with at least two of LAMA, LABA or ICS, AND C) pt meets (i or ii): i) experienced two or more COPD exacerbations requiring treatment with a systemic corticosteroid with or without an antibiotic in the previous 12 months OR ii) experienced one or more COPD exacerbations requiring a hospitalization in the previous 12 months. Cont - Approve if pt meets all (A, B and C): A) has already received at least 6 months of therapy with Nucala AND B) continues to receive combination therapy with an inhaled LABA and LAMA AND C) patient has experienced a beneficial clinical response, defined by one of the following: reduced symptoms, exacerbations, hospitalizations, ED/urgent care visits, improved lung function).
Age Restrictions	(Initial therapy only): Asthma-6 years of age and older. EGPA/Polyps/COPD-18 years of age and older. HES-12 years and older.
Prescriber Restrictions	(Initial therapy only): Asthma/COPD-Prescribed by or in consultation with an allergist, immunologist, or pulmonologist. EGPA-prescribed by or in consultation with an allergist, immunologist, pulmonologist or rheumatologist. HES-prescribed by or in consultation with an allergist, immunologist, hematologist, pulmonologist or rheumatologist. Polyps-prescribed by or in consult with allergist, immunologist or Otolaryngologist
Coverage Duration	Initial-Asthma/polyps/COPD-6 months, EGPA/HES-8 months. 12 months continuation.
Other Criteria	Asthma initial - must have blood eosinophil level of greater than or equal to 150 cells per microliter within the previous 6 wks (or prior to tx with Nucala or another monoclonal antibody therapy that may lower blood eosinophil levels) AND has received combo tx w/inhaled corticosteroid

PA Criteria	Criteria Details
	AND at least 1 additional asthma controller/maintenance med (Examples: LAMA, LABA, leukotriene receptor antagonist, monoclonal antibody) AND pt's asthma cont to be uncontrolled, or was uncontrolled prior to starting Nucala or another monoclonal antibody therapy for asthma as defined by 1 of following-pt experi 2 or more asthma exacer req tx w/systemic corticosteroids in prev yr, pt experienced 1 or more asthma exacer requiring hospitalization, urgent care visit or ED visit in the prev yr, pt has a FEV1 less than 80% predicted (90% for pt under 18), Pt has FEV1/FVC less than 0.80 (0.9 for pt under 18), or Pt's asthma worsens upon taper of oral (systemic) corticosteroid therapy. Cont-pt responded to Nucala tx as determined by the prescribing physician AND Pt cont to receive tx with an inhaled corticosteroid. EGPA initial-approve if pt has active, non-severe disease, has/had a blood eosinophil level of greater than or equal to 150 cells per microliter within the previous 6 wks or prior to any monoclonal antibody that may lower blood eosinophil levels. Cont-pt responded to Nucala tx as determined by the prescribing physician.HES initial-pt has had hypereosinophilic synd for greater than or equal to 6 months AND has FIP1L1-PDGFRalpha-negative dis AND pt does NOT have identifiable non-hematologic secondary cause of hypereosinophilic synd AND prior to initiating tx with monoclonal antibody that may lower blood eosinophil levels, pt has/had a blood eosinophil level of greater than or equal to 1,000 cells per microliter. Cont-approve if the patient has responded to Nucala tx. Nasal polyps, initial-approve if pt meets ALL of the following criteria(A, B, C and D):A) pt has chronic rhinosinusitis w/nasal polyposis as evidenced by direct examination, endoscopy, or sinus CT scan AND B)pt experienced 2 or more of the following sympt for at least 8 weeks: nasal congest/obstruct/discharge, and/or reduction/loss of smell AND C)pt meets BOTH of the following (a and b): a)Pt has received tx with intranasal corticosteroid AND b)Pt will continue to receive tx with intranasal corticosteroid concomitantly with Nucala AND D)pt meets 1 of the following (a, b or c): a)Pt has received at least 1 course of tx with a systemic corticosteroid for 5 days or more within the previous 2 years, OR b)Pt has a contraindication to systemic corticosteroid tx, OR c)Pt had prior surgery for nasal polyps.Cont-approve if the pt has received at least 6 months of therapy, continues to receive tx with an intranasal corticosteroid and has responded to tx.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

NUEDEXTA

Products Affected

- NUEDEXTA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	1 year
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

NUPLAZID

Products Affected

- NUPLAZID

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	1 year
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

NURTEC

Products Affected

- NURTEC ODT

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with another calcitonin gene-related peptide (CGRP) inhibitor being prescribed for migraine headache prevention if Nurtec ODT is being taking for the preventive treatment of episodic migraine.
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Migraine, Acute treatment-approve if the patient has tried at least one triptan or has a contraindication to triptans. Preventive treatment of episodic migraine-approve if the patient has greater than or equal to 4 but less than 15 migraine headache days per month (prior to initiating a migraine preventive medication) and if the patient is currently taking Nurtec ODT, the patient has had a significant clinical benefit from the medication. Examples of significant clinical benefit include a reduction in the overall number of migraine days per month or a reduction in number of severe migraine days per month from the time that Nurtec ODT was initiated.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

NYVEPRIA

Products Affected

- NYVEPRIA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Cancer patients receiving chemotherapy-prescribed by or in consultation with an oncologist or hematologist. PBPC-prescribed by or in consultation with an oncologist, hematologist, or physician that specializes in transplantation.
Coverage Duration	Cancer pts receiving chemo-6 mo. PBPC-1 mo
Other Criteria	Cancer patients receiving chemotherapy, approve if the patient meets one of the following: 1) is receiving myelosuppressive anti-cancer medications that are associated with a high risk of febrile neutropenia (the risk is at least 20% based on the chemotherapy regimen), 2) patient is receiving myelosuppressive anti-cancer medications that are associated with a risk of febrile neutropenia but the risk is less than 20% based on the chemotherapy regimen and the patient has one or more risk factors for febrile neutropenia according to the prescribing physician (eg, aged greater than 65 years receiving full chemotherapy dose intensity, prior chemotherapy or radiation therapy, persistent neutropenia, bone marrow involvement by tumor, recent surgery and/or open wounds, liver dysfunction (bilirubin greater than 2 mg/dL), renal dysfunction (CrCl less than 50 mL/min), poor performance status or HIV infection patients with low CD4 counts), or 3) patient has had a neutropenic complication from prior chemotherapy cycle and did not receive prophylaxis with a colony stimulating factor and a reduced dose or frequency of chemotherapy may compromise treatment.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Patients undergoing PBPC collection and therapy

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	No

OCTREOTIDE INJECTABLE

Products Affected

- *octreotide acetate*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Acromegaly-prescr/consult w/endocrinologist. NETs-prescr/consult w/oncologist, endocrinologist, or gastroenterologist. Pheochromocytoma/paraganglioma-prescr/consult w/endo/onc/neuro.Meningioma-prescr/consult w/oncologist, radiologist, neurosurg/thymoma/thymic carcinoma-presc/consult with oncologist. Diarrhea assoc w chemo-presc/consult with oncologist/gastro. Small bowel bleed/angiodysplasia-presc/consult gastroenterologist.
Coverage Duration	Enterocutaneous fistula/diarrhea assoc w chemo - 3 months, all others - 1 year
Other Criteria	ACROMEGALY (A or B): A) inadequate response to surgery and/or radiotherapy or patient not an appropriate candidate or B) patient is experiencing negative effects due to tumor size (e.g., optic nerve compression) and has pre-treatment (baseline) insulin-like growth factor-1 (IGF-1) level above the upper limit of normal based on age and gender. DIARRHEA ASSOC W CHEMO (A and B): A) grade 3 or 4 diarrhea [Examples: more than 6 bowel movements above baseline per day, colitis symptoms, interference with activities of daily living, hemodynamic instability, hospitalization, serious complications (eg, ischemic bowel, perforation, toxic mega-colon), or other colitis-related life-threatening conditions] and B) patient has tried at least one antimotility medication. SMALL BOWEL BLEEDS/ANGIODYSPLASIA RELATED BLEEDING: pt has chronic, recurrent gastrointestinal bleeds lasting greater than or equal to 3 months.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.

PA Criteria	Criteria Details
Off-Label Uses	Meningioma, thymoma and thymic carcinoma, pheochromocytoma and paraganglioma, enterocutaneous fistulas, diarrhea associated with chemotherapy, small bowel bleeds/angiodysplasia related bleeding
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ODOMZO

Products Affected

- ODOMZO

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	BCC - Must not have had disease progression while on Erivedge (vismodegib).
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Locally advanced BCC approve if the BCC has recurred following surgery/radiation therapy or if the patient is not a candidate for surgery AND the patient is not a candidate for radiation therapy, according to the prescribing physician. Metastatic BCC - approve, if the disease is limited to nodal metastases. (Note-This includes primary or recurrent nodal metastases. A patient with distant metastasis does not meet this requirement.) Diffuse Basal Cell Carcinoma Formation, including basal cell nevus syndrome (Gorlin syndrome) or other genetic forms of multiple basal cell carcinoma - approve.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Metastatic BCC, diffuse basal cell carcinoma formation
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

OFEV

Products Affected

- *nintedanib*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	18 years of age and older
Prescriber Restrictions	IPF-Prescribed by or in consultation with a pulmonologist. Interstitial lung disease associated with systemic sclerosis-prescribed by or in consultation with a pulmonologist or rheumatologist.
Coverage Duration	1 year
Other Criteria	IDIOPATHIC PULMONARY FIBROSIS (IPF), INITIAL [A and B]: A) diagnosis confirmed by presence of usual interstitial pneumonia (UIP) pattern on high-resolution computed tomography (HRCT) or surgical lung biopsy and B) forced vital capacity (FVC) greater than or equal to 40 percent of the predicted value at baseline (before any antifibrotic therapy such as nintedanib, Jascayd, pirfenidone). INTERSTITIAL LUNG DISEASE ASSOCIATED WITH SYSTEMIC SCLEROSIS, INITIAL (A and B): A) diagnosis confirmed by HRCT and B) FVC greater than or equal to 40 percent of the predicted value. CHRONIC FIBROSING INTERSTITIAL LUNG DISEASE (Progressive Pulmonary Fibrosis), INITIAL (all of A, B and C): A) FVC greater than or equal to 40 percent of the predicted value, B) fibrosing lung disease impacting more than 10 percent of lung volume on HRCT, and C) clinical signs of progression. ALL INDICATIONS, CONTINUATION: approve.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	No

OGSIVEO

Products Affected

- OGSIVEO ORAL TABLET 100 MG, 150 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Desmoid tumors (aggressive fibromatosis)-approve if the patient has progressing desmoid tumors and if the patient requires systemic treatment.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

OJEMDA

Products Affected

- OJEMDA ORAL SUSPENSION FOR RECONSTITUTION MG/WEEK (100 MG X 5), 600 MG/WEEK (100 MG X 6)
- OJEMDA ORAL TABLET 400 MG/WEEK (100 MG X 4), 500

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	6 months of age and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	PEDIATRIC LOW GRADE GLIOMA-patient has relapsed or refractory disease and the tumor is positive for one of the following: BRAF fusion, BRAF rearrangement or BRAF V600 mutation.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

OJJAARA

Products Affected

- OJJAARA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years of age and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Myelofibrosis-approve if the patient has (A, B or C): A) higher-risk disease, or B) lower-risk disease and has one disease-related symptom (Examples: fatigue, fever, night sweats, weight loss, abdominal discomfort, splenomegaly, thrombocytosis, or leukocytosis), or C) myelofibrosis-associated anemia. Accelerated or blast phase myeloproliferative neoplasm- approve if the patient has at least one disease- related symptom (Examples: fatigue, fever, night sweats, weight loss, abdominal discomfort, splenomegaly, thrombocytosis, or leukocytosis).
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Accelerated or blast phase myeloproliferative neoplasm
Part B Prerequisite	No
Prerequisite Therapy Required	No

ONUREG

Products Affected

- ONUREG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	AML - Approve if the medication is used for post-remission maintenance therapy AND allogeneic hematopoietic stem cell transplant is not planned. Peripheral T-cell lymphoma - approve.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Peripheral T-cell lymphoma
Part B Prerequisite	No
Prerequisite Therapy Required	No

OPDIVO

Products Affected

- OPDIVO

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	colon/rectal/melanoma-12 years and older, pediatric hodgkin lymphoma-less than 18 years old, All other (except gestational trophoblastic)-18 years and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist.
Coverage Duration	1 year
Other Criteria	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	anal carcinoma, cervical carcinoma, endometrial carcinoma, extranodal NK/T-Cell Lymphoma, gestational trophoblastic neoplasia, merkel cell carcinoma, neuroendocrine tumors, small bowel adenocarcinoma, small cell lung cancer, vulvar cancer, ampullary adenocarcinoma, bone cancer, diffuse high-grade gliomas, Kaposi sarcoma, primary mediastinal large B-cell lymphoma, biliary tract cancers, soft tissue sarcoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, pancreatic cancer, squamous cell skin carcinoma, thyroid carcinoma, vaginal cancer
Part B Prerequisite	No
Prerequisite Therapy Required	No

OPDIVO QVANTIG

Products Affected

- OPDIVO QVANTIG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older (all diagnoses except gestational trophoblastic neoplasia)
Prescriber Restrictions	Prescribed by or on consultation with an oncologist
Coverage Duration	1 year
Other Criteria	Part B vs Part D determination will be made at time of prior authorization review per CMS guidance.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	appendiceal cancer, ampullary adenocarcinoma, anal carcinoma, biliary tract cancers, cervical cancer, endometrial carcinoma, gestational trophoblastic neoplasia, Kaposi sarcoma, merkel cell carcinoma, mesothelioma, neuroendocrine tumors, small bowel adenocarcinoma, small cell lung cancer, squamous cell skin carcinoma, thyroid carcinoma, vaginal cancer, vulvar cancer
Part B Prerequisite	No
Prerequisite Therapy Required	No

OPDUALAG

Products Affected

- OPDUALAG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	12 years and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	1 year
Other Criteria	Part B vs Part D determination will be made at time of prior authorization review per CMS guidance. Melanoma-approve if the patient is greater than or equal to 40 kg and either (i or ii): (i) the patient has unresectable or metastatic disease or (ii) medication is used as neoadjuvant therapy.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

OPSUMIT

Products Affected

- OPSUMIT

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	PAH WHO group, right heart catheterization results
Age Restrictions	N/A
Prescriber Restrictions	PAH - must be prescribed by or in consultation with a cardiologist or a pulmonologist.
Coverage Duration	Authorization will be for 1 year.
Other Criteria	Pulmonary arterial hypertension (PAH) WHO Group 1 patients are required to have had a right-heart catheterization to confirm the diagnosis of PAH to ensure appropriate medical assessment.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

OPSYNVI

Products Affected

- OPSYNVI

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with guanylate cyclase stimulators
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a cardiologist or a pulmonologist (initial/continuation)
Coverage Duration	1 year
Other Criteria	Pulmonary arterial hypertension (PAH) WHO Group 1-approve if patient has had a right-heart catheterization to confirm the diagnosis.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

ORGOVYX

Products Affected

- ORGOVYX

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Prostate Cancer-approve.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

ORKAMBI

Products Affected

- ORKAMBI ORAL GRANULES IN PACKET
- ORKAMBI ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	Combination use with other CF Transmembrane Conductance Regulator Modulators
Required Medical Information	N/A
Age Restrictions	1 year of age and older
Prescriber Restrictions	prescribed by or in consultation with a pulmonologist or a physician who specializes in CF
Coverage Duration	1 year
Other Criteria	CF - Approve if the pt meets A, B and C: A) pt has two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator gene, and B) pt must have positive CF newborn screening test or family history of CF or clinical presentation consistent with signs and symptoms of CF and C) evidence of abnormal cystic fibrosis transmembrane conductance regulator function as demonstrated by i, ii, or iii: (i) elevated sweat chloride test or (ii) two cystic fibrosis-causing cystic fibrosis transmembrane conductance regulator mutations or (iii) abnormal nasal potential difference.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

ORSERDU

Products Affected

- ORSERDU ORAL TABLET 345 MG, 86 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Breast cancer-approve if the patient meets the following criteria (A, B, C, D, E and F): A) Patient has recurrent or metastatic disease, AND B) Patient has hormone receptor positive (HR+) [i.e. estrogen receptor positive (ER+) and/or progesterone receptor positive (PR+)] disease, AND C) Patient has human epidermal growth factor receptor 2 (HER2)-negative disease, AND D) Patient has estrogen receptor 1 gene (ESR1)-mutated disease, AND E) Patient has tried at least one endocrine therapy, Note: Examples of endocrine therapy include fulvestrant, anastrozole, exemestane, letrozole, and tamoxifen. AND F) meets one of the following (i or ii): i) pt is a postmenopausal woman or a man, or ii) pt is a pre/perimenopausal woman and meets (a or b): a) receiving ovarian suppression/ablation with a gonadotropin-releasing hormone (GnRH) agonist [examples: leuprolide acetate, Lupron Depot (leuprolide acetate intramuscular injection), Trelstar (triptorelin pamoate intramuscular injection), Zoladex (goserelin acetate subcutaneous injection)] or b) pt has had surgical bilateral oophorectomy or ovarian irradiation.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

OTEZLA

Products Affected

- OTEZLA MG (51), 10 MG (4)-20 MG (4)-30 MG (47)
- OTEZLA STARTER ORAL TABLETS,DOSE PACK 10 MG (4)- 20
- OTEZLA XR
- OTEZLA XR INITIATION

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent Use with a Biologic or with a Targeted Synthetic Disease-Modifying Antirheumatic Drugs (DMARD).
Required Medical Information	Diagnosis
Age Restrictions	PP/PsA- 6 years and older (initial), All other dx - 18 years and older (initial)
Prescriber Restrictions	All dx-initial only-PsA - Prescribed by or in consultation with a dermatologist or rheumatologist. PP - prescribed by or in consultation with a dermatologist. Behcet's-prescribed by or in consultation with a dermatologist or rheumatologist
Coverage Duration	Approve through end of plan year
Other Criteria	INITIAL THERAPY: PLAQUE PSORIASIS (PP): Approve. PSORIATIC ARTHRITIS (PsA): approve. BEHCET'S-oral ulcers or other mucocutaneous involvement. CONTINUATION THERAPY (PP/PsA/Behcet's): received 4 months of therapy and had a response.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

OXERVATE

Products Affected

- OXERVATE

PA Criteria	Criteria Details
Exclusion Criteria	Treatment duration greater than 16 weeks per affected eye(s)
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by an ophthalmologist or an optometrist.
Coverage Duration	Initial-8 weeks, continuation-approve for an additional 8 weeks
Other Criteria	Patients who have already received Oxervate-approve if the patient has previously received less than or equal to 8 weeks of treatment per affected eye(s) and the patient has a recurrence of neurotrophic keratitis.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

PADCEV

Products Affected

- PADCEV

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, prior therapies
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	1 year
Other Criteria	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Urothelial carcinoma-approve if the patient has locally advanced or metastatic disease and meets either (i or ii): (i): Padcev is used as first-line therapy and will be used in combination with Keytruda (pembrolizumab intravenous infusion), or (ii): Padcev is used as subsequent therapy.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

PANRETIN

Products Affected

- PANRETIN

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a dermatologist, oncologist, or infectious disease specialist
Coverage Duration	1 year
Other Criteria	Kaposi Sarcoma-approve if the patient is not receiving systemic therapy for Kaposi Sarcoma.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

PAVBLU

Products Affected

- PAVBLU

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Administered by or under the supervision of an ophthalmologist
Coverage Duration	1 year
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

PEMAZYRE

Products Affected

- PEMAZYRE

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, prior therapies
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 1 year.
Other Criteria	Cholangiocarcinoma-approve if the patient has unresectable locally advanced, gross residual, or metastatic disease and the tumor has a fibroblast growth factor receptor 2 (FGFR2) gene fusion or other rearrangement, as detected by an approved test AND the patient has been previously treated with at least one systemic therapy regimen. Myeloid/lymphoid neoplasms-approve if the patient has eosinophilia and the cancer has fibroblast growth factor receptor 1 (FGFR1) rearrangement, as detected by an approved test.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

PENICILLAMINE

Products Affected

- *penicillamine oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Wilson's Disease-Prescribed by or in consultation with a gastroenterologist, hepatologist or liver transplant physician
Coverage Duration	1 year
Other Criteria	Cystinuria-approve. Wilson's disease-approve if diagnosis is confirmed by ONE of the following (i or ii): i. Genetic testing results confirming biallelic pathogenic ATP7B mutations (in either symptomatic or asymptomatic individuals), OR ii. Confirmation of at least two of the following (a, b, c, d): a) Presence of Kayser-Fleischer rings, b) Serum ceruloplasmin level less than 20 mg/dL, c) Liver biopsy findings consistent with Wilson's disease, d) 24-hour urinary copper greater than 40 mcg/24 hours.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

PHENYLBUTYRATE

Products Affected

- sodium phenylbutyrate*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, genetic tests and lab results (as specified in the Other Criteria field)
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a metabolic disease specialist (or specialist who focuses in the treatment of metabolic diseases)
Coverage Duration	Pt meets criteria with no genetic test - 3 mo approval. Pt had genetic test - 12 mo approval
Other Criteria	Urea cycle disorders-approve if genetic or enzymatic testing confirmed a urea cycle disorder or if the patient has hyperammonemia diagnosed with an ammonia level above the upper limit of the normal reference range for the reporting laboratory.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

PHEOCHROMOCYTOMA

Products Affected

- *metyrosine*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, prior medication trials
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an endocrinologist or a physician who specializes in the management of pheochromocytoma (initial and continuation therapy for metyrosine)
Coverage Duration	Authorization will be for 1 year
Other Criteria	If the requested drug is metyrosine for initial therapy, approve if the patient has tried a selective alpha blocker (e.g., doxazosin, terazosin or prazosin). If the requested drug is metyrosine for continuation therapy, approve if the patient is currently receiving metyrosine or has received metyrosine in the past.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

PHOSPHATE BINDERS AND SIMILAR AGENTS

Products Affected

- *calcium acetate(phosphat bind)*
- *sevelamer carbonate oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	Patients on dialysis [non-D use].
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

PHOSPHODIESTERASE-5 INHIBITORS

Products Affected

- *alyq*
- *sildenafil (pulmonary arterial hypertension) oral tablet 20 mg*
- *tadalafil (pulmonary arterial hypertension) oral tablet 20 mg*

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent Use With Guanylate Cyclase Stimulators.
Required Medical Information	Diagnosis, right heart cath results
Age Restrictions	N/A
Prescriber Restrictions	For PAH, if prescribed by, or in consultation with, a cardiologist or a pulmonologist.
Coverage Duration	Authorization will be for 1 year.
Other Criteria	Pulmonary arterial hypertension (PAH), are required to have had a right-heart catheterization to confirm diagnosis of PAH to ensure appropriate medical assessment. Raynaud's Phenomenon-approve if the patient has tried one calcium channel blocker or if use of a calcium channel blocker is contraindicated. Clinical criteria incorporated into the quantity limit edits for sildenafil 20 mg tablets require confirmation that the indication is PAH or Raynaud's prior to reviewing for quantity exception.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Raynaud's Phenomenon
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

PIQRAY

Products Affected

- PIQRAY ORAL TABLET 200 MG/DAY (200 MG X 1), 250 MG/DAY (200 MG X 1), 300 MG/DAY (150 MG X 2)

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, prior therapies
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Breast Cancer. Approve if the patient meets the following criteria (A, B, C, D, E and F): A) The patient is a postmenopausal female, male or pre/perimenopausal and is receiving ovarian suppression with a gonadotropin-releasing hormone (GnRH) agonist or has had surgical bilateral oophorectomy or ovarian irradiation AND B) The patient has advanced or metastatic hormone receptor (HR)-positive disease AND C) The patient has human epidermal growth factor receptor 2 (HER2)-negative disease AND D) The patient has PIK3CA-mutated breast cancer as detected by an approved test AND E) The patient has progressed on or after at least one prior endocrine-based regimen (e.g., anastrozole, letrozole, exemestane, tamoxifen, toremifene or fulvestrant) AND F) Piqray will be used in combination with fulvestrant injection.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

PIRFENIDONE

Products Affected

- *pirfenidone oral capsule*
- *pirfenidone oral tablet 267 mg, 801 mg*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a pulmonologist
Coverage Duration	1 year
Other Criteria	IPF (initial therapy)- must have FVC greater than or equal to 40 percent of the predicted value at baseline (before any antifibrotic therapy such as pirfenidone, Ofev, Jascayd) AND IPF must be diagnosed with either findings on high-resolution computed tomography (HRCT) indicating usual interstitial pneumonia (UIP) or surgical lung biopsy demonstrating UIP. IPF (continuation of therapy)-approve.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

PLEGRIDY

Products Affected

- PLEGRIDY INTRAMUSCULAR
- PLEGRIDY SUBCUTANEOUS PEN INJECTOR 125 MCG/0.5 ML, 63 MCG/0.5 ML- 94 MCG/0.5 ML
- PLEGRIDY SUBCUTANEOUS SYRINGE 125 MCG/0.5 ML, 63 MCG/0.5 ML- 94 MCG/0.5 ML

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use of with other disease-modifying agents used for multiple sclerosis (MS).
Required Medical Information	Relapsing form of Multiple Sclerosis (MS), to include clinically-isolated syndrome, relapsing-remitting disease, and active secondary progressive disease
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by, or in consultation with, a neurologist or an MS specialist.
Coverage Duration	Authorization will be for 1 year
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

POLIVY

Products Affected

- POLIVY

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, prior therapies
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	6 months
Other Criteria	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Diffuse large B-cell lymphoma- Approve if the patient has International Prognostic Index score of greater than or equal to 2 and will use Polivy as first line therapy OR the patient has been treated with at least one prior chemotherapy regimen. Note: Diffuse large B-cell lymphoma includes histologic transformation of indolent lymphomas to diffuse large B-cell lymphoma. B-Cell Lymphoma (Examples include HIV-related B-cell lymphoma and post-transplant lymphoproliferative disorders) - approve if the patient has an International Prognostic Index score of at least 2 or has been treated with at least one prior chemotherapy regimen. High-Grade B-Cell Lymphoma - Approve.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	B-Cell Lymphoma
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

POMALYST

Products Affected

- *pomalidomide*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	Kaposi Sarcoma/MM/Systemic light chain amyloidosis-18 years and older
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 1 year.
Other Criteria	Primary CNS Lymphoma-approve if the patient has relapsed or refractory disease or is not a candidate for high-dose MTX or had intolerance to high-dose MTX. Kaposi Sarcoma-Approve if the patient meets one of the following (i or ii): i. patient is Human Immunodeficiency Virus (HIV)-negative OR ii. patient meets both of the following (a and b): a) The patient is Human Immunodeficiency Virus (HIV)-positive AND b) The patient continues to receive highly active antiretroviral therapy (HAART). MM-approve if the patient has tried at least one other regimen. Systemic light chain amyloidosis- approve if this is used in combination with dexamethasone and pt tried at least one other regimen.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Systemic Light Chain Amyloidosis, Primary Central Nervous System (CNS) Lymphoma
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

POSACONAZOLE (ORAL)

Products Affected

- *posaconazole oral tablet, delayed release (dr/ec)*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	6 months
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

POTELIGEO

Products Affected

- POTELIGEO

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Mycosis fungoides/Sezary-prescribed by, or in consultation with an oncologist or dermatologist. ATLL-prescribed by or in consultation with an oncologist
Coverage Duration	1 year
Other Criteria	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Mycosis Fungoides/Sezary Syndrome-Approve. ATLL- approve if pt meets (A and B): A) pt has chronic high risk, acute, or lymphoma subtypes, and B) medication is used as second-line or subsequent therapy.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Adults with T-cell leukemia/lymphoma (ATLL)
Part B Prerequisite	No
Prerequisite Therapy Required	No

PREVYMIS

Products Affected

- PREVYMIS INTRAVENOUS
- PREVYMIS ORAL TABLET 240 MG, 480 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	6 months
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

PROMACTA

Products Affected

- *eltrombopag olamine*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Cause of thrombocytopenia. Thrombocytopenia due to HCV-related cirrhosis, platelet counts. Severe aplastic anemia, platelet counts and prior therapy. MDS-platelet counts.
Age Restrictions	N/A
Prescriber Restrictions	Immune Thrombocytopenia or Aplastic Anemia, prescribed by, or after consultation with, a hematologist (initial therapy). Hep C, prescribed by, or after consultation with, a gastroenterologist, hematologist, hepatologist, or a physician who specializes in infectious disease (initial therapy). MDS-presc or after consult with heme/onc (initial therapy). Post-transplant, prescribed by or in consult with a hematologist, oncologist or stem cell transplant specialist physician (initial)
Coverage Duration	ImmuneThrombo/MDS init3mo,cont1yr,AAinit4mo,cont1yr,Thrombo/HepC1yr,Transplant-init3mo,cont6mo
Other Criteria	Thrombocytopenia in patients with immune thrombocytopenia, initial-approve if the patient has a platelet count less than 30, 000 microliters or less than 50, 000 microliters and the patient is at an increased risk for bleeding AND the patient has tried ONE other therapy (e.g., systemic corticosteroids, intravenous immunoglobulin, anti-D immunoglobulin, Nplate, Tavalisse, Doptelet, rituximab) or has undergone a splenectomy. Cont-approve if the patient demonstrates a beneficial clinical response and remains at risk for bleeding complications. Treatment of thrombocytopenia in patients with Chronic Hepatitis C initial - approve if the patient will be receiving interferon-based therapy for chronic hepatitis C AND if the patient has low platelet counts at baseline (eg, less than 75,000 microliters). Aplastic anemia initial - approve if the patient has low platelet counts at baseline/pretreatment (e.g., less than 30,000 microliter) AND tried one immunosuppressant therapy (e.g., cyclosporine) OR patient will be using eltrombopag in combination with standard immunosuppressive therapy. Cont-approve if the patient demonstrates a beneficial clinical response.

PA Criteria	Criteria Details
	MDS initial-approve if patient has low- to intermediate-risk MDS AND the patient has a platelet count less than 30, 000 microliters or less than 50, 000 microliters and is at an increased risk for bleeding. Cont-approve if the patient demonstrates a beneficial clinical response and remains at risk for bleeding complications. Thrombocytopenia post-allogeneic transplantation, initial - approve if, according to the prescriber, the patient has poor graft function AND has a platelet count less than 50,000/mcL. Cont- patient demonstrated a beneficial clinical response.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Thrombocytopenia in Myelodysplastic Syndrome (MDS), Thrombocytopenia in a patient post-allogeneic transplantation
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

PYRIMETHAMINE

Products Affected

- pyrimethamine*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Toxoplasmosis Treatment-prescribed by or in consultation with an infectious diseases specialist, a maternal-fetal medicine specialist, or an ophthalmologist. All other indications - prescribed by or in consultation with an infectious disease specialist or a physician specializing in the treatment of human immunodeficiency virus (HIV) infection
Coverage Duration	12 months
Other Criteria	N/A
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Chronic maintenance and prophylaxis of Toxoplasma Gondii encephalitis, chronic maintenance and prophylaxis of cystoisosporiasis, chronic maintenance and prophylaxis of Pneumocystis pneumonia
Part B Prerequisite	No
Prerequisite Therapy Required	No

QINLOCK

Products Affected

- QINLOCK

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, other therapies tried
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 1 year.
Other Criteria	Gastrointestinal stromal tumor (GIST)-approve if the patient has tried imatinib or avapritinib tablets, AND the patient meets one of the following criteria (i, ii, or iii): i. Patient has tried sunitinib and regorafenib tablets, OR ii. Patient has tried dasatinib tablets, OR iii. Patient is intolerant of sunitinib. Melanoma, cutaneous-approve if the patient has metastatic or unresectable disease, AND the patient has an activating KIT mutation, AND the patient has tried at least one systemic regimen.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Melanoma, cutaneous
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

QULIPTA

Products Affected

- QULIPTA

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with another calcitonin gene-related peptide (CGRP) inhibitor being prescribed for migraine headache prevention
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Migraine headache prevention-approve if the patient meets (A and B): A) has greater than or equal to 4 migraine headache days per month (prior to initiating a migraine-preventative medication, and B) if the pt is currently taking Qulipta, the pt has had significant clinical benefit. Examples of significant clinical benefit include a reduction in the overall number of migraine days per month or a reduction in number of severe migraine days per month from the time that Qulipta was initiated.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

RADICAVA ORS

Products Affected

- RADICAVA ORS
- RADICAVA ORS STARTER KIT SUSP

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	ALSFRS-R score
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a neurologist, a neuromuscular disease specialist, or a physician specializing in the treatment of ALS (initial and continuation).
Coverage Duration	Initial, 6 months. Continuation, 6 months
Other Criteria	ALS, initial therapy - approve if the patient meets ALL of the following criteria: 1. According to the prescribing physician, the patient has a definite or probable diagnosis of ALS, based on the application of the El Escorial or the revised Airlie house diagnostic criteria AND 2. Patient has a score of two points or more on each item of the ALS Functional Rating Scale - Revised (ALSFRS-R) [ie, has retained most or all activities of daily living], AND 3. Patient has adequate respiratory function according to the prescriber, AND 4. Patient has received or is currently receiving riluzole tablets. Note-a trial of Tiglutik or Exservan would also count. ALS, continuation therapy - approve if, according to the prescribing physician, the patient continues to benefit from therapy.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

RECLAST

Products Affected

- *zoledronic acid-mannitol-water*
intravenous piggyback 5 mg/100 ml

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent Use with Other Medications for Osteoporosis (e.g., other bisphosphonates, Evenity, Prolia, Forteo/Bonsity, Tymlos, calcitonin nasal spray)
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Paget's 1 month. Others 12 months.
Other Criteria	Tx of osteo in post menopausal pt or osteo in men (a man defined as an individual with biological traits of man, regardless of the individual's gender identity/gender expression), must meet ONE of the following: pt had inadequate response after 12 mo (eg, ongoing and sign loss of BMD, lack of BMD increase) or pt had osteo fracture or fragility fracture while receiving therapy or pt experienced intolerability (eg, severe GI-related adverse effects, severe musculoskeletal-related side effects, a femoral fracture), OR pt cannot take oral bisphos because pt cannot swallow or has difficulty swallowing or pt cannot remain in upright position post oral bisphos admin or pt has pre-existing GI condition (eg, pt with esophageal lesions/ulcers, or abnormal of the esophagus that delay esophageal emptying [stricture, achalasia]), OR pt had an osteo fracture or a fragility fracture OR pt has tried IV Reclast (zoledronic acid). Tx of PMO may have also tried IV Boniva (ibandronate) for approval. Prevent or tx of GIO, approve if: pt is initiating or cont therapy with systemic glucocorticoids, AND had an inadequate response after 12 months (eg, ongoing and significant loss of BMD, lack of BMD increase) or pt had an osteo fracture or fragility fracture while on therapy or pt experienced intol (eg, severe GI-related adverse effects, severe musculoskeletal-related side effects, a femoral fracture), OR pt cannot take oral bisphos because pt cannot

PA Criteria	Criteria Details
	swallow or has difficulty swallowing or pt cannot remain in an upright position post oral bisphos administration or pt has a pre-existing GI medical condition (eg, patient with esophageal lesions, esophageal ulcers, or abnormalities of the esophagus that delay esophageal emptying [stricture, achalasia]), or has tried Reclast OR patient had an osteo fracture or a fragility fracture. Tx of Paget's disease, approve if pt has elevations in serum alkaline phos of two times higher than the upper limit of the age-specific normal reference range, OR pt is symptomatic (eg, bone pain, hearing loss, osteoarthritis), OR pt is at risk for complications from their disease (eg, immobilization, bone deformity, fractures, nerve compression syndrome). Prevent of PMO - meets 1 of the following had inadequate response after trial duration of 12 months (eg, ongoing and significant loss of BMD, lack of BMD increase) or pt had osteo fracture or fragility fracture while receiving therapy or patient experienced intol (eg, severe GI-related adverse effects, severe musculoskeletal-related side effects, a femoral fracture), OR pt cannot take oral bisphos because the pt cannot swallow or has difficulty swallowing or the pt cannot remain in an upright position post oral bisphos admin or pt has a pre-existing GI medical condition (eg, patient with esophageal lesions/ulcers, or abnormalities of the esophagus that delay esophageal emptying [stricture, achalasia]), OR pt has tried Reclast or the patient has had an osteo fracture or fragility fracture.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

RELEUKO

Products Affected

- RELEUKO SUBCUTANEOUS

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Cancer/AML, MDS, ALL-oncologist or a hematologist. Cancer patients receiving BMT and PBPC-prescribed by or in consultation with an oncologist, hematologist, or a physician who specializes in transplantation. SCN-hematologist. HIV/AIDS neutropenia-infectious disease (ID) physician (MD), hematologist, or MD specializing in HIV/AIDS. Radiation syndrome-prescribed by or in consultation with expert in acute radiation.
Coverage Duration	chemo/SCN/AML-6 mo.HIV/AIDS-4 mo.MDS-3 mo.PBPC,Drug induce A/N, ALL,BMT,Radi-1 mo
Other Criteria	Cancer patients receiving chemotherapy, approve if the patient meets one of the following conditions: 1)patient is receiving myelosuppressive anti-cancer medications that are associated with a high risk of febrile neutropenia (the risk is at least 20 percent based on the chemotherapy regimen), 2)patient is receiving myelosuppressive anti-cancer medications that are associated with a risk of febrile neutropenia but the risk is less than 20 percent based on the chemotherapy regimen and the patient has one or more risk factors for febrile neutropenia (eg, aged greater than 65 years receiving full chemotherapy dose intensity, prior chemotherapy or radiation therapy, persistent neutropenia, bone marrow involvement by tumor, recent surgery and/or open wounds, liver dysfunction (bilirubin greater than 2 mg/dL), renal dysfunction (CrCl less than 50 mL/min), poor performance status, or HIV infection patients with low CD4 counts), 3)patient has had a neutropenic complication from prior chemotherapy cycle and did not receive prophylaxis with a colony stimulating factor and a reduced dose or frequency of chemotherapy may compromise treatment, or 4)patient has received chemotherapy, has febrile neutropenia and has at

PA Criteria	Criteria Details
	least one risk factor (eg, sepsis syndrome, aged greater than 65 years, severe neutropenia [absolute neutrophil count less than 100 cells/mm ³], neutropenia expected to be greater than 10 days in duration, pneumonia or other clinically documented infection, invasive fungal infection, hospitalization at the time of fever, prior episode of febrile neutropenia)
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Neutropenia associated with HIV or AIDS, Treatment of myelodysplastic syndromes (MDS), Drug induced agranulocytosis or neutropenia, Acute lymphocytic leukemia (ALL), peripheral blood progenitor cell transplantation in patients with cancer
Part B Prerequisite	No
Prerequisite Therapy Required	No

REMICADE

Products Affected

- INFLIXIMAB
- REMICADE

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with Biologic DMARD or Targeted Synthetic DMARD
Required Medical Information	Diagnosis, concurrent medication, previous medications tried
Age Restrictions	CD/UC/Behcet's/GVHD/JIA/UV - Pts aged 6 years or more (initial therapy). AS/PsA/RA/HS/PG/Sarcoidosis/Scleritis, sterile corneal ulceration/Still's/PP-18 years and older (initial therapy)
Prescriber Restrictions	All dx-initial therapy only-Prescribed by or in consult w/RA/AS/Still's/JIA/JRA-rheumatol.Plaque Psor/Pyoderma gangrenosum/HS-dermatol.Psoriatic Arthritis-rheumatol or dermatol.CD/UC-gastroenterol.Uveitis/scleritis, sterile corneal ulceration-ophthalmol.GVHD-transplant center, oncol, or hematol.Behcet's-rheumatol, dermatol,ophthalmol, gastroenterol, or neurol.Sarcoidosis-pulmonol, ophthalmol, or dermatol, cardio/neuro.
Coverage Duration	Init:GVHD1mo,PG4mo,Scler6mo,Other3mo.Cont:GVHD3mo,Other1yr
Other Criteria	INITIAL THERAPY: RHEUMATOID ARTHRITIS: tried one conventional synthetic DMARD for at least 3 months (e.g., MTX, leflunomide, hydroxychloroquine, sulfasalazine. 3-month trial of a biologic also counts). CROHN'S DISEASE: approve. ULCERATIVE COLITIS: approve. BEHCET'S (A or B): A) tried one conventional therapy (e.g., systemic CS, immunosuppressants such as AZA, MTX, mycophenolate, CSA, tacrolimus, chlorambucil, cyclophosphamide, interferon alfa. TNF inhibitor also counts.) or B) ophthalmic manifestations. STILL'S DISEASE (A and B): A) tried one CS and B) tried one DMARD for at least 2 months or intolerant (e.g., MTX. Trial of a biologic also counts.) UVEITIS: tried periocular, intraocular or systemic CS or immunosuppressive (e.g., MTX, mycophenolate, CSA. Trial of a biologic also counts.) SARCOIDOSIS (A and B): A) tried one CS and B) tried one immunosuppressant (e.g., MTX, AZA, leflunomide, mycophenolate, hydroxychloroquine, chloroquine.) PYODERMA GANGRENOSUM (A or B): A) tried one systemic CS or B)

PA Criteria	Criteria Details
	tried one immunosuppressant for at least 2 months or intolerant (e.g., mycophenolate, CSA). HIDRADENITIS SUPPURATIVA: Tried one other therapy (e.g., intralesional or oral CS, systemic antibiotics, isotretinoin). GRAFT VS HOST DISEASE: Tried one conventional systemic treatment (e.g., CS, antithymocyte globulin, CSA, tacrolimus, mycophenolate.) JUVENILE IDIOPATHIC ARTHRITIS: (A or B): A) tried one systemic medication (e.g., MTX, sulfasalazine, leflunomide, NSAID. Trial of a biologic also counts.) or B) has aggressive disease. PLAQUE PSORIASIS (A or B): A) tried at least one traditional systemic agent (e.g., MTX, cyclosporine (CSA), acitretin, PUVA) for at least 3 months, unless intolerant (Trial of a biologic will also count) or B) contraindication to MTX. SCLERITIS/STERILE CORNEAL ULCERATION: tried one other therapy for this condition (e.g., oral non-steroidal anti-inflammatory drugs (NSAIDs), oral, topical (ophthalmic), or intravenous corticosteroids, MTX, CSA, or other immunosuppressants). CONTINUATION THERAPY: ALL INDICATIONS: patient had a response to therapy.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Behcet's disease (BD). Still's disease (SD). Uveitis (UV). Pyoderma gangrenosum (PG). Hidradenitis suppurativa (HS). Graft-versus-host disease (GVHD). Juvenile Idiopathic Arthritis (JIA)/JRA, Sarcoidosis, Scleritis/ sterile corneal ulceration
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

REMODULIN

Products Affected

- treprostinil sodium*

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent Use with Other Oral or Inhaled Prostacyclin Agents Used for Pulmonary Hypertension.
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	PAH WHO Group 1, prescribed by or in consultation with a cardiologist or a pulmonologist (initial/continuation).
Coverage Duration	Authorization will be for 1 year
Other Criteria	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Pulmonary Arterial Hypertension (PAH) [World Health Organization (WHO) Group 1], Initial Therapy- Approve if the patient meets all of the following criteria (i, ii, iii, and iv): i. Patient has a diagnosis of World Health Organization (WHO) Group 1 pulmonary arterial hypertension (PAH), AND ii. Patient meets the following criteria (a and b): a) Patient has had a right heart catheterization, AND b) Results of the right heart catheterization confirm the diagnosis of WHO Group 1 PAH, AND iii. Patient meets ONE of the following criteria (a or b): a) Patient is in Functional Class III or IV, OR b) Patient is in Functional Class II and meets ONE of the following criteria [(1) or (2)]: (1) Patient has tried or is currently receiving one oral agent for PAH, OR (2) Patient has tried one inhaled or parenteral prostacyclin product for PAH, AND iv. Patient with idiopathic PAH must meet ONE of the following criteria (a, b, c, d, or e): a) Patient meets both of the following criteria [(1) and (2)]: (1) the patient has had an acute response to vasodilator testing that occurred during the right heart catheterization, AND (2) Patient has tried one calcium channel blocker (CCB) therapy, OR b) According to the prescriber, the patient did not have an acute response to vasodilator testing, OR c) According to the prescriber, the patient cannot undergo a vasodilator test, OR d) Patient cannot take CCB therapy, OR e) Patient has tried one CCB. Continuation-Approve if the patient meets ALL of the following

PA Criteria	Criteria Details
	conditions (a and b): a) Patient has a diagnosis of World Health Organization (WHO) Group 1 pulmonary arterial hypertension (PAH), AND b) Patient meets the following criteria [(1) and (2)]: (1) Patient has had a right heart catheterization, AND (2) Results of the right heart catheterization confirm the diagnosis of WHO Group 1 PAH.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

REPATHA

Products Affected

- REPATHA
- REPATHA SURECLICK

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use of Leqvio or Praluent.
Required Medical Information	LDL-C and response to other agents, prior therapies tried, medication adverse event history, medical history (as specified in the Other Criteria field)
Age Restrictions	ASCVD/Primary Hyperlipidemia - 18 yo and older, HoFH/HeFH - 10 yo and older.
Prescriber Restrictions	N/A
Coverage Duration	Approve for 1 year
Other Criteria	HYPERLIPIDEMIA WITH HeFH (both A and B): A) meets (a, b, c, or d): a) untreated LDL-C greater than or equal to 190 mg/dL (or 155 mg/dL if less than 16 years old), b) phenotypic confirmation (Note 1) of HeFH, c) Dutch Lipid Network criteria score greater than 5, or d) Simon Broome criteria met threshold for definite or possible/probable, B) meets (a or b): a) tried one high-intensity statin (throughout, see Definition 1 below) or b) statin intolerant (throughout, see Definition 2 below). ESTABLISHED CVD (both A and B): A) patient has/had one of the following conditions: prior MI, ACS, angina, CVA or TIA, CAD, PAD, coronary or other arterial revascularization procedure, B) meets (a or b): a) tried one high-intensity statin and LDL-C remains 55 mg/dL or higher or b) statin intolerant. PRIMARY HYPERLIPIDEMIA (not associated with established CVD, HeFH, or HoFH) [A or B]: A) tried one high-intensity statin and ezetimibe for 8 weeks or longer and LDL-C remains 70 mg/dL or higher or B) statin intolerant. TO REDUCE MAJOR ADVERSE CV EVENTS IN PTS AT INCREASED RISK THAT DO NOT HAVE ESTABLISHED CVD [A or B]: A) tried one high-intensity statin and ezetimibe for 8 weeks or longer or B) statin intolerant. HYPERLIPIDEMIA WITH HoFH (both A and B): A) meets (a or b): a) phenotypic confirmation of HoFH, or b) meets (i and ii): i) untreated LDL-C greater than 400 mg/dL or treated LDL-C greater than or equal to 300 mg/dL, and ii) clinical manifestations of HoFH before 20

PA Criteria	Criteria Details
	years of age or at least one parent with untreated LDL-C or total cholesterol consistent with FH, AND B) meets (a or b): a) tried one high-intensity statin or b) statin intolerant. Note 1: Examples include mutations at the low-density lipoprotein receptor (LDLR), apolipoprotein B (apo B), proprotein convertase subtilisin kexin type 9 (PCSK) or low-density lipoprotein receptor adaptor protein (LDLRAP1) gene. Definition 1: High intensity statin defined as atorvastatin greater than or equal to 40 mg daily or rosuvastatin greater than or equal to 20 mg daily. Definition 2: Statin intolerance defined as experiencing statin related rhabdomyolysis or skeletal-related muscle symptoms while receiving separate trials of atorvastatin and rosuvastatin and during both trials the skeletal-related symptoms resolved upon discontinuation of the statin.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

RETEVMO

Products Affected

- RETEVMO ORAL TABLET 120 MG, 160 MG, 40 MG, 80 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	Medullary Thyroid Cancer/Thyroid Cancer/Solid tumors-2 years and older, all others 18 years and older
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 1 year.
Other Criteria	Non-Small Cell Lung Cancer (NSCLC)-Approve if the patient has recurrent, advanced or metastatic disease AND the tumor is RET fusion-positive. Thyroid cancer-approve if the patient has rearranged during transfection (RET) fusion positive or RET mutation positive disease or RET pathogenic variant AND the patient meets i, ii or iii: i. patient has anaplastic thyroid cancer OR ii. the disease requires treatment with systemic therapy and patient has medullary thyroid cancer or iii. the disease requires treatment with systemic therapy and the disease is radioactive iodine-refractory if radioactive iodine is appropriate. Solid tumors-approve if the patient has recurrent, advanced or metastatic disease and the tumor is rearranged during transfection (RET) fusion-positive. Histiocytic neoplasm-approve if the patient has a rearranged during transfection (RET) fusion and has Langerhans cell histiocytosis or Erdheim Chester disease or Rosai-Dorfman disease.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Anaplastic thyroid carcinoma, histiocytic neoplasm
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	No

REVCovi

Products Affected

- REVCovi

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, lab values, genetic tests (as specified in the Other Criteria field)
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with, an immunologist, hematologist/oncologist, or physician that specializes in ADA-SCID or related disorders.
Coverage Duration	12 months
Other Criteria	ADA-SCID - approve if the patient had absent or very low (less than 1% of normal) ADA catalytic activity at baseline (i.e., prior to initiating enzyme replacement therapy) OR if the patient had molecular genetic testing confirming bi-allelic pathogenic variants in the ADA gene.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

REVUFORJ

Products Affected

- REVUFORJ ORAL TABLET 110 MG, 160 MG, 25 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	ACUTE LEUKEMIA-patient has relapsed or refractory disease and either (i or ii): i) acute myeloid leukemia and either (a or b): a) the disease is positive for a lysine methyltransferase 2A (KMT2A) gene translocation or rearrangement or b) the disease is positive for a susceptible nucleophosmin 1 (NPM1) mutation, OR ii) acute lymphoblastic leukemia and disease is positive for a lysine methyltransferase 2A (KMT2A) gene translocation or rearrangement.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

REZDIFFRA

Products Affected

- REZDIFFRA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older (initial)
Prescriber Restrictions	Prescribed by or in consultation with an endocrinologist, gastroenterologist, or hepatologist (initial/continuation)
Coverage Duration	1 year
Other Criteria	INITIAL THERAPY: METABOLIC-DYSFUNCTION ASSOCIATED STEATOHEPATITIS (MASH)/NON-ALCOHOLIC STEATOHEPATITIS (NASH): All of (i, ii and iii): i) Diagnosed by (a or b): a) Liver biopsy performed within 3 years preceding treatment with Rezdiffra or Wegovy, or b) One of the following within 6 months preceding treatment with Rezdiffra or Wegovy (1, 2, 3 or 4): 1) Elastography (e.g. vibration-controlled transient elastography (e.g., FibroScan), transient elastography, magnetic resonance elastography, acoustic radiation force impulse imaging, shear wave elastography) or 2) Computed tomography or 3) Magnetic resonance imaging, or 4) Enhanced Liver Fibrosis (ELF) test with score greater than or equal to 9.2 and less than or equal to 10.5, and ii) stage F2 or F3 fibrosis prior to Rezdiffra or Wegovy and iii) This will be used in combination with appropriate diet and exercise therapy (prescriber confirms the patient has received counseling on diet and exercise). CONTINUATION THERAPY (on therapy less than 1 year or restarting, review as initial therapy): MASH/NASH: All of (i, ii and iii): i) completed greater than or equal to 1 year of therapy and has not had worsening of fibrosis or MASH/NASH, and ii) has not progressed to stage F4 (cirrhosis) and iii) This will be used in combination with appropriate diet and exercise therapy (prescriber confirms the patient has received counseling on diet and exercise).
Indications	All FDA-approved Indications.

PA Criteria	Criteria Details
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

REZLIDHIA

Products Affected

- REZLIDHIA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Acute myeloid leukemia-approve if the patient has relapsed or refractory disease and the patient has isocitrate dehydrogenase-1 (IDH1) mutation positive disease as detected by an approved test.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

REZUROCK

Products Affected

- REZUROCK

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	12 years and older (initial therapy)
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Graft-versus-host disease, initial-approve if the patient has chronic graft-versus-host disease and has tried at least two systemic medications (examples: Jakafi [ruxolitinib], Niktimvo [axatilimab-csfr], ibrutinib) for chronic graft-versus-host disease. Graft-versus-host disease, continuation-approve if patient has demonstrated a beneficial clinical response.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

RILUZOLE

Products Affected

- *riluzole*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a neurologist, a neuromuscular disease specialist, or a physician specializing in the treatment of ALS.
Coverage Duration	1 year
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

RINVOQ

Products Affected

- RINVOQ ORAL TABLET EXTENDED
RELEASE 24 HR 15 MG, 30 MG, 45 MG

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with a biologic or with a targeted synthetic oral small molecule drug, Concurrent use with other potent immunosuppressants, or concurrent use with a biologic immunomodulator.
Required Medical Information	Diagnosis, concurrent medications, previous drugs tried.
Age Restrictions	PsA/JIA - 2 years and older (initial therapy), RA/UC/AS/CD/nr-axSpA/GCA-18 years and older (initial therapy), AD-12 years and older (initial therapy)
Prescriber Restrictions	RA/AS/Non-Radiographic Spondy/JIA/GCA, prescribed by or in consultation with a rheumatologist. PsA-prescribed by or in consultation with a rheumatologist or a dermatologist. AD-prescr/consult with allergist, immunologist or dermatologist. UC/CD-prescribed by or in consultation with a gastroenterologist. (all apply to initial therapy only)
Coverage Duration	Approve through end of plan year
Other Criteria	INITIAL THERAPY: RHEUMATOID ARTHRITIS (RA)/PSORITIC ARTHRITIS (PsA)/ANKYLOSING SPONDYLITIS (AS)/JUVENILE IDIOPATHIC ARTHRITIS (JIA): 3-month trial of at least one tumor necrosis factor inhibitor (TNFi) or unable to tolerate a 3-month trial. ULCERATIVE COLITIS (UC)/CROHN'S DISEASE (CD): 3-month trial of at least one tumor necrosis factor inhibitor (TNFi) or unable to tolerate a 3-month trial or use of TNFi is clinically inadvisable per the prescriber. ATOPIC DERMATITIS (AD): 90 day trial of at least one systemic therapy (e.g., Dupixent [dupilumab subcutaneous injection], Ebglyss (lebrikizumab-lbkz subcutaneous injection), Nemluvio (nemolizumab-ilt subcutaneous injection), and Adbry [tralokinumab-ldrm subcutaneous injection]. Azathioprine, cyclosporine, or mycophenolate mofetil also count.) or unable to tolerate a 90 day trial. NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (A and B): A) objective signs of inflammation defined as having at least one of the following (a or b): a) C-

PA Criteria	Criteria Details
	reactive protein elevated beyond the upper limit of normal or b) sacroiliitis reported on MRI and B) 3-month trial of at least one TNFi or was unable to tolerate a 3-month trial. GIANT CELL ARTERITIS: tried one or is currently taking a systemic corticosteroid or corticosteroids are contraindicated. CONTINUATION THERAPY: ALL INDICATIONS: patient responded to therapy.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

RINVOQ LQ

Products Affected

- RINVOQ LQ

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with a biologic or with a targeted synthetic DMARD, other potent immunosuppressants, other janus kinase inhibitors, or a biologic immunomodulator.
Required Medical Information	Diagnosis
Age Restrictions	PsA-2 years and older (initial therapy)
Prescriber Restrictions	JIA-prescribed by or in consultation with a rheumatologist (initial therapy). PsA-prescribed by or in consultation with a rheumatologist or a dermatologist (initial therapy)
Coverage Duration	Approve through end of plan year
Other Criteria	INITIAL THERAPY: JUVENILE IDIOPATHIC ARTHRITIS (JIA)/ PSORIATIC ARTHRITIS (PsA) - 3-month trial of at least one tumor necrosis factor inhibitor (TNFi) or unable to tolerate a 3-month trial. CONTINUATION THERAPY: ALL INDICATIONS - patient responded to therapy.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ROFLUMILAST (ORAL)

Products Affected

- *roflumilast*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Chronic Obstructive Pulmonary Disease (COPD), medications tried.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Initial therapy - 6 months, Continuation of therapy - 1 year
Other Criteria	INITIAL THERAPY, COPD: all of (A, B, C and D): A) patient has forced expiratory volume in 1 second (FEV1) less than 50 percent predicted, and B) history of two or more moderate COPD exacerbations or one or more severe COPD exacerbations [Note: A moderate exacerbation is an exacerbation that required treatment with a short-acting bronchodilator and a systemic corticosteroid. A severe COPD exacerbation is an exacerbation that required hospitalization or an Emergency Department visit.], and C) patient has chronic bronchitis, and D) patient tried a medication from two of the three following drug categories: long-acting beta2-agonist (LABA) [eg, salmeterol, olodaterol], long-acting muscarinic antagonist (LAMA) [eg, tiotropium], inhaled corticosteroid (eg, fluticasone). CONTINUATION THERAPY, COPD: both (A and B): A) patient continues to receive combination therapy with a LABA and a LAMA, and B) patient has beneficial response defined by one of the following: reduced COPD symptoms, reduced COPD exacerbations, reduced COPD-related hospitalizations, reduced emergency department or urgent care visits, or improved lung function parameters.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ROMVIMZA

Products Affected

- ROMVIMZA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	TENOSYNOVIAL GIANT CELL TUMOR (PIGMENTED VILLONODULAR SYNOVITIS)-tumor is not amenable to improvement with surgery.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

ROZLYTREK

Products Affected

- ROZLYTREK ORAL CAPSULE 100 MG, 200 MG
- ROZLYTREK ORAL PELLETS IN PACKET

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	NSCLC-18 years and older, Solid Tumors-1 month and older, Pediatric Diffuse High-Grade Glioma-less than 18 years old
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Solid Tumors-Approve if the patient's tumor is positive for neurotrophic receptor tyrosine kinase (NTRK) gene fusion AND the tumor is metastatic OR surgical resection of tumor will likely result in severe morbidity. Non-Small Cell Lung Cancer-Approve if the patient has ROS1-positive metastatic disease and the mutation was detected by an approved test. Pediatric Diffuse High-Grade Glioma- approve if the tumor is positive for neurotrophic receptor tyrosine kinase (NTRK) gene fusion AND the medication is used either as adjuvant therapy or for recurrent or progressive disease.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Pediatric Diffuse High-Grade Glioma
Part B Prerequisite	No
Prerequisite Therapy Required	No

RUBRACA

Products Affected

- RUBRACA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis for which Rubraca is being used. BRCA-mutation (germline or somatic) status. Other medications tried for the diagnosis provided
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Maintenance Therapy of Ovarian, Fallopian tube or Primary peritoneal cancer-Approve if (A, B and C): A) the patient is in complete or partial response after a platinum-based chemotherapy regimen, and B) meets (i or ii): i) the patient is in complete or partial response to first-line primary treatment or ii) patient has recurrent disease and has a BRCA mutation, and C) for new starts, the patient has tried the preferred product Lynparza, unless the prescriber indicates that Lynparza is inappropriate for the patient's specific clinical situation. Castration-Resistant Prostate Cancer - Approve if the patient meets the following criteria (A, B, C, and D): A) The patient has metastatic disease that is BRCA-mutation positive (germline and/or somatic) AND B) The patient meets one of the following criteria (i or ii): i. The medication is used concurrently with a gonadotropin-releasing hormone (GnRH) analog OR ii. The patient has had a bilateral orchiectomy AND C) The patient has been previously treated with at least one androgen receptor-directed therapy, and D) for new starts, the patient has tried one of the preferred products, Lynparza or Talzenna, unless the prescriber indicates that both Lynparza and Talzenna are inappropriate for the patient's specific clinical situation. Pancreatic adenocarcinoma-approve if pt has a BRCA mutation or PALB2 mutation AND pt has tried platinum-based chemotherapy AND has not had disease progression following the most recent platinum-based chemotherapy.

PA Criteria	Criteria Details
	Uterine leiomyosarcoma-approve if the patient has BRCA2-altered disease and has tried one systemic regimen.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Uterine Leiomyosarcoma, Pancreatic Adenocarcinoma
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

RUFINAMIDE

Products Affected

- *rufinamide*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	Patients 1 years of age or older
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	1 year
Other Criteria	Initial therapy-approve if rufinamide is being used for adjunctive treatment. Continuation-approve if the patient is responding to therapy
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Treatment-Refractory Seizures/Epilepsy
Part B Prerequisite	No
Prerequisite Therapy Required	No

RUXIENCE

Products Affected

- RUXIENCE

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

RYBREVANT

Products Affected

- RYBREVANT

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Authorization will be for 1 year
Other Criteria	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Non-Small Cell Lung Cancer (NSCLC) - approve if pt has locally advanced or metastatic disease AND either (A, B or C): (A) the pt has epidermal growth factor receptor (EGFR) exon 20 insertion mutations, or B) EGFR exon 19 deletion, or C) EGFR exon 21 L858R mutation (for all mutations- as detected by an approved test).
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

RYBREVANT FASPRO

Products Affected

- RYBREVANT FASPRO

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	1 year
Other Criteria	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. NON-SMALL CELL LUNG CANCER-locally advanced or metastatic disease and ONE of the following: epidermal growth factor receptor (EGFR) exon 20 insertion mutations, EGFR exon 19 deletions, or EGFR exon 21 L858R substitution mutations.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

RYDAPT

Products Affected

- RYDAPT

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	For AML, FLT3 status
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	AML-approve if the patient is FLT3-mutation positive as detected by an approved test. Myeloid or lymphoid Neoplasms with eosinophilia-approve if the patient has an FGFR1 rearrangement or has an FLT3 rearrangement. Indolent systemic mastocytosis-pt has symptomatic disease and has tried at least one systemic regimen. Smoldering systemic mastocytosis-pt has tried at least one systemic regimen.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Myeloid or lymphoid Neoplasms with eosinophilia, indolent systemic mastocytosis, smoldering systemic mastocytosis
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

RYTELO

Products Affected

- RYTELO

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older (initial)
Prescriber Restrictions	Prescribed by or in consultation with a hematologist or oncologist (initial)
Coverage Duration	1 year
Other Criteria	Part B vs Part D determination will be made at time of prior authorization review per CMS guidance. INITIAL THERAPY: MYELOYDYSPLASTIC SYNDROME-All of (i, ii, iii, and iv): i.Very low- to intermediate risk myelodysplastic syndrome (MDS), Note: MDS risk category is determined using the International Prognostic Scoring System (IPSS). AND, ii.Transfusion-dependent anemia, defined as requiring transfusion of greater than or equal to 4 red blood cell units over an 8-week period, AND iii. Has not responded, lost response to, or is ineligible for erythropoiesis-stimulating agents, Note: Examples of erythropoiesis-stimulating agents (ESA): epoetin alfa product (e.g., Epogen, Procrit, or Retacrit), a darbepoetin alfa product (e.g., Aranesp), or a methoxy polyethylene glycol-epoetin beta product (e.g., Mircera). Note: a patient with a serum erythropoietin level greater than 500 mU/mL is considered ineligible for ESA. AND, iv. Rytelo will NOT be used in combination with an ESA.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

SANDOSTATIN LAR

Products Affected

- *octreotide,microspheres*
- SANDOSTATIN LAR DEPOT
INTRAMUSCULAR

SUSPENSION,EXTENDED REL
RECON 10 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, previous treatments/therapies
Age Restrictions	N/A
Prescriber Restrictions	Acromegaly-prescr/consult w/endocrinologist. All neuroendocrine tumors-prescr/consult w/oncologist, endocrinologist, or gastroenterologist. Pheochromocytoma/paraganglioma-prescr/consult w/endo/onc/neuro.Meningioma-prescr/consult w/oncologist, radiologist or neurosurgeon. Merkel cell/Thymoma/Thymic carcinoma-prescr/consult w/oncologist. Diarrhea assoc w chemo-presc/consult oncologist/gastro. Small bowel bleed/angiodysplasia-presc/consult gastroenterologist.
Coverage Duration	Enterocutaneous fistula/diarrhea chemo - 3 months, small bowel bleed - 6 mos, all others - 1 year
Other Criteria	Acromegaly-approve if the patient has (or had) a pre-treatment (baseline) insulin-like growth factor-1 (IGF-1) level above the upper limit of normal based on age and gender for the reporting laboratory AND the patient meets i., ii., or iii: i. has had an inadequate response to surgery and/or radiotherapy or ii. is not an appropriate candidate for surgery and/or radiotherapy or iii. the patient is experiencing negative effects due to tumor size (e.g., optic nerve compression). Diarrhea assoc w chemo (A and B): A) grade 3 or 4 diarrhea [Examples: more than 6 bowel movements above baseline per day, colitis symptoms, interference with activities of daily living, hemodynamic instability, hospitalization, serious complications (eg, ischemic bowel, perforation, toxic mega-colon), or other colitis-related life-threatening conditions] and B) patient has tried at least one antimotility medication. Merkel cell carcinoma (A and B): A) patient has regional or distant metastatic disease and B) has contraindications to or has progressed on checkpoint immunotherapy. Neuroendocrine Tumor(s) [NETs] of the Gastrointestinal Tract, Lung, Thymus (Carcinoid Tumors), and Pancreas

PA Criteria	Criteria Details
	(including glucagonomas, gastrinomas, vasoactive intestinal peptides-secreting tumors [VIPomas], insulinomas)-approve. Small bowel bleeds/angiodysplasia related bleeding: pt has chronic, recurrent gastrointestinal bleeds lasting greater than or equal to 3 months.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Pheochromocytoma/paraganglioma, Meningioma, Thymoma and thymic carcinoma, enterocutaneous fistulas, diarrhea associated with chemotherapy, Merkel cell carcinoma, small bowel bleeds/angiodysplasia related bleeding
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

SAPROPTERIN

Products Affected

- *sapropterin*

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with Palynziq
Required Medical Information	Diagnosis, Phe concentration
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a specialist who focuses in the treatment of metabolic diseases (initial therapy)
Coverage Duration	Initial-12 weeks, Continuation-1 year
Other Criteria	Initial - approve. Continuation (Note-if the patient has received less than 12 weeks of therapy or is restarting therapy with sapropterin should be reviewed under initial therapy) - approve if the patient has had a response to therapy.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

SARCLISA

Products Affected

- SARCLISA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, other therapies
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Authorization will be for 1 year
Other Criteria	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Multiple myeloma-approve if pt meets (A, B, or C): A) the requested medication will be used as primary therapy in combination with (i or ii): i) bortezomib, lenalidomide, and dexamethasone, or ii) Kyprolis (carfilzomib intravenous infusion), lenalidomide, and dexamethasone, or B) the requested medication will be used in combination with Pomalyst and dexamethasone and the patient has tried at least TWO prior regimens for multiple myeloma and a proteasome inhibitor was a component of at least one previous regimen and Revlimid was a component of at least one previous regimen, or C) medication will be used in combination with Kyprolis and dexamethasone and pt has tried at least one prior regimen.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

SCEMBLIX

Products Affected

- SCEMBLIX ORAL TABLET 100 MG, 20 MG, 40 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Chronic Myeloid Leukemia (CML)-approve if the patient meets the following (A and B): A) Patient has Philadelphia chromosome-positive or BCR::ABL1-positive chronic myeloid leukemia, AND B) Patient meets one of the following (i, ii or iii): i. Patient has newly diagnosed disease, OR ii. The chronic myeloid leukemia is T315I-positive, OR iii. Patient has tried at least one other tyrosine kinase inhibitor. Note: Examples of tyrosine kinase inhibitors include imatinib, Bosulif (bosutinib tablets), Iclusig (ponatinib tablets), dasatinib, and nilotinib capsules. Myeloid/Lymphoid Neoplasms with Eosinophilia - approve if the tumor has an ABL1 rearrangement. Acute lymphoblastic leukemia (ALL)- approve if the pt has Philadelphia chromosome-positive ALL and this medication will be used in combination with dasatinib.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Myeloid/Lymphoid Neoplasms with Eosinophilia, Acute Lymphoblastic Leukemia (ALL)
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

SIGNIFOR

Products Affected

- SIGNIFOR

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	18 years and older (initial therapy)
Prescriber Restrictions	Prescribed by or in consultation with an endocrinologist or a physician or specializes in the treatment of Cushing's syndrome (initial therapy)
Coverage Duration	Cushing's disease/syndrome-Initial therapy - 4 months, Continuation therapy - 1 year.
Other Criteria	Cushing's disease, initial therapy - approve if, according to the prescribing physician, the patient is not a candidate for surgery, or surgery has not been curative. Cushing's disease, continuation therapy - approve if the patient has already been started on Signifor/Signifor LAR and, according to the prescribing physician, the patient has had a response and continuation of therapy is needed to maintain response.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

SIRTURO

Products Affected

- SIRTURO

PA Criteria	Criteria Details
Exclusion Criteria	Patients weighing less than 8 kg
Required Medical Information	Diagnosis, concomitant therapy
Age Restrictions	Patients 2 years of age or older
Prescriber Restrictions	Prescribed by, or in consultation with an infectious diseases specialist or pulmonologist
Coverage Duration	9 months
Other Criteria	Tuberculosis (Pulmonary) -Approve if the patient has Mycobacterium tuberculosis resistant to at least rifampin and isoniazid and the requested medication is prescribed as part of a combination regimen with other anti-tuberculosis agents
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

SKYRIZI

Products Affected

- SKYRIZI SUBCUTANEOUS PEN INJECTOR
- SKYRIZI SUBCUTANEOUS SYRINGE 150 MG/ML
- SKYRIZI SUBCUTANEOUS WEARABLE INJECTOR 180 MG/1.2 ML (150 MG/ML), 360 MG/2.4 ML (150 MG/ML)

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent Use with other Biologics or Targeted Synthetic Disease-Modifying Antirheumatic Drugs (DMARDs)
Required Medical Information	Diagnosis, Previous medication use
Age Restrictions	PP/UC/CD/PsA-18 years of age and older (initial therapy)
Prescriber Restrictions	PP-Prescribed by or in consultation with a dermatologist (initial therapy), PsA-prescribed by or in consultation with a rheumatologist or dermatologist (initial therapy), CD/UC-presc/consult-gastro (initial therapy)
Coverage Duration	Approve through end of plan year
Other Criteria	INITIAL THERAPY: PLAQUE PSORIASIS (PP) [A or B]: A) tried at least one traditional systemic agent for psoriasis (e.g., methotrexate [MTX], cyclosporine, acitretin tablets, or PUVA) for at least 3 months, unless intolerant. (Note: a 3-month trial or previous intolerance to at least one biologic also counts) or B) contraindication to MTX. PSORIATIC ARTHRITIS (PsA): approve. CROHN'S DISEASE (CD): approve. UICERATIVE COLITIS (UC)-approve. CD/UC: Patient must be receiving induction dosing with Skyrizi IV within 3 months of initiating therapy with Skyrizi subcutaneous. CONTINUATION THERAPY: ALL INDICATIONS: patient has responded to therapy.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

SKYRIZI IV

Products Affected

- SKYRIZI INTRAVENOUS

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent Use with other Biologics or Targeted Synthetic Disease-Modifying Antirheumatic Drugs (DMARDs)
Required Medical Information	Diagnosis, Previous medication use
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a gastroenterologist
Coverage Duration	Approve for 3 doses
Other Criteria	Crohn's Disease- approve if this medication will be used as induction therapy. Ulcerative colitis- approve if this medication will be used as induction therapy.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

SOFOSBUVIR/VELPATASVIR

Products Affected

- SOFOSBUVIR-VELPATASVIR

PA Criteria	Criteria Details
Exclusion Criteria	Combination use with other direct acting antivirals, excluding ribavirin.
Required Medical Information	Diagnosis
Age Restrictions	3 years or older
Prescriber Restrictions	Prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or a liver transplant physician
Coverage Duration	Criteria will be applied consistent with current AASLD/IDSA guidance.
Other Criteria	Criteria will be applied according to AASLD guidelines.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Indications consistent with current AASLD/IDSA guidance
Part B Prerequisite	No
Prerequisite Therapy Required	No

SOLARAZE

Products Affected

- *diclofenac sodium topical gel 3 %*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 6 months.
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

SOMAVERT

Products Affected

- SOMAVERT

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, previous therapy, concomitant therapy
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an endocrinologist
Coverage Duration	1 year
Other Criteria	ACROMEGALY (A or B): A) inadequate response to surgery and/or radiotherapy or patient not an appropriate candidate or B) patient is experiencing negative effects due to tumor size (e.g., optic nerve compression) and has pre-treatment (baseline) insulin-like growth factor-1 (IGF-1) level above the upper limit of normal based on age and gender.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

SORAFENIB

Products Affected

- *sorafenib*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 1 year.
Other Criteria	Bone cancer, approve if the patient has recurrent chordoma or has osteosarcoma and has tried one standard chemotherapy regimen. GIST, approve if the patient has tried TWO of the following: imatinib mesylate, avapritinib, sunitinib, dasatinib, ripretinib or regorafenib. Differentiated thyroid carcinoma (DTC), approve if the patient meets (A or B): A) has papillary or follicular thyroid carcinoma and the disease is refractory to radioactive iodine treatment or B) has oncocytic (formerly Hurthle cell) carcinoma. Medullary thyroid carcinoma, approve if the patient has tried at least one systemic therapy. AML - Approve if disease is FLT3-ITD mutation positive as detected by an approved test and the medication is used in combination with azacitidine or decitabine or patient has had an allogeneic stem cell transplant and is in remission. Renal cell carcinoma (RCC)-approve if the patient has relapsed or advanced clear cell histology and the patient has tried at least one systemic therapy (e.g., Inlyta, Votrient, Sutent Cabometyx). Ovarian, fallopian tube, primary peritoneal cancer-approve if the patient has platinum resistant disease and sorafenib is used in combination with topotecan. HCC-approve if the patient has unresectable or metastatic disease. Soft tissue sarcoma-approve if the patient has angiosarcoma or desmoid tumors (aggressive fibromatosis) or solitary fibrous tumor/hemangiopericytoma. Myeloid/lymphoid neoplasms with eosinophilia-approve if the tumor has an FLT3 rearrangement. Please note

PA Criteria	Criteria Details
	for all diagnoses: Part B before Part D Step Therapy applies only to beneficiaries enrolled in an MA-PD plan
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Bone cancer, Soft tissue sarcoma, gastrointestinal stromal tumors (GIST), medullary thyroid carcinoma, Acute Myeloid Leukemia, ovarian, fallopian tube, primary peritoneal cancer, myeloid/lymphoid neoplasms with eosinophilia
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

SPRAVATO

Products Affected

- SPRAVATO NASAL SPRAY, NON-AEROSOL 56 MG (28 MG X 2), 84 MG (28 MG X 3)

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by a psychiatrist or mental health provider
Coverage Duration	MDD w/Acute Suicidal Ideation or Behavior - 2 months, Treatment-Resistant Depression - 6 months
Other Criteria	Major Depressive Disorder with Acute Suicidal Ideation or Behavior: approve if the patient has major depressive disorder that is considered to be severe, AND if the patient is concomitantly receiving at least one oral antidepressant, AND the patient has no history of psychosis or has a history of psychosis but the prescriber believes that the benefits of Spravato outweigh the risks. Treatment-Resistant Depression: approve if the patient has demonstrated nonresponse (less than or equal to 25 percent improvement in depression symptoms or scores) to at least two different antidepressants, each from a different pharmacologic class and each antidepressant was used at therapeutic dosages for at least 6 weeks in the current episode of depression, AND the patient has no history of psychosis or has a history of psychosis but the prescriber believes that the benefits of Spravato outweigh the risks, AND patient's history of controlled substance prescriptions has been checked using the state prescription drug monitoring program (PDMP).
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

SPRYCEL

Products Affected

- dasatinib oral tablet 100 mg, 140 mg, 20 mg, 50 mg, 70 mg, 80 mg

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis for which dasatinib is being used. For indications of CML and ALL, the Philadelphia chromosome (Ph) status of the leukemia must be reported. For melanoma, cutaneous- KIT mutation and previous therapies.
Age Restrictions	GIST/bone cancer/ melanoma, cutaneous-18 years and older
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 1 year.
Other Criteria	For CML, patient must have Ph-positive or BCR::ABL1-positive CML. For ALL, patient must have Ph-positive ALL or ABL-class translocation. For Bone Cancer-approve if patient has chondrosarcoma or chordoma. GIST - approve if the patient has tried imatinib or avapritinib. For melanoma, cutaneous - approve if patient has metastatic or unresectable disease AND has an activating KIT mutation AND has tried at least one systemic regimen.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	GIST, bone cancer, melanoma cutaneous
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

STIVARGA

Products Affected

- STIVARGA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis for which Stivarga is being used. Prior therapies tried. For metastatic CRC, KRAS/NRAS mutation status.
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	For GIST, (A or B): A) patient has previously been treated with (i and ii): i) imatinib or Ayvakit and ii) sunitinib or Sprycel, or B) medication is used as first-line therapy for succinate dehydrogenase (SDH)-deficient disease. For HCC, patient must have previously been treated with at least one systemic regimen. Soft tissue sarcoma, advanced or metastatic disease-approve if the patient has non-adipocytic sarcoma, angiosarcoma, or pleomorphic rhabdomyosarcoma. Bone Cancer-approve if the patient has relapsed/refractory or metastatic disease AND the patient has tried one systemic chemotherapy regimen AND pt has Ewing sarcoma or osteosarcoma. Colon and Rectal cancer/Appendiceal cancer-approve if the patient has advanced or metastatic disease, has been previously treated with a fluoropyrimidine, oxaliplatin, irinotecan and if the patient meets one of the following (i or ii): i. patient's tumor or metastases are wild-type RAS (KRAS wild type and NRAS wild type), the patient has tried Erbitux or Vectibix or the patient's tumor did not originate on the left side of the colon (from the splenic fixture to rectum) or ii. the patient's tumor or metastases has a RAS mutation (either KRAS mutation or NRAS mutation). Uterine sarcoma- (A and B): A) pt has recurrent, advanced, inoperable, or metastatic disease, and B) tried at least one systemic regimen.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Soft tissue Sarcoma, Bone Cancer, Appendiceal cancer, Uterine sarcoma

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

STRENSIQ

Products Affected

- STRENSIQ

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, genetic and lab test results
Age Restrictions	Disease onset-less than or equal to 18
Prescriber Restrictions	Prescribed by or in consultation with a geneticist, endocrinologist, a metabolic disorder sub-specialist, or a physician who specializes in the treatment of hypophosphatasia or related disorders.
Coverage Duration	1 year
Other Criteria	Hypophosphatasia - Perinatal/Infantile- and Juvenile-Onset-Patient must meet both A and B for approval. A) Diagnosis is supported by one of the following (i, ii, or iii): i. Molecular genetic testing documenting tissue non-specific alkaline phosphatase (ALPL) gene variants OR ii. Low baseline serum alkaline phosphatase activity OR iii. An elevated level of a tissue non-specific alkaline phosphatase substrate (i.e., serum pyridoxal 5'-phosphate, serum or urinary inorganic pyrophosphate, urinary phosphoethanolamine) AND B) Patient meets one of the following (i or ii): i. Patient currently has, or has a history of clinical manifestations consistent with hypophosphatasia (e.g., skeletal abnormalities, premature tooth loss, muscle weakness, poor feeding, failure to thrive, respiratory problems, Vitamin B6-dependent seizures) OR ii. Patient has a family history (parent or sibling) of hypophosphatasia without current clinical manifestations of hypophosphatasia
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	No

SUCRAID

Products Affected

- SUCRAID

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, genetic and lab test results (as specified in the Other Criteria field)
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a geneticist, gastroenterologist, a metabolic disorder sub-specialist, or a physician who specializes in the treatment of congenital diarrheal disorders
Coverage Duration	1 year
Other Criteria	Approve if the patient meets the following criteria (A and B): A) The diagnosis is established by one of the following (i or ii): i. Patient has endoscopic biopsy of the small bowel with disaccharidase levels consistent with congenital sucrose-isomaltase deficiency as evidenced by ALL of the following (a, b, c, and d): a) Decreased (usually absent) sucrase (normal reference: greater than 25 U/g protein), b) Decreased or normal isomaltase (palatinase) [normal reference: greater than 5 U/g protein], c) Decreased maltase (normal reference: greater than 100 U/g protein), d) Decreased or normal lactase (normal reference: greater than 15 U/g protein) OR ii. Patient has a molecular genetic test demonstrating homozygous or compound heterozygous pathogenic or likely pathogenic sucrase-isomaltase gene variant AND B) Patient has symptomatic congenital sucrose-isomaltase deficiency (e.g., diarrhea, bloating, abdominal cramping).
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	No

SUNITINIB

Products Affected

- sunitinib malate*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Gastrointestinal stromal tumors (GIST), approve if the patient has tried imatinib or if the patient has succinate dehydrogenase (SDH)-deficient GIST. Chordoma, approve if the patient has recurrent disease. Differentiated thyroid carcinoma, approve if the patient meets (A or B): A) has papillary or follicular thyroid carcinoma and the disease is refractory to radioactive iodine therapy or B) has oncocytic (formerly Hurthle cell) carcinoma. Medullary thyroid carcinoma, approve if the patient has tried at least one systemic therapy. Meningioma, approve if the patient has recurrent or progressive disease. Thymic carcinoma - has tried at least one systemic chemotherapy. Renal Cell Carcinoma (RCC)- approve if the patient has relapsed or advanced disease. Neuroendocrine tumors of the pancreas-approve for advanced or metastatic disease. Pheochromocytoma/paraganglioma-approve if the patient has unresectable or metastatic disease. Myeloid/lymphoid neoplasms with eosinophilia-approve if the tumor has an FLT3 rearrangement.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Chordoma, angiosarcoma, solitary fibrous tumor/hemangiopericytoma, alveolar soft part sarcoma (ASPS), extraskeletal myxoid chondrosarcoma, differentiated (ie, papillary, follicular, and oncocytic carcinoma) thyroid carcinoma, medullary thyroid carcinoma, meningioma, thymic carcinoma, pheochromocytoma/paraganglioma, myeloid/lymphoid neoplasms with

PA Criteria	Criteria Details
	eosinophilia, GIST-unresectable succinate dehydrogenase (SDH)-deficient GIST.
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

SYMDEKO

Products Affected

- SYMDEKO

PA Criteria	Criteria Details
Exclusion Criteria	Combination therapy with other CF transmembrane conductance regulator modulators
Required Medical Information	Diagnosis, specific CFTR gene mutations
Age Restrictions	Six years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a pulmonologist or a physician who specializes in CF
Coverage Duration	1 year
Other Criteria	CF - Approve if the pt meets A, B and C: A) pt has at least one mutation in the cystic fibrosis transmembrane conductance regulator gene that is considered to be pathogenic or likely pathogenic or patient has TWO copies of the F508 del mutation, and B) pt must have positive CF newborn screening test or family history of CF or clinical presentation consistent with signs and symptoms of CF and C) evidence of abnormal cystic fibrosis transmembrane conductance regulator function as demonstrated by i, ii, or iii: (i) elevated sweat chloride test or (ii) two cystic fibrosis-causing cystic fibrosis transmembrane conductance regulator mutations or (iii) abnormal nasal potential difference.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

TABRECTA

Products Affected

- TABRECTA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 1 year.
Other Criteria	Non-Small Cell Lung Cancer (NSCLC)-Approve if the patient has advanced or metastatic disease AND the tumor is positive for a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping or high-level MET amplification, as detected by an approved test.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Non-small cell lung cancer with high-level MET amplification.
Part B Prerequisite	No
Prerequisite Therapy Required	No

TADALAFIL

Products Affected

- *tadalafil oral tablet 2.5 mg, 5 mg*

PA Criteria	Criteria Details
Exclusion Criteria	Treatment of erectile dysfunction (ED)
Required Medical Information	Indication for which tadalafil is being prescribed.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 12 mos.
Other Criteria	Benign prostatic hyperplasia (BPH), after confirmation that tadalafil is being prescribed as once daily dosing, to treat the signs and symptoms of BPH and not for the treatment of erectile dysfunction (ED).
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

TAFAMIDIS

Products Affected

- VYNDAMAX
- VYNDAQEL

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with other medications indicated for polyneuropathy of hereditary transthyretin-mediated amyloidosis or transthyretin-mediated amyloidosis-cardiomyopathy (e.g., Amvuttra (vutrisiran subcutaneous injection), Attruby (acoramidis tablets), Onpattro (patisiran lipid complex intravenous infusion), Tegsedi (inotersen subcutaneous injection), or Wainua [eplontersen subcutaneous injection]).
Required Medical Information	Diagnosis, genetic tests and lab results (as specified in the Other Criteria field)
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with a cardiologist or a physician who specializes in the treatment of amyloidosis
Coverage Duration	1 year
Other Criteria	Cardiomyopathy of Wild-Type or Hereditary Transthyretin Amyloidosis-approve if patient meets (A, B and C): A) the diagnosis was confirmed by one of the following (i, ii or iii): i. A technetium pyrophosphate scan (i.e., nuclear scintigraphy), ii. tissue biopsy with confirmatory TTR amyloid typing by mass spectrometry, immunoelectron microscopy or immunohistochemistry OR iii. patient had genetic testing which, according to the prescriber, identified a TTR pathogenic variant AND B) Diagnostic cardiac imaging (e.g., echocardiogram, cardiac magnetic imaging) has demonstrated cardiac involvement (e.g., increased thickness of the ventricular wall or interventricular septum), and C) patient has heart failure but does not have NYHA class IV disease.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	No

TAFINLAR

Products Affected

- TAFINLAR ORAL CAPSULE
- TAFINLAR ORAL TABLET FOR SUSPENSION

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 1 year.
Other Criteria	Glioma- approve if pt has BRAF V600 mutation-positive disease and this medication will be taken with Mekinist (trametinib). Melanoma with BRAF V600 mutation AND patient has unresectable, advanced (including Stage III or Stage IV disease) or metastatic melanoma. Note-This includes adjuvant treatment in patients with Stage III disease with no evidence of disease post-surgery. NSCLC-approve if pt has recurrent, advanced, or metastatic disease AND BRAF V600 mutation-positive disease. Thyroid Cancer, anaplastic-must have BRAF V600-positive disease AND Tafenlar will be taken in combination with Mekinist, AND the patient has locally advanced or metastatic anaplastic disease. Thyroid Cancer, differentiated (i.e., papillary, follicular, or oncocytic) AND the patient has BRAF-positive disease. Histiocytic neoplasm-approve if (A and B): A) patient has Langerhans cell histiocytosis or Erdheim Chester disease AND B) patient has BRAF V600-mutation positive disease. Solid tumors [examples: biliary tract cancer, brain metastases due to melanoma, ovarian/fallopian tube/primary peritoneal cancer, gastrointestinal stromal tumors, gastric cancer, esophageal and esophagogastric junction cancers, salivary gland tumors, occult primary, pancreatic adenocarcinoma, neuroendocrine tumors, ampullary adenocarcinoma, small bowel adenocarcinoma]-approve if BRAF V600 mutation-positive disease AND medication will be taken in combination with Mekinist (trametinib). Hairy Cell Leukemia, approve if

PA Criteria	Criteria Details
	pt has not previously been treated with a BRAF inhibitor therapy and this will be used for relapsed/refractory disease and will be taken in combination with Mekinist.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Histiocytic neoplasm, hairy cell leukemia
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

TAGRISO

Products Affected

- TAGRISO

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	NSCLC-EGFR Mutation Positive (other than EGFR T790M-Positive Mutation)- approve if the patient has advanced or metastatic disease, has EGFR mutation-positive NSCLC as detected by an approved test. Note- examples of EGFR mutation-positive NSCLC include the following mutations: exon 19 deletions, exon 21 (L858R) substitution mutations, L861Q, G719X and S7681. NSCLC-EGFR T790M mutation positive- approve if the patient has advanced or metastatic EGFR T790M mutation-positive NSCLC as detected by an approved test and has progressed on treatment with at least one of the EGFR tyrosine kinase inhibitors. NSCLC- Post resection-approve if the patient has completely resected disease and has received previous adjuvant chemotherapy or if the patient is ineligible to receive platinum based chemotherapy and the patient has EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an approved test. NSCLC- Unresectable Stage III - approve if the patient has locally advanced, unresectable (stage III) disease AND EGFR exon 19 deletions or exon 21 (L858R) substitution mutation as detected by an approved test AND not had disease progression during or following platinum-based chemoradiation therapy. (Note: Patients could have received concurrent or sequential chemoradiation therapy.)
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

Effective August 1, 2026

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

TALVEY

Products Affected

- TALVEY

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	1 year
Other Criteria	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Multiple myeloma-approve if per FDA approved labeling the patient has tried at least four systemic regimens and among the previous regimens tried, the patient has received at least one drug from each of the following classes: proteasome inhibitor, an immunomodulatory drug and an anti-CD38 monoclonal antibody.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

TALZENNA

Products Affected

- TALZENNA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Recurrent or metastatic breast cancer-approve if the patient has germline BRCA mutation-positive disease. Prostate cancer - approve if the patient has metastatic castration resistant prostate cancer, AND is using this medication concurrently with a gonadotropin-releasing hormone (GnRH) analog or has had a bilateral orchiectomy AND the patient has homologous recombination repair (HRR) gene-mutated disease [Note: HRR gene mutations include ATM, ATR, BRCA1, BRCA2, CDK12, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, or RAD51C] AND the medication is used in combination with Xtandi (enzalutamide capsules and tablets).
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

TAZAROTENE

Products Affected

- *tazarotene topical cream*
- *tazarotene topical gel*

PA Criteria	Criteria Details
Exclusion Criteria	Cosmetic uses
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

TECVAYLI

Products Affected

- TECVAYLI

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	1 year
Other Criteria	Part B vs Part D determination will be made at time of prior authorization review per CMS guidance. Multiple Myeloma-approve if the patient meets one (A, B, or C): A) has tried at least four systemic regimens which must include at least one drug from each of the following classes: proteasome inhibitor, immunomodulatory drug and Anti-CD38 monoclonal antibody OR B) tried lenalidomide and at least one proteasome inhibitor and the medication will be used in combination with Darzalex (daratumumab intravenous infusion) or Darzalex Faspro (daratumumab and hyaluronidase-fihj subcutaneous injection) OR C) tried at least three prior lines of therapy and the medication will be used in combination with Talvey (talquetamab-tgvs subcutaneous injection).
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

TEPMETKO

Products Affected

- TEPMETKO

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	NSCLC-approve if the patient has advanced or metastatic disease and the tumor is positive for mesenchymal-epithelial transition (MET) exon 14 skipping mutations or patient has high-level MET amplification, as detected by an approved test.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Non-small cell lung cancer with high-level MET amplification.
Part B Prerequisite	No
Prerequisite Therapy Required	No

TERIPARATIDE

Products Affected

- BONSITY
- teriparatide (only ndcs starting with 47781)*

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use with other medications for osteoporosis
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	High risk for fracture-2 yrs, Not high risk-approve a max of 2 yrs of therapy (total)/lifetime.
Other Criteria	INITIAL THERAPY: Postmenopausal Osteoporosis (PMO) Treatment, Increase Bone Mass in Men (see Note 1 below) with Primary or Hypogonadal Osteoporosis, and Treatment of Glucocorticosteroid-Induced Osteoporosis (GIO): (one of A, B, C, D or E): A) tried one oral bisphosphonate or cannot take due to swallowing difficulties or inability to remain upright after administration, B) pre-existing gastrointestinal condition (e.g., esophageal lesions/ulcers, abnormalities of the esophagus that delay esophageal emptying [stricture, achalasia]), C) tried an IV bisphosphonate (PMO-ibandronate or zoledronic acid, all other diagnoses-zoledronic acid), D) severe renal impairment (creatinine clearance [CrCL] less than 35 mL/min) or chronic kidney disease (CKD), or E) patient had an osteoporotic fracture or fragility fracture at any time in the past. CONTINUATION THERAPY: ALL INDICATIONS: if the patient has taken teriparatide for two years, approve if the patient is at high risk for fracture. Examples of high risk for fracture include a previous osteoporotic fracture or fragility fracture, receipt of medications that increase the risk of osteoporosis, advanced age, and very low bone mineral density. Note 1: a man is defined as an individual with the biological traits of a man, regardless of the individual's gender identity or gender expression.
Indications	All FDA-approved Indications.

PA Criteria	Criteria Details
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

TETRABENAZINE

Products Affected

- tetrabenazine oral tablet 12.5 mg, 25 mg

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	18 years and older
Prescriber Restrictions	For treatment of chorea associated with Huntington's disease, Tourette syndrome or related tic disorders, hyperkinetic dystonia, or hemiballism, must be prescribed by or after consultation with a neurologist. For TD, must be prescribed by or after consultation with a neurologist or psychiatrist.
Coverage Duration	Authorization will be for 1 year.
Other Criteria	Chorea associated with Huntington's Disease-approve if the diagnosis of Huntington's Disease is confirmed by genetic testing.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Tardive dyskinesia (TD). Tourette syndrome and related tic disorders. Hyperkinetic dystonia. Hemiballism.
Part B Prerequisite	No
Prerequisite Therapy Required	No

TEVIMBRA

Products Affected

- TEVIMBRA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis. Hepatocellular carcinoma-approve if (A or B): A) medication is used first-line and meets (i or ii): i) pt has liver-confined, unresectable disease and is deemed ineligible for transplant, or ii) pt has extrahepatic/metastatic disease and are deemed ineligible for resection, transplant, or locoregional therapy, or B) medication is being used for subsequent-line therapy. Nasopharyngeal carcinoma-approve if (A and B): A) pt has recurrent, unresectable, oligometastatic, or metastatic disease, and B) meets (i or ii): i) used as first-line treatment in combination with cisplatin and gemcitabine or ii) used as subsequent treatment. Small bowel adenocarcinoma-approve if (A, B and C): A) locally unresectable or medically inoperable disease, or advanced or metastatic disease, and B) either (i or ii): i) deficient mismatch repair/microsatellite instability-high (dMMR/MSI-H) disease or ii) polymerase epsilon/delta (POLE/POLD1) mutation positive disease with ultra-hypermutated phenotype (tumor mutation burden greater than 50 mutations/megabase), and C) is used as a single agent.
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	1 year
Other Criteria	Part B vs Part D determination will be made at time of prior authorization review per CMS guidance. ESOPHAGEAL and ESOPHAGOGASTRIC JUNCTION CANCERS-All of (A, B and C): A. Unresectable locally advanced, recurrent, or metastatic disease, AND B. Meets (i or ii): i) pt has esophageal squamous cell carcinoma with (a or b): a) tumor expression for programmed death-ligand 1 (PD-L1) has a combined positive score (CPS) greater than or equal to 1 and is used in combination with chemotherapy, or b) medication is used as a single agent or ii) pt has esophageal adenocarcinoma that is HER2 overexpression negative and tumor

PA Criteria	Criteria Details
	expression for PD-L1 has a CPS greater than or equal to 1, AND C. Patient has NOT previously received a checkpoint inhibitor or has NO tumor progression while on a checkpoint inhibitor. Note: Examples of checkpoint inhibitors include Keytruda (pembrolizumab intravenous infusion), Opdivo (nivolumab intravenous infusion). Gastric or gastroesophageal junction adenocarcinoma- approve if (A, B and C): A) unresectable locally advanced, recurrent or metastatic human epidermal growth factor receptor 2 (HER2)-negative disease, B) tumor expresses programmed death-ligand 1 (PD-L1) greater than or equal to 1 percent, C) used in combination with platinum and fluoropyrimidine-based chemotherapy. Anal carcinoma-meets (A and B): A) used as a single agent and B) meets (i or ii): i) locally recurrent, progressive disease and administered before proceeding to abdominoperineal resection, or ii) metastatic disease and used as subsequent therapy. CLL/SLL-approve if (A and B): A) patient has histologic transformation to diffuse large B-cell lymphoma, and B) is used in combination with Brukinsa (zanubrutinib capsules). Colon, rectal or appendiceal cancer-approve if pt meets (A and B): A) meets (i or ii): i) pt has mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) disease, or ii) has DNA polymerase epsilon/delta (POLE/POLD1) mutation, and B) pt has advanced or metastatic disease. Classic Hodgkin Lymphoma-approve if refractory or relapsed disease and medication is used with GEMOX (gemcitabine and oxaliplatin). Endometrial carcinoma-approve if (A, B and C): A) recurrent or metastatic disease, and B) pt has microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) tumors, and C) will be used as single agent.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Anal carcinoma, Chronic lymphocytic leukemia/small lymphocytic lymphoma, hepatocellular carcinoma, nasopharyngeal carcinoma, small bowel adenocarcinoma, colon/rectal/appendiceal cancer, Classic Hodgkin Lymphoma, endometrial carcinoma
Part B Prerequisite	No
Prerequisite Therapy Required	No

TEZSPIRE

Products Affected

- TEZSPIRE

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use of Tezspire with another monoclonal antibody therapy
Required Medical Information	Diagnosis
Age Restrictions	12 years and older
Prescriber Restrictions	CRSwNP: Prescribed by or in consultation with allergist, immunologist, or an otolaryngologist. Asthma: Prescribed by or in consultation with an allergist, immunologist, pulmonologist
Coverage Duration	Initial- 6 months, Continuation-1 year
Other Criteria	Asthma, initial-approve if the patient meets (i and ii): i. received combination therapy with BOTH of the following: an inhaled corticosteroid (CS) and at least one additional asthma controller or asthma maintenance medication, ii. Patient has asthma that is uncontrolled or was uncontrolled at baseline (baseline is defined as prior to receiving Tezspire or another monoclonal antibody therapy for asthma) as defined by ONE of the following (a, b, c, d, or e): a) Patient experienced two or more asthma exacerbations requiring systemic CS in the previous year, OR b) one or more asthma exacerbation(s) requiring hospitalization, an Emergency Department visit, or an urgent care visit in the previous year, OR c) Patient has a forced expiratory volume in 1 second (FEV1) less than 80 percent predicted or less than 90 percent predicted for patients less than 18, OR d) Patient has an FEV1/forced vital capacity (FVC) less than 0.80 or less than 0.9 for pts less than 18, OR e) asthma that worsens upon tapering of oral (systemic) CS therapy AND Note: Baseline is defined as prior to receiving any Tezspire, anti-interleukin-5 therapies (i.e., Cinqair, Fasenra, or Nucala), Dupixent, or Xolair. Asthma, continuation-approve if the patient has received at least 6 months of therapy with Tezspire (patient who has received less than 6 months of therapy or who is restarting therapy should be reviewed under initial therapy), patient continues to receive therapy with one inhaled CS or one inhaled CS-containing combination inhaler and the

PA Criteria	Criteria Details
	patient has responded to therapy. CRSwNP, initial - approve if (A, B, C, D and E): A) dx as evidenced by direct examination, endoscopy, or sinus CT scan AND B) dx of CRSwNP for at least 6 months, AND C) at least 2 symptoms for at least 8 weeks: nasal congestion/obstruction/discharge and/or reduction/loss of smell, AND D) BOTH of (a and b): a) received tx with intranasal CS AND b)will continue to receive tx with intranasal CS, AND E) at least 1 course of systemic CS in previous year (unless contraindicated) or prior surgery for nasal polyps. CRSwNP, Cont-approve if received at least 6 months of therapy, continues intranasal CS and has responded to tx.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

THALOMID

Products Affected

- THALOMID ORAL CAPSULE 100 MG, 50 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	MM, histiocytic neoplasms-18 years and older, medulloblastoma- less than 18 years old
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 1 year.
Other Criteria	Erythem Nodosum Leprosum-approve. Multiple Myeloma-approve. Discoid lupus erythematosus or cutaneous lupus erythematosus, approve if the patient has tried at least two other therapies (eg, corticosteroids [oral, topical, intralesional], hydroxychloroquine, tacrolimus [Protopic], methotrexate, dapsone, acitretin [Soriatane]). Prurigo nodularis, approve. Recurrent aphthous ulcers or aphthous stomatitis, approve if the patient has tried at least two other therapies (eg, topical or intralesional corticosteroids, systemic corticosteroids, topical anesthetics/analgesics [eg, benzocaine lozenges], antimicrobial mouthwashes [eg, tetracycline], acyclovir, colchicine). Kaposi Sarcoma-approve if the patient has tried at least one medication AND has relapsed or refractory disease. Castleman disease-approve if the patient has multicentric disease and is negative for the human immunodeficiency virus (HIV) and human herpesvirus-8 (HHV-8). Histiocytic neoplasms-approve if (A or B): A) pt has Langerhans cell histiocytosis with either (i or ii): i) single-system multifocal skin disease or ii) relapsed or refractory disease, or B) pt has or Rosai-Dorfman cutaneous disease. Medulloblastoma- approve if pt has recurrent or progressive disease AND medication is being used as a part of the MEMMAT regimen (i.e. Thalomid, celecoxib, fenofibrate, oral etoposide, cyclophosphamide, bevacizumab, and intraventricular etoposide).

PA Criteria	Criteria Details
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Discoid lupus erythematosus or cutaneous lupus erythematosus, Prurigo nodularis, Recurrent aphthous ulcers or aphthous stomatitis, Kaposi Sarcoma, Castleman Disease, histiocytic neoplasms, medulloblastoma.
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

TIBSOVO

Products Affected

- TIBSOVO

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, IDH1 Status
Age Restrictions	All diagnoses (except chondrosarcoma)-18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	AML- approve if the disease is isocitrate dehydrogenase-1 (IDH1) mutation positive, as detected by an approved test. Cholangiocarcinoma-approve if the disease is isocitrate dehydrogenase-1 (IDH1) mutation positive and has been previously treated with at least one chemotherapy regimen (Part B before Part D Step Therapy - applies only to beneficiaries enrolled in an MA-PD plan). Chondrosarcoma-approve if the disease is isocitrate dehydrogenase-1 (IDH1) mutation positive. Central nervous system cancer-approve if the patient has oligodendroglioma or astrocytoma. Myelodysplastic Syndrome-approve if patient has isocitrate dehydrogenase-1 (IDH1) mutation-positive disease AND relapsed or refractory disease.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Chondrosarcoma, Central nervous system cancer
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

TIVDAK

Products Affected

- TIVDAK

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	1 year
Other Criteria	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Cervical cancer-approve if the patient has tried at least one chemotherapy agent. Vaginal cancer- approve if the patient has tried at least one chemotherapy agent.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Vaginal cancer
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

TOBRAMYCIN (NEBULIZATION)

Products Affected

- *tobramycin in 0.225 % nacl*
- *tobramycin inhalation*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	Bronchiectasis, Non-cystic fibrosis-18 years and older
Prescriber Restrictions	CF-prescr/consult w/pulm/phys specializes in tx of CF.Bronchiectasis, non CF-prescr/consult w/pulm
Coverage Duration	1 year
Other Criteria	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Cystic fibrosis/Bronchiectasis, non-cystic fibrosis-approve if the patient has pseudomonas aeruginosa in the culture of the airway.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Bronchiectasis, non-cystic fibrosis
Part B Prerequisite	No
Prerequisite Therapy Required	No

TOLVAPTAN

Products Affected

- *tolvaptan*

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with Jynarque.
Required Medical Information	Serum sodium less than 125 mEq/L at baseline or less marked hyponatremia, defined as serum sodium less than 135 mEq/L at baseline, that is symptomatic (eg, nausea, vomiting, headache, lethargy, confusion).
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 30 days for initial therapy, 3 months for continuation of therapy
Other Criteria	Hyponatremia, initial therapy (including new starts, patients on therapy for less than 30 days, and patients restarting therapy) - Pt must meet ONE of the following: 1. serum sodium less than 125 mEq/L at baseline, OR 2. marked hyponatremia, defined as less than 135 mEq/L at baseline, that is symptomatic (eg, nausea, vomiting, headache, lethargy, confusion), OR 3. patient has already been started on tolvaptan and has received less than 30 days of therapy. Hyponatremia, continuation of therapy for patients established on therapy for at least 30 days - approve if the serum sodium level has increased from baseline (prior to initiating the requested drug) OR if the patient experienced improvement in at least one symptom, such as nausea, vomiting, headache, lethargy, or confusion.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

TOPICAL AGENTS FOR ATOPIC DERMATITIS

Products Affected

- EUCRISA
- *pimecrolimus*
- *tacrolimus topical*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 12 months.
Other Criteria	If the request is for a tacrolimus product or a pimecrolimus product: Authorize use in patients who have tried a prescription strength topical corticosteroid (brand or generic) for the current condition. Dermatologic condition on or around the eyes, eyelids, axilla, or genitalia, authorize use without a trial of a prescription strength topical corticosteroid. If the request is for Eucrisa: approve.
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

TOPICAL RETINOID PRODUCTS

Products Affected

- *tretinoin topical*

PA Criteria	Criteria Details
Exclusion Criteria	Coverage is not provided for cosmetic use.
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 12 months
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

TOPIRAMATE/ZONISAMIDE

Products Affected

- *topiramate oral capsule, sprinkle 15 mg, 25 mg*
- *topiramate oral solution*
- *topiramate oral tablet*
- ZONISADE
- *zonisamide*

PA Criteria	Criteria Details
Exclusion Criteria	Coverage is not provided for weight loss or smoking cessation.
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 1 year.
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

TRANSDERMAL FENTANYL

Products Affected

- *fentanyl transdermal patch 72 hour 100 mcg/hr, 12 mcg/hr, 25 mcg/hr, 50 mcg/hr, 75 mcg/hr*

PA Criteria	Criteria Details
Exclusion Criteria	Acute (i.e., non-chronic) pain.
Required Medical Information	Pain type (chronic vs acute)
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	For pain severe enough to require daily, around-the-clock, long-term opioid treatment, approve if all of the following criteria are met: 1) patient is not opioid naive, AND 2) the prescribing physician has checked the patient's history of controlled substance prescriptions using state prescription drug monitoring program (PDMP) AND 3) the prescribing physician has discussed risks (eg, addiction, overdose) and realistic benefits of opioid therapy with the patient, AND 4) according to the prescriber physician there is a treatment plan (including goals for pain and function) in place and reassessments are scheduled at regular intervals. Patients with cancer, in hospice, sickle cell diagnosis or who reside in a long term care facility are not required to meet above criteria. Clinical criteria incorporated into the quantity limit edits for all oral long-acting opioids (including transdermal fentanyl products) require confirmation that the indication is intractable pain (ie, FDA labeled use) prior to reviewing for quantity exception.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	No

TRELSTAR

Products Affected

- TRELSTAR INTRAMUSCULAR
SUSPENSION FOR RECONSTITUTION

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prostate cancer: Prescribed by or in consultation with a oncologist or urologist. Head and neck cancer - salivary gland tumors: Prescribed by or in consultation with a oncologist.
Coverage Duration	1 year
Other Criteria	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Prostate cancer: Patients new to therapy, are required to try Eligard prior to approval of Trelstar. Head and neck cancer - salivary gland tumors: approve if patient has recurrent, unresectable, or metastatic disease and androgen receptor-positive disease.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Head and neck cancer - salivary gland tumors
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

TREMFYA IV

Products Affected

- TREMFYA INTRAVENOUS

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with a biologic or with a targeted synthetic oral small molecule drug.
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with a gastroenterologist
Coverage Duration	3 doses for induction
Other Criteria	ULCERATIVE COLITIS-Approve if the medication will be used as induction therapy. CROHN'S DISEASE (CD): Approve if the medication will be used as induction therapy.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

TREMFYA SC

Products Affected

- TREMFYA ONE-PRESS
- TREMFYA PEN
- TREMFYA PEN INDUCTION PK(2PEN)
- TREMFYA SUBCUTANEOUS SYRINGE

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent Use with other Biologics or Targeted Synthetic Disease-Modifying Antirheumatic Drugs (DMARDs)
Required Medical Information	Diagnosis
Age Restrictions	PP/PsA - 6 years of age or older (initial therapy), UC/CD-18 years of age and older (initial therapy)
Prescriber Restrictions	PP-Prescribed by or in consultation with a dermatologist (initial therapy only). PsA-prescribed by or in consultation with a dermatologist or rheumatologist (initial therapy). UC/CD-prescribed by or in consultation with a gastroenterologist (initial therapy).
Coverage Duration	Approve through end of plan year
Other Criteria	PP, initial therapy - approve if the pt meets (A and B): A) meets (1 or 2): 1) 18 years of age or older, or 2) 6 to 17 years old and weighs at least 40 kg, and B) meets one of the following criteria: 1) pt has tried at least one traditional systemic agent (eg, MTX, cyclosporine, acitretin, PUVA) for at least 3 months, unless intolerant (note: a biologic that is not a biosimilar of the requested product will also count) OR 2) pt has a contraindication to MTX as determined by the prescribing physician. PsA, initial therapy - approve if pt meets (1 or 2): 1) 18 years of age or older, or 2) 6 to 17 years old and weighs at least 40 kg. ULCERATIVE COLITIS-approve. CROHN'S DISEASE (CD): approve. PP/PsA/UC/CD continuation of therapy - approve if the pt is responding to therapy.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Effective August 1, 2026

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

TRIENTINE

Products Affected

- *trientine oral capsule 250 mg*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a gastroenterologist, hepatologist, or liver transplant physician.
Coverage Duration	Authorization will be for 1 year
Other Criteria	For Wilson's Disease, approve if the patient meets A and B: A) Diagnosis of Wilson's disease is confirmed by ONE of the following (i or ii): i. Genetic testing results confirming biallelic pathogenic ATP7B mutations (in either symptomatic or asymptomatic individuals), OR ii. Confirmation of at least two of the following (a, b, c, or d): a. Presence of Kayser-Fleischer rings, OR b. Serum ceruloplasmin levels less than 20mg/dL, OR c. Liver biopsy findings consistent with Wilson's disease, OR d. 24-hour urinary copper greater than 40 micrograms/24 hours, AND B) Patient meets ONE of the following: 1) Patient has tried a penicillamine product and per the prescribing physician the patient is intolerant to penicillamine therapy, OR 2) Per the prescribing physician, the patient has clinical features indicating the potential for intolerance to penicillamine therapy (ie, history of any renal disease, congestive splenomegaly causing severe thrombocytopenia, autoimmune tendency), OR 3) Per the prescribing physician, the patient has a contraindication to penicillamine therapy, OR 4) The patient has neurologic manifestations of Wilson's disease, OR 5) The patient is pregnant, OR 6) the patient has been started on therapy with trientine.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

TRIKAFTA

Products Affected

- TRIKAFTA ORAL GRANULES IN PACKET, SEQUENTIAL
- TRIKAFTA ORAL TABLETS, SEQUENTIAL

PA Criteria	Criteria Details
Exclusion Criteria	Combination therapy with other CF transmembrane conductance regulator modulators.
Required Medical Information	Diagnosis
Age Restrictions	2 years of age and older
Prescriber Restrictions	Prescribed by or in consultation with a pulmonologist or a physician who specializes in CF
Coverage Duration	1 year
Other Criteria	CF -Approve if the pt meets A, B and C: A) pt has at least one mutation in the cystic fibrosis transmembrane conductance regulator gene that is considered to be pathogenic or likely pathogenic variant, and B) pt must have positive CF newborn screening test or family history of CF or clinical presentation consistent with signs and symptoms of CF and C) evidence of abnormal cystic fibrosis transmembrane conductance regulator function as demonstrated by i, ii, or iii: (i) elevated sweat chloride test or (ii) two cystic fibrosis-causing cystic fibrosis transmembrane conductance regulator mutations or (iii) abnormal nasal potential difference.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

TRODELVY

Products Affected

- TRODELVY

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, prior therapies
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Authorization will be for 1 year
Other Criteria	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Breast Cancer-approve if the patient has recurrent or metastatic, human epidermal growth factor receptor (HER2) negative breast cancer and patient meets (a or b): a) patient has hormone receptor (HR) negative disease AND has tried at least one systemic regimen in the metastatic setting, OR b) patient has HR positive disease, has tried endocrine therapy, has tried a cyclin-dependent kinase(CDK) 4/6 inhibitor, has tried at least two systemic chemotherapy regimens (one of which was tried in the metastatic setting), and patient is not a candidate for Enhertu (fam-trastuzumab deruxtecan-nxki intravenous infusion) therapy . Urothelial Cancer-approve if the patient has locally advanced or metastatic urothelial cancer AND has tried at least one systemic chemotherapy AND has tried at least one programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Urothelial cancer
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

TRUQAP

Products Affected

- TRUQAP

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Breast Cancer-Approve if the patient meets the following (A, B, C, D and E): A) Patient has locally advanced or metastatic disease, AND B) Patient has hormone receptor positive (HR+) disease, AND C) Patient has human epidermal growth factor receptor 2 (HER2)-negative disease, AND D) Patient has at least one phosphatidylinositol 3-kinase (PIK3CA), serine/threonine protein kinase (AKT1), or phosphatase and tensin homolog (PTEN)-alteration, AND E) Patient meets one of the following (i or ii): i. Patient has had progression with at least one endocrine-based regimen in the metastatic setting (Note: Examples of endocrine therapy include anastrozole, exemestane, and letrozole.) and has had progression with at least one cyclin-dependent kinase (CDK) 4/6 inhibitor in the metastatic setting (Note: Examples of CDK4/6 inhibitor include: Ibrance (palbociclib tablets or capsules), Verzenio (abemaciclib tablets), Kisqali (ribociclib tablets), Kisqali Femara Co-Pack (ribociclib and letrozole tablets) OR ii. Patient has recurrence on or within 12 months of completing adjuvant endocrine therapy.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Effective August 1, 2026

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

TUKYSA

Products Affected

- TUKYSA ORAL TABLET 150 MG, 50 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, prior therapies
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Breast Cancer-approve if the patient has recurrent or metastatic human epidermal growth factor receptor 2 (HER2)-positive disease, has received at least one prior anti-HER2-based regimen in the metastatic setting and Tukysa is used in combination with trastuzumab and capecitabine. Colon/Rectal Cancer-approve if the requested medication is used in combination with trastuzumab, patient has unresectable or metastatic disease, human epidermal growth factor receptor 2 (HER2)-amplified disease, AND Patient's tumor or metastases are wild-type RAS (KRAS wild-type and NRAS wild-type). Biliary tract cancer- approve if the patient meets all of (a, b, c, and d): a) unresectable or metastatic disease, b) HER2 positive disease, c) tried at least one systemic regimen, d) will use in combination with trastuzumab.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Biliary tract cancer
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

TURALIO

Products Affected

- TURALIO

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Tenosynovial Giant Cell Tumor (Pigmented Villonodular Synovitis)-approve if, according to the prescriber, the tumor is not amenable to improvement with surgery. Histiocytic Neoplasms-approve if the patient has a colony stimulating factor 1 receptor (CSF1R) mutation AND has one of the following conditions (i, ii, or iii): i. Langerhans cell histiocytosis OR ii. Erdheim-Chester disease OR iii. Rosai-Dorfman disease.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Histiocytic Neoplasms
Part B Prerequisite	No
Prerequisite Therapy Required	No

TYENNE IV

Products Affected

- TYENNE INTRAVENOUS

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with a Biologic Disease-Modifying Antirheumatic Drug (DMARD) or targeted synthetic DMARD. Exclude for indication of COVID-19 treatment in hospitalized patients (ie, non-D use).
Required Medical Information	Diagnosis
Age Restrictions	(Initial therapy only): GCA/RA-18 years and older. PJIA/SJIA-2 years and older.
Prescriber Restrictions	RA, SJIA, PJIA, GCA - Prescribed by or in consultation with a rheumatologist (initial therapy).
Coverage Duration	Approve through end of plan year
Other Criteria	INITIAL THERAPY- RHEUMATOID ARTHRITIS (RA) [A OR B]: A) Try ONE of the following: Enbrel, a preferred adalimumab product, Rinvoq or Xeljanz. (Note: previous trial(s) with the following drugs: Cimzia, infliximab, Simponi (IV/SC), Kevzara, Orencia or another non-preferred adalimumab product will also count.) OR B) Patient has heart failure or a previously treated lymphoproliferative disorder. POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA) [A OR B]: A) Try ONE of the following: Enbrel, Rinvoq, Xeljanz, a preferred adalimumab product, (Note: a trial with infliximab, Kevzara, Orencia or another non-preferred adalimumab product will also count.) OR B) Patient has heart failure or a previously treated lymphoproliferative disorder. SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA): Approve. GIANT CELL ARTERITIS: tried or is currently taking a systemic corticosteroid or corticosteroid is contraindicated. CYTOKINE RELEASE SYNDROME ASSOCIATED WITH CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY-approve. Please Note: preferred adalimumab products include Hadlima, Simlandi. CONTINUATION THERAPY-RA, PJIA, SJIA, GCA:patient has responded to therapy.
Indications	All FDA-approved Indications.

PA Criteria	Criteria Details
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

TYENNE SC

Products Affected

- TYENNE AUTOINJECTOR
- TYENNE SUBCUTANEOUS

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with a Biologic DMARD or Targeted Synthetic DMARD.
Required Medical Information	Diagnosis, concurrent medications, previous drugs tried.
Age Restrictions	Interstitial lung disease-18 years and older (initial and continuation). GCA/RA-18 years and older (initial only). SJIA/PJIA-2 years and older (initial only).
Prescriber Restrictions	RA/GCA/PJIA/SJIA - Prescribed by or in consultation with a rheumatologist (initial therapy only). Lung disease-presc/consult-pulmonologist or rheum (initial and cont)
Coverage Duration	Approve through end of plan year
Other Criteria	INITIAL THERAPY: RHEUMATOID ARTHRITIS (RA) [A or B]: A) tried one of the following: Enbrel, preferred adalimumab product (see Example 1), Rinvoq or Xeljanz/XR (Note: trials with the following will also count: Cimzia, infliximab, Kevzara, golimumab SC/IV, non-preferred adalimumab product, Orencia), or B) heart failure or a previously treated lymphoproliferative disorder. POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA) [A or B]: A) tried one of the following: Enbrel, Rinvoq, Xeljanz, preferred adalimumab product. (Note: trials with Kevzara, infliximab, Orencia or a non-preferred adalimumab product will also count), or B) heart failure or a previously treated lymphoproliferative disorder. SYSTEMIC-ONSET JIA (SJIA): Approve. GIANT CELL ARTERITIS: tried or is currently taking a systemic CS or CS are contraindicated. INTERSTITIAL LUNG DISEASE ASSOCIATED WITH SYSTEMIC SCLEROSIS (A and B): A) elevated acute phase reactants and B) diagnosis confirmed by high-resolution computed tomography. CONTINUATION THERAPY: ALL INDICATIONS: patient had a response to therapy. Example 1: preferred adalimumab products include Hadlima, Simlandi.
Indications	All FDA-approved Indications.

Effective August 1, 2026

PA Criteria	Criteria Details
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

TYMLOS

Products Affected

- TYMLOS

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use with other medications for osteoporosis (eg, denosumab [Prolia], bisphosphonates, calcitonin nasal spray [Fortical], Forteo), Evenity, except calcium and Vitamin D. Previous use of Tymlos for a combined total no greater than 2 years duration during a patient's lifetime.
Required Medical Information	Previous medications tried, renal function
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 2 years of total therapy over a patient's lifetime
Other Criteria	Postmenopausal Osteoporosis (PMO) Treatment and Osteoporosis Treatment in Men (see Note 1 below) [one of A, B, C, D, or E]: A) tried one oral bisphosphonate or cannot take due to swallowing difficulties or inability to remain upright after administration, B) pre-existing gastrointestinal condition (e.g., esophageal lesions/ulcers, abnormalities of the esophagus that delay esophageal emptying [stricture, achalasia]), C) tried an IV bisphosphonate (PMO-ibandronate or zoledronic acid, osteoporosis in men- zoledronic acid), D) severe renal impairment (creatinine clearance [CrCL] less than 35 mL/min) or chronic kidney disease (CKD), or E) patient had an osteoporotic fracture or fragility fracture at any time in the past. ALL INDICATIONS: must have a trial of teriparatide prior to approval of Tymlos. Note 1: a man is defined as an individual with the biological traits of a man, regardless of the individual's gender identity or gender expression.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

Effective August 1, 2026

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

UBRELVY

Products Affected

- UBRELVY

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Migraine, Acute treatment-approve if the patient has tried at least one triptan or has a contraindication to triptans.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

UPTRAVI

Products Affected

- UPTRAVI ORAL TABLET
- UPTRAVI ORAL TABLETS,DOSE PACK

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent Use with Other Inhaled or Parenteral Prostacyclin Agents Used for Pulmonary Hypertension.
Required Medical Information	Confirmation of right heart catheterization, medication history (as described in Other Criteria)
Age Restrictions	N/A
Prescriber Restrictions	PAH must be prescribed by, or in consultation with, a cardiologist or a pulmonologist.
Coverage Duration	1 year
Other Criteria	Must have PAH (WHO Group 1) and had a right heart catheterization to confirm the diagnosis of PAH (WHO Group 1). Patient new to therapy must meet a) OR b): a) tried one or is currently taking one oral therapy for PAH for 30 days, unless patient has experienced treatment failure, intolerance, or oral therapy is contraindicated: PDE5 inhibitor (eg, sildenafil, Revatio), endothelin receptor antagonist (ERA) [eg, Tracleer, Letairis or Opsumit], or Adempas, OR b) receiving or has received in the past one prostacyclin therapy for PAH (eg, Orenitram, Ventavis, or epoprostenol injection).
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

USTEKINUMAB IV

Products Affected

- OTULFI INTRAVENOUS
- PYZCHIVA (ONLY NDCS STARTING WITH 61314) INTRAVENOUS SOLUTION 130 MG/26 ML
- SELARSDI INTRAVENOUS
- STELARA INTRAVENOUS
- USTEKINUMAB INTRAVENOUS
- YESINTEK INTRAVENOUS

PA Criteria	Criteria Details
Exclusion Criteria	Ustekinumab should not be given in combination with a Biologic DMARD or Targeted Synthetic DMARD
Required Medical Information	Diagnosis
Age Restrictions	UC-18 years and older, CD-2 years and older
Prescriber Restrictions	Prescribed by or in consultation with a gastroenterologist
Coverage Duration	Approve a single dose
Other Criteria	INDUCTION THERAPY for USTEKINUMAB IV: UC: approve. Crohn's Disease: approve. ALL INDICATIONS, in addition to the above criteria: patients requesting a non-preferred ustekinumab product must try one of the following preferred ustekinumab products first: Otulfi, Pyzchiva, Selarsdi, Yesintek.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

USTEKINUMAB SC

Products Affected

- OTULFI SUBCUTANEOUS SOLUTION
- OTULFI SUBCUTANEOUS SYRINGE 45 MG/0.5 ML, 90 MG/ML
- PYZCHIVA (ONLY NDCS STARTING WITH 61314) SUBCUTANEOUS SOLUTION 45 MG/0.5 ML
- PYZCHIVA (ONLY NDCS STARTING WITH 61314) SUBCUTANEOUS SYRINGE 45 MG/0.5 ML, 90 MG/ML
- SELARSDI SUBCUTANEOUS SOLUTION
- SELARSDI SUBCUTANEOUS SYRINGE 45 MG/0.5 ML, 90 MG/ML
- STELARA SUBCUTANEOUS SOLUTION
- USTEKINUMAB SUBCUTANEOUS SOLUTION
- USTEKINUMAB-AEKN SUBCUTANEOUS SYRINGE 45 MG/0.5 ML, 90 MG/ML
- YESINTEK SUBCUTANEOUS SOLUTION
- YESINTEK SUBCUTANEOUS SYRINGE 45 MG/0.5 ML, 90 MG/ML

PA Criteria	Criteria Details
Exclusion Criteria	Ustekinumab should not be given in combination with a Biologic DMARD or Targeted Synthetic DMARD
Required Medical Information	Diagnosis, concurrent medications, previous drugs tried.
Age Restrictions	PP/PsA-6 years and older (initial therapy). UC-18 years and older (initial therapy). CD-2 years and older (initial therapy).
Prescriber Restrictions	Plaque psoriasis.Prescribed by or in consultation with a dermatologist (initial therapy). PsA-prescribed by or in consultation with a rheumatologist or dermatologist (initial therapy). CD/UC-prescribed by or in consultation with a gastroenterologist (initial therapy).
Coverage Duration	Approve through end of plan year
Other Criteria	INITIAL THERAPY: PLAQUE PSORIASIS (PP) [A or B]: A) tried one traditional systemic agent (e.g., methotrexate [MTX], cyclosporine, acitretin, psoralen plus PUVA) for at least 3 months, unless intolerant or B) contraindication to MTX. (Note: a 3-month trial or intolerance of at least one biologic that is not ustekinumab also counts.) CROHN'S DISEASE (CD): approve if pt receiving/received single IV loading dose within 2 months of initiating therapy with ustekinumab SC. ULCERATIVE COLITIS (UC): receiving/received single IV loading dose within 2 months of initiating therapy with ustekinumab SC. CONTINUATION THERAPY:

PA Criteria	Criteria Details
	PP/PsA/CD/UC: patient has responded to therapy. ALL INDICATIONS, INITIAL AND CONTINUATION in addition to the above criteria: patients requesting Stelara must have a trial of one of the following preferred ustekinumab products first: Otulfi, Pyzchiva, Selarsdi, Yesintek.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

VALCHLOR

Products Affected

- VALCHLOR

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	Cutaneous lymphoma-18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Cutaneous Lymphomas (Note-includes mycosis fungoides/Sezary syndrome, primary cutaneous B-cell lymphoma, primary cutaneous CD30+ T-cell lymphoproliferative disorders)-approve. Adult T-Cell Leukemia/Lymphoma-approve if the patient has smoldering subtype of adult T-cell leukemia/lymphoma. Langerhans cell histiocytosis-approve if the patient has unifocal Langerhans cell histiocytosis with isolated skin disease.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Adults with T-cell leukemia/lymphoma, Langerhans Cell Histiocytosis
Part B Prerequisite	No
Prerequisite Therapy Required	No

VALTOCO

Products Affected

- VALTOCO

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, other medications used at the same time
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	1 year
Other Criteria	Intermittent Episodes of Frequent Seizure Activity (i.e., seizure clusters, acute repetitive seizures)-approve if the patient is currently receiving maintenance antiseizure medication(s).
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

VANCOMYCIN

Products Affected

- *vancomycin oral capsule 125 mg, 250 mg*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	2 weeks
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

VANFLYTA

Products Affected

- VANFLYTA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Acute Myeloid Leukemia: approve if the patient has FLT3-ITD mutation-positive disease as detected by an approved test. Myeloid or lymphoid neoplasms: approve if patient has eosinophilia and the tumor has FLT3 rearrangement.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Myeloid or lymphoid neoplasms
Part B Prerequisite	No
Prerequisite Therapy Required	No

VENCLEXTA

Products Affected

- VENCLEXTA ORAL TABLET 10 MG, 100 MG, 50 MG
- VENCLEXTA STARTING PACK

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, prior therapy
Age Restrictions	18 years and older (all diagnoses except ALL)
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	AML-approve if used in combination with azacitidine, decitabine, or cytarabine. CLL/SLL- approve. ALL- approve if relapsed/refractory disease and will be used in combination with chemotherapy. Hairy cell leukemia- approve if disease resistance to BRAF inhibitor therapy. Mantle Cell Lymphoma- approve if (A or B): A) the patient has tried at least one systemic regimen or B) patient has TP53 mutation and will use this as induction therapy in combination with Brukinsa (zanubrutinib) and Gazyva (obinutuzumab intravenous infusion). MDS- approve if pt meets (A and B): A) pt meets (i or ii): (i) has chronic myelomonocytic leukemia-2 or (ii) has higher risk disease (note: includes international prognostic scoring system (IPSS-R) intermediate-, high-, or very-high risk disease) and B) will use in combination with azacitidine or decitabine. Myeloproliferative neoplasm- approve if pt has accelerated or blast phase disease and will use in combination with azacitidine or decitabine. Multiple Myeloma- approve if the patient has t (11,14) translocation AND has tried at least one systemic regimen for multiple myeloma AND Venclexta will be used in combination with dexamethasone. Systemic light chain amyloidosis-approve if the patient has t (11, 14) translocation and has tried at least one systemic regimen. Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma-approve if the patient has tried at least one systemic regimen.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.

PA Criteria	Criteria Details
Off-Label Uses	Mantle Cell Lymphoma, waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma, multiple myeloma, systemic light chain amyloidosis, acute lymphoblastic leukemia, hairy cell leukemia, myelodysplastic syndrome, myeloproliferative neoplasm
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

VERZENIO

Products Affected

- VERZENIO

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Breast cancer: HR status, HER2 status, previous medications/therapies tried, concomitant therapy, menopausal status
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Breast Cancer, Early-pt meets (A,B,C and D): A)Pt HR+disease, AND B) HER2-negative breast cancer, AND C)node-positive disease at high risk of recurrence AND D)meets 1 of the following (i or ii): i.Verzenio will be used in combo w/anastrozole, exemestane, or letrozole AND pt meets one of the following (a,b, or c): a)Pt is postmenopausal woman, OR b)Pt is pre/perimenopausal woman and meets one of the following 1 or 2:1-Pt receiving ovarian suppression/ablation with a GnRH agonist, OR 2-Pt had surgical bilateral oophorectomy or ovarian irradiation, OR c)Pt is man and pt is receiving a GnRH analog, OR ii.Verzenio will be used in combo with tamoxifen AND pt meets 1 of the following (a or b): a)Pt is postmenopausal woman or man OR b)Pt is pre/perimenopausal woman and meets 1 of the following 1 or 2:1-Pt is receiving ovarian suppression/ablation with a GnRH agonist, OR 2-Pt had surgical bilateral oophorectomy or ovarian irradiation. Breast Cancer-Recurrent or Metastatic in Women-pt meets (A, B and C): A)has HR+ disease, AND B)Pt meets 1 of following criteria (i or ii): i.Pt is postmenopausal woman, OR ii.Pt is pre/perimenopausal woman and meets 1 of the following (a or b): a)receiving ovarian suppression/ablation with a GnRH agonist, OR b)Pt had surgical bilateral oophorectomy or ovarian irradiation, AND C) either (1 or 2): 1) HER2-negative breast cancer and Pt meets 1 of following criteria (i, ii, or iii): i.Verzenio will be used in combo with anastrozole, exemestane, or letrozole, OR ii.Verzenio will be used in combo with

PA Criteria	Criteria Details
	fulvestrant, OR iii.pt meets following conditions (a, b, and c): a)Verzenio will be used as monotherapy, AND b)Pt's breast cancer has progressed on at least 1 prior endocrine therapy, AND c)has tried chemo for metastatic breast cancer or 2)has HER2-positive breast cancer and has received at least 3 prior anti-HER2-based regimens in metastatic setting and will use this in combo with fulvestrant and trastuzumab.Breast Cancer-Recurrent or Metastatic in Men-pt meets following criteria (A and B): A)HR+ disease, AND B)either (1 or 2): 1) HER2-negative disease and Pt meets 1 of following criteria (i, ii, or iii): i.Pt meets BOTH of the following conditions (a and b): a)receiving a GnRH analog, AND b)Verzenio will be used in combo with anastrozole, exemestane, or letrozole, OR ii.Verzenio will be used in combo with fulvestrant, OR iii.Pt meets the following conditions (a, b, and c): a)Verzenio will be used as monotherapy, AND b)Pt's breast cancer has progressed on at least 1 prior endocrine therapy, AND c)Pt has tried chemo for metastatic breast cancer, or 2) has HER2-positive disease and has received at least 3 prior anti-HER2-based regimen in metastatic setting and will use this medication in combo with fulvestrant and trastuzumab. Endometrial cancer-pt meets all of (A, B, And C): A)has recurrent or metastatic disease, and B)has estrogen receptor (ER)-positive tumors, and C)will be using in combination with letrozole.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Endometrial cancer
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

VIGABATRIN

Products Affected

- *vigabatrin*
- *vigadrone*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, medication history (complex partial seizures)
Age Restrictions	Refractory complex partial seizures - patients 2 years of age or older. Infantile spasms - patients less than or equal to 2 years of age
Prescriber Restrictions	Prescribed by, or in consultation with, a neurologist
Coverage Duration	Infantile spasms- 6 months. Treatment-Refractory Partial Seizures- initial 3 months, cont 1 year
Other Criteria	Infantile spasms-requested medication is being used as monotherapy. Treatment refractory complex partial seizures initial-patient has tried and/or is concomitantly receiving at least two other antiepileptic drugs. Treatment refractory complex partial seizures continuation- the patient is responding to therapy (e.g., reduced seizure severity, frequency, and/or duration).
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

VIMIZIM

Products Affected

- VIMIZIM

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, genetic and lab test results
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a geneticist, endocrinologist, a metabolic disorder sub-specialist, or a physician who specializes in the treatment of lysosomal storage disorders.
Coverage Duration	1 year
Other Criteria	Approve if the patient has a laboratory test demonstrating deficient N-acetylgalactosamine-6-sulfatase activity in leukocytes or fibroblasts OR has a molecular genetic test demonstrating biallelic pathogenic or likely pathogenic N-acetylgalactosamine-6-sulfatase gene variants.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

VITRAKVI

Products Affected

- VITRAKVI ORAL CAPSULE 100 MG, 25 MG
- VITRAKVI ORAL SOLUTION

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, NTRK gene fusion status
Age Restrictions	Pediatric Diffuse High-Grade Glioma- less than or equal to 21 years old
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Solid tumors - approve if the tumor is positive for neurotrophic receptor tyrosine kinase (NTRK) gene fusion AND the tumor is metastatic or surgical resection of tumor will likely result in severe morbidity. Pediatric diffuse high grade glioma - approve if (A and B): A) tumor is positive for NTRK gene fusion and B) meets (i or ii): i) medication is used as adjuvant therapy or ii) medication is used for recurrent or progressive disease.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Pediatric Diffuse High-Grade Glioma
Part B Prerequisite	No
Prerequisite Therapy Required	No

VONJO

Products Affected

- VONJO

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Myelofibrosis (MF), including primary MF, post-polycythemia Vera MF, and Post-Essential Thrombocythemia MF-approve if the patient meets either (A, B, or C): (A) meets (i and ii): i) the patient has a platelet count of less than $50 \times 10^9 /L$ (less than 50,000/mcL) and (ii): meets (a or b): a) has higher-risk disease or b) has lower-risk disease and at least one disease-related symptom (examples: fatigue, fever, night sweats, weight loss, abdominal discomfort, splenomegaly, thrombocytosis, or leukocytosis) OR (B) Patient has a platelet count of greater than or equal to $50 \times 10^9 /L$ (greater than or equal to 50,000/mcL) and has higher-risk disease and has at least one disease-related symptom, OR (C) patient has myelofibrosis-associated anemia. Accelerated or blast phase myeloproliferative neoplasm- approve if the patient has at least one disease-related symptom (Examples: fatigue, fever, night sweats, weight loss, abdominal discomfort, splenomegaly, thrombocytosis, or leukocytosis).
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Accelerated or blast phase myeloproliferative neoplasm
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	No

VORANIGO

Products Affected

- VORANIGO ORAL TABLET 10 MG, 40 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	12 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	GLIOMAS-All of (A, B and C): A. Susceptible isocitrate dehydrogenase-1 (IDH1) or IDH2 mutation-positive disease, AND B. Grade 2 or greater oligodendroglioma OR Grade 2 or greater astrocytoma, AND C. Prior surgery, including biopsy, sub-total resection, or gross total resection
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

VORICONAZOLE (ORAL)

Products Affected

- *voriconazole oral*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	6 months
Other Criteria	N/A
Indications	All Medically-accepted Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

VOSEVI

Products Affected

- VOSEVI

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years or older
Prescriber Restrictions	Prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or a liver transplant physician
Coverage Duration	Will be c/w AASLD guidance and inclusive of treatment already received for the requested drug
Other Criteria	Criteria will be applied consistent with current AASLD/IDSA guidance.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Indications consistent with current AASLD/IDSA guidance
Part B Prerequisite	No
Prerequisite Therapy Required	No

VOTRIENT

Products Affected

- *pazopanib oral tablet 200 mg*
- PAZOPANIB ORAL TABLET 400 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Soft tissue sarcoma other than GIST-approve if the patient has advanced or metastatic disease and has ONE of the following: alveolar soft part sarcoma, angiosarcoma, dedifferentiated chordoma, dedifferentiated liposarcoma, desmoid tumors (aggressive fibromatosis), dermatofibrosarcoma protuberans with fibrosarcomatous transformation, epithelioid hemangioendothelioma, extraskeletal myxoid chondrosarcoma, non-adipocytic sarcoma, pleomorphic rhabdomyosarcoma, or solitary fibrous tumor/hemangiopericytoma. Differentiated thyroid carcinoma, approve if the patient meets (A or B): A) has papillary or follicular thyroid carcinoma and the disease is refractory to radioactive iodine therapy or B) has oncocytic (formerly Hurthle cell) carcinoma. Renal Cell Carcinoma, Clear Cell or non-Clear Cell histology-approved if the patient has relapsed or advanced disease or VonHippel-Lindau disease. Ovarian Cancer (ie, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer) - approve if the patient has persistent or recurrent disease. GIST - approve if the patient has succinate dehydrogenase (SDH)-deficient GIST OR the patient has tried TWO of the following: Gleevec, Ayvakit, Sutent, Sprycel, Qinlock or Stivarga. Medullary Thyroid Carcinoma, approve if the patient has tried at least one systemic therapy. Bone cancer-approve if the patient has chondrosarcoma and has metastatic widespread disease.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.

PA Criteria	Criteria Details
Off-Label Uses	Differentiated (ie, papillary, follicular, oncocytic carcinoma) thyroid carcinoma. Uterine sarcoma, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, Gastrointestinal Stromal Tumor (GIST), Medullary thyroid carcinoma, bone cancer.
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

VOWST

Products Affected

- VOWST

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	30 days
Other Criteria	Prevention of recurrence of clostridioides difficile infection (CDI)-approve if the patient has completed a bowel prep (or will start a bowel prep the day before and at least 8 hours prior to taking the first dose), will not eat or drink for at least 8 hours prior to the first dose and will complete their antibacterial treatment for recurrent CDI 2-4 days before initiating treatment with Vowst and Vowst will not be used for the TREATMENT of CDI.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

VUMERITY

Products Affected

- VUMERITY

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with other disease-modifying agents used for multiple sclerosis (MS)
Required Medical Information	Relapsing form of Multiple Sclerosis (MS), to include clinically-isolated syndrome, relapsing-remitting disease, and active secondary progressive disease
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a neurologist or a physician who specializes in the treatment of MS.
Coverage Duration	Authorization will be for 1 year.
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

VYLOY

Products Affected

- VYLOY

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	1 year
Other Criteria	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA (all of A, B, C, and D): A. Unresectable locally advanced, recurrent, metastatic disease, or palliative therapy, AND B. Tumor is claudin 18.2 positive, Note: Claudin 18.2 positivity is defined as greater than or equal to 75 percent of tumor cells demonstrating moderate to strong membranous claudin 18.2 immunohistochemical staining. AND C. Tumor is human epidermal growth factor receptor 2 (HER2)-negative, AND D. Used in combination with fluoropyrimidine- and platinum-containing chemotherapy. Note: Examples of fluoropyrimidines include 5-fluorouracil and capecitabine. Examples of platinum chemotherapy agents include oxaliplatin. Esophageal adenocarcinoma- all of (A, B, C, and D): A. unresectable locally advanced, recurrent, metastatic disease, or palliative therapy, AND B. tumor is is claudin 18.2 positive, AND C. tumor is human epidermal growth factor receptor 2 (HER2)-negative, and D. used in combination with fluoropyrimidine- and platinum-containing chemotherapy.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Esophageal adenocarcinoma

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	No

VYVGART

Products Affected

- VYVGART
- VYVGART HYTRULO

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older (initial and continuation)
Prescriber Restrictions	Prescribed by or in consultation with a neurologist (initial and continuation)
Coverage Duration	Initial-6 months, Continuation-1 year
Other Criteria	CIDP (Vyvgart Hytrulo only), Initial Therapy - approve if diagnosis was supported by electrodiagnostic studies AND pt previously received treatment with an intravenous or subcutaneous immune globulin and had inadequate efficacy or significant intolerance or patient has a contraindication to IV or SC immune globulin. Generalized myasthenia gravis, Initial Therapy-Approve if the patient meets the following criteria (A and B): A. Patient has evidence of unresolved symptoms of generalized myasthenia gravis, such as difficulty swallowing, difficulty breathing, or a functional disability resulting in the discontinuation of physical activity (e.g., double vision, talking, impairment of mobility) AND B. patient has myasthenia gravis foundation of america classification of II to IV. CIDP (Vyvgart Hytrulo only), Cont therapy - pt has clinically significant improvement in neurologic symptoms (Examples include improvement in disability: nerve conduction study results improved or stabilized, physical examination shows improvement in neurological symptoms, strength, and sensation). Generalized myasthenia gravis, Continuation Therapy-Approve if patient is continuing to derive benefit from Vyvgart.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

WELIREG

Products Affected

- WELIREG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	Pheochromocytoma/paraganglioma-12 years and older, Other indications-18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Pheochromocytoma/paraganglioma- approve if pt has locally advanced, unresectable, or metastatic disease. Renal Cell Carcinoma- approve if patient meets the following (A, B, C and D): A) pt has advanced disease AND B) has clear cell histology AND C) has tried at least one programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor AND D) has tried at least one a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI). [Note: Examples of PD-1 inhibitor or PD-L1 inhibitor include: Keytruda (pembrolizumab intravenous infusion), Opdivo (nivolumab intravenous infusion), and Bavencio (avelumab intravenous infusion). Examples of VEGF-TKI include Cabometyx (cabozantinib tablets), Lenvima (lenvatinib capsules), Inlyta (axitinib tablets), Fotivda (tivozanib capsules), pazopanib, sunitinib, and sorafenib.] Van Hippel-Lindau Disease-approve if the patient meets the following (A, B, and C): A) Patient has a von Hippel-Lindau (VHL) germline alteration as detected by genetic testing, B) Does not require immediate surgery and C) Patient requires therapy for ONE of the following conditions (i, ii, iii, or iv): i. Central nervous system hemangioblastomas, OR ii. Pancreatic neuroendocrine tumors, OR iii. Renal cell carcinoma, OR iv. Retinal hemangioblastoma.
Indications	All FDA-approved Indications.

PA Criteria	Criteria Details
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

WINREVAIR

Products Affected

- WINREVAIR

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older (initial)
Prescriber Restrictions	Prescribed by or in consultation with a cardiologist or a pulmonologist (initial/continuation)
Coverage Duration	Initial-6 months, Continuation-1 year
Other Criteria	INITIAL THERAPY-PULMONARY ARTERIAL HYPERTENSION (PAH) WHO GROUP 1-All of (A, B, C): A) right-heart catheterization to confirm the diagnosis, and B) Functional Class II or III or IV, and C) One of (a or b): a)currently receiving at least two other PAH therapies from the following different pharmacologic categories, each for greater than or equal to 60 days: phosphodiesterase type 5 inhibitors (PDE5i), endothelin receptor antagonists (ERAs), soluble guanylate cyclase stimulator (sGCs), and prostacyclins or b) currently receiving at least one other PAH therapy for greater than or equal to 60 days and is intolerant to combination therapy with a phosphodiesterase type 5 inhibitors (PDE5i), endothelin receptor antagonists (ERAs), soluble guanylate cyclase stimulator (sGCs), or prostacyclin. CONTINUATION THERAPY-PAH WHO GROUP 1-patient has had a right heart catheterization to confirm the diagnosis.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

XALKORI

Products Affected

- XALKORI ORAL CAPSULE
- XALKORI ORAL PELLETT 150 MG, 20 MG, 50 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	Anaplastic large cell lymphoma/IMT-patients greater than or equal to 1 year of age. All other diagnoses-18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Metastatic non-small cell lung cancer-approve if the patient has anaplastic lymphoma kinase (ALK)-positive disease, as detected by an approved test and patients new to therapy must have a trial of Alecensa, Ensacove or Lorbrena prior to approval of Xalkori. Metastatic non-small cell lung cancer, approve if the patient has ROS1 rearrangement positive disease, as detected by an approved test. Anaplastic Large Cell Lymphoma-approve if the patient has anaplastic lymphoma kinase (ALK)-positive disease AND (i or ii): (i) the medication is used for palliative-intent therapy, or (ii) pt has relapsed or refractory disease. Histiocytic neoplasm-approve if the patient has ALK rearrangement/fusion-positive disease and meets one of the following criteria (i, ii, or iii): (i. Patient has Langerhans cell histiocytosis, OR ii. Patient has Erdheim-Chester disease OR iii. Patient has Rosai-Dorfman disease. NSCLC with MET mutation-approve if the patient has high level MET amplification or MET exon 14 skipping mutation. Inflammatory Myofibroblastic Tumor-approve if the patient has ALK positive disease and the patient has advanced, recurrent or metastatic disease or the tumor is inoperable. Melanoma, cutaneous-approve if the patient has ALK fusion disease or ROS1 fusion disease.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.

PA Criteria	Criteria Details
Off-Label Uses	NSCLC with high level MET amplification or MET Exon 14 skipping mutation, Histiocytic neoplasms, melanoma, cutaneous.
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

XDEMVY

Products Affected

- XDEMVY

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	6 months
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

XELJANZ

Products Affected

- XELJANZ ORAL SOLUTION
- XELJANZ ORAL TABLET
- XELJANZ XR

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with a biologic or with a Targeted Synthetic DMARD for an inflammatory condition (eg, tocilizumab, anakinra, abatacept, rituximab, certolizumab pegol, etanercept, adalimumab, infliximab, golimumab). Concurrent use with potent immunosuppressants that are not methotrexate (MTX) [eg, azathioprine, tacrolimus, cyclosporine, mycophenolate mofetil].
Required Medical Information	Diagnosis, concurrent medications, previous drugs tried.
Age Restrictions	AS/RA/UC-18 years and older (initial therapy), JIA/JRA/PsA-2 years and older (initial therapy)
Prescriber Restrictions	RA, JIA/JRA/AS prescribed by or in consultation with a rheumatologist. PsA-prescribed by or in consultation with a rheumatologist or a dermatologist. UC-prescribed by or in consultation with a gastroenterologist. (all apply to initial therapy only)
Coverage Duration	Approve through end of plan year
Other Criteria	RA initial-approve Xeljanz/XR tablets if the patient has had a 3 month trial of at least one tumor necrosis factor inhibitor or was unable to tolerate a 3 month trial. PsA initial, approve Xeljanz immediate release tablets or oral solution (patients 2 years and older) or Xeljanz XR tablets (patients 18 years and older) if the patient has had a 3 month trial of at least one tumor necrosis factor inhibitor or was unable to tolerate a 3 month trial. UC- Approve Xeljanz/XR tablets if the patient has had a 3 month trial of at least ONE tumor necrosis factor inhibitor for ulcerative colitis or was unable to tolerate a 3-month trial. Juvenile Idiopathic Arthritis (JIA) [or Juvenile Rheumatoid Arthritis] (regardless of type of onset) [Note: This includes patients with juvenile spondyloarthritis/active sacroiliac arthritis]-initial-approve Xeljanz immediate release tablets or solution if the patient meets the following: patient has had a 3 month trial of at least one tumor necrosis factor inhibitor or was unable to tolerate a 3 month trial. AS-approve Xeljanz/XR tablets if the patient has had a 3 month trial of at least

PA Criteria	Criteria Details
	one tumor necrosis factor inhibitor or was unable to tolerate a 3 month trial. Continuation Therapy - Patient must have responded, as determined by the prescriber.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

XERMELO

Products Affected

- XERMELO

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, previous therapy, concomitant therapy
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Initial therapy - approve if the patient meets ALL of the following criteria: 1) patient has been on short-acting octreotide or long-acting somatostatin analog (SSA) therapy (eg, Somatuline Depot [lanreotide for injection]) AND 2) while on short-acting octreotide or long-acting SSA therapy (prior to starting Xermelo), the patient continues to have at least four bowel movements per day, AND 3) Xermelo will be used concomitantly with short-acting octreotide or a long-acting SSA therapy. Continuation therapy - approve if the patient is continuing to take Xermelo concomitantly with short-acting octreotide or a long-acting SSA therapy for carcinoid syndrome diarrhea.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

XIAFLEX

Products Affected

- XIAFLEX

PA Criteria	Criteria Details
Exclusion Criteria	Retreatment for Peyronie's Disease (i.e., treatment beyond eight injections).
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Dupuytren's Contracture-administered by a healthcare provider experienced in injection procedures of the hand and in the treatment of Dupuytren's contracture. Peyronie's Disease -administered by a healthcare provider experienced in the treatment of male urological diseases.
Coverage Duration	Dupuytren's Contracture-3 months, Peyronie's Disease-6 months
Other Criteria	Dupuytren's Contracture-approve if (A, B, C and D): A) pt has at least one palpable cord in the affected hand, and B) pt has contracture of a metacarpophalangeal or proximal interphalangeal joint that is associated with the palpable cord, and C) at baseline (prior to initial injection of Xiaflex), the contracture measures at least 20 degrees AND D) the patient will not be treated with more than a total of three injections (maximum) per affected cord as part of the current treatment course. Peyronie's Disease-approve if (A, B and C): A) pt has at least one palpable plaque in the penis, and B) the patient meets ONE of the following (i or ii): i) at baseline (prior to use of Xiaflex), the patient has a penile curvature deformity of at least 30 degrees OR ii) in a patient who has received prior treatment with Xiaflex, the patient has a penile curvature deformity of at least 15 degrees AND C) the patient has not previously been treated with a complete course (8 injections) of Xiaflex for Peyronie's disease.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	No

XIFAXAN

Products Affected

- XIFAXAN ORAL TABLET 200 MG, 550 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	Traveler's diarrhea - 12 years of age or older. Hepatic encephalopathy, irritable bowel syndrome with diarrhea - 18 years of age or older.
Prescriber Restrictions	Pouchitis - prescribed by or in consultation with a gastroenterologist
Coverage Duration	Enceph-6 mo, IBS w/diarrhea-14 days, TD-3 days, intest bact overgrowth-14 days, Pouchitis - 1 year
Other Criteria	Hepatic Encephalopathy-approve Xifaxan 550 mg tablets if the patient has previously had overt hepatic encephalopathy and the requested medication will be used concomitantly with lactulose, unless the patient has a contraindication or significant intolerance to treatment with lactulose. Irritable bowel syndrome with diarrhea-approve Xifaxan 550 mg tablets. Travelers Diarrhea-approve Xifaxan 200 mg tablets if the patient is afebrile and does not have blood in the stool. Small intestine bacterial overgrowth-approve Xifaxan 200mg or 550 mg tablets if the diagnosis has been confirmed by a glucose hydrogen breath test, lactulose hydrogen breath test, or small bowel aspiration and culture. Chronic antibiotic-dependent pouchitis- approve Xifaxan 200mg or 550mg tablets if patient meets all of (a, b, c and d): a) recurrent pouchitis (Note: recurrent pouchitis is typically considered history of at least 3 pouchitis episodes within a 12 month period), and b) episodes of pouchitis respond to antibiotic therapy but relapse shortly after antibiotic discontinuation, and c) alternative causes of recurrent pouchitis have been ruled out, and d) has tried long-term antibiotic therapy trials (at least 4 weeks) of BOTH ciprofloxacin and metronidazole for remission maintenance.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.

PA Criteria	Criteria Details
Off-Label Uses	Small intestine bacterial overgrowth, chronic antibiotic-dependent pouchitis
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

XOLAIR

Products Affected

- XOLAIR SUBCUTANEOUS AUTO-INJECTOR 150 MG/ML, 300 MG/2 ML, 75 MG/0.5 ML
- XOLAIR SUBCUTANEOUS RECON SOLN
- XOLAIR SUBCUTANEOUS SYRINGE 150 MG/ML, 300 MG/2 ML, 75 MG/0.5 ML

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with another monoclonal antibody therapy.
Required Medical Information	Diagnosis
Age Restrictions	Moderate to severe persistent asthma-6 years and older. CIU-12 years and older. Polyps-18 years and older. Food Allergy-1 yr and older
Prescriber Restrictions	Moderate to severe persistent asthma if prescribed by, or in consultation with an allergist, immunologist, or pulmonologist. CIU if prescribed by or in consultation with an allergist, immunologist, or dermatologist. Polyps-prescribed by or in consult with an allergist, immunologist, or otolaryngologist. Food allergy- allergist or immunologist
Coverage Duration	asthma-1 year, Polyps/CIU-initial-6 months, continued tx 12 months, Food allergy-1 yr
Other Criteria	MODERATE TO SEVERE PERSISTENT ASTHMA (A, B, C and D): A)baseline IgE greater than or equal to 30 IU/mL, and B)baseline positive skin test or in vitro test for 1 or more perennial or seasonal aeroallergens C)received at least 3 months of combination therapy with an inhaled corticosteroid (ICS) and additional asthma controller/maintenance medication (e.g., LABA, LAMA, leukotriene receptor antagonist, monoclonal antibody) [see Exception 1 below] and D)asthma is uncontrolled or was uncontrolled prior to receiving Xolair or another monoclonal antibody and meets one of (a, b, c, d, or e): a) experienced two or more asthma exacerbations requiring systemic CSs in the past year, b) experienced one or more asthma exacerbation requiring hospitalization/urgent care visit/emergency department visit in the past year, c) FEV1 less than 80% predicted or less than 90% for pts less than 18, d) FEV1/forced vital capacity (FVC) less than 0.80 or 0.90 for pts less than 18, or e) asthma worsens upon tapering of oral CS. CHRONIC RHINOSINUSITIS WITH NASAL POLYPS (CRwNP) [all of A, B, C, D,

PA Criteria	Criteria Details
	and E]: A) diagnosis by direct exam, endoscopy, or sinus CT scan, B) baseline (prior to Xolair or another monoclonal antibody that may lower IgE) IgE at least 30 IU/ml, C) at least two of the following symptoms for 8 weeks: nasal congestion, obstruction, discharge, reduction/loss of smell, D) tried intranasal CS and will continue in combination with Xolair, and E) one of the following (a, b, or c): a) had systemic CS at least 5 days in past 2 years, b) contraindication to systemic CS, or c) had nasal polyp surgery. CHRONIC IDIOPATHIC URTICARIA (CIU): urticaria more than 6 weeks prior to treatment with Xolair with symptoms despite non-sedating H1-antihistamine therapy. IgE-MEDIATED FOOD ALLERGY (all of A, B, C and D): A) baseline IgE greater than or equal to 30 IU/mL, B) positive skin prick test or positive in vitro test for IgE to one or more foods, C) history of allergic reaction that met all of the following (a, b, and c): a) signs and symptoms of a significant systemic allergic reaction, b) reaction occurred within a short period of time following a known ingestion of the food, and c) prescriber deemed this reaction significant enough to require a prescription for injectable/nasal epinephrine, and D) patient has been prescribed injectable/nasal epinephrine. CONTINUATION THERAPY: ASTHMA: patient responded to therapy and continues to receive an ICS. CRwNP: patient responded after 6 months of therapy and continues intranasal CS. CIU: received at least 6 months of Xolair and experienced a beneficial clinical response, defined by decreased itch severity, decreased number of hives or decreased size of hives. Exception 1: an exception to the requirement of a trial of one additional asthma controller/maintenance medication can be made if the patient has already received anti-IL-4/13 therapy (Dupixent) used concomitantly with an ICS.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

XOSPATA

Products Affected

- XOSPATA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, FLT3-mutation status
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	AML - approve if the disease is FLT3-mutation positive as detected by an approved test. Lymphoid, Myeloid Neoplasms-approve if the patient has eosinophilia and the disease is FLT3-mutation positive as detected by an approved test.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Lymphoid, Myeloid Neoplasms
Part B Prerequisite	No
Prerequisite Therapy Required	No

XPOVIO

Products Affected

- XPOVIO ORAL TABLET 100 MG/WEEK (50 MG X 2), 40 MG/WEEK (10 MG X 4), 40MG TWICE WEEK (40 MG X 2), 60 MG/WEEK (60 MG X 1), 60MG TWICE WEEK (120 MG/WEEK), 80 MG/WEEK (40 MG X 2), 80 MG/WEEK (80 MG X 1), 80MG TWICE WEEK (160 MG/WEEK)

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, prior therapies
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Multiple Myeloma-Approve if the patient meets the following (A and B): A) The medication will be taken in combination with dexamethasone AND B) Patient meets one of the following (i, ii, or iii): i. Patient has tried at least four prior regimens for multiple myeloma OR ii. Patient meets both of the following (a and b): a) Patient has tried at least two prior regimens for multiple myeloma AND b) The medication will be taken in combination with Pomalyst (pomalidomide) OR iii. Patient meets both of the following (a and b): a) Patient has tried at least one prior regimen for multiple myeloma AND b) The medication will be taken in combination with bortezomib, Darzalex (daratumumab infusion), Darzlaex Faspro (daratumumab and hyaluronidase-fihj injection), or Kyprolis (carfilzomib intravenous infusion). Note: Examples of prior regimens include Darzalex (daratumumab intravenous infusion)/bortezomib/lenalidomide/dexamethasone, bortezomib/lenalidomide/dexamethasone, Kyprolis (carfilzomib infusion)/lenalidomide/dexamethasone, Darzalex (daratumumab injection)/bortezomib or Kyprolis/dexamethasone, or other regimens containing a proteasome inhibitor, immunomodulatory drug, and/or anti-CD38 monoclonal antibody. Diffuse large B-cell lymphoma Note:this

PA Criteria	Criteria Details
	includes patients with histologic transformation of indolent lymphomas to diffuse large B-cell lymphoma)-approve if the patient has tried at least two prior therapies. B-Cell lymphoma-approve if (A and B): A) pt has high-grade B-cell lymphoma or HIV-related B-cell lymphoma or post-transplant lymphoproliferative disorders and B) has tried at least two prior therapies.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Treatment of multiple myeloma in combination with daratumumb or pomalidomide, B-cell lymphoma
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

XTANDI

Products Affected

- XTANDI ORAL CAPSULE
- XTANDI ORAL TABLET 40 MG, 80 MG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis for which Xtandi is being used.
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 1 year.
Other Criteria	Prostate cancer-castration-resistant [Metastatic or Non-metastatic] and Prostate cancer-metastatic, castration sensitive-approve if Xtandi will be used concurrently with a gonadotropin-releasing hormone (GnRH) analog [for example: leuprolide acetate, Lupron Depot (leuprolide acetate intramuscular injection), Trelstar (triptorelin pamoate intramuscular injection), Zoladex (goserelin acetate subcutaneous implant), Vantas (histrelin acetate subcutaneous implant), Firmagon (degarelix subcutaneous injection), Orgovyx (relugolix tablets)] or if the patient has had a bilateral orchiectomy. Prostate cancer- Non-Metastatic, Castration-Sensitive - approve if pt has biochemical recurrence and is at high risk for metastasis. [Note: High-risk biochemical recurrence is defined as prostate-specific antigen (PSA) doubling time less than or equal to 9 months.]
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	No

XYREM

Products Affected

- *sodium oxybate*

PA Criteria	Criteria Details
Exclusion Criteria	Concomitant use with Xywav, Wakix or Sunosi
Required Medical Information	Medication history (as described in Other Criteria field)
Age Restrictions	7 years and older
Prescriber Restrictions	Prescribed by a sleep specialist physician or a Neurologist
Coverage Duration	12 months.
Other Criteria	For Excessive daytime sleepiness (EDS) in patients with narcolepsy - narcolepsy has been confirmed with polysomnography and a multiple sleep latency test (MSLT). Patients requesting sodium oxybate who are 18 years or older-approve if the patient has tried one CNS stimulant (e.g., methylphenidate, dextroamphetamine), modafinil, or armodafinil. Patients less than 18 years old requesting sodium oxybate-approve if the patient has tried one CNS stimulant (e.g., methylphenidate, dextramphetamine) or modafinil. Cataplexy treatment in patients with narcolepsy-approve if narcolepsy has been confirmed with polysomnography and a multiple sleep latency test (MSLT).
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ZEJULA

Products Affected

- ZEJULA ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Ovarian, fallopian tube, or primary peritoneal cancer, maintenance therapy - approve if the patient is in complete or partial response after platinum-based chemotherapy regimen and if the patient is new to therapy they must have a trial of Lynparza prior to approval of Zejula. Patients who have had a complete or partial response to first-line platinum based chemotherapy and do not have BRCA altered disease are not required to try Lynparza. Uterine leiomyosarcoma-approve if the patient has BRCA2-altered disease and has tried one systemic regimen. In addition, patients new to therapy must have a trial of Lynparza prior to approval of Zejula.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Uterine Leiomyosarcoma
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ZELBORAF

Products Affected

- ZELBORAF

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	BRAFV600 mutation status required.
Age Restrictions	All diagnoses (except CNS cancer)-18 years and older
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 1 year.
Other Criteria	Melanoma, patient new to therapy must have BRAFV600 mutation for approval AND have unresectable, advanced or metastatic melanoma. HCL - meets (A or B): A) must have tried at least one other systemic therapy for hairy cell leukemia OR B) meets (i and ii): i) is unable to tolerate purine analogs and ii) Zelboraf will be used in combination with rituximab or Gazyva (obinutuzumab intravenous infusion). Thyroid Cancer-patient has disease that is refractory to radioactive iodine therapy. Erdheim-Chester disease, in patients with BRAF V600 mutation-approve. Central Nervous System Cancer-approve if the patient has BRAF V600 mutation-positive disease AND medication is being used for one of the following situations (i, ii, or iii): i. Adjuvant treatment of one of the following conditions (a, b, c or d): a) Pilocytic astrocytoma OR b) Pleomorphic xanthoastrocytoma OR c) Circumscribed ganglioglioma/neuroglioma/glioneuronal tumor OR d) pediatric diffuse high-grade glioma OR ii. Recurrent or progressive disease for one of the following conditions (a, b or c): a) high grade glioma b) circumscribed glioma OR c) Glioblastoma OR iii. Melanoma with brain metastases AND the medication with be taken in combination with Cotellic (cobimetinib tablets). Histiocytic Neoplasm-approve if the patient has Langerhans cell histiocytosis AND the patient has BRAF V600-mutation positive disease.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.

PA Criteria	Criteria Details
Off-Label Uses	Patients with Hairy Cell Leukemia, Non-Small Cell Lung Cancer (NSCLC) with BRAF V600E Mutation, Differentiated thyroid carcinoma (i.e., papillary, follicular, or oncocytic carcinoma) with BRAF-positive disease, Central Nervous System Cancer, Histiocytic Neoplasm
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ZEPOSIA

Products Affected

- ZEPOSIA
- ZEPOSIA STARTER KIT (28-DAY)
- ZEPOSIA STARTER PACK (7-DAY)

PA Criteria	Criteria Details
Exclusion Criteria	MS-Concurrent use with other disease-modifying agents used for multiple sclerosis. UC- Concurrent Use with a Biologic or with a Targeted Synthetic Disease-modifying Antirheumatic Drug (DMARD) for Ulcerative Colitis
Required Medical Information	Diagnosis
Age Restrictions	UC-18 years and older
Prescriber Restrictions	MS-Prescribed by or in consultation with a neurologist or a physician who specializes in the treatment of multiple sclerosis. UC-Prescribed by or in consultation with a gastroenterologist
Coverage Duration	MS-1 year, UC initial, 6 months, cont-1 year
Other Criteria	MS-approve. Ulcerative Colitis, initial-approve if the patient has tried TWO of the following: a preferred adalimumab product, a preferred ustekinumab product, a preferred infliximab product, Rinvoq, Skyrizi, Tremfya. Note-a trial of Simponi SC, Entyvio IV/SC, Omvoh IV/SC, a non-preferred adalimumab product, a non-preferred ustekinumab product or a non-preferred infliximab would also count). Cont tx-approve if the patient has been established on Zeposia. Please Note: preferred adalimumab products include Hadlima, Simlandi. Preferred infliximab products include Remicade, infliximab IV (brand name product), Zymfentra. Preferred ustekinumab products include Otulfi, Pyzchiva, Selarsdi, Yesintek.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

ZEPZELCA

Products Affected

- ZEPZELCA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	1 year
Other Criteria	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Small cell lung cancer-approve.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

ZIIHERA

Products Affected

- ZIIHERA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	1 year
Other Criteria	Part B vs Part D determination will be made at time of prior authorization review per CMS guidance. BILIARY TRACT CANCER - (all of A, B, C, D and E): A.Patient has ONE of the following (i, ii, or iii): i. Gallbladder cancer, OR ii. Intrahepatic cholangiocarcinoma, OR iii. Extrahepatic cholangiocarcinoma, AND B. Patient has unresectable, resected gross residual, or metastatic disease, AND C. The tumor is human epidermal growth factor receptor 2 (HER2) positive with immunohistochemistry score of 3+ (IHC3+) as determined by an approved test, AND D. The medication is used for subsequent therapy, AND E. The medication is used as a single agent.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ZOLINZA

Products Affected

- ZOLINZA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	Classic Hodgkin Lymphoma-18 years and older
Prescriber Restrictions	N/A
Coverage Duration	1 year
Other Criteria	Cutaneous T-Cell Lymphoma including Mycosis Fungoides/Sezary Syndrome-approve. Classic Hodgkin Lymphoma- tried at least three systemic regimens AND used in combination with pembrolizumab.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Classic Hodgkin Lymphoma
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ZTALMY

Products Affected

- ZTALMY

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	2 years and older
Prescriber Restrictions	Prescribed by or in consultation with a neurologist
Coverage Duration	1 year
Other Criteria	Seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder-approve if the patient has a molecularly confirmed pathogenic or likely pathogenic mutation in the CDKL5 gene.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

ZURZUVAE

Products Affected

- ZURZUVAE ORAL CAPSULE 20 MG, 25 MG, 30 MG

PA Criteria	Criteria Details
Exclusion Criteria	Previous treatment with Zurzuvae during the current episode of postpartum depression
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with a psychiatrist or an obstetrician-gynecologist
Coverage Duration	14 days
Other Criteria	Postpartum depression-approve if the patient meets the following (A, B and C): A.Patient meets BOTH of the following (i and ii): i. Patient has been diagnosed with depression, AND ii. Symptom onset began during the third trimester of pregnancy or up to 4 weeks post-delivery, AND B. Patient is less than or equal to 12 months postpartum, AND C. Patient is not currently pregnant.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

ZYDELIG

Products Affected

- ZYDELIG

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 1 year.
Other Criteria	CLL/SLL-approve if the patient has tried at least one Bruton tyrosine kinase inhibitor (examples: ibrutinib, zanubrutinib, acalabrutinib, pirtobrutinib) and at least one Venclexta (venetoclax)-based regimen.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	small lymphocytic lymphoma
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ZYKADIA

Products Affected

- ZYKADIA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 1 year.
Other Criteria	Erdheim-Chester Disease-approve if the patient has anaplastic lymphoma kinase (ALK) rearrangement/fusion-positive disease. NSCLC, ALK positive-approve if the patient has advanced or metastatic disease that is ALK positive as detected by an approved test and for patients new to therapy must have a trial of Alecensa, Ensacove or Lorbrena prior to approval of Zykadia. Peripheral T-Cell Lymphoma- approve if patient has ALK-positive anaplastic large cell lymphoma (ALCL).
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Inflammatory Myofibroblastic Tumor (IMT) with ALK Translocation. Erdheim-Chester disease. Peripheral T-Cell Lymphoma.
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ZYMFENTRA

Products Affected

- ZYMFENTRA

PA Criteria	Criteria Details
Exclusion Criteria	Concurrent use with a biologic or with a targeted synthetic disease-modifying antirheumatic drug (DMARD).
Required Medical Information	Diagnosis
Age Restrictions	18 years and older (initial therapy)
Prescriber Restrictions	Prescribed by or in consultation with a gastroenterologist (initial therapy)
Coverage Duration	Approve through end of plan year
Other Criteria	Crohn's Disease, initial therapy-Approve if the patient is currently receiving infliximab intravenous maintenance therapy or will receive induction dosing with an infliximab intravenous product within 3 months of initiating therapy with Zymfentra. Crohn's Disease, continuation-approve if the patient has had a response to therapy. Ulcerative Colitis, initial therapy-Approve if the patient is currently receiving infliximab intravenous maintenance therapy or will receive induction dosing with an infliximab intravenous product within 3 months of initiating therapy with Zymfentra. Ulcerative Colitis, continuation-approve if the patient has had a response to therapy.
Indications	All FDA-approved Indications.
Off-Label Uses	N/A
Part B Prerequisite	No
Prerequisite Therapy Required	No

ZYNLONTA

Products Affected

- ZYNLONTA

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Authorization will be for 1 year
Other Criteria	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance. Large B-Cell Lymphoma, HIV-Related B-Cell Lymphoma and post-transplant lymphoproliferative disorder-approve if the patient has tried at least two systemic regimens.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	HIV-related B-Cell Lymphoma, Post-transplant lymphoproliferative disorders
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ZYNYZ

Products Affected

- ZYNYZ

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	Diagnosis
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	Authorization will be for 1 year
Other Criteria	Part B vs Part D determination will be made at time of prior authorization review per CMS guidance. Merkel Cell Carcinoma-approve if (A, B or C): A) pt has primary or recurrent locally advanced disease, if according to the prescriber curative surgery and curative radiation therapy are not feasible, or B) pt has primary or recurrent regional disease, if according to the prescriber curative surgery and curative radiation therapy are not feasible, or C) pt has metastatic disease. Anal carcinoma- approve if (A and B): A) pt has locally recurrent, progressive, or metastatic disease and, B) meets (i, ii, or iii): i) medication is used first-line and in combination with chemotherapy, or ii) pt progressed on or was intolerant to platinum-based chemotherapy, or iii) medication is administered before proceeding to abdominoperineal resection. Colon, rectal or appendiceal cancer- approve if (A and B): A) meets one of (i, ii or iii): i) locally unresectable or medically inoperable disease, or ii) advanced or metastatic disease, or iii) medication is used as neoadjuvant therapy, and B) meets (i or ii): i) pt has a deficient mismatch repair/microsatellite instability-high (dMMR/MSI-H) or ii) pt has polymerase epsilon/delta (POLE/POLD1) mutation with ultra-hypermutated phenotype. Small bowel adenocarcinoma- approve if (A and B): A) meets (i or ii): i) pt has has locally unresectable or medically inoperable disease or ii) pt has advanced or metastatic disease, and B) meets (i or ii): i) pt has a deficient mismatch repair/microsatellite

PA Criteria	Criteria Details
	instability-high (dMMR/MSI-H) or ii) pt has polymerase epsilon/delta (POLE/POLD1) mutation with ultra-hypermutated phenotype.
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	colon/rectal/appendiceal cancer, small bowel adenocarcinoma
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

ZYTIGA

Products Affected

- *abiraterone oral tablet 250 mg, 500 mg*
- *abirtega*

PA Criteria	Criteria Details
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	18 years and older
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for 1 year.
Other Criteria	Prostate Cancer-Metastatic, Castration-Resistant (mCRPC)-Approve if abiraterone is being used in combination with prednisone or dexamethasone and the medication is used concurrently used with a gonadotropin-releasing hormone (GnRH) analog (see Note 1) or the patient has had a bilateral orchiectomy. Prostate cancer-metastatic, castration-sensitive (mCSPC)- approve if the medication is used in combination with prednisone and the medication is concurrently used with a GnRH analog (see Note 1) or the patient has had a bilateral orchiectomy. Prostate Cancer - Regional Risk Group - Approve if the patient meets all of the following criteria (A, B, and C): A) abiraterone is used in combination with prednisone AND B) Patient has regional lymph node metastases and no distant metastases AND C) Patient meets one of the following criteria (i or ii): i. abiraterone with prednisone is used in combination with a GnRH analog (see Note 1) OR ii. Patient has had a bilateral orchiectomy. Prostate cancer-very-high-risk-group-approve if according to the prescriber the patient is in the very-high-risk group, the medication will be used in combination with prednisone, the medication will be used in combination with external beam radiation therapy and the patient meets one of the following criteria (i or ii): i. abiraterone is used in combination with a GnRH analog (see Note 1) OR ii. Patient has had a bilateral orchiectomy. Prostate cancer- radical prostatectomy or post radiation therapy-approve if patient meets (A, B, C and D): A) the medication is used in combination

PA Criteria	Criteria Details
	with prednisone, B) meets (i or ii): i) the patient has prostate specific antigen (PSA) persistence or recurrence following radical prostatectomy or ii) PSA recurrence or positive digital rectal examination (DRE) after radiation therapy, C) patient has pelvic recurrence or positive regional lymph nodes, and D) the medication will be used concurrently with GnRH analog (see Note 1) or the patient has had a bilateral orchiectomy. Salivary Gland Tumors- approve if (A, B and C): A) used in combination with prednisone, B) androgen receptor-positive (AR+) recurrent, unresectable or metastatic tumor, and C) used in combination with a GnRH analog (see Note 1). Note 1: examples of GnRH analogs are leuprolide acetate, Lupron Depot (leuprolide acetate intramuscular injection), Trelstar (triptorelin pamoate intramuscular injection), Zoladex (goserelin acetate subcutaneous implant), Vantas (histrelin acetate subcutaneous implant), Firmagon (degarelix subcutaneous injection), Orgovyx (relugolix tablets).
Indications	All FDA-approved Indications, Some Medically-accepted Indications.
Off-Label Uses	Prostate Cancer-Regional Risk Group, Prostate cancer-very-high-risk group, Prostate cancer- radical prostatectomy or post radiation, Salivary Gland Tumors
Part B Prerequisite	No
Prerequisite Therapy Required	No

PART B VERSUS PART D

Products Affected

- *acetylcysteine*
- *acyclovir sodium intravenous solution*
- ADCETRIS
- *albuterol sulfate inhalation solution for nebulization 0.63 mg/3 ml, 1.25 mg/3 ml, 2.5 mg /3 ml (0.083 %), 2.5 mg/0.5 ml*
- *amphotericin b*
- *amphotericin b liposome*
- *aprepitant*
- *arformoterol*
- *arsenic trioxide*
- *azacitidine*
- *azathioprine oral tablet 50 mg*
- *azathioprine sodium*
- BAVENCIO
- BEIZRAY-ALBUMIN
- BELEODAQ
- *bendamustine intravenous recon soln*
- BENDEKA
- BESPONSA
- *bleomycin*
- BLINCYTO INTRAVENOUS KIT
- BOMYNTRA
- BORTEZOMIB INJECTION RECON SOLN 1 MG, 2.5 MG
- *bortezomib injection recon soln 3.5 mg*
- *budesonide inhalation suspension for nebulization 0.25 mg/2 ml, 0.5 mg/2 ml, 1 mg/2 ml*
- *busulfan*
- *carboplatin intravenous solution*
- *carmustine intravenous recon soln 100 mg*
- *cisplatin intravenous solution*
- *cladribine*
- CLINIMIX 5%/D15W SULFITE FREE
- CLINIMIX 4.25%/D10W SULF FREE
- CLINIMIX 4.25%/D5W SULFIT FREE
- CLINIMIX 5%-D20W(SULFITE-FREE)
- CLINIMIX 6%-D5W (SULFITE-FREE)
- CLINIMIX 8%-D10W(SULFITE-FREE)
- CLINIMIX 8%-D14W(SULFITE-FREE)
- *clofarabine*
- *cromolyn inhalation*
- *cyclophosphamide intravenous recon soln*
- *cyclophosphamide oral capsule*
- CYCLOPHOSPHAMIDE ORAL TABLET 50 MG
- *cyclosporine modified*
- *cyclosporine oral capsule*
- CYRAMZA
- *cytarabine*
- *cytarabine (pf)*
- *dacarbazine*
- *dactinomycin*
- DANYELZA
- DARZALEX
- DARZALEX FASPRO
- *daunorubicin*
- *decitabine*
- *deferoxamine*
- *dexrazoxane hcl*
- *dobutamine*
- *dobutamine in d5w intravenous parenteral solution 1,000 mg/250 ml (4,000 mcg/ml), 250 mg/250 ml (1 mg/ml), 500 mg/250 ml (2,000 mcg/ml)*
- *docetaxel*
- *dopamine in 5 % dextrose*
- *dopamine intravenous solution*
- *doxorubicin*
- *doxorubicin, peg-liposomal*
- ELZONRIS
- EMPLICITI
- ENGERIX-B (PF)
- ENGERIX-B PEDIATRIC (PF)
- ENVARSUS XR
- ERBITUX
- *eribulin*
- ETOPOPHOS
- *etoposide intravenous*
- *everolimus (immunosuppressive)*
- *floxuridine*
- *fludarabine*
- *fluorouracil intravenous*
- *formoterol fumarate*
- *fulvestrant*

- *ganciclovir sodium*
- GAZYVA
- *gemcitabine intravenous recon soln*
- *gemcitabine intravenous solution 1 gram/26.3 ml (38 mg/ml), 2 gram/52.6 ml (38 mg/ml), 200 mg/5.26 ml (38 mg/ml)*
- GEMCITABINE INTRAVENOUS SOLUTION 100 MG/ML
- *gengraf oral capsule*
- GRAFAPEX
- *granisetron hcl oral*
- HEPLISAV-B (PF)
- *idarubicin*
- *ifosfamide*
- IMFINZI
- IMOVAX RABIES VACCINE (PF)
- *intralipid intravenous emulsion 20 %*
- *ipratropium bromide inhalation solution*
- *ipratropium-albuterol*
- *irinotecan*
- ISTODAX
- IXEMPRA
- JEVTANA
- JYLAMVO
- JYNNEOS (PF)
- KHAPZORY INTRAVENOUS RECON SOLN 175 MG
- KIMMTRAK
- KYPROLIS
- *levoleucovorin calcium intravenous solution*
- LIORESAL
- *melphalan hcl*
- *mesna intravenous*
- *methotrexate sodium*
- *methotrexate sodium (pf)*
- *methylprednisolone oral tablet*
- *milrinone*
- *milrinone in 5 % dextrose*
- *mitomycin intravenous*
- *mitoxantrone*
- *mycophenolate mofetil*
- *mycophenolate mofetil (hcl)*
- *mycophenolate sodium*
- MYHIBBIN
- MYLOTARG
- NELARABINE
- NULOJIX
- ONCASPAR
- *ondansetron hcl oral solution*
- *ondansetron hcl oral tablet 4 mg, 8 mg*
- *ondansetron oral tablet, disintegrating 4 mg, 8 mg*
- ONIVYDE
- *oxaliplatin*
- *paclitaxel*
- *paclitaxel protein-bound*
- *pemetrexed disodium intravenous recon soln*
- *pentamidine inhalation*
- PERJETA
- PLENAMINE
- *plerixafor*
- *pralatrexate intravenous solution 20 mg/ml (1 ml)*
- PRALATREXATE INTRAVENOUS SOLUTION 40 MG/2 ML (20 MG/ML)
- *premasol 10 %*
- PROGRAF INTRAVENOUS
- PROGRAF ORAL GRANULES IN PACKET
- PULMOZYME
- RABAVERT (PF)
- RECOMBIVAX HB (PF)
- *romidepsin intravenous recon soln*
- RYLAZE
- SIMULECT
- *sirolimus*
- SYLVANT
- *tacrolimus oral capsule*
- TECENTRIQ
- TECENTRIQ HYBREZA
- TEMODAR
- *temsirolimus*
- *thiotepa*
- TICE BCG
- *topotecan*
- *travasol 10 %*
- TRAZIMERA
- TROPHAMINE 10 %
- TYVASO

- TYVASO INSTITUTIONAL START KIT
- TYVASO REFILL KIT
- TYVASO STARTER KIT
- UNITUXIN
- *valrubicin*
- VARUBI
- VECTIBIX
- *veletri*
- *vinblastine*
- *vincristine*
- *vinorelbine*
- VYXEOS
- WYOST
- XEMBIFY
- YERVOY
- YONDELIS
- ZALTRAP
- ZIRABEV
- *zoledronic acid intravenous solution*

Details

This drug may be covered under Medicare Part B or D depending upon the circumstances. Information may need to be submitted describing the use and setting of the drug to make the determination.

Index

A

abiraterone oral tablet 250 mg, 500 mg . 526, 527
 abirtega..... 526, 527
 acetylcysteine..... 528
 ACTEMRA ACTPEN 3, 4
 ACTEMRA INTRAVENOUS..... 1, 2
 ACTEMRA SUBCUTANEOUS 3, 4
 ACTIMMUNE..... 5
 acyclovir sodium intravenous solution ... 528
 acyclovir topical ointment..... 6
 ADBRY..... 9
 ADCETRIS 528
 ADEMPAS 10
 ADSTILADRIN..... 11
 AIMOVIG AUTOINJECTOR..... 12
 AKEEGA 13
 albuterol sulfate inhalation solution for nebulization 0.63 mg/3 ml, 1.25 mg/3 ml, 2.5 mg /3 ml (0.083 %), 2.5 mg/0.5 ml528
 alcohol pads 95
 ALDURAZYME..... 14
 ALECENSA..... 15, 16
 alosetron..... 17
 ALUNBRIG ORAL TABLET 180 MG, 30 MG, 90 MG..... 19
 ALUNBRIG ORAL TABLETS,DOSE PACK..... 19
 alyq..... 329
 ambrisentan 49
 amikacin injection solution 1,000 mg/4 ml, 500 mg/2 ml 21, 22
 amphotericin b 528
 amphotericin b liposome..... 528
 ampicillin sodium injection recon soln 1 gram, 10 gram, 2 gram, 250 mg, 500 mg 21, 22
 ampicillin sodium intravenous 21, 22
 ampicillin-sulbactam 21, 22
 ANKTIVA 20
 aprepitant..... 528
 ARCALYST 24
 arformoterol 528
 ARIKAYCE..... 25, 26

armodafinil..... 267
 arsenic trioxide..... 528
 ASPARLAS 27
 ASSURE ID INSULIN SAFETY SYRINGE 1 ML 29 GAUGE X 1/2 97
 AUGTYRO ORAL CAPSULE 160 MG, 40 MG 29, 30
 AUSTEDO ORAL TABLET 12 MG, 6 MG, 9 MG 31
 AUSTEDO XR 31
 AUSTEDO XR TITRATION KT(WK1-4) ORAL TABLET, EXT REL 24HR DOSE PACK 12-18-24-30 MG 31
 AVMAPKI-FAKZYNJA 32
 AVONEX INTRAMUSCULAR PEN INJECTOR KIT 33
 AVONEX INTRAMUSCULAR SYRINGE KIT 33
 AYVAKIT 34
 azacitidine 528
 azathioprine oral tablet 50 mg..... 528
 azathioprine sodium 528
 azithromycin intravenous..... 21, 22
 aztreonam 21, 22
B
 BALVERSA 35
 BAVENCIO..... 528
 BEIZRAY-ALBUMIN 528
 BELBUCA..... 237, 238
 BELEODAQ..... 528
 BELSOMRA..... 105
 bendamustine intravenous recon soln 528
 BENDEKA 528
 BENLYSTA..... 36, 37, 38, 39
 benztropine oral 154
 BESPONSA 528
 BESREMI 40
 BETASERON SUBCUTANEOUS KIT .. 41
 bexarotene 42, 43
 BICILLIN L-A..... 21, 22
 BIZENGRI..... 44, 45
 BLENREP 46
 bleomycin..... 528
 BLINCYTO INTRAVENOUS KIT 528

BOMYNTRA.....	528	cinacalcet.....	72
BONSITY	421, 422	CINRYZE	57
BORTEZOMIB INJECTION RECON		ciprofloxacin in 5 % dextrose	21, 22
SOLN 1 MG, 2.5 MG	528	cisplatin intravenous solution	528
bortezomib injection recon soln 3.5 mg..	528	cladribine.....	528
bosentan oral tablet	49	clindamycin in 5 % dextrose.....	21, 22
BOSULIF ORAL CAPSULE 100 MG, 50		clindamycin phosphate injection.....	21, 22
MG	50	CLINIMIX 5%/D15W SULFITE FREE	528
BOSULIF ORAL TABLET 100 MG, 400		CLINIMIX 4.25%/D10W SULF FREE .	528
MG, 500 MG.....	50	CLINIMIX 4.25%/D5W SULFIT FREE	528
BRAFTOVI.....	51, 52	CLINIMIX 5%-D20W(SULFITE-FREE)	
BRIUMVI	53		528
BRUKINSA ORAL TABLET	54, 55	CLINIMIX 6%-D5W (SULFITE-FREE)	528
budesonide inhalation suspension for		CLINIMIX 8%-D10W(SULFITE-FREE)	
nebulization 0.25 mg/2 ml, 0.5 mg/2 ml, 1			528
mg/2 ml	528	CLINIMIX 8%-D14W(SULFITE-FREE)	
buprenorphine transdermal patch....	237, 238		528
busulfan.....	528	clobazam oral suspension	73
BYOOVIZ.....	56	clobazam oral tablet	73
C		clofarabine.....	528
CABLIVI INJECTION KIT	58	clomid	74
CABOMETYX	59, 60	clomiphene citrate	74
calcium acetate(phosphat bind).....	328	clorazepate dipotassium oral tablet 15 mg,	
CALQUENCE (ACALABRUTINIB MAL)		3.75 mg, 7.5 mg	155, 156
.....	61, 62	colistin (colistimethate na).....	21, 22
CAMZYOS	63, 64	COLUMVI.....	75, 76
CAPRELSA ORAL TABLET 100 MG, 300		COMETRIQ ORAL CAPSULE 100	
MG	65	MG/DAY(80 MG X1-20 MG X1), 140	
carboplatin intravenous solution.....	528	MG/DAY(80 MG X1-20 MG X3), 60	
carglumic acid.....	66	MG/DAY (20 MG X 3/DAY).....	77
carmustine intravenous recon soln 100 mg		COPIKTRA.....	78
.....	528	COSENTYX (2 SYRINGES).....	79, 80
CAYSTON.....	67	COSENTYX INTRAVENOUS.....	81
cefoxitin	21, 22	COSENTYX PEN.....	79, 80
cefoxitin in dextrose, iso-osm.....	21, 22	COSENTYX PEN (2 PENS)	79, 80
ceftaroline fosamil	21, 22	COSENTYX SUBCUTANEOUS	
ceftazidime	21, 22	SYRINGE 150 MG/ML, 75 MG/0.5 ML	
cefuroxime sodium injection recon soln 750			79, 80
mg	21, 22	COSENTYX UNOREADY PEN	79, 80
cefuroxime sodium intravenous.....	21, 22	COTELLIC	82, 83
CEPROTIN (BLUE BAR).....	68	CRESEMBA ORAL	84
CEPROTIN (GREEN BAR).....	68	cromolyn inhalation	528
CHEMET	69	CRYSVITA.....	85, 86
CIMZIA	70, 71	cyclobenzaprine oral tablet 10 mg, 5 mg	159
CIMZIA POWDER FOR RECONST	70, 71	cyclophosphamide intravenous recon soln	
CIMZIA STARTER KIT	70, 71		528

cyclophosphamide oral capsule 528
 CYCLOPHOSPHAMIDE ORAL TABLET
 50 MG 528
 cyclosporine modified..... 528
 cyclosporine oral capsule..... 528
 CYRAMZA..... 528
 CYSTAGON..... 88
 CYSTARAN..... 87
 cytarabine..... 528
 cytarabine (pf)..... 528
D
 dacarbazine 528
 dactinomycin..... 528
 dalfampridine 89
 DANYELZA..... 528
 DANZITEN 282, 283
 DARZALEX..... 528
 DARZALEX FASPRO..... 528
 dasatinib oral tablet 100 mg, 140 mg, 20 mg,
 50 mg, 70 mg, 80 mg 398
 DATROWAY 90, 91
 daunorubicin 528
 DAURISMO ORAL TABLET 100 MG, 25
 MG 92
 decitabine 528
 deferasirox..... 93
 deferiprone 94
 deferoxamine..... 528
 dermacinrx lidocan..... 231
 dexrazoxane hcl 528
 DIACOMIT..... 99
 diazepam injection 155, 156
 diazepam intensol..... 155, 156
 diazepam oral concentrate..... 155, 156
 diazepam oral solution 155, 156
 diazepam oral tablet 155, 156
 diclofenac sodium topical gel 3 %..... 392
 dimethyl fumarate oral capsule,delayed
 release(dr/ec) 120 mg, 120 mg (14)- 240
 mg (46), 240 mg..... 100
 dobutamine..... 528
 dobutamine in d5w intravenous parenteral
 solution 1,000 mg/250 ml (4,000
 mcg/ml), 250 mg/250 ml (1 mg/ml), 500
 mg/250 ml (2,000 mcg/ml) 528
 docetaxel 528

dopamine in 5 % dextrose..... 528
 dopamine intravenous solution 528
 DOPTELET (10 TAB PACK)..... 101, 102
 DOPTELET (15 TAB PACK)..... 101, 102
 DOPTELET (30 TAB PACK)..... 101, 102
 DOPTELET SPRINKLE 101, 102
 doxorubicin 528
 doxorubicin, peg-liposomal 528
 doxy-100 21, 22
 doxycycline hyclate intravenous..... 21, 22
 dronabinol oral capsule 103
 DROPSAFE ALCOHOL PREP PADS 95
 droxidopa 104
 DUPIXENT PEN SUBCUTANEOUS PEN
 INJECTOR 200 MG/1.14 ML, 300 MG/2
 ML..... 106, 107, 108
 DUPIXENT SYRINGE SUBCUTANEOUS
 SYRINGE 200 MG/1.14 ML, 300 MG/2
 ML..... 106, 107, 108
E
 ELAHERE 109
 ELAPRASE 110
 ELIGARD 148
 ELIGARD (3 MONTH)..... 148
 ELIGARD (4 MONTH)..... 148
 ELIGARD (6 MONTH)..... 148
 ELREXFIO 111
 eltrombopag olamine 339, 340
 ELZONRIS 528
 EMGALITY PEN 112
 EMGALITY SYRINGE
 SUBCUTANEOUS SYRINGE 120
 MG/ML 112
 EMLICITI..... 528
 EMRELIS 113
 ENBREL MINI..... 114, 115
 ENBREL SUBCUTANEOUS SOLUTION
 114, 115
 ENBREL SUBCUTANEOUS SYRINGE
 114, 115
 ENBREL SURECLICK..... 114, 115
 ENGERIX-B (PF)..... 528
 ENGERIX-B PEDIATRIC (PF) 528
 ENSACOVE 117
 ENVARUSUS XR..... 528
 EPIDIOLEX..... 118

EPKINLY 119
 ERBITUX 528
 eribulin 528
 ERIVEDGE..... 122
 ERLEADA ORAL TABLET 240 MG, 60
 MG 123
 erlotinib oral tablet 100 mg, 150 mg, 25 mg
 124, 125
 ertapenem..... 21, 22
 ETOPOPHOS 528
 etoposide intravenous..... 528
 EUCRISA 434
 everolimus (antineoplastic) oral tablet... 126,
 127
 everolimus (antineoplastic) oral tablet for
 suspension 2 mg, 3 mg, 5 mg..... 126, 127
 everolimus (immunosuppressive) 528
F
 FABRAZYME..... 128
 FASENRA PEN..... 129, 130
 FASENRA SUBCUTANEOUS SYRINGE
 10 MG/0.5 ML, 30 MG/ML 129, 130
 fentanyl transdermal patch 72 hour 100
 mcg/hr, 12 mcg/hr, 25 mcg/hr, 50 mcg/hr,
 75 mcg/hr 437, 438
 fingolimod..... 131
 FINTEPLA..... 132
 FIRMAGON KIT W DILUENT SYRINGE
 133
 floxuridine..... 528
 fluconazole in nacl (iso-osm) intravenous
 piggyback 200 mg/100 ml, 400 mg/200
 ml 23
 fludarabine 528
 fluorouracil intravenous 528
 formoterol fumarate 528
 FOTIVDA 134
 FRUZAQLA ORAL CAPSULE 1 MG, 5
 MG 135, 136
 FULPHILA SUBCUTANEOUS SYRINGE
 6 MG/0.6 ML 137, 138
 fulvestrant 528
 FYARRO 139

G
 gabapentin oral tablet extended release 24 hr
 300 mg, 450 mg, 600 mg, 750 mg, 900
 mg 149
 GAMUNEX-C 193
 ganciclovir sodium..... 529
 GATTEX 30-VIAL..... 140
 GATTEX ONE-VIAL 140
 GAUZE PAD TOPICAL BANDAGE 2 X 2
 96
 GAVRETO 141
 GAZYVA..... 529
 gefitinib 142
 gemcitabine intravenous recon soln..... 529
 gemcitabine intravenous solution 1
 gram/26.3 ml (38 mg/ml), 2 gram/52.6 ml
 (38 mg/ml), 200 mg/5.26 ml (38 mg/ml)
 529
 GEMCITABINE INTRAVENOUS
 SOLUTION 100 MG/ML 529
 gengraf oral capsule 529
 gentamicin in nacl (iso-osm) intravenous
 piggyback 100 mg/100 ml, 60 mg/50 ml,
 80 mg/100 ml, 80 mg/50 ml..... 21, 22
 gentamicin injection..... 21, 22
 gentamicin sulfate (ped) (pf)..... 21, 22
 GILOTRIF 143
 glatiramer subcutaneous syringe 20 mg/ml,
 40 mg/ml 144
 glatopa subcutaneous syringe 20 mg/ml, 40
 mg/ml 144
 glutamine (sickle cell)..... 116
 GOMEKLI ORAL CAPSULE 1 MG, 2 MG
 147
 GOMEKLI ORAL TABLET FOR
 SUSPENSION 147
 GRAFAPEX 529
 granisetron hcl oral 529
H
 HADLIMA..... 7, 8
 HADLIMA PUSHTOUCH..... 7, 8
 HADLIMA(CF) 7, 8
 HADLIMA(CF) PUSHTOUCH 7, 8
 HEPLISAV-B (PF) 529
 HERNEXEOS..... 153

hydromorphone oral tablet extended release
 24 hr 237, 238
 hydroxyzine hcl oral tablet..... 157
 HYRNUO 160
I
 ibandronate intravenous 47, 48
 IBRANCE ORAL CAPSULE 125 MG. 161,
 162
 IBRANCE ORAL TABLET 161, 162
 IBTROZI 163
 icatibant 164, 165
 ICLUSIG 166, 167
 idarubicin 529
 IDHIFA 168
 ifosfamide 529
 ILARIS (PF)..... 169, 170
 imatinib oral tablet 100 mg, 400 mg 171, 172
 IMBRUVICA ORAL CAPSULE 140 MG,
 70 MG 173, 174
 IMBRUVICA ORAL SUSPENSION.... 173,
 174
 IMBRUVICA ORAL TABLET 173, 174
 IMDELLTRA 175
 IMFINZI 529
 imipenem-cilastatin..... 21, 22
 IMJUDO 176, 177
 IMKELDI..... 171, 172
 IMOVAX RABIES VACCINE (PF)..... 529
 IMPAVIDO..... 178
 INBRIJA INHALATION CAPSULE,
 W/INHALATION DEVICE 179
 INFLIXIMAB 349, 350
 INGREZZA..... 180
 INGREZZA INITIATION PK(TARDIV)
 180
 INGREZZA SPRINKLE 180
 INLEXZO 183
 INLURIYO 184, 185
 INLYTA ORAL TABLET 1 MG, 5 MG 186
 INPEFA..... 187
 INQOVI 188
 INREBIC..... 189
 INSULIN SYRINGE-NEEDLE U-100
 SYRINGE 0.3 ML 29 GAUGE, 1 ML 29
 GAUGE X 1/2..... 98
 intralipid intravenous emulsion 20 % 529

ipratropium bromide inhalation solution 529
 ipratropium-albuterol 529
 irinotecan..... 529
 ISTODAX..... 529
 ITOVEBI ORAL TABLET 3 MG, 9 MG
 190, 191
 ivermectin oral tablet 3 mg, 6 mg 192
 IWILFIN 194
 IXEMPRA..... 529
J
 JAKAFI..... 195, 196
 JAKAFI XR 195, 196
 JAYPIRCA ORAL TABLET 100 MG, 50
 MG 197, 198
 JEMPERLI..... 199, 200
 JEVTANA..... 529
 JYLAMVO 529
 JYNNEOS (PF)..... 529
K
 KADCYLA 202
 KALYDECO..... 203
 KANUMA..... 204
 KERENDIA 205, 206
 KESIMPTA PEN 207
 KEYTRUDA..... 208
 KEYTRUDA QLEX..... 209
 KHAPZORY INTRAVENOUS RECON
 SOLN 175 MG..... 529
 KIMMTRAK 529
 KINERET 210, 211
 KISQALI ORAL TABLET 200 MG/DAY
 (200 MG X 1), 400 MG/DAY (200 MG X
 2), 600 MG/DAY (200 MG X 3) 212, 213
 KOMZIFTI 214
 KOSELUGO 216
 KRAZATI..... 217, 218
 KYPROLIS 529
L
 lanreotide subcutaneous syringe 120 mg/0.5
 ml 219, 220
 lapatinib..... 221, 222
 LAZCLUZE ORAL TABLET 240 MG, 80
 MG 223
 LEDIPASVIR-SOFOSBUVIR..... 224
 lenalidomide..... 225, 226

LENVIMA ORAL CAPSULE 10 MG/DAY
 (10 MG X 1), 12 MG/DAY (4 MG X 3),
 14 MG/DAY(10 MG X 1-4 MG X 1), 18
 MG/DAY (10 MG X 1-4 MG X2), 20
 MG/DAY (10 MG X 2), 24 MG/DAY(10
 MG X 2-4 MG X 1), 4 MG, 8 MG/DAY
 (4 MG X 2)..... 227, 228
 leuprolide subcutaneous kit..... 148
 levofloxacin in d5w..... 21, 22
 levoleucovorin calcium intravenous solution
 529
 LIBTAYO 229, 230
 lidocaine topical adhesive patch,medicated 5
 % 231
 lidocan iii 231
 lidocan iv 231
 lidocan v 231
 LIFYORLI ORAL CAPSULE 125
 MG/DAY(100 MG X1-25MG X1), 150
 MG/DAY(100 MG X1-25MG X2)..... 232
 lincomycin..... 21, 22
 linezolid in dextrose 5%..... 21, 22
 LIORESAL 529
 liraglutide 145
 LIVDELZI 233, 234
 LIVTENCITY 235, 236
 LONSURF 239, 240
 LOQTORZI..... 241, 242
 lorazepam injection 155, 156
 lorazepam intensol 155, 156
 lorazepam oral concentrate 155, 156
 lorazepam oral tablet 0.5 mg, 1 mg, 2 mg
 155, 156
 LORBRENA ORAL TABLET 100 MG, 25
 MG 243, 244
 LUMAKRAS ORAL TABLET 120 MG,
 240 MG, 320 MG..... 245, 246
 LUMIZYME 247
 LUNSUMIO 248, 249
 LUNSUMIO VELO..... 250, 251
 LUPRON DEPOT..... 252, 253
 LYOZYFIC..... 254, 255
 LYNPARZA 256, 257
 LYTGABI ORAL TABLET 12 MG/DAY
 (4 MG X 3), 16 MG/DAY (4 MG X 4),
 20 MG/DAY (4 MG X 5) 258

M

MAVYRET ORAL PELLETS IN PACKET
 259
 MAVYRET ORAL TABLET..... 259
 megestrol oral suspension 400 mg/10 ml (10
 ml), 400 mg/10 ml (40 mg/ml), 625 mg/5
 ml (125 mg/ml) 260
 megestrol oral tablet..... 260
 MEKINIST ORAL RECON SOLN 261, 262
 MEKINIST ORAL TABLET 0.5 MG, 2
 MG 261, 262
 MEKTOVI 263
 melphalan hcl 529
 memantine oral capsule,sprinkle,er 24hr 264
 memantine oral solution..... 264
 memantine oral tablet..... 264
 memantine-donepezil..... 264
 MEPSEVII 265
 meropenem intravenous recon soln 1 gram,
 2 gram, 500 mg 21, 22
 mesna intravenous..... 529
 methadone intensol 237, 238
 methadone oral concentrate 237, 238
 methadone oral solution 10 mg/5 ml, 5 mg/5
 ml 237, 238
 methadone oral tablet 10 mg, 5 mg. 237, 238
 methadose oral concentrate..... 237, 238
 methotrexate sodium..... 529
 methotrexate sodium (pf)..... 529
 methylergonovine oral 266
 methylprednisolone oral tablet..... 529
 metro i.v. 21, 22
 metronidazole in nacl (iso-os)..... 21, 22
 metyrosine..... 327
 mifepristone oral tablet 300 mg 215
 milophene..... 74
 milrinone 529
 milrinone in 5 % dextrose 529
 mitomycin intravenous..... 529
 mitoxantrone 529
 modafinil oral tablet 100 mg, 200 mg..... 267
 MODEYSO 268
 MONJUVI..... 269
 morphine oral tablet extended release.... 237,
 238
 MOUNJARO 145

moxifloxacin-sod.chloride(iso) 21, 22
 mycophenolate mofetil..... 529
 mycophenolate mofetil (hcl) 529
 mycophenolate sodium 529
 MYFEMBREE..... 270, 271
 MYHIBBIN 529
 MYLOTARG..... 529

N

nafcillin in dextrose iso-osm intravenous
 piggyback 2 gram/100 ml 21, 22
 nafcillin injection 21, 22
 NAGLAZYME 272
 NANO PEN NEEDLE 97
 NAYZILAM 273
 NELARABINE..... 529
 NEMLUVIO 274, 275
 NERLYNX 276, 277
 NEXLETOL..... 278, 279
 NEXLIZET 280, 281
 nilotinib hcl oral capsule 150 mg, 200 mg,
 50 mg 282, 283
 nilutamide 284
 NINLARO..... 285, 286
 nintedanib..... 304, 305
 nitisinone..... 287
 NIVESTYM..... 288, 289
 NUBEQA..... 292
 NUCALA SUBCUTANEOUS AUTO-
 INJECTOR..... 293, 294, 295
 NUCALA SUBCUTANEOUS RECON
 SOLN 293, 294, 295
 NUCALA SUBCUTANEOUS SYRINGE
 100 MG/ML, 40 MG/0.4 ML 293, 294,
 295
 NUEDEXTA..... 296
 NULOJIX..... 529
 NUPLAZID..... 297
 NURTEC ODT 298
 NYVEPRIA 299, 300

O

octreotide acetate 301, 302
 octreotide,microspheres 380, 381
 ODOMZO 303
 OGSIVEO ORAL TABLET 100 MG, 150
 MG 306

OJEMDA ORAL SUSPENSION FOR
 RECONSTITUTION 307
 OJEMDA ORAL TABLET 400 MG/WEEK
 (100 MG X 4), 500 MG/WEEK (100 MG
 X 5), 600 MG/WEEK (100 MG X 6) . 307
 OJJAARA 308
 OMNITROPE 150, 151, 152
 ONCASPAR 529
 ondansetron hcl oral solution 529
 ondansetron hcl oral tablet 4 mg, 8 mg... 529
 ondansetron oral tablet,disintegrating 4 mg,
 8 mg 529
 ONIVYDE 529
 ONUREG..... 309
 OPDIVO 310
 OPDIVO QVANTIG 311
 OPDUALAG..... 312
 OPSUMIT 313
 OPSYNVI 314
 ORGOVYX..... 315
 ORKAMBI ORAL GRANULES IN
 PACKET 316
 ORKAMBI ORAL TABLET 316
 ORSERDU ORAL TABLET 345 MG, 86
 MG 317, 318
 OTEZLA 319
 OTEZLA STARTER ORAL
 TABLETS,DOSE PACK 10 MG (4)- 20
 MG (51), 10 MG (4)-20 MG (4)-30 MG
 (47)..... 319
 OTEZLA XR 319
 OTEZLA XR INITIATION..... 319
 OTULFI INTRAVENOUS 461
 OTULFI SUBCUTANEOUS SOLUTION
 462, 463
 OTULFI SUBCUTANEOUS SYRINGE 45
 MG/0.5 ML, 90 MG/ML 462, 463
 oxacillin..... 21, 22
 oxacillin in dextrose(iso-osm) intravenous
 piggyback 2 gram/50 ml 21, 22
 oxaliplatin 529
 OXERVATE 320
 OZEMPIC ORAL 145
 OZEMPIC SUBCUTANEOUS 145

P

paclitaxel 529

paclitaxel protein-bound 529
 PADCEV..... 321
 PANRETIN..... 322
 PAVBLU..... 323
 pazopanib oral tablet 200 mg..... 480, 481
 PAZOPANIB ORAL TABLET 400 MG
 480, 481
 PEMAZYRE..... 324
 pemetrexed disodium intravenous recon soln
 529
 PEN NEEDLE, DIABETIC NEEDLE 29
 GAUGE X 1/2..... 97
 penicillamine oral tablet..... 325
 PENICILLIN G POT IN DEXTROSE
 INTRAVENOUS PIGGYBACK 2
 MILLION UNIT/50 ML, 3 MILLION
 UNIT/50 ML 21, 22
 penicillin g potassium 21, 22
 penicillin g sodium..... 21, 22
 pentamidine inhalation..... 529
 PERJETA..... 529
 pfizerpen-g 21, 22
 phenobarbital..... 158
 pimecrolimus..... 434
 PIQRAY ORAL TABLET 200 MG/DAY
 (200 MG X 1), 250 MG/DAY (200 MG
 X1-50 MG X1), 300 MG/DAY (150 MG
 X 2) 330, 331
 pirfenidone oral capsule..... 332
 pirfenidone oral tablet 267 mg, 801 mg.. 332
 PLEGRIDY INTRAMUSCULAR 333
 PLEGRIDY SUBCUTANEOUS PEN
 INJECTOR 125 MCG/0.5 ML, 63
 MCG/0.5 ML- 94 MCG/0.5 ML..... 333
 PLEGRIDY SUBCUTANEOUS SYRINGE
 125 MCG/0.5 ML, 63 MCG/0.5 ML- 94
 MCG/0.5 ML 333
 PLENAMINE 529
 plerixafor..... 529
 POLIVY 334
 pomalidomide 335
 posaconazole oral tablet, delayed release
 (dr/ec)..... 336
 POTELIGEO..... 337
 pralatrexate intravenous solution 20 mg/ml
 (1 ml)..... 529

PRALATREXATE INTRAVENOUS
 SOLUTION 40 MG/2 ML (20 MG/ML)
 529
 premasol 10 %..... 529
 PREVYMIS INTRAVENOUS..... 338
 PREVYMIS ORAL TABLET 240 MG, 480
 MG 338
 PROCIT..... 120, 121
 PROGRAF INTRAVENOUS..... 529
 PROGRAF ORAL GRANULES IN
 PACKET 529
 PROLASTIN-C INTRAVENOUS
 SOLUTION..... 18
 promethazine oral..... 157
 PULMOZYME 529
 pyrimethamine 341
 PYZCHIVA (ONLY NDCS STARTING
 WITH 61314) INTRAVENOUS
 SOLUTION 130 MG/26 ML 461
 PYZCHIVA (ONLY NDCS STARTING
 WITH 61314) SUBCUTANEOUS
 SOLUTION 45 MG/0.5 ML 462, 463
 PYZCHIVA (ONLY NDCS STARTING
 WITH 61314) SUBCUTANEOUS
 SYRINGE 45 MG/0.5 ML, 90 MG/ML
 462, 463
Q
 QINLOCK..... 342
 QULIPTA 343
R
 RABAVERT (PF)..... 529
 RADICAVA ORS..... 344
 RADICAVA ORS STARTER KIT SUSP
 344
 RECOMBIVAX HB (PF)..... 529
 RELEUKO SUBCUTANEOUS 347, 348
 REMICADE..... 349, 350
 REPATHA 353, 354
 REPATHA SURECLICK..... 353, 354
 RETACRIT 120, 121
 RETEVMO ORAL TABLET 120 MG, 160
 MG, 40 MG, 80 MG 355, 356
 REVCovi..... 357
 REVUFORJ ORAL TABLET 110 MG, 160
 MG, 25 MG..... 358
 REZDIFFRA..... 359, 360

REZLIDHIA	361	SIMLANDI(CF) SUBCUTANEOUS	
REZUROCK	362	SYRINGE KIT 20 MG/0.2 ML, 40	
riluzole	363	MG/0.4 ML	7, 8
RINVOQ LQ.....	366	SIMULECT.....	529
RINVOQ ORAL TABLET EXTENDED		sirolimus.....	529
RELEASE 24 HR 15 MG, 30 MG, 45		SIRTURO	387
MG	364, 365	SKYRIZI INTRAVENOUS	390
roflumilast.....	367, 368	SKYRIZI SUBCUTANEOUS PEN	
romidepsin intravenous recon soln	529	INJECTOR.....	388, 389
ROMVIMZA	369	SKYRIZI SUBCUTANEOUS SYRINGE	
ROZLYTREK ORAL CAPSULE 100 MG,		150 MG/ML	388, 389
200 MG	370	SKYRIZI SUBCUTANEOUS WEARABLE	
ROZLYTREK ORAL PELLETS IN		INJECTOR 180 MG/1.2 ML (150	
PACKET	370	MG/ML), 360 MG/2.4 ML (150 MG/ML)	
RUBRACA	371, 372		388, 389
rufinamide	373	sodium oxybate	509
RUXIENCE	374	sodium phenylbutyrate.....	326
RYBELSUS	145	SOFOSBUVIR-VELPATASVIR.....	391
RYBREVA NT	375	SOMATULINE DEPOT	
RYBREVA NT FASPRO	376	SUBCUTANEOUS SYRINGE 60	
RYDAPT.....	377	MG/0.2 ML, 90 MG/0.3 ML	219, 220
RYLAZE.....	529	SOMAVERT.....	393
RYTELO.....	378, 379	sorafenib.....	394, 395
S		SPRAVATO NASAL SPRAY, NON-	
sajazir	164, 165	AEROSOL 56 MG (28 MG X 2), 84 MG	
SANDOSTATIN LAR DEPOT		(28 MG X 3).....	396, 397
INTRAMUSCULAR		STELARA INTRAVENOUS	461
SUSPENSION, EXTENDED REL		STELARA SUBCUTANEOUS	
RECON 10 MG.....	380, 381	SOLUTION.....	462, 463
sapropterin.....	382	STIVARGA	399, 400
SARCLISA	383	STRENSIQ	401, 402
SCEMBLIX ORAL TABLET 100 MG, 20		STREPTOMYCIN	21, 22
MG, 40 MG.....	384, 385	SUCRAID	403, 404
SELARSDI INTRAVENOUS	461	sulfamethoxazole-trimethoprim intravenous	
SELARSDI SUBCUTANEOUS			21, 22
SOLUTION.....	462, 463	sunitinib malate	405, 406
SELARSDI SUBCUTANEOUS SYRINGE		SYLVANT	529
45 MG/0.5 ML, 90 MG/ML	462, 463	SYMDEKO.....	407
sevelamer carbonate oral tablet.....	328	SYMPAZAN.....	73
SIGNIFOR	386	T	
sildenafil (pulmonary arterial hypertension)		TABRECTA	408
oral tablet 20 mg	329	tacrolimus oral capsule	529
SIMLANDI(CF) AUTOINJECTOR		tacrolimus topical.....	434
SUBCUTANEOUS AUTO-INJECTOR,		tadalafil (pulm. hypertension).....	329
KIT 40 MG/0.4 ML, 80 MG/0.8 ML..	7, 8	tadalafil oral tablet 2.5 mg, 5 mg	409
		TAFINLAR ORAL CAPSULE	412, 413

TAFINLAR ORAL TABLET FOR	
SUSPENSION	412, 413
TAGRISO	414, 415
TALVEY.....	416
TALZENNA	417
tazarotene topical cream	418
tazarotene topical gel	418
tazicef injection.....	21, 22
TECENTRIQ	529
TECENTRIQ HYBREZA	529
TECVAYLI.....	419
TEFLARO.....	21, 22
TEMODAR.....	529
temsirolimus.....	529
TEPMETKO	420
teriflunomide	28
teriparatide subcutaneous pen injector 20	
mcg/dose (560mcg/2.24ml)	421, 422
testosterone cypionate	181, 182
testosterone enanthate	181, 182
testosterone transdermal gel.....	290, 291
testosterone transdermal gel in metered-dose	
pump 12.5 mg/ 1.25 gram (1 %), 20.25	
mg/1.25 gram (1.62 %)	290, 291
testosterone transdermal gel in packet 1 %	
(25 mg/2.5gram), 1 % (50 mg/5 gram),	
1.62 % (20.25 mg/1.25 gram), 1.62 %	
(40.5 mg/2.5 gram)	290, 291
testosterone transdermal solution in metered	
pump w/app.....	290, 291
tetrabenazine oral tablet 12.5 mg, 25 mg	423
TEVIMBRA.....	424, 425
TEZSPIRE	426, 427
THALOMID ORAL CAPSULE 100 MG,	
50 MG	428, 429
thiotepa.....	529
TIBSOVO	430
TICE BCG	529
tigecycline	21, 22
TIVDAK	431
tobramycin in 0.225 % nacl	432
tobramycin inhalation	432
tobramycin sulfate injection recon soln ...	21,
22	
tobramycin sulfate injection solution..	21, 22
tolvaptan.....	433
tolvaptan (polycys kidney dis).....	201
topiramate oral capsule, sprinkle 15 mg, 25	
mg	436
topiramate oral solution	436
topiramate oral tablet	436
topotecan	529
torpenz.....	126, 127
travasol 10 %.....	529
TRAZIMERA	529
TRELSTAR INTRAMUSCULAR	
SUSPENSION FOR	
RECONSTITUTION	439
TREMFYA INTRAVENOUS	440
TREMFYA ONE-PRESS	441, 442
TREMFYA PEN.....	441, 442
TREMFYA PEN INDUCTION PK(2PEN)	
.....	441, 442
TREMFYA SUBCUTANEOUS SYRINGE	
.....	441, 442
treprostinil sodium	351, 352
tretinoin topical	435
trientine oral capsule 250 mg.....	443, 444
TRIKAFTA ORAL GRANULES IN	
PACKET, SEQUENTIAL	445
TRIKAFTA ORAL TABLETS,	
SEQUENTIAL.....	445
TRODELVY	446, 447
TROPHAMINE 10 %.....	529
TRULICITY	145
TRUQAP.....	448, 449
TUKYSA ORAL TABLET 150 MG, 50	
MG	450, 451
TURALIO	452
TYENNE AUTOINJECTOR.....	455, 456
TYENNE INTRAVENOUS	453, 454
TYENNE SUBCUTANEOUS.....	455, 456
TYMLOS	457, 458
TYVASO	529
TYVASO INSTITUTIONAL START KIT	
.....	530
TYVASO REFILL KIT	530
TYVASO STARTER KIT.....	530
U	
UBRELVY.....	459

ULTRA-FINE INSULIN SYRINGE	
SYRINGE 1/2 ML 31 GAUGE X 15/64	
.....	98
UNITUXIN	530
UPTRAVI ORAL TABLET	460
UPTRAVI ORAL TABLETS,DOSE PACK	
.....	460
USTEKINUMAB INTRAVENOUS	461
USTEKINUMAB SUBCUTANEOUS	
SOLUTION.....	462, 463
USTEKINUMAB-AEKN	
SUBCUTANEOUS SYRINGE 45	
MG/0.5 ML, 90 MG/ML	462, 463
V	
VALCHLOR.....	464
valrubicin	530
VALTOCO	465
vancomycin oral capsule 125 mg, 250 mg	
.....	466
VANFLYTA	467
VARUBI	530
VECTIBIX.....	530
velettri	530
VENCLEXTA ORAL TABLET 10 MG,	
100 MG, 50 MG.....	468, 469
VENCLEXTA STARTING PACK	468, 469
VERZENIO.....	470, 471
VIBATIV INTRAVENOUS RECON SOLN	
750 MG	21, 22
vigabatrin	472
vigadrone.....	472
VIMIZIM	473
vinblastine	530
vincristine.....	530
vinorelbine	530
VITRAKVI ORAL CAPSULE 100 MG, 25	
MG	474
VITRAKVI ORAL SOLUTION	474
VONJO	475, 476
VORANIGO ORAL TABLET 10 MG, 40	
MG	477
voriconazole intravenous recon soln.....	23
voriconazole oral.....	478
voriconazole-hpbcd.....	23
VOSEVI.....	479
VOWST	482
VUMERITY	483
VYLOY.....	484, 485
VYNDAMAX.....	410, 411
VYNDAQEL	410, 411
VYVGART	486, 487
VYVGART HYTRULO	486, 487
VYXEOS	530
W	
WELIREG.....	488, 489
WINREVAIR.....	490, 491
WYOST	530
X	
XALKORI ORAL CAPSULE.....	492, 493
XALKORI ORAL PELLET 150 MG, 20	
MG, 50 MG.....	492, 493
XDEMVY	494
XELJANZ ORAL SOLUTION	495, 496
XELJANZ ORAL TABLET.....	495, 496
XELJANZ XR	495, 496
XEMBIFY.....	530
XERMELO	497
XIAFLEX	498, 499
XIFAXAN ORAL TABLET 200 MG, 550	
MG	500, 501
XOLAIR SUBCUTANEOUS AUTO-	
INJECTOR 150 MG/ML, 300 MG/2 ML,	
75 MG/0.5 ML	502, 503
XOLAIR SUBCUTANEOUS RECON	
SOLN	502, 503
XOLAIR SUBCUTANEOUS SYRINGE	
150 MG/ML, 300 MG/2 ML, 75 MG/0.5	
ML.....	502, 503
XOSPATA	504
XPOVIO ORAL TABLET 100 MG/WEEK	
(50 MG X 2), 40 MG/WEEK (10 MG X	
4), 40MG TWICE WEEK (40 MG X 2),	
60 MG/WEEK (60 MG X 1), 60MG	
TWICE WEEK (120 MG/WEEK), 80	
MG/WEEK (40 MG X 2), 80 MG/WEEK	
(80 MG X 1), 80MG TWICE WEEK (160	
MG/WEEK)	505, 506
XTANDI ORAL CAPSULE.....	507, 508
XTANDI ORAL TABLET 40 MG, 80 MG	
.....	507, 508
Y	
YERVOY	530

YESINTEK INTRAVENOUS..... 461
 YESINTEK SUBCUTANEOUS
 SOLUTION..... 462, 463
 YESINTEK SUBCUTANEOUS SYRINGE
 45 MG/0.5 ML, 90 MG/ML 462, 463
 YONDELIS..... 530
 yulithira..... 126, 127
Z
 ZALTRAP..... 530
 ZEJULA ORAL TABLET..... 510
 ZELBORAF 511, 512
 ZEPOSIA 513, 514
 ZEPOSIA STARTER KIT (28-DAY)... 513,
 514
 ZEPOSIA STARTER PACK (7-DAY). 513,
 514
 ZEPZELCA..... 515

ZIIHERA..... 516
 ZIRABEV 530
 ZOLADEX..... 146
 zoledronic acid intravenous solution 530
 zoledronic acid-mannitol-water intravenous
 piggyback 5 mg/100 ml 345, 346
 ZOLINZA 517
 ZONISADE..... 436
 zonisamide 436
 ZTALMY 518
 ZURZUVAE ORAL CAPSULE 20 MG, 25
 MG, 30 MG..... 519
 ZYDELIG 520
 ZYKADIA 521
 ZYMFENTRA 522
 ZYNLONTA..... 523
 ZYNYZ 524, 525